

PRODUCTION OF TAILORED OILS IN HETEROTROPHIC MICROORGANISMS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. 119(e) of US Provisional Patent Application No. 61/118,590, filed November 28, 2008, US Provisional Patent Application No. 61/118,994, filed December 1, 2008, US Provisional Patent Application No. 61/174,357, filed April 30, 2009, and US Provisional Patent Application No. 61/219,525, filed June 23, 2009. Each of these applications is incorporated herein by reference in its entirety for all purposes.

REFERENCE TO A SEQUENCE LISTING

[0002] This application includes a sequence listing as shown in pages 1-72, appended hereto.

FIELD OF THE INVENTION

[0003] The present invention relates to the production of oils, fuels, and oleochemicals made from microorganisms. In particular, the disclosure relates to oil-bearing microalgae, methods of cultivating them for the production of useful compounds, including lipids, fatty acid esters, fatty acids, aldehydes, alcohols, and alkanes, and methods and reagents for genetically altering them to improve production efficiency and alter the type and composition of the oils produced by them.

BACKGROUND OF THE INVENTION

[0004] Fossil fuel is a general term for buried combustible geologic deposits of organic materials, formed from decayed plants and animals that have been converted to crude oil, coal, natural gas, or heavy oils by exposure to heat and pressure in the earth's crust over hundreds of millions of years. Fossil fuels are a finite, non-renewable resource.

[0005] Increased demand for energy by the global economy has also placed increasing pressure on the cost of hydrocarbons. Aside from energy, many industries, including plastics and chemical manufacturers, rely heavily on the availability of hydrocarbons as a feedstock for their manufacturing processes. Cost-effective alternatives to current sources of supply could help mitigate the upward pressure on energy and these raw material costs.

[0006] PCT Pub. No. 2008/151149 describes methods and materials for cultivating microalgae for the production of oil and particularly exemplifies the production of diesel fuel from oil produced by the microalgae *Chlorella protothecoides*. There remains a need for improved methods for producing oil in microalgae, particularly for methods that produce oils

with shorter chain length and a higher degree of saturation and without pigments, with greater yield and efficiency. The present invention meets this need.

SUMMARY

[0007] The disclosure provides cells of the genus *Prototheca* comprising an exogenous gene, and in some embodiments the cell is a strain of the species *Prototheca moriformis*, *Prototheca krugani*, *Prototheca stagnora* or *Prototheca zopfii* and in other embodiment the cell has a 23S rRNA sequence with at least 70, 75, 80, 85 or 95% nucleotide identity to one or more of SEQ ID NOs: 11-19. In some cells the exogenous gene is coding sequence and is in operable linkage with a promoter, and in some embodiments the promoter is from a gene endogenous to a species of the genus *Prototheca*. In further embodiments the coding sequence encodes a protein selected from the group consisting of a sucrose invertase, a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty aldehyde decarbonylase, an acyl carrier protein and a protein that imparts resistance to an antibiotic. Some embodiments of a fatty acyl-ACP thioesterase that has hydrolysis activity towards one or more fatty acyl-ACP substrates of chain length C8, C10, C12 or C14, including acyl-ACP thioesterases with at least 50, 60, 70, 80, or 90% amino acid identity with one or more sequences selected from the group consisting of SEQ ID NOs: 59, 61, 63 and 138-140. In further embodiments the coding sequence comprises a plastid targeting sequence from microalgae, and in some embodiments the microalgae is a species of the genus *Prototheca* or *Chlorella* as well as other genera from the family *Chlorellaceae*. In some embodiments the plastid targeting sequence has at least 20, 25, 35, 45, or 55% amino acid sequence identity to one or more of SEQ ID NOs: 127-133 and is capable of targeting a protein encoded by an exogenous gene not located in the plastid genome to the plastid. In other embodiments the promoter is upregulated in response to reduction or elimination of nitrogen in the culture media of the cell, such as at least a 3-fold upregulation as determined by transcript abundance in a cell of the genus *Prototheca* when the extracellular environment changes from containing at least 10mM or 5mM nitrogen to containing no nitrogen. In further embodiments the promoter comprises a segment of 50 or more nucleotides of one of SEQ ID NOs: 91-102. In other embodiments the cell has a 23S rRNA sequence with at least 70, 75, 80, 85 or 95% nucleotide identity to one or more of SEQ ID NOs: 11-19. In other embodiments the exogenous gene is integrated into a chromosome of the cell.

[0008] In additional embodiments of cells of the disclosure, the cell is of the genus *Prototheca* and comprises an exogenous fatty acyl-ACP thioesterase gene and a lipid profile

of at least 4% C8-C14 of total lipids of the cell, an amount of C8 that is at least 0.3% of total lipids of the cell, an amount of C10 that is at least 2% of total lipids of the cell, an amount of C12 that is at least 2% of total lipids of the cell, an amount of C14 that is at least 4% of total lipids of the cell, and an amount of C8-C14 that is 10-30%, 20-30%, or at least 10, 20, or 30% of total lipids of the cell. In some embodiments the cell further comprises an exogenous sucrose invertase gene. In some embodiments the cell is a strain of the species *Prototheca moriformis*, *Prototheca krugani*, *Prototheca stagnora* or *Prototheca zopfii*, and in other embodiment the cell has a 23S rRNA sequence with at least 70, 75, 80, 85 or 95% nucleotide identity to one or more of SEQ ID NOs: 11-19. In other embodiments the exogenous fatty acyl-ACP thioesterase gene is integrated into a chromosome of the cell. Other embodiments of the disclosure comprise methods of making triglyceride compositions of a lipid profile of at least 4% C8-C14 w/w or area percent of the triglyceride composition, an amount of C8 that is at least 0.3% w/w or area percent, an amount of C10 that is at least 2% w/w or area percent, an amount of C12 that is at least 2% w/w or area percent, an amount of C14 that is at least 4% w/w or area percent, and an amount of C8-C14 that is 10-30%, 20-30%, or at least 10, 20, or 30% w/w or area percent. The disclosure also comprises methods of making triglyceride compositions comprising cultivating the foregoing cells, wherein the cells also comprise an exogenous gene encoding a sucrose invertase and sucrose is provided as a carbon source. In some embodiments the sucrose invertase has at least 50, 60, 70, 80, or 90% amino acid identity to one or more of SEQ ID NOs: 3, 20-29 and 90.

[0009] Embodiments of the disclosure include triglyceride oil compositions as well as cells containing triglyceride oil compositions comprising a lipid profile of at least 4% C8-C14 and one or more of the following attributes: 0.1-0.4 micrograms/ml total carotenoids, less than 0.4 micrograms/ml total carotenoids, less than 0.001 micrograms/ml lycopene; less than 0.02 micrograms/ml beta carotene, less than 0.02 milligrams of chlorophyll per kilogram of oil; 0.40-0.60 milligrams of gamma tocopherol per 100 grams of oil; 0.2-0.5 milligrams of total tocotrienols per gram of oil, less than 0.4 milligrams of total tocotrienols per gram of oil, 4-8 mg per 100 grams of oil of campesterol, and 40-60 mg per 100 grams of oil of stigmasterol. In some embodiments of the disclosure the triglyceride oil compositions have a lipid profile of at least 4% C8-C14 w/w or area percent of the triglyceride composition, an amount of C8 that is at least 0.3% w/w or area percent, an amount of C10 that is at least 2% w/w or area percent, an amount of C12 that is at least 2% w/w or area percent, an amount of C14 that is at least 4% w/w or area percent, and an amount of C8-C14 that is 10-30%, 20-30%, or at least 10, 20, or 30% w/w or area percent. In other embodiments the triglyceride oil composition is

blended with at least one other composition selected from the group consisting of soy, rapeseed, canola, palm, palm kernel, coconut, corn, waste vegetable, Chinese tallow, olive, sunflower, cotton seed, chicken fat, beef tallow, porcine tallow, microalgae, macroalgae, *Cuphea*, flax, peanut, choice white grease, lard, *Camelina sativa*, mustard seed cashew nut, oats, lupine, kenaf, calendula, hemp, coffee, linseed (flax), hazelnut, euphorbia, pumpkin seed, coriander, camellia, sesame, safflower, rice, tung tree, cocoa, copra, pium poppy, castor beans, pecan, jojoba, jatropha, macadamia, Brazil nuts, avocado, petroleum, or a distillate fraction of any of the preceding oils.

[0010] Methods of the disclosure also include processing the aforementioned oils of by performing one or more chemical reactions from the list consisting of transesterification, hydrogenation, hydrocracking, deoxygenation, isomerization, interesterification, hydroxylation, hydrolysis to yield free fatty acids, and saponification. The disclosure also includes hydrocarbon fuels made from hydrogenation and isomerization of the aforementioned oils and fatty acid alkyl esters made from transesterification of the aforementioned oils. In some embodiments the hydrocarbon fuel is made from triglyceride isolated from cells of the genus *Prototheca* wherein the ASTM D86 T10-T90 distillation range is at least 25°C. In other embodiments the fatty acid alkyl ester fuel is made from triglyceride isolated from cells of the genus *Prototheca*, wherein the composition has an ASTM D6751 A1 cold soak time of less than 120 seconds.

[0011] The disclosure also includes composition comprising (a) polysaccharide comprising one or more monosaccharides from the list consisting of 20-30 mole percent galactose; 55-65 mole percent glucose; and 5-15 mole percent mannose; (b) protein; and (c) DNA comprising a 23S rRNA sequence with at least 70, 75, 80, 85 or 95% nucleotide identity to one or more of SEQ ID NOs: 11-19; and (d) an exogenous gene. In some embodiments the exogenous gene is selected from a sucrose invertase and a fatty acyl-ACP thioesterase, and in further embodiments the composition further comprises lipid with a lipid profile of at least 4% C8-C14. In other embodiments the composition is formulated for consumption as an animal feed.

[0012] The disclosure includes recombinant nucleic acids encoding promoters that are upregulated in response to reduction or elimination of nitrogen in the culture media of a cell of the genus *Prototheca*, such as at least a 3-fold upregulation as determined by transcript abundance when the extracellular environment changes from containing at least 10mM or 5mM nitrogen to containing no nitrogen. In some embodiments the recombinant nucleic acid comprises a segment of 50 or more nucleotides of one of SEQ ID NOs: 91-102. The

disclosure also includes nucleic acid vectors comprising an expression cassette comprising (a) a promoter that is active in a cell of the genus *Prototheca*; and (b) a coding sequence in operable linkage with the promoter wherein the coding sequence contains the most or second most preferred codons of Table 1 for at least 20, 30, 40, 50, 60, or 80% of the codons of the coding sequence. In some vectors the coding sequence comprises a plastid targeting sequence in-frame with a fatty acyl-ACP thioesterase, including thioesterase that have hydrolysis activity towards one or more fatty acyl-ACP substrates of chain length C8, C10, C12 or C14. Some vectors include plastid targeting sequences that encode peptides that are capable of targeting a protein to the plastid of a cell of the genus *Prototheca*, including those from microalgae and those wherein the plastid targeting sequence has at least 20, 25, 35, 45, or 55% amino acid sequence identity to one or more of SEQ ID NOs. 127-133 and is capable of targeting a protein to the plastid of a cell of the genus *Prototheca*. Additional vectors of the disclosure comprise nucleic acid sequences endogenous to the nuclear genome of a cell of the genus *Prototheca*, wherein the sequence is at least 200 nucleotides long, and some vectors comprise first and second nucleic acid sequences endogenous to the nuclear genome of a cell of the genus *Prototheca*, wherein the first and second sequences (a) are each at least 200 nucleotides long; (b) flank the expression cassette; and (c) are located on the same *Prototheca* chromosome no more than 5, 10, 15, 20, and 50kB apart.

[0013] The disclosure also includes a recombinant nucleic acid with at least 80, 90, 95 or 98% nucleotide identity to one or both of SEQ ID NOs: 134-135 and a recombinant nucleic acid encoding a protein with at least 80, 90, 95 or 98% amino acid identity to one or both of SEQ ID NOs: 136-137.

[0014] The disclosure also comprises methods of producing triglyceride compositions, comprising (a) culturing a population of cells of the genus *Prototheca* in the presence of a fixed carbon source, wherein: (i) the cells contain an exogenous gene; (ii) the cells accumulate at least 10, 20, 30, 40, 60, or 70% of their dry cell weight as lipid; and (iii) the fixed carbon source is selected from the group consisting of sorghum and depolymerized cellulosic material; and (b) isolating lipid components from the cultured microorganisms. In some embodiments the fixed carbon source is depolymerized cellulosic material selected from the group consisting of corn stover, *Miscanthus*, forage sorghum, sugar beet pulp and sugar cane bagasse, optionally that has been subjected to washing with water prior to the culturing step. In some methods the fixed carbon source is depolymerized cellulosic material and the glucose level of the depolymerized cellulosic material is concentrated to a level of at least 300 g/liter, at least 400 g/liter, at least 500 g/liter, or at least 600 g/liter of prior to the

culturing step and is fed to the culture over time as the cells grow and accumulate lipid. In some methods the exogenous gene encodes a fatty acyl-ACP thioesterase that has hydrolysis activity towards one or more fatty acyl-ACP substrates of chain length C8, C10, C12 or C14, and in some methods the triglyceride has a lipid profile of at least 4% C8-C14 and one or more of the following attributes: 0.1-0.4 micrograms/ml total carotenoids; less than 0.02 milligrams of chlorophyll per kilogram of oil; 0.40-0.60 milligrams of gamma tocopherol per 100 grams of oil; 0.2-0.5 milligrams of total tocotrienols per gram of oil, 4-8 mg per 100 grams of oil of campesterol, and 40-60 mg per 100 grams of oil of stigmaterol.

[0015] Further methods of the disclosure include producing a triglyceride composition, comprising: (a) culturing a population of microorganisms in the presence of depolymerized cellulosic material, wherein: (i) the depolymerized cellulosic material is subjected to washing with water prior to the culturing step; (ii) the cells accumulate at least 10, 20, 30, 40, 60, or 70% of their dry cell weight as lipid; and (iii) the depolymerized cellulosic material is concentrated to at least 300, 400, 500, or 600 g/liter of glucose prior to the cultivation step; (iv) the microorganisms are cultured in a fed-batch reaction in which depolymerized cellulosic material of at least 300, 400, 500, or 600 g/liter of glucose is fed to the microorganisms; and (b) isolating lipid components from the cultured microorganisms. In some embodiments the the fixed carbon source is depolymerized cellulosic material selected from the group consisting of corn stover, *Miscanthus*, forage sorghum, sugar beet pulp and sugar cane bagasse. In further embodiments the microorganisms are a species of the genus *Prototheca* and contain an exogenous gene, including a fatty acyl-ACP thioesterase that has hydrolysis activity towards one or more fatty acyl-ACP substrates of chain length C8, C10, C12 or C14. A further method of the disclosure comprises manufacturing triglyceride oil comprising cultivating a cell that has a 23S rRNA sequence with at least 90 or 96% nucleotide identity to SEQ ID NO: 30 in the presence of sucrose as a carbon source.

[0016] The disclosure also includes methods of manufacturing a chemical comprising performing one or more chemical reactions from the list consisting of transesterification, hydrogenation, hydrocracking, deoxygenation, isomerization, interesterification, hydroxylation, hydrolysis, and saponification on a triglyceride oil, wherein the oil has a lipid profile of at least 4% C8-C14 and one or more of the following attributes: 0.1-0.4 micrograms/ml total carotenoids; less than 0.02 milligrams of chlorophyll per kilogram of oil; 0.10-0.60 milligrams of gamma tocopherol per 100 grams of oil; 0.1-0.5 milligrams of total tocotrienols per gram of oil, 1-8 mg per 100 grams of oil of campesterol, and 10-60 mg per 100 grams of oil of stigmaterol. Some methods are performed by manufacturing the oil by

cultivating a cell of the genus *Prototheca* that comprises an exogenous fatty acyl-ACP thioesterase gene that encodes a fatty acyl-ACP thioesterase having hydrolysis activity towards one or more fatty acyl-ACP substrates of chain length C8, C10, C12 or C14. In some methods the hydrolysis reaction is selected from the group consisting of saponification, acid hydrolysis, alkaline hydrolysis, enzymatic hydrolysis, catalytic hydrolysis, and hot-compressed water hydrolysis, including a catalytic hydrolysis reaction wherein the oil is split into glycerol and fatty acids. In further methods the fatty acids undergo an amination reaction to produce fatty nitrogen compounds or an ozonolysis reaction to produce mono- and dibasic-acids. In some embodiments the oil undergoes a triglyceride splitting method selected from the group consisting of enzymatic splitting and pressure splitting. In some methods a condensation reaction follows the hydrolysis reaction. Other methods include performing a hydroprocessing reaction on the oil, optionally wherein the product of the hydroprocessing reaction undergoes a deoxygenation reaction or a condensation reaction prior to or simultaneous with the hydroprocessing reaction. Some methods additionally include a gas removal reaction. Additional methods include processing the aforementioned oils by performing a deoxygenation reaction selected from the group consisting of: a hydrogenolysis reaction, hydrogenation, a consecutive hydrogenation-hydrogenolysis reaction, a consecutive hydrogenolysis-hydrogenation reaction, and a combined hydrogenation-hydrogenolysis reaction. In some methods a condensation reaction follows the deoxygenation reaction. Other methods include performing an esterification reaction on the aforementioned oils, optionally an interestification reaction or a transesterification reaction. Other methods include performing a hydroxylation reaction on the aforementioned oils, optionally wherein a condensation reaction follows the hydroxylation reaction.

[0016a] In one aspect, there is provided a method of manufacturing a chemical, the method comprising:

(a) providing a triglyceride oil isolated from a cultivated oleaginous microorganism, wherein the oleaginous microorganism comprises an exogenous fatty acyl-ACP thioesterase gene that encodes a fatty acyl-ACP thioesterase having hydrolysis activity towards one or more fatty acyl-ACP substrates of chain length 8 to 18 carbon atoms, and produces triglyceride oil enriched in the chain lengths for which the thioesterase is specific;

(b) performing one or more chemical reactions on the triglyceride oil to produce the chemical; and

(c) separating the chemical from the reaction mixture after performing step (b).

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figures 1 and 2 illustrate the growth curves of *Prototheca* species and *Chlorella luteoviridis* strain SAG 2214 grown on sorghum as the carbon source.

[0018] Figure 3 shows time course growth of SAG 2214 on glucose and sucrose.

[0019] Figure 4 shows maps of the cassettes using in *Prototheca* transformations, as described in Example 3.

[0020] Figure 5 shows the results of Southern blot analysis on three transformants of UTEX strain 1435, as described in Example 3.

[0021] Figure 6 shows a schematic of the codon optimized and non-codon optimized *suc2* (yeast sucrose invertase (yInv)) transgene construct. The relevant restriction cloning sites are indicated and arrows indicate the direction of transcription.

[0022] Figure 7a shows the results of *Prototheca moriformis* grown on cellulosic-derived sugars (corn stover, beet pulp, sorghum cane, *Miscanthus* and glucose control). Growth is expressed in optical density measurements (A750 readings).

[0023] Figure 7b shows the results of growth experiments using *Prototheca moriformis* using different levels of corn stover-derived cellulosic sugar as compared to glucose/xylose control.

[0024] Figure 7c shows the impact that xylose has on the lipid production in *Prototheca* cultures.

[0025] Figure 7d shows the impact of salt concentration (Na_2SO_4) and antifoam on the growth (in dry cell weight (DCW)) of *Prototheca*.

[0026] Figure 8 shows the impact of hydrothermal treatment of various cellulosic materials (sugar cane bagasse, sorghum cane, *Miscanthus* and beet pulp) and the resulting sugar stream on the growth of *Prototheca*.

[0027] Figure 9 shows decreasing levels of hydroxymethyl furfurals (HMF) and furfurals in cellulosic biomass (sugar cane bagasse, sorghum cane, *Miscanthus* and beet pulp) after repeated cycles of hydrothermal treatment.

[0028] Figure 10 shows a schematic of a saccharification process of cellulosic materials to generate sugar streams suitable for use in heterotrophic oil production in a fermentor.

[0029] Figure 11 shows decreasing levels of HMF and furfurals in exploded sugar cane bagasse after repeated cycles of hydrothermal treatment.

[0030] Figure 12 shows a schematic of thioesterase constructs used in *Prototheca* transformations. The heterologous beta-tubulin (driving Neo^R) and glutamate dehydrogenase promoters are derived from *Chlamydomonas reinhardtii* and *Chlorella sorokiniana*, respectively. The nitrate reductase 3'UTR was derived from *Chlorella vulgaris*. The relevant restriction cloning sites are indicated and arrows indicate the direction of transcription.

[0031] Figure 13 shows a chromatogram of renewable diesel produced from *Prototheca* triglyceride oil.

DETAILED DESCRIPTION OF THE INVENTION

[0032] The present invention arises from the discovery that *Prototheca* and certain related microorganisms have unexpectedly advantageous properties for the production of oils, fuels, and other hydrocarbon or lipid compositions economically and in large quantities, as well as from the discovery of methods and reagents for genetically altering these microorganisms to improve these properties. The oils produced by these microorganisms can be used in the transportation fuel, petrochemical, and/or food and cosmetic industries, among other

applications. Transesterification of lipids yields long-chain fatty acid esters useful as biodiesel. Other enzymatic and chemical processes can be tailored to yield fatty acids, aldehydes, alcohols, alkanes, and alkenes. In some applications, renewable diesel, jet fuel, or other hydrocarbon compounds are produced. The present invention also provides methods of cultivating microalgae for increased productivity and increased lipid yield, and/or for more cost-effective production of the compositions described herein.

[0033] This detailed description of the invention is divided into sections for the convenience of the reader. Section I provides definitions of terms used herein. Section 2 provides a description of culture conditions useful in the methods of the invention. Section 3 provides a description of genetic engineering methods and materials. Section 4 provides a description of genetic engineering of *Prototheca* to enable sucrose utilization. Section 5 provides a description of genetic engineering of *Prototheca* to modify lipid biosynthesis. Section 6 describes methods for making fuels and chemicals. Section 7 discloses examples and embodiments of the invention. The detailed description of the invention is followed by examples that illustrate the various aspects and embodiments of the invention.

I. DEFINITIONS

[0034] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton *et al.*, *Dictionary of Microbiology and Molecular Biology* (2nd ed. 1994); *The Cambridge Dictionary of Science and Technology* (Walker ed., 1988); *The Glossary of Genetics*, 5th Ed., R. Rieger *et al.* (eds.), Springer Verlag (1991); and Hale & Marham, *The Harper Collins Dictionary of Biology* (1991). As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

[0035] "Active in microalgae" refers to a nucleic acid that is functional in microalgae. For example, a promoter that has been used to drive an antibiotic resistance gene to impart antibiotic resistance to a transgenic microalgae is active in microalgae.

[0036] "Acyl carrier protein" or "ACP" is a protein that binds a growing acyl chain during fatty acid synthesis as a thiol ester at the distal thiol of the 4'-phosphopantetheine moiety and comprises a component of the fatty acid synthase complex.

[0037] "Acyl-CoA molecule" or "acyl-CoA" is a molecule comprising an acyl moiety covalently attached to coenzyme A through a thiol ester linkage at the distal thiol of the 4'-phosphopantetheine moiety of coenzyme A.

[0038] “Area Percent” refers to the area of peaks observed using FAME GC/FID detection methods in which every fatty acid in the sample is converted into a fatty acid methyl ester (FAME) prior to detection. For example, a separate peak is observed for a fatty acid of 14 carbon atoms with no unsaturation (C14:0) compared to any other fatty acid such as C14:1. The peak area for each class of FAME is directly proportional to its percent composition in the mixture and is calculated based on the sum of all peaks present in the sample (i.e. [area under specific peak/ total area of all measured peaks] X 100). When referring to lipid profiles of oils and cells of the invention, “at least 4% C8-C14” means that at least 4% of the total fatty acids in the cell or in the extracted glycerolipid composition have a chain length that includes 8, 10, 12 or 14 carbon atoms.

[0039] “Axenic” is a culture of an organism free from contamination by other living organisms.

[0040] “Biodiesel” is a biologically produced fatty acid alkyl ester suitable for use as a fuel in a diesel engine.

[0041] “Biomass” is material produced by growth and/or propagation of cells. Biomass may contain cells and/or intracellular contents as well as extracellular material, includes, but is not limited to, compounds secreted by a cell.

[0042] “Bioreactor” is an enclosure or partial enclosure in which cells are cultured, optionally in suspension.

[0043] “Catalyst” is an agent, such as a molecule or macromolecular complex, capable of facilitating or promoting a chemical reaction of a reactant to a product without becoming a part of the product. A catalyst increases the rate of a reaction, after which, the catalyst may act on another reactant to form the product. A catalyst generally lowers the overall activation energy required for the reaction such that it proceeds more quickly or at a lower temperature. Thus, a reaction equilibrium may be more quickly attained. Examples of catalysts include enzymes, which are biological catalysts; heat, which is a non-biological catalyst; and metals used in fossil oil refining processes.

[0044] “Cellulosic material” is the product of digestion of cellulose, including glucose and xylose, and optionally additional compounds such as disaccharides, oligosaccharides, lignin, furfurals and other compounds. Nonlimiting examples of sources of cellulosic material include sugar cane bagasses, sugar beet pulp, corn stover, wood chips, sawdust and switchgrass.

[0045] “Co-culture”, and variants thereof such as “co-cultivate” and “co-ferment”, refer to the presence of two or more types of cells in the same bioreactor. The two or more types of

cells may both be microorganisms, such as microalgae, or may be a microalgal cell cultured with a different cell type. The culture conditions may be those that foster growth and/or propagation of the two or more cell types or those that facilitate growth and/or proliferation of one, or a subset, of the two or more cells while maintaining cellular growth for the remainder.

[0046] "Cofactor" is any molecule, other than the substrate, required for an enzyme to carry out its enzymatic activity.

[0047] "Complementary DNA" or "cDNA" is a DNA copy of mRNA, usually obtained by reverse transcription of messenger RNA (mRNA) or amplification (e.g., via polymerase chain reaction ("PCR")).

[0048] "Cultivated", and variants thereof such as "cultured" and "fermented", refer to the intentional fostering of growth (increases in cell size, cellular contents, and/or cellular activity) and/or propagation (increases in cell numbers via mitosis) of one or more cells by use of selected and/or controlled conditions. The combination of both growth and propagation may be termed proliferation. Examples of selected and/or controlled conditions include the use of a defined medium (with known characteristics such as pH, ionic strength, and carbon source), specified temperature, oxygen tension, carbon dioxide levels, and growth in a bioreactor. Cultivate does not refer to the growth or propagation of microorganisms in nature or otherwise without human intervention; for example, natural growth of an organism that ultimately becomes fossilized to produce geological crude oil is not cultivation.

[0049] "Cytolysis" is the lysis of cells in a hypotonic environment. Cytolysis is caused by excessive osmosis, or movement of water, towards the inside of a cell (hyperhydration). The cell cannot withstand the osmotic pressure of the water inside, and so it explodes.

[0050] "Delipidated meal" and "delipidated microbial biomass" is microbial biomass after oil (including lipids) has been extracted or isolated from it, either through the use of mechanical (i.e., exerted by an expeller press) or solvent extraction or both. Delipidated meal has a reduced amount of oil/lipids as compared to before the extraction or isolation of oil/lipids from the microbial biomass but does contain some residual oil/lipid.

[0051] "Expression vector" or "expression construct" or "plasmid" or "recombinant DNA construct" refer to a nucleic acid that has been generated via human intervention, including by recombinant means or direct chemical synthesis, with a series of specified nucleic acid elements that permit transcription and/or translation of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

[0052] "Exogenous gene" is a nucleic acid that codes for the expression of an RNA and/or protein that has been introduced ("transformed") into a cell. A transformed cell may be referred to as a recombinant cell, into which additional exogenous gene(s) may be introduced. The exogenous gene may be from a different species (and so heterologous), or from the same species (and so homologous), relative to the cell being transformed. Thus, an exogenous gene can include a homologous gene that occupies a different location in the genome of the cell or is under different control, relative to the endogenous copy of the gene. An exogenous gene may be present in more than one copy in the cell. An exogenous gene may be maintained in a cell as an insertion into the genome or as an episomal molecule.

[0053] "Exogenously provided" refers to a molecule provided to the culture media of a cell culture.

[0054] "Expeller pressing" is a mechanical method for extracting oil from raw materials such as soybeans and rapeseed. An expeller press is a screw type machine, which presses material through a caged barrel-like cavity. Raw materials enter one side of the press and spent cake exits the other side while oil seeps out between the bars in the cage and is collected. The machine uses friction and continuous pressure from the screw drives to move and compress the raw material. The oil seeps through small openings that do not allow solids to pass through. As the raw material is pressed, friction typically causes it to heat up.

[0055] "Fatty acyl-ACP thioesterase" is an enzyme that catalyzes the cleavage of a fatty acid from an acyl carrier protein (ACP) during lipid synthesis.

[0056] "Fatty acyl-CoA/aldehyde reductase" is an enzyme that catalyzes the reduction of an acyl-CoA molecule to a primary alcohol.

[0057] "Fatty acyl-CoA reductase" is an enzyme that catalyzes the reduction of an acyl-CoA molecule to an aldehyde.

[0058] "Fatty aldehyde decarbonylase" is an enzyme that catalyzes the conversion of a fatty aldehyde to an alkane.

[0059] "Fatty aldehyde reductase" is an enzyme that catalyzes the reduction of an aldehyde to a primary alcohol.

[0060] "Fixed carbon source" is a molecule(s) containing carbon, typically an organic molecule, that is present at ambient temperature and pressure in solid or liquid form in a culture media that can be utilized by a microorganism cultured therein.

[0061] "Homogenate" is biomass that has been physically disrupted.

[0062] "Hydrocarbon" is (a) a molecule containing only hydrogen and carbon atoms wherein the carbon atoms are covalently linked to form a linear, branched, cyclic, or partially

cyclic backbone to which the hydrogen atoms are attached. The molecular structure of hydrocarbon compounds varies from the simplest, in the form of methane (CH₄), which is a constituent of natural gas, to the very heavy and very complex, such as some molecules such as asphaltenes found in crude oil, petroleum, and bitumens. Hydrocarbons may be in gaseous, liquid, or solid form, or any combination of these forms, and may have one or more double or triple bonds between adjacent carbon atoms in the backbone. Accordingly, the term includes linear, branched, cyclic, or partially cyclic alkanes, alkenes, lipids, and paraffin. Examples include propane, butane, pentane, hexane, octane, and squalene.

[0063] “Hydrogen:carbon ratio” is the ratio of hydrogen atoms to carbon atoms in a molecule on an atom-to-atom basis. The ratio may be used to refer to the number of carbon and hydrogen atoms in a hydrocarbon molecule. For example, the hydrocarbon with the highest ratio is methane CH₄ (4:1).

[0064] “Hydrophobic fraction” is the portion, or fraction, of a material that is more soluble in a hydrophobic phase in comparison to an aqueous phase. A hydrophobic fraction is substantially insoluble in water and usually non-polar.

[0065] “Increase lipid yield” refers to an increase in the productivity of a microbial culture by, for example, increasing dry weight of cells per liter of culture, increasing the percentage of cells that constitute lipid, or increasing the overall amount of lipid per liter of culture volume per unit time.

[0066] “Inducible promoter” is a promoter that mediates transcription of an operably linked gene in response to a particular stimulus.

[0067] “In operable linkage” is a functional linkage between two nucleic acid sequences, such a control sequence (typically a promoter) and the linked sequence (typically a sequence that encodes a protein, also called a coding sequence). A promoter is in operable linkage with an exogenous gene if it can mediate transcription of the gene.

[0068] “In situ” means “in place” or “in its original position”.

[0069] “Limiting concentration of a nutrient” is a concentration of a compound in a culture that limits the propagation of a cultured organism. A “non-limiting concentration of a nutrient” is a concentration that supports maximal propagation during a given culture period. Thus, the number of cells produced during a given culture period is lower in the presence of a limiting concentration of a nutrient than when the nutrient is non-limiting. A nutrient is said to be “in excess” in a culture, when the nutrient is present at a concentration greater than that which supports maximal propagation.

[0070] “Lipase” is a water-soluble enzyme that catalyzes the hydrolysis of ester bonds in water-insoluble, lipid substrates. Lipases catalyze the hydrolysis of lipids into glycerols and fatty acids.

[0071] “Lipid modification enzyme” refers to an enzyme that alters the covalent structure of a lipid. Examples of lipid modification enzymes include a lipase, a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, and a fatty aldehyde decarboxylase.

[0072] “Lipid pathway enzyme” is any enzyme that plays a role in lipid metabolism, i.e., either lipid synthesis, modification, or degradation, and any proteins that chemically modify lipids, as well as carrier proteins.

[0073] “Lipids” are a class of molecules that are soluble in nonpolar solvents (such as ether and chloroform) and are relatively or completely insoluble in water. Lipid molecules have these properties, because they consist largely of long hydrocarbon tails which are hydrophobic in nature. Examples of lipids include fatty acids (saturated and unsaturated); glycerides or glycerolipids (such as monoglycerides, diglycerides, triglycerides or neutral fats, and phosphoglycerides or glycerophospholipids); nonglycerides (sphingolipids, sterol lipids including cholesterol and steroid hormones, prenol lipids including terpenoids, fatty alcohols, waxes, and polyketides); and complex lipid derivatives (sugar-linked lipids, or glycolipids, and protein-linked lipids). “Fats” are a subgroup of lipids called “triacylglycerides.”

[0074] “Lysate” is a solution containing the contents of lysed cells.

[0075] “Lysis” is the breakage of the plasma membrane and optionally the cell wall of a biological organism sufficient to release at least some intracellular content, often by mechanical, viral or osmotic mechanisms that compromise its integrity.

[0076] “Lysing” is disrupting the cellular membrane and optionally the cell wall of a biological organism or cell sufficient to release at least some intracellular content.

[0077] “Microalgae” is a eukaryotic microbial organism that contains a chloroplast or plastid, and optionally that is capable of performing photosynthesis, or a prokaryotic microbial organism capable of performing photosynthesis. Microalgae include obligate photoautotrophs, which cannot metabolize a fixed carbon source as energy, as well as heterotrophs, which can live solely off of a fixed carbon source. Microalgae include unicellular organisms that separate from sister cells shortly after cell division, such as *Chlamydomonas*, as well as microbes such as, for example, *Volvox*, which is a simple multicellular photosynthetic microbe of two distinct cell types. Microalgae include cells such

as *Chlorella*, *Dunaliella*, and *Prototheca*. Microalgae also include other microbial photosynthetic organisms that exhibit cell-cell adhesion, such as *Agmenellum*, *Anabaena*, and *Pyrobotrys*. Microalgae also include obligate heterotrophic microorganisms that have lost the ability to perform photosynthesis, such as certain dinoflagellate algae species and species of the genus *Prototheca*.

[0078] "Microorganism" and "microbe" are microscopic unicellular organisms.

[0079] "Naturally co-expressed" with reference to two proteins or genes means that the proteins or their genes are co-expressed naturally in a tissue or organism from which they are derived, e.g., because the genes encoding the two proteins are under the control of a common regulatory sequence or because they are expressed in response to the same stimulus.

[0080] "Osmotic shock" is the rupture of cells in a solution following a sudden reduction in osmotic pressure. Osmotic shock is sometimes induced to release cellular components of such cells into a solution.

[0081] "Polysaccharide-degrading enzyme" is any enzyme capable of catalyzing the hydrolysis, or saccharification, of any polysaccharide. For example, cellulases catalyze the hydrolysis of cellulose.

[0082] "Polysaccharides" or "glycans" are carbohydrates made up of monosaccharides joined together by glycosidic linkages. Cellulose is a polysaccharide that makes up certain plant cell walls. Cellulose can be depolymerized by enzymes to yield monosaccharides such as xylose and glucose, as well as larger disaccharides and oligosaccharides.

[0083] "Promoter" is a nucleic acid control sequence that directs transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.

[0084] "Recombinant" is a cell, nucleic acid, protein or vector, that has been modified due to the introduction of an exogenous nucleic acid or the alteration of a native nucleic acid.

Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes differently than those genes are expressed by a non-recombinant cell. A "recombinant nucleic acid" is a nucleic acid originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, or otherwise is in a form not normally found in nature. Recombinant nucleic acids may be produced, for example, to place two or more nucleic acids in operable linkage. Thus, an isolated nucleic acid or an expression vector formed in vitro by

ligating DNA molecules that are not normally joined in nature, are both considered recombinant for the purposes of this invention. Once a recombinant nucleic acid is made and introduced into a host cell or organism, it may replicate using the in vivo cellular machinery of the host cell; however, such nucleic acids, once produced recombinantly, although subsequently replicated intracellularly, are still considered recombinant for purposes of this invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid.

[0085] "Renewable diesel" is a mixture of alkanes (such as C10:0, C12:0, C14:0, C16:0 and C18:0) produced through hydrogenation and deoxygenation of lipids.

[0086] "Saccharification" is a process of converting biomass, usually cellulosic or lignocellulosic biomass, into monomeric sugars, such as glucose and xylose. "Saccharified" or "depolymerized" cellulosic material or biomass refers to cellulosic material or biomass that has been converted into monomeric sugars through saccharification.

[0087] "Sonication" is a process of disrupting biological materials, such as a cell, by use of sound wave energy.

[0088] "Species of furfural" is 2-furancarboxaldehyde or a derivative that retains the same basic structural characteristics.

[0089] "Stover" is the dried stalks and leaves of a crop remaining after a grain has been harvested.

[0090] "Sucrose utilization gene" is a gene that, when expressed, aids the ability of a cell to utilize sucrose as an energy source. Proteins encoded by a sucrose utilization gene are referred to herein as "sucrose utilization enzymes" and include sucrose transporters, sucrose invertases, and hexokinases such as glucokinases and fructokinases.

II. CULTIVATION

[0091] The present invention generally relates to cultivation of *Prototheca* strains, particularly recombinant *Prototheca* strains, for the production of lipid. For the convenience of the reader, this section is subdivided into subsections. Subsection 1 describes *Prototheca* species and strains and how to identify new *Prototheca* species and strains and related microalgae by genomic DNA comparison. Subsection 2 describes bioreactors useful for cultivation. Subsection 3 describes media for cultivation. Subsection 4 describes oil production in accordance with illustrative cultivation methods of the invention.

1. Prototheca species and strains

[0092] *Prototheca* is a remarkable microorganism for use in the production of lipid, because it can produce high levels of lipid, particularly lipid suitable for fuel production. The

lipid produced by *Prototheca* has hydrocarbon chains of shorter chain length and a higher degree of saturation than that produced by other microalgae. Moreover, *Prototheca* lipid is generally free of pigment (low to undetectable levels of chlorophyll and certain carotenoids) and in any event contains much less pigment than lipid from other microalgae. Moreover, recombinant *Prototheca* cells provided by the invention can be used to produce lipid in greater yield and efficiency, and with reduced cost, relative to the production of lipid from other microorganisms. Illustrative *Prototheca* strains for use in the methods of the invention include In addition, this microalgae grows heterotrophically and can be genetically engineered as *Prototheca wickerhamii*, *Prototheca stagnora* (including UTEX 327), *Prototheca portoricensis*, *Prototheca moriformis* (including UTEX strains 1441, 1435), and *Prototheca zopfii*. Species of the genus *Prototheca* are obligate heterotrophs.

[0093] Species of *Prototheca* for use in the invention can be identified by amplification of certain target regions of the genome. For example, identification of a specific *Prototheca* species or strain can be achieved through amplification and sequencing of nuclear and/or chloroplast DNA using primers and methodology using any region of the genome, for example using the methods described in Wu *et al.*, *Bot. Bull. Acad. Sin.* (2001) 42:115-121 Identification of *Chlorella spp.* isolates using ribosomal DNA sequences. Well established methods of phylogenetic analysis, such as amplification and sequencing of ribosomal internal transcribed spacer (ITS1 and ITS2 rDNA), 23S rRNA, 18S rRNA, and other conserved genomic regions can be used by those skilled in the art to identify species of not only *Prototheca*, but other hydrocarbon and lipid producing organisms with similar lipid profiles and production capability. For examples of methods of identification and classification of algae also see for example *Genetics*, 2005 Aug;170(4):1601-10 and *RNA*, 2005 Apr;11(4):361-4.

[0094] Thus, genomic DNA comparison can be used to identify suitable species of microalgae to be used in the present invention. Regions of conserved genomic DNA, such as but not limited to DNA encoding for 23S rRNA, can be amplified from microalgal species and compared to consensus sequences in order to screen for microalgal species that are taxonomically related to the preferred microalgae used in the present invention. Examples of such DNA sequence comparison for species within the *Prototheca* genus are shown below. Genomic DNA comparison can also be useful to identify microalgal species that have been misidentified in a strain collection. Often a strain collection will identify species of microalgae based on phenotypic and morphological characteristics. The use of these characteristics may lead to miscategorization of the species or the genus of a microalgae. The

use of genomic DNA comparison can be a better method of categorizing microalgae species based on their phylogenetic relationship.

[0095] Microalgae for use in the present invention typically have genomic DNA sequences encoding for 23S rRNA that have at least 99%, least 95%, at least 90%, or at least 85% nucleotide identity to at least one of the sequences listed in SEQ ID NOs: 11-19.

[0096] For sequence comparison to determine percent nucleotide or amino acid identity, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0097] Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally Ausubel *et al.*, *supra*).

[0098] Another example algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (at the web address www.ncbi.nlm.nih.gov). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score

falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. For identifying whether a nucleic acid or polypeptide is within the scope of the invention, the default parameters of the BLAST programs are suitable. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, $M=5$, $N=-4$, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix. The TBLASTN program (using protein sequence for nucleotide sequence) uses as defaults a word length (W) of 3, an expectation (E) of 10, and a BLOSUM 62 scoring matrix. (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)).

[0099] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability ($P(N)$), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0100] Other considerations affecting the selection of microorganisms for use in the invention include, in addition to production of suitable lipids or hydrocarbons for production of oils, fuels, and oleochemicals: (1) high lipid content as a percentage of cell weight; (2) ease of growth; (3) ease of genetic engineering; and (4) ease of biomass processing. In particular embodiments, the wild-type or genetically engineered microorganism yields cells that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70% or more lipid. Preferred organisms grow heterotrophically (on sugars in the absence of light).

2. Bioreactor

[0101] Microorganisms are cultured both for purposes of conducting genetic manipulations and for production of hydrocarbons (e.g., lipids, fatty acids, aldehydes, alcohols, and alkanes). The former type of culture is conducted on a small scale and initially, at least, under conditions in which the starting microorganism can grow. Culture for purposes of hydrocarbon production is usually conducted on a large scale (e.g., 10,000 L, 40,000 L,

100,000 L or larger bioreactors) in a bioreactor. *Prototheca* are typically cultured in the methods of the invention in liquid media within a bioreactor. Typically, the bioreactor does not allow light to enter.

[0102] The bioreactor or fermentor is used to culture microalgal cells through the various phases of their physiological cycle. Bioreactors offer many advantages for use in heterotrophic growth and propagation methods. To produce biomass for use in food, microalgae are preferably fermented in large quantities in liquid, such as in suspension cultures as an example. Bioreactors such as steel fermentors can accommodate very large culture volumes (40,000 liter and greater capacity bioreactors are used in various embodiments of the invention). Bioreactors also typically allow for the control of culture conditions such as temperature, pH, oxygen tension, and carbon dioxide levels. For example, bioreactors are typically configurable, for example, using ports attached to tubing, to allow gaseous components, like oxygen or nitrogen, to be bubbled through a liquid culture. Other culture parameters, such as the pH of the culture media, the identity and concentration of trace elements, and other media constituents can also be more readily manipulated using a bioreactor.

[0103] Bioreactors can be configured to flow culture media through the bioreactor throughout the time period during which the microalgae reproduce and increase in number. In some embodiments, for example, media can be infused into the bioreactor after inoculation but before the cells reach a desired density. In other instances, a bioreactor is filled with culture media at the beginning of a culture, and no more culture media is infused after the culture is inoculated. In other words, the microalgal biomass is cultured in an aqueous medium for a period of time during which the microalgae reproduce and increase in number; however, quantities of aqueous culture medium are not flowed through the bioreactor throughout the time period. Thus in some embodiments, aqueous culture medium is not flowed through the bioreactor after inoculation.

[0104] Bioreactors equipped with devices such as spinning blades and impellers, rocking mechanisms, stir bars, means for pressurized gas infusion can be used to subject microalgal cultures to mixing. Mixing may be continuous or intermittent. For example, in some embodiments, a turbulent flow regime of gas entry and media entry is not maintained for reproduction of microalgae until a desired increase in number of said microalgae has been achieved.

[0105] Bioreactor ports can be used to introduce, or extract, gases, solids, semisolids, and liquids, into the bioreactor chamber containing the microalgae. While many bioreactors have

more than one port (for example, one for media entry, and another for sampling), it is not necessary that only one substance enter or leave a port. For example, a port can be used to flow culture media into the bioreactor and later used for sampling, gas entry, gas exit, or other purposes. Preferably, a sampling port can be used repeatedly without altering compromising the axenic nature of the culture. A sampling port can be configured with a valve or other device that allows the flow of sample to be stopped and started or to provide a means of continuous sampling. Bioreactors typically have at least one port that allows inoculation of a culture, and such a port can also be used for other purposes such as media or gas entry.

[0106] Bioreactors ports allow the gas content of the culture of microalgae to be manipulated. To illustrate, part of the volume of a bioreactor can be gas rather than liquid, and the gas inlets of the bioreactor to allow pumping of gases into the bioreactor. Gases that can be beneficially pumped into a bioreactor include air, air/CO₂ mixtures, noble gases, such as argon, and other gases. Bioreactors are typically equipped to enable the user to control the rate of entry of a gas into the bioreactor. As noted above, increasing gas flow into a bioreactor can be used to increase mixing of the culture.

[0107] Increased gas flow affects the turbidity of the culture as well. Turbulence can be achieved by placing a gas entry port below the level of the aqueous culture media so that gas entering the bioreactor bubbles to the surface of the culture. One or more gas exit ports allow gas to escape, thereby preventing pressure buildup in the bioreactor. Preferably a gas exit port leads to a "one-way" valve that prevents contaminating microorganisms from entering the bioreactor.

3. Media

[0108] Microalgal culture media typically contains components such as a fixed nitrogen source, a fixed carbon source, trace elements, optionally a buffer for pH maintenance, and phosphate (typically provided as a phosphate salt). Other components can include salts such as sodium chloride, particularly for seawater microalgae. Nitrogen sources include organic and inorganic nitrogen sources, including, for example, without limitation, molecular nitrogen, nitrate, nitrate salts, ammonia (pure or in salt form, such as, (NH₄)₂SO₄ and NH₄OH), protein, soybean meal, cornsteep liquor, and yeast extract. Examples of trace elements include zinc, boron, cobalt, copper, manganese, and molybdenum in, for example, the respective forms of ZnCl₂, H₃BO₃, CoCl₂·6H₂O, CuCl₂·2H₂O, MnCl₂·4H₂O and (NH₄)₆Mo₇O₂₄·4H₂O.

[0109] Microorganisms useful in accordance with the methods of the present invention are found in various locations and environments throughout the world. As a consequence of their isolation from other species and their resulting evolutionary divergence, the particular growth medium for optimal growth and generation of lipid and/or hydrocarbon constituents can be difficult to predict. In some cases, certain strains of microorganisms may be unable to grow on a particular growth medium because of the presence of some inhibitory component or the absence of some essential nutritional requirement required by the particular strain of microorganism.

[0110] Solid and liquid growth media are generally available from a wide variety of sources, and instructions for the preparation of particular media that is suitable for a wide variety of strains of microorganisms can be found, for example, online at <http://www.utex.org/>, a site maintained by the University of Texas at Austin, 1 University Station A6700, Austin, Texas, 78712-0183, for its culture collection of algae (UTEX). For example, various fresh water and salt water media include those described in PCT Pub. No. 2008/151149, incorporated herein by reference.

[0111] In a particular example, Proteose Medium is suitable for axenic cultures, and a 1L volume of the medium (pH ~6.8) can be prepared by addition of 1g of proteose peptone to 1 liter of Bristol Medium. Bristol medium comprises 2.94 mM NaNO₃, 0.17 mM CaCl₂·2H₂O, 0.3 mM MgSO₄·7H₂O, 0.43 mM, 1.29 mM KH₂PO₄, and 1.43 mM NaCl in an aqueous solution. For 1.5% agar medium, 15 g of agar can be added to 1 L of the solution. The solution is covered and autoclaved, and then stored at a refrigerated temperature prior to use. Another example is the *Prototheca* isolation medium (PIM), which comprises 10g/L postassium hydrogen phthalate (KHP), 0.9g/L sodium hydroxide, 0.1g/L magnesium sulfate, 0.2g/L potassium hydrogen phosphate, 0.3g/L ammonium chloride, 10g/L glucose 0.001g/L thiamine hydrochloride, 20g/L agar, 0.25g/L 5-fluorocytosine, at a pH in the range of 5.0 to 5.2 (see Pore, 1973, App. Microbiology, 26: 648-649). Other suitable media for use with the methods of the invention can be readily identified by consulting the URL identified above, or by consulting other organizations that maintain cultures of microorganisms, such as SAG, CCAP, or CCALA. SAG refers to the Culture Collection of Algae at the University of Göttingen (Göttingen, Germany), CCAP refers to the culture collection of algae and protozoa managed by the Scottish Association for Marine Science (Scotland, United Kingdom), and CCALA refers to the culture collection of algal laboratory at the Institute of Botany (Třeboň, Czech Republic). Additionally, US Patent No. 5,900,370 describes media formulations and conditions suitable for heterotrophic fermentation of *Prototheca* species.

[0112] For oil production, selection of a fixed carbon source is important, as the cost of the fixed carbon source must be sufficiently low to make oil production economical. Thus, while suitable carbon sources include, for example, acetate, floridoside, fructose, galactose, glucuronic acid, glucose, glycerol, lactose, mannose, N-acetylglucosamine, rhamnose, sucrose, and/or xylose, selection of feedstocks containing those compounds is an important aspect of the methods of the invention. Suitable feedstocks useful in accordance with the methods of the invention include, for example, black liquor, corn starch, depolymerized cellulosic material, milk whey, molasses, potato, sorghum, sucrose, sugar beet, sugar cane, rice, and wheat. Carbon sources can also be provided as a mixture, such as a mixture of sucrose and depolymerized sugar beet pulp. The one or more carbon source(s) can be supplied at a concentration of at least about 50 μM , at least about 100 μM , at least about 500 μM , at least about 5 mM, at least about 50 mM, and at least about 500 mM, of one or more exogenously provided fixed carbon source(s). Carbon sources of particular interest for purposes of the present invention include cellulose (in a depolymerized form), glycerol, sucrose, and sorghum, each of which is discussed in more detail below.

[0113] In accordance with the present invention, microorganisms can be cultured using depolymerized cellulosic biomass as a feedstock. Cellulosic biomass (e.g., stover, such as corn stover) is inexpensive and readily available; however, attempts to use this material as a feedstock for yeast have failed. In particular, such feedstocks have been found to be inhibitory to yeast growth, and yeast cannot use the 5-carbon sugars produced from cellulosic materials (e.g., xylose from hemi-cellulose). By contrast, microalgae can grow on processed cellulosic material. Cellulosic materials generally include about 40-60% cellulose; about 20-40% hemicellulose; and 10-30% lignin.

[0114] Suitable cellulosic materials include residues from herbaceous and woody energy crops, as well as agricultural crops, i.e., the plant parts, primarily stalks and leaves, not removed from the fields with the primary food or fiber product. Examples include agricultural wastes such as sugarcane bagasse, rice hulls, corn fiber (including stalks, leaves, husks, and cobs), wheat straw, rice straw, sugar beet pulp, citrus pulp, citrus peels; forestry wastes such as hardwood and softwood thinnings, and hardwood and softwood residues from timber operations; wood wastes such as saw mill wastes (wood chips, sawdust) and pulp mill waste; urban wastes such as paper fractions of municipal solid waste, urban wood waste and urban green waste such as municipal grass clippings; and wood construction waste. Additional cellulose include dedicated cellulosic crops such as switchgrass, hybrid poplar

wood, and miscanthus, fiber cane, and fiber sorghum. Five-carbon sugars that are produced from such materials include xylose.

[0115] Cellulosic materials are treated to increase the efficiency with which the microbe can utilize the sugar(s) contained within the materials. The invention provides novel methods for the treatment of cellulosic materials after acid explosion so that the materials are suitable for use in a heterotrophic culture of microbes (e.g., microalgae and oleaginous yeast). As discussed above, lignocellulosic biomass is comprised of various fractions, including cellulose, a crystalline polymer of beta 1,4 linked glucose (a six-carbon sugar), hemicellulose, a more loosely associated polymer predominantly comprised of xylose (a five-carbon sugar) and to a lesser extent mannose, galactose, arabinose, lignin, a complex aromatic polymer comprised of sinapyl alcohol and its derivatives, and pectins, which are linear chains of an alpha 1,4 linked polygalacturonic acid. Because of the polymeric structure of cellulose and hemicellulose, the sugars (e.g., monomeric glucose and xylose) in them are not in a form that can be efficiently used (metabolized) by many microbes. For such microbes, further processing of the cellulosic biomass to generate the monomeric sugars that make up the polymers can be very helpful to ensuring that the cellulosic materials are efficiently utilized as a feedstock (carbon source).

[0116] Cellulose or cellulosic biomass is subjected to a process, termed "explosion", in which the biomass is treated with dilute sulfuric (or other) acid at elevated temperature and pressure. This process conditions the biomass such that it can be efficiently subjected to enzymatic hydrolysis of the cellulosic and hemicellulosic fractions into glucose and xylose monomers. The resulting monomeric sugars are termed cellulosic sugars. Cellulosic sugars can subsequently be utilized by microorganisms to produce a variety of metabolites (e.g., lipid). The acid explosion step results in a partial hydrolysis of the hemicellulose fraction to constituent monosaccharides. These sugars can be completely liberated from the biomass with further treatment. In some embodiments, the further treatment is a hydrothermal treatment that includes washing the exploded material with hot water, which removes contaminants such as salts. This step is not necessary for cellulosic ethanol fermentations due to the more dilute sugar concentrations used in such processes. In other embodiments, the further treatment is additional acid treatment. In still other embodiments, the further treatment is enzymatic hydrolysis of the exploded material. These treatments can also be used in any combination. The type of treatment can affect the type of sugars liberated (e.g., five carbon sugars versus six carbon sugars) and the stage at which they are liberated in the process. As a consequence, different streams of sugars, whether they are predominantly five-carbon or six-

carbon, can be created. These enriched five-carbon or six-carbon streams can thus be directed to specific microorganisms with different carbon utilization capabilities.

[0117] The methods of the present invention typically involve fermentation to higher cell densities than what is achieved in ethanol fermentation. , Because of the higher densities of the cultures for heterotrophic cellulosic oil production, the fixed carbon source (e.g., the cellulosic derived sugar stream(s)) is preferably in a concentrated form. The glucose level of the depolymerized cellulosic material is preferably at least 300 g/liter, at least 400 g/liter, at least 500 g/liter or at least 600 g/liter prior to the cultivation step, which is optionally a fed batch cultivation in which the material is fed to the cells over time as the cells grow and accumulate lipid. Cellulosic sugar streams are not used at or near this concentration range in the production of cellulosic ethanol. Thus, in order to generate and sustain the very high cell densities during the production of lignocellulosic oil, the carbon feedstock(s) must be delivered into the heterotrophic cultures in a highly concentrated form. However, any component in the feedstream that is not a substrate for, and is not metabolized by, the oleaginous microorganism will accumulate in the bioreactor, which can lead to problems if the component is toxic or inhibitory to production of the desired end product. While lignin and lignin-derived by-products, carbohydrate-derived byproducts such as furfurals and hydroxymethyl furfurals and salts derived from the generation of the cellulosic materials (both in the explosion process and the subsequent neutralization process), and even non-metabolized pentose/hexose sugars can present problems in ethanolic fermentations, these effects are amplified significantly in a process in which their concentration in the initial feedstock is high. To achieve sugar concentrations in the 300g/L range (or higher) for six-carbon sugars that may be used in large scale production of lignocellulosic oil described in the present invention, the concentration of these toxic materials can be 20 times higher than the concentrations typically present in ethanolic fermentations of cellulosic biomass.

[0118] The explosion process treatment of the cellulosic material utilizes significant amounts of sulfuric acid, heat and pressure, thereby liberating by-products of carbohydrates, namely furfurals and hydroxymethyl furfurals. Furfurals and hydroxymethyl furfurals are produced during hydrolysis of hemicellulose through dehydration of xylose into furfural and water. In some embodiments of the present invention, these by-products (e.g., furfurals and hydroxymethyl furfurals) are removed from the saccharified lignocellulosic material prior to introduction into the bioreactor. In certain embodiments of the present invention, the process for removal of the by-products of carbohydrates is hydrothermal treatment of the exploded cellulosic materials. In addition, the present invention provides methods in which strains

capable of tolerating compounds such as furfurals or hydroxymethyl furfurals are used for lignocellulosic oil production. In another embodiment, the present invention also provides methods and microorganisms that are not only capable of tolerating furfurals in the fermentation media, but are actually able to metabolize these by-products during the production of lignocellulosic oil.

[0119] The explosion process also generates significant levels of salts. For example, typical conditions for explosion can result in conductivities in excess of 5 mS/cm when the exploded cellulosic biomass is resuspended at a ratio of 10:1 water:solids (dry weight). In certain embodiments of the present invention, the diluted exploded biomass is subjected to enzymatic saccharification, and the resulting supernatant is concentrated up to 25 fold for use in the bioreactor. The salt level (as measured by conductivity) in the concentrated sugar stream(s) can be unacceptably high (up to 1.5 M Na⁺ equivalents). Additional salts are generated upon neutralization of the exploded materials for the subsequent enzymatic saccharification process as well. The present invention provides methods for removing these salts so that the resulting concentrated cellulosic sugar stream(s) can be used in heterotrophic processes for producing lignocellulosic oil. In some embodiments, the method of removing these salts is deionization with resins, such as, but not limited to, DOWEX Marathon MR3. In certain embodiments, the deionization with resin step occurs before sugar concentration or pH adjustment and hydrothermal treatment of biomass prior to saccharification, or any combination of the preceding; in other embodiments, the step is conducted after one or more of these processes. In other embodiments, the explosion process itself is changed so as to avoid the generation of salts at unacceptably high levels. For example, a suitable alternative to sulfuric acid (or other acid) explosion of the cellulosic biomass is mechanical pulping to render the cellulosic biomass receptive to enzymatic hydrolysis (saccharification). In still other embodiments, native strains of microorganisms resistant to high levels of salts or genetically engineered strains with resistance to high levels of salts are used.

[0120] A preferred embodiment for the process of preparing of exploded cellulosic biomass for use in heterotrophic lignocellulosic oil production using oleaginous microbes is diagrammed in Figure 10. Step I. comprises adjusting the pH of the resuspended exploded cellulosic biomass to the range of 5.0-5.3 followed by washing the cellulosic biomass three times. This washing step can be accomplished by a variety of means including the use of desalting and ion exchange resins, reverse osmosis, hydrothermal treatment (as described above), or just repeated re-suspension and centrifugation in deionized water. This wash step results in a cellulosic stream whose conductivity is between 100-300 μ S/cm and the removal

of significant amounts of furfurals and hydroxymethyl furfurals. Decants from this wash step can be saved to concentrate five-carbon sugars liberated from the hemicellulose fraction. Step II comprises enzymatic saccharification of the washed cellulosic biomass. In a preferred embodiment, Accellerase (Genencor) is used. Step III comprises the recovery of sugars via centrifugation or decanting and rinsing of the saccharified biomass. The resulting biomass (solids) is an energy dense, lignin rich component that can be used as fuel or sent to waste. The recovered sugar stream in the centrifugation/decanting and rinse process is collected. Step IV comprises microfiltration to remove contaminating solids with recovery of the permeate. Step V comprises a concentration step which can be accomplished using a vacuum evaporator. This step can optionally include the addition of antifoam agents such as P'2000 (Sigma/Fluka), which is sometimes necessary due to the protein content of the resulting sugar feedstock.

[0121] In another embodiment of the methods of the invention, the carbon source is glycerol, including acidulated and non-acidulated glycerol byproduct from biodiesel transesterification. In one embodiment, the carbon source includes glycerol and at least one other carbon source. In some cases, all of the glycerol and the at least one other fixed carbon source are provided to the microorganism at the beginning of the fermentation. In some cases, the glycerol and the at least one other fixed carbon source are provided to the microorganism simultaneously at a predetermined ratio. In some cases, the glycerol and the at least one other fixed carbon source are fed to the microbes at a predetermined rate over the course of fermentation.

[0122] Some microalgae undergo cell division faster in the presence of glycerol than in the presence of glucose (see PCT Pub. No. 2008/151149). In these instances, two-stage growth processes in which cells are first fed glycerol to rapidly increase cell density, and are then fed glucose to accumulate lipids can improve the efficiency with which lipids are produced. The use of the glycerol byproduct of the transesterification process provides significant economic advantages when put back into the production process. Other feeding methods are provided as well, such as mixtures of glycerol and glucose. Feeding such mixtures also captures the same economic benefits. In addition, the invention provides methods of feeding alternative sugars to microalgae such as sucrose in various combinations with glycerol.

[0123] In another embodiment of the methods of the invention, the carbon source is sucrose, including a complex feedstock containing sucrose, such as thick cane juice from sugar cane processing. In one embodiment, the culture medium further includes at least one sucrose utilization enzyme. In some cases, the culture medium includes a sucrose invertase.

In one embodiment, the sucrose invertase enzyme is a secretable sucrose invertase enzyme encoded by an exogenous sucrose invertase gene expressed by the population of microorganisms. Thus, in some cases, as described in more detail in Section IV, below, the microalgae has been genetically engineered to express a sucrose utilization enzyme, such as a sucrose transporter, a sucrose invertase, a hexokinase, a glucokinase, or a fructokinase.

[0124] Complex feedstocks containing sucrose include waste molasses from sugar cane processing; the use of this low-value waste product of sugar cane processing can provide significant cost savings in the production of hydrocarbons and other oils. Another complex feedstock containing sucrose that is useful in the methods of the invention is sorghum, including sorghum syrup and pure sorghum. Sorghum syrup is produced from the juice of sweet sorghum cane. Its sugar profile consists of mainly glucose (dextrose), fructose and sucrose.

4. Oil production

[0125] For the production of oil in accordance with the methods of the invention, it is preferable to culture cells in the dark, as is the case, for example, when using extremely large (40,000 liter and higher) fermentors that do not allow light to strike the culture. *Prototheca* species are grown and propagated for the production of oil in a medium containing a fixed carbon source and in the absence of light; such growth is known as heterotrophic growth.

[0126] As an example, an inoculum of lipid-producing microalgal cells are introduced into the medium; there is a lag period (lag phase) before the cells begin to propagate. Following the lag period, the propagation rate increases steadily and enters the log, or exponential, phase. The exponential phase is in turn followed by a slowing of propagation due to decreases in nutrients such as nitrogen, increases in toxic substances, and quorum sensing mechanisms. After this slowing, propagation stops, and the cells enter a stationary phase or steady growth state, depending on the particular environment provided to the cells. For obtaining lipid rich biomass, the culture is typically harvested well after the end of the exponential phase, which may be terminated early by allowing nitrogen or another key nutrient (other than carbon) to become depleted, forcing the cells to convert the carbon sources, present in excess, to lipid. Culture condition parameters can be manipulated to optimize total oil production, the combination of lipid species produced, and/or production of a specific oil.

[0127] As discussed above, a bioreactor or fermentor is used to allow cells to undergo the various phases of their growth cycle. As an example, an inoculum of lipid-producing cells can be introduced into a medium followed by a lag period (lag phase) before the cells begin

growth. Following the lag period, the growth rate increases steadily and enters the log, or exponential, phase. The exponential phase is in turn followed by a slowing of growth due to decreases in nutrients and/or increases in toxic substances. After this slowing, growth stops, and the cells enter a stationary phase or steady state, depending on the particular environment provided to the cells. Lipid production by cells disclosed herein can occur during the log phase or thereafter, including the stationary phase wherein nutrients are supplied, or still available, to allow the continuation of lipid production in the absence of cell division.

[0128] Preferably, microorganisms grown using conditions described herein and known in the art comprise at least about 20% by weight of lipid, preferably at least about 40% by weight, more preferably at least about 50% by weight, and most preferably at least about 60% by weight. Process conditions can be adjusted to increase the yield of lipids suitable for a particular use and/or to reduce production cost. For example, in certain embodiments, a microalgae is cultured in the presence of a limiting concentration of one or more nutrients, such as, for example, nitrogen, phosphorous, or sulfur, while providing an excess of fixed carbon energy such as glucose. Nitrogen limitation tends to increase microbial lipid yield over microbial lipid yield in a culture in which nitrogen is provided in excess. In particular embodiments, the increase in lipid yield is at least about: 10%, 50%, 100%, 200%, or 500%. The microbe can be cultured in the presence of a limiting amount of a nutrient for a portion of the total culture period or for the entire period. In particular embodiments, the nutrient concentration is cycled between a limiting concentration and a non-limiting concentration at least twice during the total culture period. Lipid content of cells can be increased by continuing the culture for increased periods of time while providing an excess of carbon, but limiting or no nitrogen.

[0129] In another embodiment, lipid yield is increased by culturing a lipid-producing microbe (e.g., microalgae) in the presence of one or more cofactor(s) for a lipid pathway enzyme (e.g., a fatty acid synthetic enzyme). Generally, the concentration of the cofactor(s) is sufficient to increase microbial lipid (e.g., fatty acid) yield over microbial lipid yield in the absence of the cofactor(s). In a particular embodiment, the cofactor(s) are provided to the culture by including in the culture a microbe (e.g., microalgae) containing an exogenous gene encoding the cofactor(s). Alternatively, cofactor(s) may be provided to a culture by including a microbe (e.g., microalgae) containing an exogenous gene that encodes a protein that participates in the synthesis of the cofactor. In certain embodiments, suitable cofactors include any vitamin required by a lipid pathway enzyme, such as, for example: biotin, pantothenate. Genes encoding cofactors suitable for use in the invention or that participate in

the synthesis of such cofactors are well known and can be introduced into microbes (e.g., microalgae), using constructs and techniques such as those described above.

[0130] The specific examples of bioreactors, culture conditions, and heterotrophic growth and propagation methods described herein can be combined in any suitable manner to improve efficiencies of microbial growth and lipid and/or protein production.

[0131] Microalgal biomass with a high percentage of oil/lipid accumulation by dry weight has been generated using different methods of culture, which are known in the art (see PCT Pub. No. 2008/151149). Microalgal biomass generated by the culture methods described herein and useful in accordance with the present invention comprises at least 10% microalgal oil by dry weight. In some embodiments, the microalgal biomass comprises at least 25%, at least 50%, at least 55%, or at least 60% microalgal oil by dry weight. In some embodiments, the microalgal biomass contains from 10-90% microalgal oil, from 25-75% microalgal oil, from 40-75% microalgal oil, or from 50-70% microalgal oil by dry weight.

[0132] The microalgal oil of the biomass described herein, or extracted from the biomass for use in the methods and compositions of the present invention can comprise glycerolipids with one or more distinct fatty acid ester side chains. Glycerolipids are comprised of a glycerol molecule esterified to one, two or three fatty acid molecules, which can be of varying lengths and have varying degrees of saturation. The length and saturation characteristics of the fatty acid molecules (and the microalgal oils) can be manipulated to modify the properties or proportions of the fatty acid molecules in the microalgal oils of the present invention via culture conditions or via lipid pathway engineering, as described in more detail in Section IV, below. Thus, specific blends of algal oil can be prepared either within a single species of algae by mixing together the biomass or algal oil from two or more species of microalgae, or by blending algal oil of the invention with oils from other sources such as soy, rapeseed, canola, palm, palm kernel, coconut, corn, waste vegetable, Chinese tallow, olive, sunflower, cottonseed, chicken fat, beef tallow, porcine tallow, microalgae, macroalgae, microbes, Cuphea, flax, peanut, choice white grease, lard, Camelina sativa, mustard seed, cashew nut, oats, lupine, kenaf, calendula, hemp, coffee, linseed (flax), hazelnut, euphorbia, pumpkin seed, coriander, camellia, sesame, safflower, rice, tung tree, cocoa, copra, pium poppy, castor beans, pecan, jojoba, macadamia, Brazil nuts, avocado, petroleum, or a distillate fraction of any of the preceding oils.

[0133] The oil composition, *i.e.*, the properties and proportions of the fatty acid constituents of the glycerolipids, can also be manipulated by combining biomass or oil from at least two distinct species of microalgae. In some embodiments, at least two of the distinct

species of microalgae have different glycerolipid profiles. The distinct species of microalgae can be cultured together or separately as described herein, preferably under heterotrophic conditions, to generate the respective oils. Different species of microalgae can contain different percentages of distinct fatty acid constituents in the cell's glycerolipids.

[0134] Generally, *Prototheca* strains have very little or no fatty acids with the chain length C8-C14. For example, *Prototheca moriformis* (UTEX 1435), *Prototheca krugani* (UTEX 329), *Prototheca stagnora* (UTEX 1442) and *Prototheca zopfii* (UTEX 1438) contains no (or undetectable amounts) C8 fatty acids, between 0-0.01% C10 fatty acids, between 0.03-2.1% C12 fatty acids and between 1.0-1.7% C14 fatty acids.

[0135] In some cases, the *Prototheca* strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain lengths C8-10 has at least 0.3%, at least 0.8%, at least 1.5% or more fatty acids of chain length C8 and at least 0.3%, at least 1.0%, at least 3.0%, at least 5% or more fatty acids of chain length C10. In other instances, the *Prototheca* strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C12 has at least 3.0%, at least 5%, at least 7%, at least 10%, at least 13% or more fatty acids of the chain length C12 and at least 1.5%, at least 2%, or at least 3% or more fatty acids of the chain length C14. In other cases, the *Prototheca* strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C14 has at least 4.0%, at least 7%, at least 10%, at least 15%, at least 20%, at least 25% or more fatty acids of the chain length C14, and at least 0.4%, at least 1%, at least 1.5%, or more fatty acids of the chain length C12.

[0136] In non-limiting examples, the *Prototheca* strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C8 and C10 has between 0.3-1.58 % fatty acids of chain length C8 and between 0.35-6.76 % fatty acids of the chain length C10. In other non-limiting examples, *Prototheca* strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C12 has between 3.9-14.11% fatty acids of the chain length C12 and between 1.95-3.05% fatty acids of the chain length C14. In other non-limiting examples, *Prototheca* strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C14 has between 4.40-17.35 % fatty acids of the chain length C14 and between 0.4-1.83 Area % fatty acids of the chain length C12. In some cases, the *Prototheca* strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain

lengths between C8 and C14 have between 3.5- 20% medium chain (C8-C14) fatty acids. In some instances, keeping the transgenic *Prototheca* strains under constant and high selective pressure to retain exogenous genes is advantageous due to the increase in the desired fatty acid of a specific chain length. In a non-limiting example, Example 5 demonstrates a two fold increase in C14 chain length fatty acids (more than 30% C8-C14 chain length fatty acids) when the culture of *Prototheca moriformis* containing a C14 preferring thioesterase exogenous gene is retained. High levels of exogenous gene retention can also be achieved by inserting exogenous genes into the nuclear chromosomes of the cells using homologous recombination vectors and methods disclosed herein. Recombinant cells containing exogenous genes integrated into nuclear chromosomes are an object of the invention.

[0137] Microalgal oil can also include other constituents produced by the microalgae, or incorporated into the microalgal oil from the culture medium. These other constituents can be present in varying amount depending on the culture conditions used to culture the microalgae, the species of microalgae, the extraction method used to recover microalgal oil from the biomass and other factors that may affect microalgal oil composition. Non-limiting examples of such constituents include carotenoids, present from 0.1-0.4 micrograms/ml, chlorophyll present from 0-0.02 milligrams/kilogram of oil, gamma tocopherol present from 0.4-0.6 milligrams/100 grams of oil, and total tocotrienols present from 0.2-0.5 milligrams/gram of oil.

[0138] The other constituents can include, without limitation, phospholipids, tocopherols, tocotrienols, carotenoids (e.g., alpha-carotene, beta-carotene, lycopene, etc.), xanthophylls (e.g., lutein, zeaxanthin, alpha-cryptoxanthin and beta-cryptoxanthin), and various organic or inorganic compounds.

[0139] In some cases, the oil extracted from *Prototheca* species comprises no more than 0.02mg/kg chlorophyll. In some cases, the oil extracted from *Prototheca* species comprises no more than 0.4 mcg/ml total carotenoids. In some cases the *Prototheca* oil comprises between 0.40-0.60 milligrams of gamma tocopherol per 100 grams of oil. In other cases, the *Prototheca* oil comprises between 0.2-0.5 milligrams of total tocotrienols per gram of oil.

III. GENETIC ENGINEERING METHODS AND MATERIALS

[0140] The present invention provides methods and materials for genetically modifying *Prototheca* cells and recombinant host cells useful in the methods of the present invention, including but not limited to recombinant *Prototheca moriformis*, *Prototheca zopfii*, *Prototheca krugani*, and *Prototheca stagnora* host cells. The description of these methods and materials is divided into subsections for the convenience of the reader. In subsection 1,

transformation methods are described. In subsection 2, genetic engineering methods using homologous recombination are described. In subsection 3, expression vectors and components are described.

1. Engineering Methods - Transformation

[0141] Cells can be transformed by any suitable technique including, e.g., biolistics, electroporation (see Maruyama et al. (2004), *Biotechnology Techniques* 8:821-826), glass bead transformation and silicon carbide whisker transformation. Another method that can be used involves forming protoplasts and using CaCl_2 and polyethylene glycol (PEG) to introduce recombinant DNA into microalgal cells (see Kim et al. (2002), *Mar. Biotechnol.* 4:63-73, which reports the use of this method for the transformation of *Chorella ellipsoidea*). Co-transformation of microalgae can be used to introduce two distinct vector molecules into a cell simultaneously (see for example Protist 2004 Dec;155(4):381-93).

[0142] Biolistic methods (see, for example, Sanford, *Trends In Biotech.* (1988) 6:299 302, U.S. Patent No. 4,945,050; electroporation (Fromm et al., *Proc. Nat'l. Acad. Sci. (USA)* (1985) 82:5824 5828); use of a laser beam, microinjection or any other method capable of introducing DNA into a microalgae can also be used for transformation of a *Prototheca* cell.

2. Engineering Methods - Homologous Recombination

[0143] Homologous recombination is the ability of complementary DNA sequences to align and exchange regions of homology. Transgenic DNA ("donor") containing sequences homologous to the genomic sequences being targeted ("template") is introduced into the organism and then undergoes recombination into the genome at the site of the corresponding genomic homologous sequences. The mechanistic steps of this process, in most cases, include: (1) pairing of homologous DNA segments; (2) introduction of double-stranded breaks into the donor DNA molecule; (3) invasion of the template DNA molecule by the free donor DNA ends followed by DNA synthesis; and (4) resolution of double-strand break repair events that result in final recombination products.

[0144] The ability to carry out homologous recombination in a host organism has many practical implications for what can be carried out at the molecular genetic level and is useful in the generation of an oleaginous microbe that can produced tailored oils. By its very nature homologous recombination is a precise gene targeting event, hence, most transgenic lines generated with the same targeting sequence will be essentially identical in terms of phenotype, necessitating the screening of far fewer transformation events. Homologous recombination also targets gene insertion events into the host chromosome, resulting in excellent genetic stability, even in the absence of genetic selection. Because different

chromosomal loci will likely impact gene expression, even from heterologous promoters/UTRs, homologous recombination can be a method of querying loci in an unfamiliar genome environment and to assess the impact of these environments on gene expression.

[0145] Particularly useful genetic engineering applications using homologous recombination is to co-opt specific host regulatory elements such as promoters/UTRs to drive heterologous gene expression in a highly specific fashion. For example, precise ablation of the endogenous stearoyl ACP desaturase gene with a heterologous C12:0 specific FATB (thioesterase) gene cassette and suitable selective marker, might be expected to dramatically decrease endogenous levels of C18:1 fatty acids concomitant with increased levels of the C12:0 fatty acids. Example 13 describes the homologous recombination targeting construct that is suitable for the ablation of an endogenous *Prototheca moriformis* stearoyl ACP desaturase gene.

[0146] Because homologous recombination is a precise gene targeting event, it can be used to precisely modify any nucleotide(s) within a gene or region of interest, so long as sufficient flanking regions have been identified. Therefore, homologous recombination can be used as a means to modify regulatory sequences impacting gene expression of RNA and/or proteins. It can also be used to modify protein coding regions in an effort to modify enzyme activities such as substrate specificity, affinities and K_m , and thus affecting the desired change in metabolism of the host cell. Homologous recombination provides a powerful means to manipulate the host genome resulting in gene targeting, gene conversion, gene deletion, gene duplication, gene inversion and exchanging gene expression regulatory elements such as promoters, enhancers and 3'UTRs.

[0147] Homologous recombination can be achieved by using targeting constructs containing pieces of endogenous sequences to "target" the gene or region of interest within the endogenous host cell genome. Such targeting sequences can either be located 5' of the gene or region of interest, 3' of the gene/region of interest or even flank the gene/region of interest. Such targeting constructs can be transformed into the host cell either as a supercoiled plasmid DNA with additional vector backbone, a PCR product with no vector backbone, or as a linearized molecule. In some cases, it may be advantageous to first expose the homologous sequences within the transgenic DNA (donor DNA) with a restriction enzyme. This step can increase the recombination efficiency and decrease the occurrence of undesired events. Other methods of increasing recombination efficiency include using PCR to generate transforming transgenic DNA containing linear ends homologous to the genomic sequences being targeted.

3. Vectors and Vector Components

[0148] Vectors for transformation of microorganisms in accordance with the present invention can be prepared by known techniques familiar to those skilled in the art in view of the disclosure herein. A vector typically contains one or more genes, in which each gene codes for the expression of a desired product (the gene product) and is operably linked to one or more control sequences that regulate gene expression or target the gene product to a particular location in the recombinant cell. To aid the reader, this subsection is divided into subsections. Subsection A describes control sequences typically contained on vectors as well as novel control sequences provided by the present invention. Subsection B describes genes typically contained in vectors as well as novel codon optimization methods and genes prepared using them provided by the invention.

A. Control Sequences

[0149] Control sequences are nucleic acids that regulate the expression of a coding sequence or direct a gene product to a particular location in or outside a cell. Control sequences that regulate expression include, for example, promoters that regulate transcription of a coding sequence and terminators that terminate transcription of a coding sequence. Another control sequence is a 3' untranslated sequence located at the end of a coding sequence that encodes a polyadenylation signal. Control sequences that direct gene products to particular locations include those that encode signal peptides, which direct the protein to which they are attached to a particular location in or outside the cell.

[0150] Thus, an exemplary vector design for expression of an exogenous gene in a microalgae contains a coding sequence for a desired gene product (for example, a selectable marker, a lipid pathway modification enzyme, or a sucrose utilization enzyme) in operable linkage with a promoter active in microalgae. Alternatively, if the vector does not contain a promoter in operable linkage with the coding sequence of interest, the coding sequence can be transformed into the cells such that it becomes operably linked to an endogenous promoter at the point of vector integration. The promoterless method of transformation has been proven to work in microalgae (see for example Plant Journal 14:4, (1998), pp.441-447).

[0151] Many promoters are active in microalgae, including promoters that are endogenous to the algae being transformed, as well as promoters that are not endogenous to the algae being transformed (i.e., promoters from other algae, promoters from higher plants, and promoters from plant viruses or algae viruses). Illustrative exogenous and/or endogenous promoters that are active in microalgae (as well as antibiotic resistance genes functional in microalgae) are described in PCT Pub. No. 2008/151149 and references cited therein).

[0152] The promoter used to express an exogenous gene can be the promoter naturally linked to that gene or can be a heterologous gene. Some promoters are active in more than one species of microalgae. Other promoters are species-specific. Illustrative promoters include promoters such as β -tubulin from *Chlamydomonas reinhardtii*, used in the Examples below, and viral promoters, such as cauliflower mosaic virus (CMV) and chlorella virus, which have been shown to be active in multiple species of microalgae (see for example Plant Cell Rep. 2005 Mar;23(10-11):727-35; J Microbiol. 2005 Aug;43(4):361-5; Mar Biotechnol (NY). 2002 Jan;4(1):63-73). Another promoter that is suitable for use for expression of exogenous genes in *Prototheca* is the *Chlorella sorokiniana* glutamate dehydrogenase promoter/5'UTR (SEQ ID NO: 69). Optionally, at least 10, 20, 30, 40, 50, or 60 nucleotides or more of these sequences containing a promoter are used. Illustrative promoters useful for expression of exogenous genes in *Prototheca* are listed in the sequence listing of this application, such as the promoter of the *Chlorella* HUP1 gene (SEQ ID NO:1) and the *Chlorella ellipsoidea* nitrate reductase promoter (SEQ ID NO:2). Chlorella virus promoters can also be used to express genes in *Prototheca*, such as SEQ ID NOs: 1-7 of U.S. Patent 6,395,965. Additional promoters active in *Prototheca* can be found, for example, in Biochem Biophys Res Commun. 1994 Oct 14;204(1):187-94; Plant Mol Biol. 1994 Oct;26(1):85-93; Virology. 2004 Aug 15;326(1):150-9; and Virology. 2004 Jan 5;318(1):214-23.

[0153] A promoter can generally be characterized as either constitutive or inducible. Constitutive promoters are generally active or function to drive expression at all times (or at certain times in the cell life cycle) at the same level. Inducible promoters, conversely, are active (or rendered inactive) or are significantly up- or down-regulated only in response to a stimulus. Both types of promoters find application in the methods of the invention. Inducible promoters useful in the invention include those that mediate transcription of an operably linked gene in response to a stimulus, such as an exogenously provided small molecule (e.g., glucose, as in SEQ ID NO:1), temperature (heat or cold), lack of nitrogen in culture media, etc. Suitable promoters can activate transcription of an essentially silent gene or upregulate, preferably substantially, transcription of an operably linked gene that is transcribed at a low level.

[0154] Inclusion of termination region control sequence is optional, and if employed, then the choice is primarily one of convenience, as the termination region is relatively interchangeable. The termination region may be native to the transcriptional initiation region (the promoter), may be native to the DNA sequence of interest, or may be obtainable from another source. See, for example, Chen and Orozco, Nucleic Acids Res. (1988) 16:8411.

[0155] The present invention also provides control sequences and recombinant genes and vectors containing them that provide for the compartmentalized expression of a gene of interest. Organelles for targeting are chloroplasts, plastids, mitochondria, and endoplasmic reticulum. In addition, the present invention provides control sequences and recombinant genes and vectors containing them that provide for the secretion of a protein outside the cell.

[0156] Proteins expressed in the nuclear genome of *Prototheca* can be targeted to the plastid using plastid targeting signals. Plastid targeting sequences endogenous to *Chlorella* are known, such as genes in the *Chlorella* nuclear genome that encode proteins that are targeted to the plastid; see for example GenBank Accession numbers AY646197 and AF499684, and in one embodiment, such control sequences are used in the vectors of the present invention to target expression of a protein to a *Prototheca* plastid.

[0157] The Examples below describe the use of algal plastid targeting sequences to target heterologous proteins to the correct compartment in the host cell. cDNA libraries were made using *Prototheca moriformis* and *Chlorella protothecoides* cells and are described in Examples 12 and Example 11 below. Sequences were BLASTed and analyzed for homology to known proteins that traffic to the plastid/chloroplast. The cDNAs encoding these proteins were cloned and plastid targeting sequences were isolated from these cDNAs. The amino acid sequences of the algal plastid targeting sequences identified from the cDNA libraries and the amino acid sequences of plant fatty acyl-ACP thioesterases that are used in the heterologous expression Examples below are listed in SEQ ID NOs: 127-133.

[0158] In another embodiment of the present invention, the expression of a polypeptide in *Prototheca* is targeted to the endoplasmic reticulum. The inclusion of an appropriate retention or sorting signal in an expression vector ensure that proteins are retained in the endoplasmic reticulum (ER) and do not go downstream into Golgi. For example, the IMPACTVECTOR1.3 vector, from Wageningen UR- Plant Research International, includes the well known KDEL retention or sorting signal. With this vector, ER retention has a practical advantage in that it has been reported to improve expression levels 5-fold or more. The main reason for this appears to be that the ER contains lower concentrations and/or different proteases responsible for post-translational degradation of expressed proteins than are present in the cytoplasm. ER retention signals functional in green microalgae are known. For example, see Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6225-30.

[0159] In another embodiment of the present invention, a polypeptide is targeted for secretion outside the cell into the culture media. See Hawkins et al., Current Microbiology

Vol. 38 (1999), pp. 335–341 for examples of secretion signals active in *Chlorella* that can be used, in accordance with the methods of the invention, in *Prototheca*.

B. Genes and Codon Optimization

[0160] Typically, a gene includes a promoter, coding sequence, and termination control sequences. When assembled by recombinant DNA technology, a gene may be termed an expression cassette and may be flanked by restriction sites for convenient insertion into a vector that is used to introduce the recombinant gene into a host cell. The expression cassette can be flanked by DNA sequences from the genome or other nucleic acid target to facilitate stable integration of the expression cassette into the genome by homologous recombination. Alternatively, the vector and its expression cassette may remain unintegrated, in which case, the vector typically includes an origin of replication, which is capable of providing for replication of the heterologous vector DNA.

[0161] A common gene present on a vector is a gene that codes for a protein, the expression of which allows the recombinant cell containing the protein to be differentiated from cells that do not express the protein. Such a gene, and its corresponding gene product, is called a selectable marker. Any of a wide variety of selectable markers can be employed in a transgene construct useful for transforming *Prototheca*. Examples of suitable selectable markers include the G418 resistance gene, the nitrate reductase gene (see Dawson et al. (1997), Current Microbiology 35:356-362), the hygromycin phosphotransferase gene (HPT; see Kim et al. (2002), Mar. Biotechnol. 4:63-73), the neomycin phosphotransferase gene, and the ble gene, which confers resistance to phleomycin (Huang et al. (2007), Appl. Microbiol. Biotechnol. 72:197-205). Methods of determining sensitivity of microalgae to antibiotics are well known. For example, Mol Gen Genet. 1996 Oct 16;252(5):572-9.

[0162] For purposes of the present invention, the expression vector used to prepare a recombinant host cell of the invention will include at least two, and often three, genes, if one of the genes is a selectable marker. For example, a genetically engineered *Prototheca* of the invention can be made by transformation with vectors of the invention that comprise, in addition to a selectable marker, one or more exogenous genes, such as, for example, sucrose invertase gene or acyl ACP-thioesterase gene. One or both genes can be expressed using an inducible promoter, which allows the relative timing of expression of these genes to be controlled to enhance the lipid yield and conversion to fatty acid esters. Expression of the two or more exogenous genes may be under control of the same inducible promoter or under control of different inducible (or constitutive) promoters. In the latter situation, expression of a first exogenous gene can be induced for a first period of time (during which expression of a

second exogenous gene may or may not be induced) and expression of a second exogenous gene can be induced for a second period of time (during which expression of a first exogenous gene may or may not be induced).

[0163] In other embodiments, the two or more exogenous genes (in addition to any selectable marker) are: a fatty acyl-ACP thioesterase and a fatty acyl-CoA/aldehyde reductase, the combined action of which yields an alcohol product. Further provided are other combinations of exogenous genes, including without limitation, a fatty acyl-ACP thioesterase and a fatty acyl-CoA reductase to generate aldehydes. In one embodiment, the vector provides for the combination of a fatty acyl-ACP thioesterase, a fatty acyl-CoA reductase, and a fatty aldehyde decarbonylase to generate alkanes. In each of these embodiments, one or more of the exogenous genes can be expressed using an inducible promoter.

[0164] Other illustrative vectors of the invention that express two or more exogenous genes include those encoding both a sucrose transporter and a sucrose invertase enzyme and those encoding both a selectable marker and a secreted sucrose invertase. The recombinant *Prototheca* transformed with either type of vector produce lipids at lower manufacturing cost due to the engineered ability to use sugar cane (and sugar cane-derived sugars) as a carbon source. Insertion of the two exogenous genes described above can be combined with the disruption of polysaccharide biosynthesis through directed and/or random mutagenesis, which steers ever greater carbon flux into lipid production. Individually and in combination, trophic conversion, engineering to alter lipid production and treatment with exogenous enzymes alter the lipid composition produced by a microorganism. The alteration can be a change in the amount of lipids produced, the amount of one or more hydrocarbon species produced relative to other lipids, and/or the types of lipid species produced in the microorganism. For example, microalgae can be engineered to produce a higher amount and/or percentage of TAGs.

[0165] For optimal expression of a recombinant protein, it is beneficial to employ coding sequences that produce mRNA with codons preferentially used by the host cell to be transformed. Thus, proper expression of transgenes can require that the codon usage of the transgene matches the specific codon bias of the organism in which the transgene is being expressed. The precise mechanisms underlying this effect are many, but include the proper balancing of available aminoacylated tRNA pools with proteins being synthesized in the cell, coupled with more efficient translation of the transgenic messenger RNA (mRNA) when this need is met. When codon usage in the transgene is not optimized, available tRNA pools are

not sufficient to allow for efficient translation of the heterologous mRNA resulting in ribosomal stalling and termination and possible instability of the transgenic mRNA.

[0166] The present invention provides codon-optimized nucleic acids useful for the successful expression of recombinant proteins in *Prototheca*. Codon usage in *Prototheca* species was analyzed by studying cDNA sequences isolated from *Prototheca moriformis*. This analysis represents the interrogation over 24, 000 codons and resulted in Table 1 below.

[0167] Table 1. Preferred codon usage in *Prototheca* strains.

Ala	GCG	345 (0.36)	Asn	AAT	8 (0.04)
	GCA	66 (0.07)		AAC	201 (0.96)
	GCT	101 (0.11)	Pro	CCG	161 (0.29)
	GCC	442 (0.46)		CCA	49 (0.09)
Cys	TGT	12 (0.10)		CCT	71 (0.13)
	TGC	105 (0.90)		CCC	267 (0.49)
Asp	GAT	43 (0.12)	Gln	CAG	226 (0.82)
	GAC	316 (0.88)		CAA	48 (0.18)
Glu	GAG	377 (0.96)	Arg	AGG	33 (0.06)
	GAA	14 (0.04)		AGA	14 (0.02)
Phe	TTT	89 (0.29)		CGG	102 (0.18)
	TTC	216 (0.71)		CGA	49 (0.08)
				CGT	51 (0.09)
Gly	GGG	92 (0.12)		CGC	331 (0.57)
	GGA	56 (0.07)	Ser	AGT	16 (0.03)
	GGT	76 (0.10)		AGC	123 (0.22)
	GGC	559 (0.71)		TCG	152 (0.28)
His	CAT	42 (0.21)		TCA	31 (0.06)
	CAC	154 (0.79)		TCT	55 (0.10)
Ile	ATA	4 (0.01)	Thr	TCC	173 (0.31)
	ATT	30 (0.08)		ACG	184 (0.38)
	ATC	338 (0.91)		ACA	24 (0.05)
Lys	AAG	284 (0.98)		ACT	21 (0.05)
	AAA	7 (0.02)	Val	ACC	249 (0.52)
Leu	TTG	26 (0.04)		GTG	308 (0.50)
	TTA	3 (0.00)		GTA	9 (0.01)
	CTG	447 (0.61)		GTT	35 (0.06)
	CTA	20 (0.03)		GTC	262 (0.43)
	CTT	45 (0.06)	Trp	TGG	107 (1.00)
	CTC	190 (0.26)		TAT	10 (0.05)
			Tyr	TAC	180 (0.95)

Met	ATG	191 (1.00)	Stop	TGA/TAG/TAA
-----	-----	------------	------	-------------

[0168] In other embodiments, the gene in the recombinant vector has been codon-optimized with reference to a microalgal strain other than a *Prototheca* strain. For example, methods of recoding genes for expression in microalgae are described in U.S. Patent 7,135,290. Additional information for codon optimization is available, e.g., at the codon usage database of GenBank.

[0169] While the methods and materials of the invention allow for the introduction of any exogenous gene into *Prototheca*, genes relating to sucrose utilization and lipid pathway modification are of particular interest, as discussed in the following sections.

IV. SUCROSE UTILIZATION

[0170] In embodiment, the recombinant *Prototheca* cell of the invention further contains one or more exogenous sucrose utilization genes. In various embodiments, the one or more genes encode one or more proteins selected from the group consisting of a fructokinase, a glucokinase, a hexokinase, a sucrose invertase, a sucrose transporter. For example, expression of a sucrose transporter and a sucrose invertase allows *Prototheca* to transport sucrose into the cell from the culture media and hydrolyze sucrose to yield glucose and fructose. Optionally, a fructokinase can be expressed as well in instances where endogenous hexokinase activity is insufficient for maximum phosphorylation of fructose. Examples of suitable sucrose transporters are Genbank accession numbers CAD91334, CAB92307, and CAA53390. Examples of suitable fructokinases are Genbank accession numbers P26984, P26420 and CAA43322.

[0171] In one embodiment, the present invention provides a *Prototheca* host cell that secretes a sucrose invertase. Secretion of a sucrose invertase obviates the need for expression of a transporter that can transport sucrose into the cell. This is because a secreted invertase catalyzes the conversion of a molecule of sucrose into a molecule of glucose and a molecule of fructose, both of which can be transported and utilized by microbes provided by the invention. For example, expression of a sucrose invertase (such as SEQ ID NO:3) with a secretion signal (such as that of SEQ ID NO: 4 (from yeast), SEQ ID NO: 5 (from higher plants), SEQ ID NO: 6 (eukaryotic consensus secretion signal), and SEQ ID NO: 7 (combination of signal sequence from higher plants and eukaryotic consensus) generates invertase activity outside the cell. Expression of such a protein, as enabled by the genetic

engineering methodology disclosed herein, allows cells already capable of utilizing extracellular glucose as an energy source to utilize sucrose as an extracellular energy source.

[0172] *Prototheca* species expressing an invertase in media containing sucrose are a preferred microalgal species for the production of oil. Example 3 illustrates how the methods and reagents of the invention can be used to express a recombinant yeast invertase and secrete it from a recombinant *Prototheca* cell. The expression and extracellular targeting of this fully active protein allows the resulting host cells to grow on sucrose, whereas their non-transformed counterparts cannot. Thus, the present invention provides *Prototheca* recombinant cells with a codon-optimized invertase gene, including but not limited to the yeast invertase gene, integrated into their genome such that the invertase gene is expressed as assessed by invertase activity and sucrose hydrolysis. The present invention also provides invertase genes useful as selectable markers in *Prototheca* recombinant cells, as such cells are able to grow on sucrose, while their non-transformed counterparts cannot; and methods for selecting recombinant host cells using an invertase as a powerful, selectable marker for algal molecular genetics.

[0173] The successful expression of a sucrose invertase in *Prototheca* also illustrates another aspect of the present invention in that it demonstrates that heterologous (recombinant) proteins can be expressed in the algal cell and successfully transit outside of the cell and into the culture medium in a fully active and functional form. Thus, the present invention provides methods and reagents for expressing a wide and diverse array of heterologous proteins in microalgae and secreting them outside of the host cell. Such proteins include, for example, industrial enzymes such as, for example, lipases, proteases, cellulases, pectinases, amylases, esterases, oxidoreductases, transferases, lactases, isomerases, and invertases, as well as therapeutic proteins such as, for example, growth factors, cytokines, full length antibodies comprising two light and two heavy chains, Fabs, scFvs (single chain variable fragment), camellid-type antibodies, antibody fragments, antibody fragment-fusions, antibody-receptor fusions, insulin, interferons, and insulin-like growth factors.

[0174] The successful expression of a sucrose invertase in *Prototheca* also illustrates another aspect of the present invention in that it provides methods and reagents for the use of fungal transit peptides in algae to direct secretion of proteins in *Prototheca*; and methods and reagents for determining if a peptide can function, and the ability of it to function, as a transit peptide in *Prototheca* cells. The methods and reagents of the invention can be used as a tool and platform to identify other transit peptides that can successfully traffic proteins outside of a cell, and that the yeast invertase has great utility in these methods. As demonstrated in this

example, removal of the endogenous yeast invertase transit peptide and its replacement by other transit peptides, either endogenous to the host algae or from other sources (eukaryotic, prokaryotic and viral), can identify whether any peptide of interest can function as a transit peptide in guiding protein egress from the cell.

[0175] Examples of suitable sucrose invertases include those identified by Genbank accession numbers CAB95010, NP_012104 and CAA06839. Non-limiting examples of suitable invertases are listed below in Table 2. Amino acid sequences for each listed invertase are included in the Sequence Listing below. In some cases, the exogenous sucrose utilization gene suitable for use in the methods and vectors of the invention encodes a sucrose invertase that has at least 40, 50, 60, 75, or 90% or higher amino acid identity with a sucrose invertase selected from Table 2.

[0176] Table 2. Sucrose invertases.

Description	Organism	GenBank Accession No.	SEQ ID NO:
Invertase	<i>Chicorium intybus</i>	Y11124	SEQ ID NO:20
Invertase	<i>Schizosaccharomyces pombe</i>	AB011433	SEQ ID NO:21
beta-fructofuranosidase (invertase)	<i>Pichia anomala</i>	X80640	SEQ ID NO:22
Invertase	<i>Debaryomyces occidentalis</i>	X17604	SEQ ID NO:23
Invertase	<i>Oryza sativa</i>	AF019113	SEQ ID NO:24
Invertase	<i>Allium cepa</i>	AJ006067	SEQ ID NO:25
Invertase	<i>Beta vulgaris subsp. Vulgaris</i>	AJ278531	SEQ ID NO:26
beta-fructofuranosidase (invertase)	<i>Bifidobacterium breve UCC2003</i>	AAT28190	SEQ ID NO:27
Invertase	<i>Saccharomyces cerevisiae</i>	NP_012104	SEQ ID NO:8 (nucleotide) SEQ ID NO:28 (amino acid)
Invertase A	<i>Zymomonas mobilis</i>	AAO38865	SEQ ID NO:29

[0177] The secretion of an invertase to the culture medium by *Prototheca* enable the cells to grow as well on waste molasses from sugar cane processing as they do on pure reagent-grade glucose; the use of this low-value waste product of sugar cane processing can provide significant cost savings in the production of lipids and other oils. Thus, the present invention provides a microbial culture containing a population of *Prototheca* microorganisms, and a culture medium comprising (i) sucrose and (ii) a sucrose invertase enzyme. In various embodiments the sucrose in the culture comes from sorghum, sugar beet, sugar cane, molasses, or depolymerized cellulosic material (which may optionally contain lignin). In another aspect, the methods and reagents of the invention significantly increase the number and type of feedstocks that can be utilized by recombinant *Prototheca*. While the microbes exemplified here are altered such that they can utilize sucrose, the methods and reagents of the invention can be applied so that feedstocks such as cellulose are utilizable by an engineered host microbe of the invention with the ability to secrete cellulases, pectinases, isomerases, or the like, such that the breakdown products of the enzymatic reactions are no longer just simply tolerated but rather utilized as a carbon source by the host.

V. LIPID PATHWAY ENGINEERING

[0178] In addition to altering the ability of *Prototheca* to utilize feedstocks such as sucrose-containing feedstocks, the present invention also provides recombinant *Prototheca* that have been modified to alter the properties and/or proportions of lipids produced. The pathway can further, or alternatively, be modified to alter the properties and/or proportions of various lipid molecules produced through enzymatic processing of lipids and intermediates in the fatty acid pathway. In various embodiments, the recombinant *Prototheca* cells of the invention have, relative to their untransformed counterparts, optimized lipid yield per unit volume and/or per unit time, carbon chain length (e.g., for renewable diesel production or for industrial chemicals applications requiring lipid feedstock), reduced number of double or triple bonds, optionally to zero, and increasing the hydrogen:carbon ratio of a particular species of lipid or of a population of distinct lipid.

[0179] In particular embodiments, one or more key enzymes that control branch points in metabolism to fatty acid synthesis have been up-regulated or down-regulated to improve lipid production. Up-regulation can be achieved, for example, by transforming cells with expression constructs in which a gene encoding the enzyme of interest is expressed, e.g., using a strong promoter and/or enhancer elements that increase transcription. Such constructs can include a selectable marker such that the transformants can be subjected to selection, which can result in amplification of the construct and an increase in the expression level of

the encoded enzyme. Examples of enzymes suitable for up-regulation according to the methods of the invention include pyruvate dehydrogenase, which plays a role in converting pyruvate to acetyl-CoA (examples, some from microalgae, include Genbank accession numbers NP_415392; AAA53047; Q1XDM1; and CAF05587). Up-regulation of pyruvate dehydrogenase can increase production of acetyl-CoA, and thereby increase fatty acid synthesis. Acetyl-CoA carboxylase catalyzes the initial step in fatty acid synthesis. Accordingly, this enzyme can be up-regulated to increase production of fatty acids (examples, some from microalgae, include Genbank accession numbers BAA94752; AAA75528; AAA81471; YP_537052; YP_536879; NP_045833; and BAA57908). Fatty acid production can also be increased by up-regulation of acyl carrier protein (ACP), which carries the growing acyl chains during fatty acid synthesis (examples, some from microalgae, include Genbank accession numbers A0T0F8; P51280; NP_849041; YP_874433). Glycerol-3-phosphate acyltransferase catalyzes the rate-limiting step of fatty acid synthesis. Up-regulation of this enzyme can increase fatty acid production (examples, some from microalgae, include Genbank accession numbers AAA74319; AAA33122; AAA37647; P44857; and ABO94442).

[0180] Up- and/or down-regulation of genes can be applied to global regulators controlling the expression of the genes of the fatty acid biosynthetic pathways. Accordingly, one or more global regulators of fatty acid synthesis can be up- or down-regulated, as appropriate, to inhibit or enhance, respectively, the expression of a plurality of fatty acid synthetic genes and, ultimately, to increase lipid production. Examples include sterol regulatory element binding proteins (SREBPs), such as SREBP-1a and SREBP-1c (for examples see Genbank accession numbers NP_035610 and Q9WTN3).

[0181] The present invention also provides recombinant *Prototheca* cells that have been modified to contain one or more exogenous genes encoding lipid modification enzymes such as, for example, fatty acyl-ACP thioesterases (see Table 3), fatty acyl-CoA/aldehyde reductases (see Table 4), fatty acyl-CoA reductases (see Table 5), fatty aldehyde decarbonylase (see Table 6), fatty aldehyde reductases, and squalene synthases (see GenBank Accession number AF205791). In some embodiments, genes encoding a fatty acyl-ACP thioesterase and a naturally co-expressed acyl carrier protein are transformed into a *Prototheca* cell, optionally with one or more genes encoding other lipid modification enzymes. In other embodiments, the ACP and the fatty acyl-ACP thioesterase may have an affinity for one another that imparts an advantage when the two are used together in the microbes and methods of the present invention, irrespective of whether they are or are not

naturally co-expressed in a particular tissue or organism. Thus, the present invention contemplates both naturally co-expressed pairs of these enzymes as well as those that share an affinity for interacting with one another to facilitate cleavage of a length-specific carbon chain from the ACP.

[0182] In still other embodiments, an exogenous gene encoding a desaturase is transformed into the *Prototheca* cell in conjunction with one or more genes encoding other lipid modification enzymes to provide modifications with respect to lipid saturation. Stearoyl-ACP desaturase (see, e.g., GenBank Accession numbers AAF15308; ABM45911; and AAY86086), for example, catalyzes the conversion of stearoyl-ACP to oleoyl-ACP. Up-regulation of this gene can increase the proportion of monounsaturated fatty acids produced by a cell; whereas down-regulation can reduce the proportion of monounsaturates. Similarly, the expression of one or more glycerolipid desaturases can be controlled to alter the ratio of unsaturated to saturated fatty acids such as ω -6 fatty acid desaturase, ω -3 fatty acid desaturase, or ω -6-oleate desaturase. In some embodiments, the desaturase can be selected with reference to a desired carbon chain length, such that the desaturase is capable of making location specific modifications within a specified carbon-length substrate, or substrates having a carbon-length within a specified range.

[0183] Thus, in particular embodiments, microbes of the present invention are genetically engineered to express one or more exogenous genes selected from an acyl-ACP thioesterase, an acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty aldehyde decarbonylase, or a naturally co-expressed acyl carrier protein. Suitable expression methods are described above with respect to the expression of a lipase gene, including, among other methods, inducible expression and compartmentalized expression. A fatty acyl-ACP thioesterase cleaves a fatty acid from an acyl carrier protein (ACP) during lipid synthesis. Through further enzymatic processing, the cleaved fatty acid is then combined with a coenzyme to yield an acyl-CoA molecule. This acyl-CoA is the substrate for the enzymatic activity of a fatty acyl-CoA reductase to yield an aldehyde, as well as for a fatty acyl-CoA/aldehyde reductase to yield an alcohol. The aldehyde produced by the action of the fatty acyl-CoA reductase identified above is the substrate for further enzymatic activity by either a fatty aldehyde reductase to yield an alcohol, or a fatty aldehyde decarbonylase to yield an alkane or alkene.

[0184] In some embodiments, fatty acids, glycerolipids, or the corresponding primary alcohols, aldehydes, alkanes or alkenes, generated by the methods described herein, contain 8, 10, 12, or 14 carbon atoms. Preferred fatty acids for the production of diesel, biodiesel,

renewable diesel, or jet fuel, or the corresponding primary alcohols, aldehydes, alkanes and alkenes, for industrial applications contain 8 to 14 carbon atoms. In certain embodiments, the above fatty acids, as well as the other corresponding hydrocarbon molecules, are saturated (with no carbon-carbon double or triple bonds); mono unsaturated (single double bond); poly unsaturated (two or more double bonds); are linear (not cyclic) or branched. For fuel production, greater saturation is preferred.

[0185] The enzymes described directly above have a preferential specificity for hydrolysis of a substrate containing a specific number of carbon atoms. For example, a fatty acyl-ACP thioesterase may have a preference for cleaving a fatty acid having 12 carbon atoms from the ACP. In some embodiments, the ACP and the length-specific thioesterase may have an affinity for one another that makes them particularly useful as a combination (e.g., the exogenous ACP and thioesterase genes may be naturally co-expressed in a particular tissue or organism from which they are derived). Therefore, in various embodiments, the recombinant *Prototheca* cell of the invention can contain an exogenous gene that encodes a protein with specificity for catalyzing an enzymatic activity (e.g., cleavage of a fatty acid from an ACP, reduction of an acyl-CoA to an aldehyde or an alcohol, or conversion of an aldehyde to an alkane) with regard to the number of carbon atoms contained in the substrate. The enzymatic specificity can, in various embodiments, be for a substrate having from 8 to 34 carbon atoms, preferably from 8 to 18 carbon atoms, and more preferably from 8 to 14 carbon atoms. A preferred specificity is for a substrate having fewer, i.e., 12, rather than more, i.e., 18, carbon atoms.

[0186] In non-limiting but illustrative examples, the present invention provides vectors and *Prototheca* host cells that express an exogenous thioesterase and accordingly produce lipid enriched, relative to the lipid profile of untransformed *Prototheca* cells, in the chain length for which the thioesterase is specific. The thioesterases illustrated are (i) *Cinnamomum camphorum* FatB1 (GenBank Accension No. Q39473, amino acid sequence is in SEQ ID NO: 59, amino acid sequence without plastid targeting sequence (PTS) is in SEQ ID NO: 139, and codon optimized cDNA sequence based on Table 1 is in SEQ ID NO: 60), which has a preference for fatty acyl-ACP substrate with a carbon chain length of 14; (ii) *Cuphea hookeriana* FatB2 (GenBank Accension No. AAC49269, amino acid sequence is in SEQ ID NO: 61, amino acid sequence without PTS is in SEQ ID NO: 138, and codon optimized cDNA sequence based on Table 1 is in SEQ ID NO: 62), which has a preference for a fatty acyl-ACP substrate with a carbon chain length of 8-10; and (iii) *Umbellularia* Fat B1 (GenBank Accession No. Q41635, amino acid sequence is included in SEQ ID NO: 63, amino

acid sequence without PTS is in SEQ ID NO: 139, and codon optimized cDNA sequence based on Table 1 is included in SEQ ID NO: 64), which has a preference for a fatty acyl-ACP substrate with a carbon chain length of 12.

[0187] Other fatty acyl-ACP thioesterases suitable for use with the microbes and methods of the invention include, without limitation, those listed in Table 3.

[0188] Table 3. Fatty acyl-ACP thioesterases and GenBank accession numbers.

<i>Umbellularia californica</i> fatty acyl-ACP thioesterase (GenBank #AAC49001)
<i>Cinnamomum camphora</i> fatty acyl-ACP thioesterase (GenBank #Q39473)
<i>Umbellularia californica</i> fatty acyl-ACP thioesterase (GenBank #Q41635)
<i>Myristica fragrans</i> fatty acyl-ACP thioesterase (GenBank #AAB71729)
<i>Myristica fragrans</i> fatty acyl-ACP thioesterase (GenBank #AAB71730)
<i>Elaeis guineensis</i> fatty acyl-ACP thioesterase (GenBank #ABD83939)
<i>Elaeis guineensis</i> fatty acyl-ACP thioesterase (GenBank #AAD42220)
<i>Populus tomentosa</i> fatty acyl-ACP thioesterase (GenBank #ABC47311)
<i>Arabidopsis thaliana</i> fatty acyl-ACP thioesterase (GenBank #NP_172327)
<i>Arabidopsis thaliana</i> fatty acyl-ACP thioesterase (GenBank #CAA85387)
<i>Arabidopsis thaliana</i> fatty acyl-ACP thioesterase (GenBank #CAA85388)
<i>Gossypium hirsutum</i> fatty acyl-ACP thioesterase (GenBank #Q9SQI3)
<i>Cuphea lanceolata</i> fatty acyl-ACP thioesterase (GenBank #CAA54060)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank #AAC72882)
<i>Cuphea calophylla</i> subsp. <i>mesostemon</i> fatty acyl-ACP thioesterase (GenBank #ABB71581)
<i>Cuphea lanceolata</i> fatty acyl-ACP thioesterase (GenBank #CAC19933)
<i>Elaeis guineensis</i> fatty acyl-ACP thioesterase (GenBank #AAL15645)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank #Q39513)
<i>Gossypium hirsutum</i> fatty acyl-ACP thioesterase (GenBank #AAD01982)
<i>Vitis vinifera</i> fatty acyl-ACP thioesterase (GenBank #CAN81819)
<i>Garcinia mangostana</i> fatty acyl-ACP thioesterase (GenBank #AAB51525)
<i>Brassica juncea</i> fatty acyl-ACP thioesterase (GenBank #ABI18986)
<i>Madhuca longifolia</i> fatty acyl-ACP thioesterase (GenBank #AAX51637)
<i>Brassica napus</i> fatty acyl-ACP thioesterase (GenBank #ABH11710)
<i>Oryza sativa</i> (indica cultivar-group) fatty acyl-ACP thioesterase (GenBank #EAY86877)
<i>Oryza sativa</i> (japonica cultivar-group) fatty acyl-ACP thioesterase (GenBank #NP_001068400)
<i>Oryza sativa</i> (indica cultivar-group) fatty acyl-ACP thioesterase (GenBank #EAY99617)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank #AAC49269)
<i>Ulmus Americana</i> fatty acyl-ACP thioesterase (GenBank #AAB71731)
<i>Cuphea lanceolata</i> fatty acyl-ACP thioesterase (GenBank #CAB60830)
<i>Cuphea palustris</i> fatty acyl-ACP thioesterase (GenBank #AAC49180)
<i>Iris germanica</i> fatty acyl-ACP thioesterase (GenBank #AAG43858)
<i>Cuphea palustris</i> fatty acyl-ACP thioesterase (GenBank #AAC49179)
<i>Myristica fragrans</i> fatty acyl-ACP thioesterase (GenBank #AAB71729)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank #U39834)
<i>Umbellularia californica</i> fatty acyl-ACP thioesterase (GenBank #M94159)
<i>Cinnamomum camphora</i> fatty acyl-ACP thioesterase (GenBank #U31813)

[0189] The Examples below describe the successful targeting and expression of heterologous fatty acyl-ACP thioesterases from *Cuphea hookeriana*, *Umbellularia californica*, *Cinnamomum camphora* in *Prototheca* species. Additionally, alterations in fatty acid profiles were confirmed in the host cells expression these heterologous fatty acyl-ACP thioesterases. These results were quite unexpected given the lack of sequence identity between algal and higher plant thioesterases in general, and between *Prototheca moriformis* fatty acyl-ACP thioesterase and the above listed heterologous fatty acyl-ACP thioesterases. Two *Prototheca moriformis* acyl-ACP thioesterases were isolated and sequenced. The sequences of the two cDNAs showed a high degree of identity between each other, differing in only 12 positions at the nucleotide level and five positions at the amino acid level, four of these in the plastid transit peptide. Further analysis of genomic sequence from *Prototheca moriformis* confirmed that these two cDNAs were indeed encoded on separate contigs, and although highly homologous, are encoded by two distinct genes. The cDNA and amino acid sequence of the two *Prototheca moriformis* fatty acyl-ACP thioesterase, *P.moriformis* fatty acyl-ACP thioesterase-1 and *P.moriformis* fatty acyl-ACP thioesterase-2, are listed as SEQ ID NOs: 134-137.

[0190] When the amino acid sequences of these two cDNAs were BLASTed against the NCBI database, the two most homologous sequences were fatty acyl-ACP thioesterases from *Chlamydomonas reinhardtii* and *Arabidopsis thaliana*. Surprisingly, the level of amino acid identity between the *Prototheca moriformis* fatty acyl-ACP thioesterases and higher plant thioesterases was fairly low, at only 49 and 37% identity. In addition, there also is a subtle difference in the sequences surrounding the amino terminal portion of the catalytic triad (NXHX₃₆C) among these fatty acyl-ACP thioesterases. Thirty nine of forty higher plant fatty acyl-ACP thioesterases surveyed showed the sequence LDMNQH surrounding the N and H residues at the amino terminus of the triad, while all of the algal sequences identified had the sequence MDMNGH. Given the low amino acid sequence identity and the differences surrounding the catalytic triad of the thioesterases, the successful results of expression of exogenous fatty acyl-ACP thioesterases obtained and described in the Examples were unexpected, particularly given the fact that activity of the exogenous fatty acyl-ACP thioesterases was dependent on a functional protein-protein interaction with the endogenous *Prototheca* acyl carrier protein.

[0191] Fatty acyl-CoA/aldehyde reductases suitable for use with the microbes and methods of the invention include, without limitation, those listed in Table 4.

[0192] Table 4. Fatty acyl-CoA/aldehyde reductases listed by GenBank accession numbers.

AAC45217, YP_047869, BAB85476, YP_001086217, YP_580344, YP_001280274, YP_264583, YP_436109, YP_959769, ZP_01736962, ZP_01900335, ZP_01892096, ZP_01103974, ZP_01915077, YP_924106, YP_130411, ZP_01222731, YP_550815, YP_983712, YP_001019688, YP_524762, YP_856798, ZP_01115500, YP_001141848, NP_336047, NP_216059, YP_882409, YP_706156, YP_001136150, YP_952365, ZP_01221833, YP_130076, NP_567936, AAR88762, ABK28586, NP_197634, CAD30694, NP_001063962, BAD46254, NP_001030809, EAZ10132, EAZ43639, EAZ07989, NP_001062488, CAB88537, NP_001052541, CAH66597, CAE02214, CAH66590, CAB88538, EAZ39844, AAZ06658, CAA68190, CAA52019, and BAC84377

[0193] Fatty acyl-CoA reductases suitable for use with the microbes and methods of the invention include, without limitation, those listed in Table 5.

[0194] Table 5. Fatty acyl-CoA reductases listed by GenBank accession numbers.

NP_187805, ABO14927, NP_001049083, CAN83375, NP_191229, EAZ42242, EAZ06453, CAD30696, BAD31814, NP_190040, AAD38039, CAD30692, CAN81280, NP_197642, NP_190041, AAL15288, and NP_190042

[0195] Fatty aldehyde decarboxylases suitable for use with the microbes and methods of the invention include, without limitation, those listed in Table 6.

[0196] Table 6. Fatty aldehyde decarboxylases listed by GenBank accession numbers.

NP_850932, ABN07985, CAN60676, AAC23640, CAA65199, AAC24373, CAE03390, ABD28319, NP_181306, EAZ31322, CAN63491, EAY94825, EAY86731, CAL55686, XP_001420263, EAZ23849, NP_200588, NP_001063227, CAN83072, AAR90847, and AAR97643

[0197] Combinations of naturally co-expressed fatty acyl-ACP thioesterases and acyl carrier proteins are suitable for use with the microbes and methods of the invention.

[0198] Additional examples of hydrocarbon or lipid modification enzymes include amino acid sequences contained in, referenced in, or encoded by nucleic acid sequences contained or referenced in, any of the following US patents: 6,610,527; 6,451,576; 6,429,014; 6,342,380; 6,265,639; 6,194,185; 6,114,160; 6,083,731; 6,043,072 ; 5,994,114; 5,891,697; 5,871,988; 6,265,639, and further described in GenBank Accession numbers: AAO18435;

ZP_00513891; Q38710; AAK60613; AAK60610; AAK60611; NP_113747; CAB75874; AAK60612; AAF20201; BAA11024; AF205791; and CAA03710.

[0199] Other suitable enzymes for use with the microbes and the methods of the invention include those that have at least 70% amino acid identity with one of the proteins listed in Tables 3-6, and that exhibit the corresponding desired enzymatic activity (e.g., cleavage of a fatty acid from an acyl carrier protein, reduction of an acyl-CoA to an aldehyde or an alcohol, or conversion of an aldehyde to an alkane). In additional embodiments, the enzymatic activity is present in a sequence that has at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identity with one of the above described sequences, all of which are hereby incorporated by reference as if fully set forth.

[0200] By selecting the desired combination of exogenous genes to be expressed, one can tailor the product generated by the microbe, which may then be extracted from the aqueous biomass. For example, the microbe can contain: (i) an exogenous gene encoding a fatty acyl-ACP thioesterase; and, optionally, (ii) a naturally co-expressed acyl carrier protein or an acyl carrier protein otherwise having affinity for the fatty acyl-ACP thioesterase (or conversely); and, optionally, (iii) an exogenous gene encoding a fatty acyl-CoA/aldehyde reductase or a fatty acyl-CoA reductase; and, optionally, (iv) an exogenous gene encoding a fatty aldehyde reductase or a fatty aldehyde decarbonylase. The microbe, under culture conditions described herein, synthesizes a fatty acid linked to an ACP and the fatty acyl-ACP thioesterase catalyzes the cleavage of the fatty acid from the ACP to yield, through further enzymatic processing, a fatty acyl-CoA molecule. When present, the fatty acyl-CoA/aldehyde reductase catalyzes the reduction of the acyl-CoA to an alcohol. Similarly, the fatty acyl-CoA reductase, when present, catalyzes the reduction of the acyl-CoA to an aldehyde. In those embodiments in which an exogenous gene encoding a fatty acyl-CoA reductase is present and expressed to yield an aldehyde product, a fatty aldehyde reductase, encoded by the third exogenous gene, catalyzes the reduction of the aldehyde to an alcohol. Similarly, a fatty aldehyde decarbonylase catalyzes the conversion of the aldehyde to an alkane or an alkene, when present.

[0201] Genes encoding such enzymes can be obtained from cells already known to exhibit significant lipid production such as *Chlorella protothecoides*. Genes already known to have a role in lipid production, e.g., a gene encoding an enzyme that saturates double bonds, can be transformed individually into recipient cells. However, to practice the invention it is not necessary to make *a priori* assumptions as to which genes are required. Methods for

identifying genes that can alter (improve) lipid production in microalgae are described in PCT Pub. No. 2008/151149.

[0202] Thus, the present invention provides a *Prototheca* cell that has been genetically engineered to express a lipid pathway enzyme at an altered level compared to a wild-type cell of the same species. In some cases, the cell produces more lipid compared to the wild-type cell when both cells are grown under the same conditions. In some cases, the cell has been genetically engineered and/or selected to express a lipid pathway enzyme at a higher level than the wild-type cell. In some cases, the lipid pathway enzyme is selected from the group consisting of pyruvate dehydrogenase, acetyl-CoA carboxylase, acyl carrier protein, and glycerol-3 phosphate acyltransferase. In some cases, the cell has been genetically engineered and/or selected to express a lipid pathway enzyme at a lower level than the wild-type cell. In at least one embodiment in which the cell expresses the lipid pathway enzyme at a lower level, the lipid pathway enzyme comprises citrate synthase.

[0203] In some embodiments, the cell has been genetically engineered and/or selected to express a global regulator of fatty acid synthesis at an altered level compared to the wild-type cell, whereby the expression levels of a plurality of fatty acid synthetic genes are altered compared to the wild-type cell. In some cases, the lipid pathway enzyme comprises an enzyme that modifies a fatty acid. In some cases, the lipid pathway enzyme is selected from a stearoyl-ACP desaturase and a glycerolipid desaturase.

[0204] In other embodiments, the present invention is directed to an oil-producing microbe containing one or more exogenous genes, wherein the exogenous genes encode protein(s) selected from the group consisting of a fatty acyl-ACP thioesterase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty acyl-CoA/aldehyde reductase, a fatty aldehyde decarbonylase, and an acyl carrier protein. In one embodiment, the exogenous gene is in operable linkage with a promoter, which is inducible or repressible in response to a stimulus. In some cases, the stimulus is selected from the group consisting of an exogenously provided small molecule, heat, cold, and limited or no nitrogen in the culture media. In some cases, the exogenous gene is expressed in a cellular compartment. In some embodiments, the cellular compartment is selected from the group consisting of a chloroplast, a plastid and a mitochondrion. In some embodiments the microbe is *Prototheca moriformis*, *Prototheca krugani*, *Prototheca stagnora* or *Prototheca zopfii*.

[0205] In one embodiment, the exogenous gene encodes a fatty acid acyl-ACP thioesterase. In some cases, the thioesterase encoded by the exogenous gene catalyzes the cleavage of an 8 to 18-carbon fatty acid from an acyl carrier protein (ACP). In some cases, the thioesterase

encoded by the exogenous gene catalyzes the cleavage of a 10 to 14-carbon fatty acid from an ACP. In one embodiment, the thioesterase encoded by the exogenous gene catalyzes the cleavage of a 12-carbon fatty acid from an ACP.

[0206] In one embodiment, the exogenous gene encodes a fatty acyl-CoA/aldehyde reductase. In some cases, the reductase encoded by the exogenous gene catalyzes the reduction of an 8 to 18-carbon fatty acyl-CoA to a corresponding primary alcohol. In some cases, the reductase encoded by the exogenous gene catalyzes the reduction of a 10 to 14-carbon fatty acyl-CoA to a corresponding primary alcohol. In one embodiment, the reductase encoded by the exogenous gene catalyzes the reduction of a 12-carbon fatty acyl-CoA to dodecanol.

[0207] The present invention also provides a recombinant *Prototheca* cell containing two exogenous genes, wherein a first exogenous gene encodes a fatty acyl-ACP thioesterase and a second exogenous gene encodes a protein selected from the group consisting of a fatty acyl-CoA reductase, a fatty acyl-CoA/aldehyde reductase, and an acyl carrier protein. In some cases, the two exogenous genes are each in operable linkage with a promoter, which is inducible in response to a stimulus. In some cases, each promoter is inducible in response to an identical stimulus, such as limited or no nitrogen in the culture media. Limitation or complete lack of nitrogen in the culture media stimulates oil production in some microorganisms such as *Prototheca* species, and can be used as a trigger to induce oil production to high levels. When used in combination with the genetic engineering methods disclosed herein, the lipid as a percentage of dry cell weight can be pushed to high levels such as at least 30%, at least 40%, at least 50%, at least 60%, at least 70% and at least 75%; methods disclosed herein provide for cells with these levels of lipid, wherein the lipid is at least 4% C8-C14, at least 0.3% C8, at least 2% C10, at least 2% C12, and at least 2% C14. In some embodiments the cells are over 25% lipid by dry cell weight and contain lipid that is at least 10% C8-C14, at least 20% C8-C14, at least 30% C8-C14, 10-30% C8-C14 and 20-30% C8-C14.

[0208] The novel oils disclosed herein are distinct from other naturally occurring oils that are high in mic-chain fatty acids, such as palm oil, palm kernel oil, and coconut oil. For example, levels of contaminants such as carotenoids are far higher in palm oil and palm kernel oil than in the oils of the invention. Palm and palm kernel oils in particular contain alpha and beta carotenes and lycopene in much higher amounts than is in the oils of the invention. In addition, over 20 different carotenoids are found in palm and palm kernel oil, whereas the Examples demonstrate that the oils of the invention contain very few carotenoids

species and very low levels. In addition, the levels of vitamin E compounds such as tocotrienols are far higher in palm, palm kernel, and coconut oil than in the oils of the invention.

[0209] In one embodiment, the thioesterase encoded by the first exogenous gene catalyzes the cleavage of an 8 to 18-carbon fatty acid from an ACP. In some embodiments, the second exogenous gene encodes a fatty acyl-CoA/aldehyde reductase which catalyzes the reduction of an 8 to 18-carbon fatty acyl-CoA to a corresponding primary alcohol. In some cases, the thioesterase encoded by the first exogenous gene catalyzes the cleavage of a 10 to 14-carbon fatty acid from an ACP, and the reductase encoded by the second exogenous gene catalyzes the reduction of a 10 to 14-carbon fatty acyl-CoA to the corresponding primary alcohol, wherein the thioesterase and the reductase act on the same carbon chain length. In one embodiment, the thioesterase encoded by the first exogenous gene catalyzes the cleavage of a 12-carbon fatty acid from an ACP, and the reductase encoded by the second exogenous gene catalyzes the reduction of a 12-carbon fatty acyl-CoA to dodecanol. In some embodiments, the second exogenous gene encodes a fatty acyl-CoA reductase which catalyzes the reduction of an 8 to 18-carbon fatty acyl-CoA to a corresponding aldehyde. In some embodiments, the second exogenous gene encodes an acyl carrier protein that is naturally co-expressed with the fatty acyl-ACP thioesterase.

[0210] In some embodiments, the second exogenous gene encodes a fatty acyl-CoA reductase, and the microbe further contains a third exogenous gene encoding a fatty aldehyde decarbonylase. In some cases, the thioesterase encoded by the first exogenous gene catalyzes the cleavage of an 8 to 18-carbon fatty acid from an ACP, the reductase encoded by the second exogenous gene catalyzes the reduction of an 8 to 18-carbon fatty acyl-CoA to a corresponding fatty aldehyde, and the decarbonylase encoded by the third exogenous gene catalyzes the conversion of an 8 to 18-carbon fatty aldehyde to a corresponding alkane, wherein the thioesterase, the reductase, and the decarbonylase act on the same carbon chain length.

[0211] In some embodiments, the second exogenous gene encodes an acyl carrier protein, and the microbe further contains a third exogenous gene encoding a protein selected from the group consisting of a fatty acyl-CoA reductase and a fatty acyl-CoA/aldehyde reductase. In some cases, the third exogenous gene encodes a fatty acyl-CoA reductase, and the microbe further contains a fourth exogenous gene encoding a fatty aldehyde decarbonylase.

[0212] The present invention also provides methods for producing an alcohol comprising culturing a population of recombinant *Prototheca* cells in a culture medium, wherein the cells

contain (i) a first exogenous gene encoding a fatty acyl-ACP thioesterase, and (ii) a second exogenous gene encoding a fatty acyl-CoA/aldehyde reductase, and the cells synthesize a fatty acid linked to an acyl carrier protein (ACP), the fatty acyl-ACP thioesterase catalyzes the cleavage of the fatty acid from the ACP to yield, through further processing, a fatty acyl-CoA, and the fatty acyl-CoA/aldehyde reductase catalyzes the reduction of the acyl-CoA to an alcohol.

[0213] The present invention also provides methods of producing a lipid molecule in a *Prototheca* cell. In one embodiment, the method comprises culturing a population of *Prototheca* cells in a culture medium, wherein the cells contain (i) a first exogenous gene encoding a fatty acyl-ACP thioesterase, and (ii) a second exogenous gene encoding a fatty acyl-CoA reductase, and wherein the microbes synthesize a fatty acid linked to an acyl carrier protein (ACP), the fatty acyl-ACP thioesterase catalyzes the cleavage of the fatty acid from the ACP to yield, through further processing, a fatty acyl-CoA, and the fatty acyl-CoA reductase catalyzes the reduction of the acyl-CoA to an aldehyde.

[0214] The present invention also provides methods of producing a fatty acid molecule having a specified carbon chain length in a *Prototheca* cell. In one embodiment, the method comprises culturing a population of lipid-producing *Prototheca* cells in a culture medium, wherein the microbes contain an exogenous gene encoding a fatty acyl-ACP thioesterase having an activity specific or preferential to a certain carbon chain length, such as 8, 10, 12 or 14 carbon atoms, and wherein the microbes synthesize a fatty acid linked to an acyl carrier protein (ACP) and the thioesterase catalyzes the cleavage of the fatty acid from the ACP when the fatty acid has been synthesized to the specific carbon chain length.

[0215] In the various embodiments described above, the *Prototheca* cell can contain at least one exogenous gene encoding a lipid pathway enzyme. In some cases, the lipid pathway enzyme is selected from the group consisting of a stearoyl-ACP desaturase, a glycerolipid desaturase, a pyruvate dehydrogenase, an acetyl-CoA carboxylase, an acyl carrier protein, and a glycerol-3 phosphate acyltransferase. In other cases, the *Prototheca* cell contains a lipid modification enzyme selected from the group consisting of a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty aldehyde decarbonylase, and/or an acyl carrier protein.

VI. FUELS AND CHEMICALS PRODUCTION

[0216] For the production of fuel in accordance with the methods of the invention lipids produced by cells of the invention are harvested, or otherwise collected, by any convenient means. Lipids can be isolated by whole cell extraction. The cells are first disrupted, and then

intracellular and cell membrane/cell wall-associated lipids as well as extracellular hydrocarbons can be separated from the cell mass, such as by use of centrifugation as described above. Intracellular lipids produced in microorganisms are, in some embodiments, extracted after lysing the cells of the microorganism. Once extracted, the lipids are further refined to produce oils, fuels, or oleochemicals.

[0217] After completion of culturing, the microorganisms can be separated from the fermentation broth. Optionally, the separation is effected by centrifugation to generate a concentrated paste. Centrifugation does not remove significant amounts of intracellular water from the microorganisms and is not a drying step. The biomass can then optionally be washed with a washing solution (e.g., DI water) to get rid of the fermentation broth and debris. Optionally, the washed microbial biomass may also be dried (oven dried, lyophilized, etc.) prior to cell disruption. Alternatively, cells can be lysed without separation from some or all of the fermentation broth when the fermentation is complete. For example, the cells can be at a ratio of less than 1:1 v:v cells to extracellular liquid when the cells are lysed.

[0218] Microorganisms containing a lipid can be lysed to produce a lysate. As detailed herein, the step of lysing a microorganism (also referred to as cell lysis) can be achieved by any convenient means, including heat-induced lysis, adding a base, adding an acid, using enzymes such as proteases and polysaccharide degradation enzymes such as amylases, using ultrasound, mechanical lysis, using osmotic shock, infection with a lytic virus, and/or expression of one or more lytic genes. Lysis is performed to release intracellular molecules which have been produced by the microorganism. Each of these methods for lysing a microorganism can be used as a single method or in combination simultaneously or sequentially. The extent of cell disruption can be observed by microscopic analysis. Using one or more of the methods described herein, typically more than 70% cell breakage is observed. Preferably, cell breakage is more than 80%, more preferably more than 90% and most preferred about 100%.

[0219] In particular embodiments, the microorganism is lysed after growth, for example to increase the exposure of cellular lipid and/or hydrocarbon for extraction or further processing. The timing of lipase expression (e.g., via an inducible promoter) or cell lysis can be adjusted to optimize the yield of lipids and/or hydrocarbons. Below are described a number of lysis techniques. These techniques can be used individually or in combination.

[0220] In one embodiment of the present invention, the step of lysing a microorganism comprises heating of a cellular suspension containing the microorganism. In this embodiment, the fermentation broth containing the microorganisms (or a suspension of

microorganisms isolated from the fermentation broth) is heated until the microorganisms, i.e., the cell walls and membranes of microorganisms degrade or breakdown. Typically, temperatures applied are at least 50°C. Higher temperatures, such as, at least 30°C at least 60°C, at least 70°C, at least 80°C, at least 90°C, at least 100°C, at least 110°C, at least 120°C, at least 130°C or higher are used for more efficient cell lysis. Lysing cells by heat treatment can be performed by boiling the microorganism. Alternatively, heat treatment (without boiling) can be performed in an autoclave. The heat treated lysate may be cooled for further treatment. Cell disruption can also be performed by steam treatment, i.e., through addition of pressurized steam. Steam treatment of microalgae for cell disruption is described, for example, in U.S. Patent No. 6,750,048. In some embodiments, steam treatment may be achieved by sparging steam into the fermentor and maintaining the broth at a desired temperature for less than about 90 minutes, preferably less than about 60 minutes, and more preferably less than about 30 minutes.

[0221] In another embodiment of the present invention, the step of lysing a microorganism comprises adding a base to a cellular suspension containing the microorganism. The base should be strong enough to hydrolyze at least a portion of the proteinaceous compounds of the microorganisms used. Bases which are useful for solubilizing proteins are known in the art of chemistry. Exemplary bases which are useful in the methods of the present invention include, but are not limited to, hydroxides, carbonates and bicarbonates of lithium, sodium, potassium, calcium, and mixtures thereof. A preferred base is KOH. Base treatment of microalgae for cell disruption is described, for example, in U.S. Patent No. 6,750,048.

[0222] In another embodiment of the present invention, the step of lysing a microorganism comprises adding an acid to a cellular suspension containing the microorganism. Acid lysis can be effected using an acid at a concentration of 10-500 mM or preferably 40-160 mM. Acid lysis is preferably performed at above room temperature (e.g., at 40-160°, and preferably a temperature of 50-130°. For moderate temperatures (e.g., room temperature to 100°C and particularly room temperature to 65°, acid treatment can usefully be combined with sonication or other cell disruption methods.

[0223] In another embodiment of the present invention, the step of lysing a microorganism comprises lysing the microorganism by using an enzyme. Preferred enzymes for lysing a microorganism are proteases and polysaccharide-degrading enzymes such as hemicellulase (e.g., hemicellulase from *Aspergillus niger*; Sigma Aldrich, St. Louis, MO; #H2125), pectinase (e.g., pectinase from *Rhizopus sp.*; Sigma Aldrich, St. Louis, MO; #P2401), Mannaway 4.0 L (Novozymes), cellulase (e.g., cellulose from *Trichoderma viride*; Sigma

Aldrich, St. Louis, MO; #C9422), and driselase (e.g., driselase from *Basidiomycetes* sp.; Sigma Aldrich, St. Louis, MO; #D9515).

[0224] In other embodiments of the present invention, lysis is accomplished using an enzyme such as, for example, a cellulase such as a polysaccharide-degrading enzyme, optionally from *Chlorella* or a *Chlorella* virus, or a proteases, such as *Streptomyces griseus* protease, chymotrypsin, proteinase K, proteases listed in Degradation of Polylactide by Commercial Proteases, Oda Yet al., Journal of Polymers and the Environment, Volume 8, Number 1, January 2000 , pp. 29-32(4), Alcalase 2.4 FG (Novozymes), and Flavourzyme 100 L (Novozymes). Any combination of a protease and a polysaccharide-degrading enzyme can also be used, including any combination of the preceding proteases and polysaccharide-degrading enzymes.

[0225] In another embodiment, lysis can be performed using an expeller press. In this process, biomass is forced through a screw-type device at high pressure, lysing the cells and causing the intracellular lipid to be released and separated from the protein and fiber (and other components) in the cell.

[0226] In another embodiment of the present invention, the step of lysing a microorganism is performed by using ultrasound, i.e., sonication. Thus, cells can also be lysed with high frequency sound. The sound can be produced electronically and transported through a metallic tip to an appropriately concentrated cellular suspension. This sonication (or ultrasonication) disrupts cellular integrity based on the creation of cavities in cell suspension.

[0227] In another embodiment of the present invention, the step of lysing a microorganism is performed by mechanical lysis. Cells can be lysed mechanically and optionally homogenized to facilitate hydrocarbon (e.g., lipid) collection. For example, a pressure disrupter can be used to pump a cell containing slurry through a restricted orifice valve. High pressure (up to 1500 bar) is applied, followed by an instant expansion through an exiting nozzle. Cell disruption is accomplished by three different mechanisms: impingement on the valve, high liquid shear in the orifice, and sudden pressure drop upon discharge, causing an explosion of the cell. The method releases intracellular molecules. Alternatively, a ball mill can be used. In a ball mill, cells are agitated in suspension with small abrasive particles, such as beads. Cells break because of shear forces, grinding between beads, and collisions with beads. The beads disrupt the cells to release cellular contents. Cells can also be disrupted by shear forces, such as with the use of blending (such as with a high speed or Waring blender as examples), the french press, or even centrifugation in case of weak cell walls, to disrupt cells.

[0228] In another embodiment of the present invention, the step of lysing a microorganism is performed by applying an osmotic shock.

[0229] In another embodiment of the present invention, the step of lysing a microorganism comprises infection of the microorganism with a lytic virus. A wide variety of viruses are known to lyse microorganisms suitable for use in the present invention, and the selection and use of a particular lytic virus for a particular microorganism is within the level of skill in the art. For example, *paramecium bursaria chlorella* virus (PBCV-1) is the prototype of a group (family Phycodnaviridae, genus Chlorovirus) of large, icosahedral, plaque-forming, double-stranded DNA viruses that replicate in, and lyse, certain unicellular, eukaryotic chlorella-like green algae. Accordingly, any susceptible microalgae can be lysed by infecting the culture with a suitable chlorella virus. Methods of infecting species of *Chlorella* with a chlorella virus are known. See for example *Adv. Virus Res.* 2006;66:293-336; *Virology*, 1999 Apr 25;257(1):15-23; *Virology*, 2004 Jan 5;318(1):214-23; *Nucleic Acids Symp. Ser.* 2000;(44):161-2; *J. Virol.* 2006 Mar;80(5):2437-44; and *Annu. Rev. Microbiol.* 1999;53:447-94.

[0230] In another embodiment of the present invention, the step of lysing a microorganism comprises autolysis. In this embodiment, a microorganism according to the invention is genetically engineered to produce a lytic protein that will lyse the microorganism. This lytic gene can be expressed using an inducible promoter so that the cells can first be grown to a desirable density in a fermentor, followed by induction of the promoter to express the lytic gene to lyse the cells. In one embodiment, the lytic gene encodes a polysaccharide-degrading enzyme. In certain other embodiments, the lytic gene is a gene from a lytic virus. Thus, for example, a lytic gene from a Chlorella virus can be expressed in an algal cell; see *Virology* 260, 308-315 (1999); *FEMS Microbiology Letters* 180 (1999) 45-53; *Virology* 263, 376-387 (1999); and *Virology* 230, 361-368 (1997). Expression of lytic genes is preferably done using an inducible promoter, such as a promoter active in microalgae that is induced by a stimulus such as the presence of a small molecule, light, heat, and other stimuli.

[0231] Various methods are available for separating lipids from cellular lysates produced by the above methods. For example, lipids and lipid derivatives such as fatty aldehydes, fatty alcohols, and hydrocarbons such as alkanes can be extracted with a hydrophobic solvent such as hexane (see Frenz et al. 1989, *Enzyme Microb. Technol.*, 11:717). Lipids and lipid derivatives can also be extracted using liquefaction (see for example Sawayama et al. 1999, *Biomass and Bioenergy* 17:33-39 and Inoue et al. 1993, *Biomass Bioenergy* 6(4):269-274); oil liquefaction (see for example Minowa et al. 1995, *Fuel* 74(12):1735-1738); and

supercritical CO₂ extraction (see for example Mendes et al. 2003, *Inorganica Chimica Acta* 356:328-334). Miao and Wu describe a protocol of the recovery of microalgal lipid from a culture of *Chlorella prototheocoides* in which the cells were harvested by centrifugation, washed with distilled water and dried by freeze drying. The resulting cell powder was pulverized in a mortar and then extracted with *n*-hexane. Miao and Wu, *Biosource Technology* (2006) 97:841-846.

[0232] Thus, lipids, lipid derivatives and hydrocarbons generated by the microorganisms of the present invention can be recovered by extraction with an organic solvent. In some cases, the preferred organic solvent is hexane. Typically, the organic solvent is added directly to the lysate without prior separation of the lysate components. In one embodiment, the lysate generated by one or more of the methods described above is contacted with an organic solvent for a period of time sufficient to allow the lipid and/or hydrocarbon components to form a solution with the organic solvent. In some cases, the solution can then be further refined to recover specific desired lipid or hydrocarbon components. Hexane extraction methods are well known in the art.

[0233] Lipids and lipid derivatives such as fatty aldehydes, fatty alcohols, and hydrocarbons such as alkanes produced by cells as described herein can be modified by the use of one or more enzymes, including a lipase, as described above. When the hydrocarbons are in the extracellular environment of the cells, the one or more enzymes can be added to that environment under conditions in which the enzyme modifies the hydrocarbon or completes its synthesis from a hydrocarbon precursor. Alternatively, the hydrocarbons can be partially, or completely, isolated from the cellular material before addition of one or more catalysts such as enzymes. Such catalysts are exogenously added, and their activity occurs outside the cell or *in vitro*.

[0234] Thus, lipids and hydrocarbons produced by cells *in vivo*, or enzymatically modified *in vitro*, as described herein can be optionally further processed by conventional means. The processing can include "cracking" to reduce the size, and thus increase the hydrogen:carbon ratio, of hydrocarbon molecules. Catalytic and thermal cracking methods are routinely used in hydrocarbon and triglyceride oil processing. Catalytic methods involve the use of a catalyst, such as a solid acid catalyst. The catalyst can be silica-alumina or a zeolite, which result in the heterolytic, or asymmetric, breakage of a carbon-carbon bond to result in a carbocation and a hydride anion. These reactive intermediates then undergo either rearrangement or hydride transfer with another hydrocarbon. The reactions can thus regenerate the intermediates to result in a self-propagating chain mechanism. Hydrocarbons

can also be processed to reduce, optionally to zero, the number of carbon-carbon double, or triple, bonds therein. Hydrocarbons can also be processed to remove or eliminate a ring or cyclic structure therein. Hydrocarbons can also be processed to increase the hydrogen:carbon ratio. This can include the addition of hydrogen ("hydrogenation") and/or the "cracking" of hydrocarbons into smaller hydrocarbons.

[0235] Thermal methods involve the use of elevated temperature and pressure to reduce hydrocarbon size. An elevated temperature of about 800°C and pressure of about 700kPa can be used. These conditions generate "light," a term that is sometimes used to refer to hydrogen-rich hydrocarbon molecules (as distinguished from photon flux), while also generating, by condensation, heavier hydrocarbon molecules which are relatively depleted of hydrogen. The methodology provides homolytic, or symmetrical, breakage and produces alkenes, which may be optionally enzymatically saturated as described above.

[0236] Catalytic and thermal methods are standard in plants for hydrocarbon processing and oil refining. Thus hydrocarbons produced by cells as described herein can be collected and processed or refined via conventional means. See Hillen et al. (Biotechnology and Bioengineering, Vol. XXIV:193-205 (1982)) for a report on hydrocracking of microalgae-produced hydrocarbons. In alternative embodiments, the fraction is treated with another catalyst, such as an organic compound, heat, and/or an inorganic compound. For processing of lipids into biodiesel, a transesterification process is used as described in Section IV herein.

[0237] Hydrocarbons produced via methods of the present invention are useful in a variety of industrial applications. For example, the production of linear alkylbenzene sulfonate (LAS), an anionic surfactant used in nearly all types of detergents and cleaning preparations, utilizes hydrocarbons generally comprising a chain of 10-14 carbon atoms. See, for example, US Patent Nos.: 6,946,430; 5,506,201; 6,692,730; 6,268,517; 6,020,509; 6,140,302; 5,080,848; and 5,567,359. Surfactants, such as LAS, can be used in the manufacture of personal care compositions and detergents, such as those described in US Patent Nos.: 5,942,479; 6,086,903; 5,833,999; 6,468,955; and 6,407,044.

[0238] Increasing interest is directed to the use of hydrocarbon components of biological origin in fuels, such as biodiesel, renewable diesel, and jet fuel, since renewable biological starting materials that may replace starting materials derived from fossil fuels are available, and the use thereof is desirable. There is an urgent need for methods for producing hydrocarbon components from biological materials. The present invention fulfills this need by providing methods for production of biodiesel, renewable diesel, and jet fuel using the

lipids generated by the methods described herein as a biological material to produce biodiesel, renewable diesel, and jet fuel.

[0239] Traditional diesel fuels are petroleum distillates rich in paraffinic hydrocarbons. They have boiling ranges as broad as 370° to 780°F, which are suitable for combustion in a compression ignition engine, such as a diesel engine vehicle. The American Society of Testing and Materials (ASTM) establishes the grade of diesel according to the boiling range, along with allowable ranges of other fuel properties, such as cetane number, cloud point, flash point, viscosity, aniline point, sulfur content, water content, ash content, copper strip corrosion, and carbon residue. Technically, any hydrocarbon distillate material derived from biomass or otherwise that meets the appropriate ASTM specification can be defined as diesel fuel (ASTM D975), jet fuel (ASTM D1655), or as biodiesel if it is a fatty acid methyl ester (ASTM D6751).

[0240] After extraction, lipid and/or hydrocarbon components recovered from the microbial biomass described herein can be subjected to chemical treatment to manufacture a fuel for use in diesel vehicles and jet engines.

[0241] Biodiesel is a liquid which varies in color - between golden and dark brown - depending on the production feedstock. It is practically immiscible with water, has a high boiling point and low vapor pressure. Biodiesel refers to a diesel-equivalent processed fuel for use in diesel-engine vehicles. Biodiesel is biodegradable and non-toxic. An additional benefit of biodiesel over conventional diesel fuel is lower engine wear. Typically, biodiesel comprises C14-C18 alkyl esters. Various processes convert biomass or a lipid produced and isolated as described herein to diesel fuels. A preferred method to produce biodiesel is by transesterification of a lipid as described herein. A preferred alkyl ester for use as biodiesel is a methyl ester or ethyl ester.

[0242] Biodiesel produced by a method described herein can be used alone or blended with conventional diesel fuel at any concentration in most modern diesel-engine vehicles. When blended with conventional diesel fuel (petroleum diesel), biodiesel may be present from about 0.1% to about 99.9%. Much of the world uses a system known as the "B" factor to state the amount of biodiesel in any fuel mix. For example, fuel containing 20% biodiesel is labeled B20. Pure biodiesel is referred to as B100.

[0243] Biodiesel can also be used as a heating fuel in domestic and commercial boilers. Existing oil boilers may contain rubber parts and may require conversion to run on biodiesel. The conversion process is usually relatively simple, involving the exchange of rubber parts for synthetic parts due to biodiesel being a strong solvent. Due to its strong solvent power,


burning biodiesel will increase the efficiency of boilers. Biodiesel can be used as an additive in formulations of diesel to increase the lubricity of pure Ultra-Low Sulfur Diesel (ULSD) fuel, which is advantageous because it has virtually no sulfur content. Biodiesel is a better solvent than petrodiesel and can be used to break down deposits of residues in the fuel lines of vehicles that have previously been run on petrodiesel.

[0244] Biodiesel can be produced by transesterification of triglycerides contained in oil-rich biomass. Thus, in another aspect of the present invention a method for producing biodiesel is provided. In a preferred embodiment, the method for producing biodiesel comprises the steps of (a) cultivating a lipid-containing microorganism using methods disclosed herein (b) lysing a lipid-containing microorganism to produce a lysate, (c) isolating lipid from the lysed microorganism, and (d) transesterifying the lipid composition, whereby biodiesel is produced. Methods for growth of a microorganism, lysing a microorganism to produce a lysate, treating the lysate in a medium comprising an organic solvent to form a heterogeneous mixture and separating the treated lysate into a lipid composition have been described above and can also be used in the method of producing biodiesel.

[0245] The lipid profile of the biodiesel is usually highly similar to the lipid profile of the feedstock oil. Other oils provided by the methods and compositions of the invention can be subjected to transesterification to yield biodiesel with lipid profiles including (a) at least 4% C8-C14; (b) at least 0.3% C8; (c) at least 2% C10; (d) at least 2% C12; and (3) at least 30% C8-C14.

[0246] Lipid compositions can be subjected to transesterification to yield long-chain fatty acid esters useful as biodiesel. Preferred transesterification reactions are outlined below and include base catalyzed transesterification and transesterification using recombinant lipases. In a base-catalyzed transesterification process, the triacylglycerides are reacted with an alcohol, such as methanol or ethanol, in the presence of an alkaline catalyst, typically potassium hydroxide. This reaction forms methyl or ethyl esters and glycerin (glycerol) as a byproduct.

[0247] Animal and plant oils are typically made of triglycerides which are esters of free fatty acids with the trihydric alcohol, glycerol. In transesterification, the glycerol in a triacylglyceride (TAG) is replaced with a short-chain alcohol such as methanol or ethanol. A typical reaction scheme is as follows:



In this reaction, the alcohol is deprotonated with a base to make it a stronger nucleophile. Commonly, ethanol or methanol is used in vast excess (up to 50-fold). Normally, this reaction will proceed either exceedingly slowly or not at all. Heat, as well as an acid or base can be used to help the reaction proceed more quickly. The acid or base are not consumed by the transesterification reaction, thus they are not reactants but catalysts. Almost all biodiesel has been produced using the base-catalyzed technique as it requires only low temperatures and pressures and produces over 98% conversion yield (provided the starting oil is low in moisture and free fatty acids).

[0248] Transesterification has also been carried out, as discussed above, using an enzyme, such as a lipase instead of a base. Lipase-catalyzed transesterification can be carried out, for example, at a temperature between the room temperature and 80° C, and a mole ratio of the TAG to the lower alcohol of greater than 1:1, preferably about 3:1. Lipases suitable for use in transesterification include, but are not limited to, those listed in Table 7. Other examples of lipases useful for transesterification are found in, e.g. U.S. Patent Nos. 4,798,793; 4,940,845 5,156,963; 5,342,768; 5,776,741 and WO89/01032. Such lipases include, but are not limited to, lipases produced by microorganisms of *Rhizopus*, *Aspergillus*, *Candida*, *Mucor*, *Pseudomonas*, *Rhizomucor*, *Candida*, and *Humicola* and pancreas lipase.

[0249] Table 7. Lipases suitable for use in transesterification.

<i>Aspergillus niger</i> lipase ABG73614, <i>Candida antarctica</i> lipase B (novozym-435) CAA83122, <i>Candida cylindracea</i> lipase AAR24090, <i>Candida lipolytica</i> lipase (Lipase L; Amano Pharmaceutical Co., Ltd.), <i>Candida rugosa</i> lipase (e.g., Lipase-OF; Meito Sangyo Co., Ltd.), <i>Mucor miehei</i> lipase (Lipozyme IM 20), <i>Pseudomonas fluorescens</i> lipase AAA25882, <i>Rhizopus japonicus</i> lipase (Lilipase A-10FG) Q7M4U7_1, <i>Rhizomucor miehei</i> lipase B34959, <i>Rhizopus oryzae</i> lipase (Lipase F) AAF32408, <i>Serratia marcescens</i> lipase (SM Enzyme) ABI13521, <i>Thermomyces lanuginosa</i> lipase CAB58509, Lipase P (Nagase ChemteX Corporation), and Lipase QLM (Meito Sangyo Co., Ltd., Nagoya, Japan)
--

[0250] One challenge to using a lipase for the production of fatty acid esters suitable for biodiesel is that the price of lipase is much higher than the price of sodium hydroxide (NaOH) used by the strong base process. This challenge has been addressed by using an immobilized lipase, which can be recycled. However, the activity of the immobilized lipase must be maintained after being recycled for a minimum number of cycles to allow a lipase-

based process to compete with the strong base process in terms of the production cost. Immobilized lipases are subject to poisoning by the lower alcohols typically used in transesterification. U.S. Patent No. 6,398,707 (issued June 4, 2002 to Wu et al.) describes methods for enhancing the activity of immobilized lipases and regenerating immobilized lipases having reduced activity. Some suitable methods include immersing an immobilized lipase in an alcohol having a carbon atom number not less than 3 for a period of time, preferably from 0.5-48 hours, and more preferably from 0.5-1.5 hours. Some suitable methods also include washing a deactivated immobilized lipase with an alcohol having a carbon atom number not less than 3 and then immersing the deactivated immobilized lipase in a vegetable oil for 0.5-48 hours.

[0251] In particular embodiments, a recombinant lipase is expressed in the same microorganisms that produce the lipid on which the lipase acts. Suitable recombinant lipases include those listed above in Table 7 and/or having GenBank Accession numbers listed above in Table 7, or a polypeptide that has at least 70% amino acid identity with one of the lipases listed above in Table 7 and that exhibits lipase activity. In additional embodiments, the enzymatic activity is present in a sequence that has at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identity with one of the above described sequences, all of which are hereby incorporated by reference as if fully set forth. DNA encoding the lipase and selectable marker is preferably codon-optimized cDNA. Methods of recoding genes for expression in microalgae are described in US Patent 7,135,290.

[0252] The common international standard for biodiesel is EN 14214. ASTM D6751 is the most common biodiesel standard referenced in the United States and Canada. Germany uses DIN EN 14214 and the UK requires compliance with BS EN 14214. Basic industrial tests to determine whether the products conform to these standards typically include gas chromatography, HPLC, and others. Biodiesel meeting the quality standards is very non-toxic, with a toxicity rating (LD_{50}) of greater than 50 mL/kg.

[0253] Although biodiesel that meets the ASTM standards has to be non-toxic, there can be contaminants which tend to crystallize and/or precipitate and fall out of solution as sediment. Sediment formation is particularly a problem when biodiesel is used at lower temperatures. The sediment or precipitates may cause problems such as decreasing fuel flow, clogging fuel lines, clogging filters, etc. Processes are well-known in the art that specifically deal with the removal of these contaminants and sediments in biodiesel in order to produce a higher quality product. Examples for such processes include, but are not limited to, pretreatment of the oil to

remove contaminants such as phospholipids and free fatty acids (e.g., degumming, caustic refining and silica adsorbant filtration) and cold filtration. Cold filtration is a process that was developed specifically to remove any particulates and sediments that are present in the biodiesel after production. This process cools the biodiesel and filters out any sediments or precipitates that might form when the fuel is used at a lower temperature. Such a process is well known in the art and is described in US Patent Application Publication No. 2007-0175091. Suitable methods may include cooling the biodiesel to a temperature of less than about 38°C so that the impurities and contaminants precipitate out as particulates in the biodiesel liquid. Diatomaceous earth or other filtering material may then added to the cooled biodiesel to form a slurry, which may then filtered through a pressure leaf or other type of filter to remove the particulates. The filtered biodiesel may then be run through a polish filter to remove any remaining sediments and diatomaceous earth, so as to produce the final biodiesel product.

[0254] Example 14 described the production of biodiesel using triglyceride oil from *Prototheca moriformis*. The Cold Soak Filterability by the ASTM D6751 A1 method of the biodiesel produced in Example 14 was 120 seconds for a volume of 300ml. This test involves filtration of 300 ml of B100, chilled to 40°F for 16 hours, allowed to warm to room temp, and filtered under vacuum using 0.7 micron glass fiber filter with stainless steel support. Oils of the invention can be transesterified to generate biodiesel with a cold soak time of less than 120 seconds, less than 100 seconds, and less than 90 seconds.

[0255] Subsequent processes may also be used if the biodiesel will be used in particularly cold temperatures. Such processes include winterization and fractionation. Both processes are designed to improve the cold flow and winter performance of the fuel by lowering the cloud point (the temperature at which the biodiesel starts to crystallize). There are several approaches to winterizing biodiesel. One approach is to blend the biodiesel with petroleum diesel. Another approach is to use additives that can lower the cloud point of biodiesel. Another approach is to remove saturated methyl esters indiscriminately by mixing in additives and allowing for the crystallization of saturates and then filtering out the crystals. Fractionation selectively separates methyl esters into individual components or fractions, allowing for the removal or inclusion of specific methyl esters. Fractionation methods include urea fractionation, solvent fractionation and thermal distillation.

[0256] Another valuable fuel provided by the methods of the present invention is renewable diesel, which comprises alkanes, such as C10:0, C12:0, C14:0, C16:0 and C18:0 and thus, are distinguishable from biodiesel. High quality renewable diesel conforms to the

ASTM D975 standard. The lipids produced by the methods of the present invention can serve as feedstock to produce renewable diesel. Thus, in another aspect of the present invention, a method for producing renewable diesel is provided. Renewable diesel can be produced by at least three processes: hydrothermal processing (hydrotreating); hydroprocessing; and indirect liquefaction. These processes yield non-ester distillates. During these processes, triacylglycerides produced and isolated as described herein, are converted to alkanes.

[0257] In one embodiment, the method for producing renewable diesel comprises (a) cultivating a lipid-containing microorganism using methods disclosed herein (b) lysing the microorganism to produce a lysate, (c) isolating lipid from the lysed microorganism, and (d) deoxygenating and hydrotreating the lipid to produce an alkane, whereby renewable diesel is produced. Lipids suitable for manufacturing renewable diesel can be obtained via extraction from microbial biomass using an organic solvent such as hexane, or via other methods, such as those described in US Patent 5,928,696. Some suitable methods may include mechanical pressing and centrifuging.

[0258] In some methods, the microbial lipid is first cracked in conjunction with hydrotreating to reduce carbon chain length and saturate double bonds, respectively. The material is then isomerized, also in conjunction with hydrotreating. The naptha fraction can then be removed through distillation, followed by additional distillation to vaporize and distill components desired in the diesel fuel to meet an ASTM D975 standard while leaving components that are heavier than desired for meeting the D975 standard. Hydrotreating, hydrocracking, deoxygenation and isomerization methods of chemically modifying oils, including triglyceride oils, are well known in the art. See for example European patent applications EP1741768 (A1); EP1741767 (A1); EP1682466 (A1); EP1640437 (A1); EP1681337 (A1); EP1795576 (A1); and U.S. Patents 7,238,277; 6,630,066; 6,596,155; 6,977,322; 7,041,866; 6,217,746; 5,885,440; 6,881,873.

[0259] In one embodiment of the method for producing renewable diesel, treating the lipid to produce an alkane is performed by hydrotreating of the lipid composition. In hydrothermal processing, typically, biomass is reacted in water at an elevated temperature and pressure to form oils and residual solids. Conversion temperatures are typically 300° to 660°F, with pressure sufficient to keep the water primarily as a liquid, 100 to 170 standard atmosphere (atm). Reaction times are on the order of 15 to 30 minutes. After the reaction is completed, the organics are separated from the water. Thereby a distillate suitable for diesel is produced.

[0260] In some methods of making renewable diesel, the first step of treating a triglyceride is hydroprocessing to saturate double bonds, followed by deoxygenation at elevated

temperature in the presence of hydrogen and a catalyst. In some methods, hydrogenation and deoxygenation occur in the same reaction. In other methods deoxygenation occurs before hydrogenation. Isomerization is then optionally performed, also in the presence of hydrogen and a catalyst. Naphtha components are preferably removed through distillation. For examples, see U.S. Patents 5,475,160 (hydrogenation of triglycerides); 5,091,116 (deoxygenation, hydrogenation and gas removal); 6,391,815 (hydrogenation); and 5,888,947 (isomerization).

[0261] One suitable method for the hydrogenation of triglycerides includes preparing an aqueous solution of copper, zinc, magnesium and lanthanum salts and another solution of alkali metal or preferably, ammonium carbonate. The two solutions may be heated to a temperature of about 20°C to about 85°C and metered together into a precipitation container at rates such that the pH in the precipitation container is maintained between 5.5 and 7.5 in order to form a catalyst. Additional water may be used either initially in the precipitation container or added concurrently with the salt solution and precipitation solution. The resulting precipitate may then be thoroughly washed, dried, calcined at about 300°C and activated in hydrogen at temperatures ranging from about 100°C to about 400°C. One or more triglycerides may then be contacted and reacted with hydrogen in the presence of the above-described catalyst in a reactor. The reactor may be a trickle bed reactor, fixed bed gas-solid reactor, packed bubble column reactor, continuously stirred tank reactor, a slurry phase reactor, or any other suitable reactor type known in the art. The process may be carried out either batchwise or in continuous fashion. Reaction temperatures are typically in the range of from about 170°C to about 250°C while reaction pressures are typically in the range of from about 300 psig to about 2000 psig. Moreover, the molar ratio of hydrogen to triglyceride in the process of the present invention is typically in the range of from about 20:1 to about 700:1. The process is typically carried out at a weight hourly space velocity (WHSV) in the range of from about 0.1 hr⁻¹ to about 5 hr⁻¹. One skilled in the art will recognize that the time period required for reaction will vary according to the temperature used, the molar ratio of hydrogen to triglyceride, and the partial pressure of hydrogen. The products produced by the such hydrogenation processes include fatty alcohols, glycerol, traces of paraffins and unreacted triglycerides. These products are typically separated by conventional means such as, for example, distillation, extraction, filtration, crystallization, and the like.

[0262] Petroleum refiners use hydroprocessing to remove impurities by treating feeds with hydrogen. Hydroprocessing conversion temperatures are typically 300° to 700°F. Pressures are typically 40 to 100 atm. The reaction times are typically on the order of 10 to 60 minutes.

Solid catalysts are employed to increase certain reaction rates, improve selectivity for certain products, and optimize hydrogen consumption.

[0263] Suitable methods for the deoxygenation of an oil includes heating an oil to a temperature in the range of from about 350°F to about 550°F and continuously contacting the heated oil with nitrogen under at least pressure ranging from about atmospheric to above for at least about 5 minutes.

[0264] Suitable methods for isomerization includes using alkali isomerization and other oil isomerization known in the art.

[0265] Hydrotreating and hydroprocessing ultimately lead to a reduction in the molecular weight of the triglyceride feed. The triglyceride molecule is reduced to four hydrocarbon molecules under hydroprocessing conditions: a propane molecule and three heavier hydrocarbon molecules, typically in the C8 to C18 range.

[0266] Thus, in one embodiment, the product of one or more chemical reaction(s) performed on lipid compositions of the invention is an alkane mixture that comprises ASTM D975 renewable diesel. Production of hydrocarbons by microorganisms is reviewed by Metzger et al. Appl Microbiol Biotechnol (2005) 66: 486–496 and A Look Back at the U.S. Department of Energy's Aquatic Species Program: Biodiesel from Algae, NREL/TP-580-24190, John Sheehan, Terri Dunahay, John Benemann and Paul Roessler (1998).

[0267] The distillation properties of a diesel fuel is described in terms of T10-T90 (temperature at 10% and 90%, respectively, volume distilled). Renewable diesel was produced from *Prototheca moriformis* triglyceride oil and is described in Example 14. The T10-T90 of the material produced in Example 14 was 57.9°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other T10-T90 ranges, such as 20, 25, 30, 35, 40, 45, 50, 60 and 65°C using triglyceride oils produced according to the methods disclosed herein.

[0268] The T10 of the material produced in Example 14 was 242.1°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other T10 values, such as T10 between 180 and 295, between 190 and 270, between 210 and 250, between 225 and 245, and at least 290.

[0269] The T90 of the material produced in Example 14 was 300°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein can be employed to generate renewable diesel compositions with other T90 values, such as T90 between 280 and 380, between 290 and 360, between 300 and 350, between 310 and 340, and at least 290.

[0270] The FBP of the material produced in Example 14 was 300°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other FBP values, such as FBP between 290 and 400, between 300 and 385, between 310 and 370, between 315 and 360, and at least 300.

[0271] Other oils provided by the methods and compositions of the invention can be subjected to combinations of hydrotreating, isomerization, and other covalent modification including oils with lipid profiles including (a) at least 4% C8-C14; (b) at least 0.3% C8; (c) at least 2% C10; (d) at least 2% C12; and (3) at least 30% C8-C14.

[0272] A traditional ultra-low sulfur diesel can be produced from any form of biomass by a two-step process. First, the biomass is converted to a syngas, a gaseous mixture rich in hydrogen and carbon monoxide. Then, the syngas is catalytically converted to liquids. Typically, the production of liquids is accomplished using Fischer-Tropsch (FT) synthesis. This technology applies to coal, natural gas, and heavy oils. Thus, in yet another preferred embodiment of the method for producing renewable diesel, treating the lipid composition to produce an alkane is performed by indirect liquefaction of the lipid composition.

[0273] The present invention also provides methods to produce jet fuel. Jet fuel is clear to straw colored. The most common fuel is an unleaded/paraffin oil-based fuel classified as Aeroplane A-1, which is produced to an internationally standardized set of specifications. Jet fuel is a mixture of a large number of different hydrocarbons, possibly as many as a thousand or more. The range of their sizes (molecular weights or carbon numbers) is restricted by the requirements for the product, for example, freezing point or smoke point. Kerosene-type Aeroplane fuel (including Jet A and Jet A-1) has a carbon number distribution between about 8 and 16 carbon numbers. Wide-cut or naphta-type Aeroplane fuel (including Jet B) typically has a carbon number distribution between about 5 and 15 carbons.

[0274] Both Aeroplanes (Jet A and Jet B) may contain a number of additives. Useful additives include, but are not limited to, antioxidants, antistatic agents, corrosion inhibitors,

and fuel system icing inhibitor (FSII) agents. Antioxidants prevent gumming and usually, are based on alkylated phenols, for example, AO-30, AO-31, or AO-37. Antistatic agents dissipate static electricity and prevent sparking. Stadis 450 with dinonylnaphthylsulfonic acid (DINNSA) as the active ingredient, is an example. Corrosion inhibitors, e.g., DCI-4A is used for civilian and military fuels and DCI-6A is used for military fuels. FSII agents, include, e.g., Di-EGME.

[0275] In one embodiment of the invention, a jet fuel is produced by blending algal fuels with existing jet fuel. The lipids produced by the methods of the present invention can serve as feedstock to produce jet fuel. Thus, in another aspect of the present invention, a method for producing jet fuel is provided. Herewith two methods for producing jet fuel from the lipids produced by the methods of the present invention are provided: fluid catalytic cracking (FCC); and hydrodeoxygenation (HDO).

[0276] Fluid Catalytic Cracking (FCC) is one method which is used to produce olefins, especially propylene from heavy crude fractions. The lipids produced by the method of the present invention can be converted to olefins. The process involves flowing the lipids produced through an FCC zone and collecting a product stream comprised of olefins, which is useful as a jet fuel. The lipids produced are contacted with a cracking catalyst at cracking conditions to provide a product stream comprising olefins and hydrocarbons useful as jet fuel.

[0277] In one embodiment, the method for producing jet fuel comprises (a) cultivating a lipid-containing microorganism using methods disclosed herein, (b) lysing the lipid-containing microorganism to produce a lysate, (c) isolating lipid from the lysate, and (d) treating the lipid composition, whereby jet fuel is produced. In one embodiment of the method for producing a jet fuel, the lipid composition can be flowed through a fluid catalytic cracking zone, which, in one embodiment, may comprise contacting the lipid composition with a cracking catalyst at cracking conditions to provide a product stream comprising C₂-C₅ olefins.

[0278] In certain embodiments of this method, it may be desirable to remove any contaminants that may be present in the lipid composition. Thus, prior to flowing the lipid composition through a fluid catalytic cracking zone, the lipid composition is pretreated. Pretreatment may involve contacting the lipid composition with an ion-exchange resin. The ion exchange resin is an acidic ion exchange resin, such as AmberlystTM-15 and can be used as a bed in a reactor through which the lipid composition is flowed, either upflow or downflow. Other pretreatments may include mild acid washes by contacting the lipid

composition with an acid, such as sulfuric, acetic, nitric, or hydrochloric acid. Contacting is done with a dilute acid solution usually at ambient temperature and atmospheric pressure.

[0279] The lipid composition, optionally pretreated, is flowed to an FCC zone where the hydrocarbonaceous components are cracked to olefins. Catalytic cracking is accomplished by contacting the lipid composition in a reaction zone with a catalyst composed of finely divided particulate material. The reaction is catalytic cracking, as opposed to hydrocracking, and is carried out in the absence of added hydrogen or the consumption of hydrogen. As the cracking reaction proceeds, substantial amounts of coke are deposited on the catalyst. The catalyst is regenerated at high temperatures by burning coke from the catalyst in a regeneration zone. Coke-containing catalyst, referred to herein as "coked catalyst", is continually transported from the reaction zone to the regeneration zone to be regenerated and replaced by essentially coke-free regenerated catalyst from the regeneration zone.

Fluidization of the catalyst particles by various gaseous streams allows the transport of catalyst between the reaction zone and regeneration zone. Methods for cracking hydrocarbons, such as those of the lipid composition described herein, in a fluidized stream of catalyst, transporting catalyst between reaction and regeneration zones, and combusting coke in the regenerator are well known by those skilled in the art of FCC processes.

Exemplary FCC applications and catalysts useful for cracking the lipid composition to produce C₂-C₅ olefins are described in U.S. Pat. Nos. 6,538,169, 7,288,685, which are incorporated in their entirety by reference.

[0280] Suitable FCC catalysts generally comprise at least two components that may or may not be on the same matrix. In some embodiments, both two components may be circulated throughout the entire reaction vessel. The first component generally includes any of the well-known catalysts that are used in the art of fluidized catalytic cracking, such as an active amorphous clay-type catalyst and/or a high activity, crystalline molecular sieve. Molecular sieve catalysts may be preferred over amorphous catalysts because of their much-improved selectivity to desired products. IN some preferred embodiments, zeolites may be used as the molecular sieve in the FCC processes. Preferably, the first catalyst component comprises a large pore zeolite, such as an Y-type zeolite, an active alumina material, a binder material, comprising either silica or alumina and an inert filler such as kaolin.

[0281] In one embodiment, cracking the lipid composition of the present invention, takes place in the riser section or, alternatively, the lift section, of the FCC zone. The lipid composition is introduced into the riser by a nozzle resulting in the rapid vaporization of the lipid composition. Before contacting the catalyst, the lipid composition will ordinarily have a

temperature of about 149°C to about 316°C (300°F to 600°F). The catalyst is flowed from a blending vessel to the riser where it contacts the lipid composition for a time of about 2 seconds or less.

[0282] The blended catalyst and reacted lipid composition vapors are then discharged from the top of the riser through an outlet and separated into a cracked product vapor stream including olefins and a collection of catalyst particles covered with substantial quantities of coke and generally referred to as "coked catalyst." In an effort to minimize the contact time of the lipid composition and the catalyst which may promote further conversion of desired products to undesirable other products, any arrangement of separators such as a swirl arm arrangement can be used to remove coked catalyst from the product stream quickly. The separator, e.g. swirl arm separator, is located in an upper portion of a chamber with a stripping zone situated in the lower portion of the chamber. Catalyst separated by the swirl arm arrangement drops down into the stripping zone. The cracked product vapor stream comprising cracked hydrocarbons including light olefins and some catalyst exit the chamber via a conduit which is in communication with cyclones. The cyclones remove remaining catalyst particles from the product vapor stream to reduce particle concentrations to very low levels. The product vapor stream then exits the top of the separating vessel. Catalyst separated by the cyclones is returned to the separating vessel and then to the stripping zone. The stripping zone removes adsorbed hydrocarbons from the surface of the catalyst by counter-current contact with steam.

[0283] Low hydrocarbon partial pressure operates to favor the production of light olefins. Accordingly, the riser pressure is set at about 172 to 241 kPa (25 to 35 psia) with a hydrocarbon partial pressure of about 35 to 172 kPa (5 to 25 psia), with a preferred hydrocarbon partial pressure of about 69 to 138 kPa (10 to 20 psia). This relatively low partial pressure for hydrocarbon is achieved by using steam as a diluent to the extent that the diluent is 10 to 55 wt-% of lipid composition and preferably about 15 wt-% of lipid composition. Other diluents such as dry gas can be used to reach equivalent hydrocarbon partial pressures.

[0284] The temperature of the cracked stream at the riser outlet will be about 510°C to 621°C (950°F to 1150°F). However, riser outlet temperatures above 566°C (1050°F) make more dry gas and more olefins. Whereas, riser outlet temperatures below 566°C (1050°F) make less ethylene and propylene. Accordingly, it is preferred to run the FCC process at a preferred temperature of about 566°C to about 630°C, preferred pressure of about 138 kPa to about 240 kPa (20 to 35 psia). Another condition for the process is the catalyst to lipid

composition ratio which can vary from about 5 to about 20 and preferably from about 10 to about 15.

[0285] In one embodiment of the method for producing a jet fuel, the lipid composition is introduced into the lift section of an FCC reactor. The temperature in the lift section will be very hot and range from about 700°C (1292°F) to about 760°C (1400°F) with a catalyst to lipid composition ratio of about 100 to about 150. It is anticipated that introducing the lipid composition into the lift section will produce considerable amounts of propylene and ethylene.

[0286] In another embodiment of the method for producing a jet fuel using the lipid composition or the lipids produced as described herein, the structure of the lipid composition or the lipids is broken by a process referred to as hydrodeoxygenation (HDO). HDO means removal of oxygen by means of hydrogen, that is, oxygen is removed while breaking the structure of the material. Olefinic double bonds are hydrogenated and any sulphur and nitrogen compounds are removed. Sulphur removal is called hydrodesulphurization (HDS). Pretreatment and purity of the raw materials (lipid composition or the lipids) contribute to the service life of the catalyst.

[0287] Generally in the HDO/HDS step, hydrogen is mixed with the feed stock (lipid composition or the lipids) and then the mixture is passed through a catalyst bed as a co-current flow, either as a single phase or a two phase feed stock. After the HDO/MDS step, the product fraction is separated and passed to a separate isomerization reactor. An isomerization reactor for biological starting material is described in the literature (FI 100 248) as a co-current reactor.

[0288] The process for producing a fuel by hydrogenating a hydrocarbon feed, e.g., the lipid composition or the lipids herein, can also be performed by passing the lipid composition or the lipids as a co-current flow with hydrogen gas through a first hydrogenation zone, and thereafter the hydrocarbon effluent is further hydrogenated in a second hydrogenation zone by passing hydrogen gas to the second hydrogenation zone as a counter-current flow relative to the hydrocarbon effluent. Exemplary HDO applications and catalysts useful for cracking the lipid composition to produce C₂-C₅ olefins are described in U.S. Pat. No. 7,232,935, which is incorporated in its entirety by reference.

[0289] Typically, in the hydrodeoxygenation step, the structure of the biological component, such as the lipid composition or lipids herein, is decomposed, oxygen, nitrogen, phosphorus and sulphur compounds, and light hydrocarbons as gas are removed, and the olefinic bonds are hydrogenated. In the second step of the process, i.e. in the so-called

isomerization step, isomerization is carried out for branching the hydrocarbon chain and improving the performance of the paraffin at low temperatures.

[0290] In the first step, i.e. HDO step, of the cracking process, hydrogen gas and the lipid composition or lipids herein which are to be hydrogenated are passed to a HDO catalyst bed system either as co-current or counter-current flows, said catalyst bed system comprising one or more catalyst bed(s), preferably 1-3 catalyst beds. The HDO step is typically operated in a co-current manner. In case of a HDO catalyst bed system comprising two or more catalyst beds, one or more of the beds may be operated using the counter-current flow principle. In the HDO step, the pressure varies between 20 and 150 bar, preferably between 50 and 100 bar, and the temperature varies between 200 and 500°C, preferably in the range of 300-400°C. In the HDO step, known hydrogenation catalysts containing metals from Group VII and/or VIB of the Periodic System may be used. Preferably, the hydrogenation catalysts are supported Pd, Pt, Ni, NiMo or a CoMo catalysts, the support being alumina and/or silica. Typically, NiMo/Al₂O₃ and CoMo/Al₂O₃ catalysts are used.

[0291] Prior to the HDO step, the lipid composition or lipids herein may optionally be treated by prehydrogenation under milder conditions thus avoiding side reactions of the double bonds. Such prehydrogenation is carried out in the presence of a prehydrogenation catalyst at temperatures of 50-400°C and at hydrogen pressures of 1-200 bar, preferably at a temperature between 150 and 250°C and at a hydrogen pressure between 10 and 100 bar. The catalyst may contain metals from Group VIII and/or VIB of the Periodic System. Preferably, the prehydrogenation catalyst is a supported Pd, Pt, Ni, NiMo or a CoMo catalyst, the support being alumina and/or silica.

[0292] A gaseous stream from the HDO step containing hydrogen is cooled and then carbon monoxide, carbon dioxide, nitrogen, phosphorus and sulphur compounds, gaseous light hydrocarbons and other impurities are removed therefrom. After compressing, the purified hydrogen or recycled hydrogen is returned back to the first catalyst bed and/or between the catalyst beds to make up for the withdrawn gas stream. Water is removed from the condensed liquid. The liquid is passed to the first catalyst bed or between the catalyst beds.

[0293] After the HDO step, the product is subjected to an isomerization step. It is substantial for the process that the impurities are removed as completely as possible before the hydrocarbons are contacted with the isomerization catalyst. The isomerization step comprises an optional stripping step, wherein the reaction product from the HDO step may be purified by stripping with water vapour or a suitable gas such as light hydrocarbon, nitrogen

or hydrogen. The optional stripping step is carried out in counter-current manner in a unit upstream of the isomerization catalyst, wherein the gas and liquid are contacted with each other, or before the actual isomerization reactor in a separate stripping unit utilizing counter-current principle.

[0294] After the stripping step the hydrogen gas and the hydrogenated lipid composition or lipids herein, and optionally an n-paraffin mixture, are passed to a reactive isomerization unit comprising one or several catalyst bed(s). The catalyst beds of the isomerization step may operate either in co-current or counter-current manner.

[0295] It is important for the process that the counter-current flow principle is applied in the isomerization step. In the isomerization step this is done by carrying out either the optional stripping step or the isomerization reaction step or both in counter-current manner. In the isomerization step, the pressure varies in the range of 20 150 bar, preferably in the range of 20 100 bar, the temperature being between 200 and 500°C, preferably between 300 and 400°C. In the isomerization step, isomerization catalysts known in the art may be used. Suitable isomerization catalysts contain molecular sieve and/or a metal from Group VII and/or a carrier. Preferably, the isomerization catalyst contains SAPO-11 or SAPO41 or ZSM-22 or ZSM-23 or ferrierite and Pt, Pd or Ni and Al₂O₃ or SiO₂. Typical isomerization catalysts are, for example, Pt/SAPO-11/Al₂O₃, Pt/ZSM-22/Al₂O₃, Pt/ZSM-23/Al₂O₃ and Pt/SAPO-11/SiO₂. The isomerization step and the HDO step may be carried out in the same pressure vessel or in separate pressure vessels. Optional prehydrogenation may be carried out in a separate pressure vessel or in the same pressure vessel as the HDO and isomerization steps.

[0296] Thus, in one embodiment, the product of the one or more chemical reactions is an alkane mixture that comprises ASTM D1655 jet fuel. In some embodiments, the composition conforming to the specification of ASTM 1655 jet fuel has a sulfur content that is less than 10 ppm. In other embodiments, the composition conforming to the specification of ASTM 1655 jet fuel has a T10 value of the distillation curve of less than 205° C. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a final boiling point (FBP) of less than 300° C. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a flash point of at least 38° C. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a density between 775K/M³ and 840K/M³. In yet another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a freezing point that is below -47° C. In another embodiment, the composition conforming to the specification of ASTM 1655

jet fuel has a net Heat of Combustion that is at least 42.8 MJ/K. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a hydrogen content that is at least 13.4 mass %. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a thermal stability, as tested by quantitative gravimetric JFTOT at 260° C, that is below 3mm of Hg. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has an existent gum that is below 7 mg/dl.

[0297] Thus, the present invention discloses a variety of methods in which chemical modification of microalgal lipid is undertaken to yield products useful in a variety of industrial and other applications. Examples of processes for modifying oil produced by the methods disclosed herein include, but are not limited to, hydrolysis of the oil, hydroprocessing of the oil, and esterification of the oil. The modification of the microalgal oil produces basic oleochemicals that can be further modified into selected derivative oleochemicals for a desired function. In a manner similar to that described above with reference to fuel producing processes, these chemical modifications can also be performed on oils generated from the microbial cultures described herein. Examples of basic oleochemicals include, but are not limited to, soaps, fatty acids, fatty acid methyl esters, and glycerol. Examples of derivative oleochemicals include, but are not limited to, fatty nitriles, esters, dimer acids, quats, surfactants, fatty alkanolamides, fatty alcohol sulfates, resins, emulsifiers, fatty alcohols, olefins, and higher alkanes.

[0298] Hydrolysis of the fatty acid constituents from the glycerolipids produced by the methods of the invention yields free fatty acids that can be derivatized to produce other useful chemicals. Hydrolysis occurs in the presence of water and a catalyst which may be either an acid or a base. The liberated free fatty acids can be derivatized to yield a variety of products, as reported in the following: US Patent Nos. 5,304,664 (Highly sulfated fatty acids); 7,262,158 (Cleansing compositions); 7,115,173 (Fabric softener compositions); 6,342,208 (Emulsions for treating skin); 7,264,886 (Water repellent compositions); 6,924,333 (Paint additives); 6,596,768 (Lipid-enriched ruminant feedstock); and 6,380,410 (Surfactants for detergents and cleaners).

[0299] With regard to hydrolysis, in one embodiment of the invention, a triglyceride oil is optionally first hydrolyzed in a liquid medium such as water or sodium hydroxide so as to obtain glycerol and soaps. There are various suitable triglyceride hydrolysis methods, including, but not limited to, saponification, acid hydrolysis, alkaline hydrolysis, enzymatic hydrolysis (referred herein as splitting), and hydrolysis using hot-compressed water. One

skilled in the art will recognize that a triglyceride oil need not be hydrolyzed in order to produce an oleochemical; rather, the oil may be converted directly to the desired oleochemical by other known process. For example, the triglyceride oil may be directly converted to a methyl ester fatty acid through esterification.

[0300] In some embodiments, catalytic hydrolysis of the oil produced by methods disclosed herein occurs by splitting the oil into glycerol and fatty acids. As discussed above, the fatty acids may then be further processed through several other modifications to obtain derivative oleochemicals. For example, in one embodiment the fatty acids may undergo an amination reaction to produce fatty nitrogen compounds. In another embodiment, the fatty acids may undergo ozonolysis to produce mono- and dibasic-acids.

[0301] In other embodiments hydrolysis may occur via the, splitting of oils produced herein to create oleochemicals. In some preferred embodiments of the invention, a triglyceride oil may be split before other processes is performed. One skilled in the art will recognize that there are many suitable triglyceride splitting methods, including, but not limited to, enzymatic splitting and pressure splitting.

[0302] Generally, enzymatic oil splitting methods use enzymes, lipases, as biocatalysts acting on a water/oil mixture. Enzymatic splitting then splits the oil or fat, respectively, is into glycerol and free fatty acids. The glycerol may then migrate into the water phase whereas the organic phase enriches with free fatty acids.

[0303] The enzymatic splitting reactions generally take place at the phase boundary between organic and aqueous phase, where the enzyme is present only at the phase boundary. Triglycerides that meet the phase boundary then contribute to or participate in the splitting reaction. As the reaction proceeds, the occupation density or concentration of fatty acids still chemically bonded as glycerides, in comparison to free fatty acids, decreases at the phase boundary so that the reaction is slowed down. In certain embodiments, enzymatic splitting may occur at room temperature. One of ordinary skill in the art would know the suitable conditions for splitting oil into the desired fatty acids.

[0304] By way of example, the reaction speed can be accelerated by increasing the interface boundary surface. Once the reaction is complete, free fatty acids are then separated from the organic phase freed from enzyme, and the residue which still contains fatty acids chemically bonded as glycerides is fed back or recycled and mixed with fresh oil or fat to be subjected to splitting. In this manner, recycled glycerides are then subjected to a further enzymatic splitting process. In some embodiments, the free fatty acids are extracted from an oil or fat partially split in such a manner. In that way, if the chemically bound fatty acids

(triglycerides) are returned or fed back into the splitting process, the enzyme consumption can be drastically reduced.

[0305] The splitting degree is determined as the ratio of the measured acid value divided by the theoretically possible acid value which can be computed for a given oil or fat. Preferably, the acid value is measured by means of titration according to standard common methods. Alternatively, the density of the aqueous glycerol phase can be taken as a measure for the splitting degree.

[0306] In one embodiment, the splitting process as described herein is also suitable for splitting the mono-, di- and triglyceride that are contained in the so-called soap-stock from the alkali refining processes of the produced oils. In this manner, the soap-stock can be quantitatively converted without prior saponification of the neutral oils into the fatty acids. For this purpose, the fatty acids being chemically bonded in the soaps are released, preferably before splitting, through an addition of acid. In certain embodiments, a buffer solution is used in addition to water and enzyme for the splitting process.

[0307] In one embodiment, oils produced in accordance with the methods of the invention can also be subjected to saponification as a method of hydrolysis. Animal and plant oils are typically made of triacylglycerols (TAGs), which are esters of fatty acids with the trihydric alcohol, glycerol. In an alkaline hydrolysis reaction, the glycerol in a TAG is removed, leaving three carboxylic acid anions that can associate with alkali metal cations such as sodium or potassium to produce fatty acid salts. In this scheme, the carboxylic acid constituents are cleaved from the glycerol moiety and replaced with hydroxyl groups. The quantity of base (e.g., KOH) that is used in the reaction is determined by the desired degree of saponification. If the objective is, for example, to produce a soap product that comprises some of the oils originally present in the TAG composition, an amount of base insufficient to convert all of the TAGs to fatty acid salts is introduced into the reaction mixture. Normally, this reaction is performed in an aqueous solution and proceeds slowly, but may be expedited by the addition of heat. Precipitation of the fatty acid salts can be facilitated by addition of salts, such as water-soluble alkali metal halides (e.g., NaCl or KCl), to the reaction mixture. Preferably, the base is an alkali metal hydroxide, such as NaOH or KOH. Alternatively, other bases, such as alkanolamines, including for example triethanolamine and aminomethylpropanol, can be used in the reaction scheme. In some cases, these alternatives may be preferred to produce a clear soap product.

[0308] In some methods, the first step of chemical modification may be hydroprocessing to saturate double bonds, followed by deoxygenation at elevated temperature in the presence of

hydrogen and a catalyst. In other methods, hydrogenation and deoxygenation may occur in the same reaction. In still other methods deoxygenation occurs before hydrogenation. Isomerization may then be optionally performed, also in the presence of hydrogen and a catalyst. Finally, gases and naphtha components can be removed if desired. For example, see U.S. Patents 5,475,160 (hydrogenation of triglycerides); 5,091,116 (deoxygenation, hydrogenation and gas removal); 6,391,815 (hydrogenation); and 5,888,947 (isomerization).

[0309] In some embodiments of the invention, the triglyceride oils are partially or completely deoxygenated. The deoxygenation reactions form desired products, including, but not limited to, fatty acids, fatty alcohols, polyols, ketones, and aldehydes. In general, without being limited by any particular theory, the deoxygenation reactions involve a combination of various different reaction pathways, including without limitation: hydrogenolysis, hydrogenation, consecutive hydrogenation-hydrogenolysis, consecutive hydrogenolysis-hydrogenation, and combined hydrogenation-hydrogenolysis reactions, resulting in at least the partial removal of oxygen from the fatty acid or fatty acid ester to produce reaction products, such as fatty alcohols, that can be easily converted to the desired chemicals by further processing. For example, in one embodiment, a fatty alcohol may be converted to olefins through FCC reaction or to higher alkanes through a condensation reaction.

[0310] One such chemical modification is hydrogenation, which is the addition of hydrogen to double bonds in the fatty acid constituents of glycerolipids or of free fatty acids. The hydrogenation process permits the transformation of liquid oils into semi-solid or solid fats, which may be more suitable for specific applications.

[0311] Hydrogenation of oil produced by the methods described herein can be performed in conjunction with one or more of the methods and/or materials provided herein, as reported in the following: US Patent Nos. 7,288,278 (Food additives or medicaments); 5,346,724 (Lubrication products); 5,475,160 (Fatty alcohols); 5,091,116 (Edible oils); 6,808,737 (Structural fats for margarine and spreads); 5,298,637 (Reduced-calorie fat substitutes); 6,391,815 (Hydrogenation catalyst and sulfur adsorbent); 5,233,099 and 5,233,100 (Fatty alcohols); 4,584,139 (Hydrogenation catalysts); 6,057,375 (Foam suppressing agents); and 7,118,773 (Edible emulsion spreads).

[0312] One skilled in the art will recognize that various processes may be used to hydrogenate carbohydrates. One suitable method includes contacting the carbohydrate with hydrogen or hydrogen mixed with a suitable gas and a catalyst under conditions sufficient in a hydrogenation reactor to form a hydrogenated product. The hydrogenation catalyst

generally can include Cu, Re, Ni, Fe, Co, Ru, Pd, Rh, Pt, Os, Ir, and alloys or any combination thereof, either alone or with promoters such as W, Mo, Au, Ag, Cr, Zn, Mn, Sn, B, P, Bi, and alloys or any combination thereof. Other effective hydrogenation catalyst materials include either supported nickel or ruthenium modified with rhenium. In an embodiment, the hydrogenation catalyst also includes any one of the supports, depending on the desired functionality of the catalyst. The hydrogenation catalysts may be prepared by methods known to those of ordinary skill in the art.

[0313] In some embodiments the hydrogenation catalyst includes a supported Group VIII metal catalyst and a metal sponge material (e.g., a sponge nickel catalyst). Raney nickel provides an example of an activated sponge nickel catalyst suitable for use in this invention. In other embodiment, the hydrogenation reaction in the invention is performed using a catalyst comprising a nickel-rhenium catalyst or a tungsten-modified nickel catalyst. One example of a suitable catalyst for the hydrogenation reaction of the invention is a carbon-supported nickel-rhenium catalyst.

[0314] In an embodiment, a suitable Raney nickel catalyst may be prepared by treating an alloy of approximately equal amounts by weight of nickel and aluminum with an aqueous alkali solution, e.g., containing about 25 weight % of sodium hydroxide. The aluminum is selectively dissolved by the aqueous alkali solution resulting in a sponge shaped material comprising mostly nickel with minor amounts of aluminum. The initial alloy includes promoter metals (i.e., molybdenum or chromium) in the amount such that about 1 to 2 weight % remains in the formed sponge nickel catalyst. In another embodiment, the hydrogenation catalyst is prepared using a solution of ruthenium(III) nitrosylnitrate, ruthenium (III) chloride in water to impregnate a suitable support material. The solution is then dried to form a solid having a water content of less than about 1% by weight. The solid may then be reduced at atmospheric pressure in a hydrogen stream at 300°C (uncalcined) or 400°C (calcined) in a rotary ball furnace for 4 hours. After cooling and rendering the catalyst inert with nitrogen, 5% by volume of oxygen in nitrogen is passed over the catalyst for 2 hours.

[0315] In certain embodiments, the catalyst described includes a catalyst support. The catalyst support stabilizes and supports the catalyst. The type of catalyst support used depends on the chosen catalyst and the reaction conditions. Suitable supports for the invention include, but are not limited to, carbon, silica, silica-alumina, zirconia, titania, ceria, vanadia, nitride, boron nitride, heteropolyacids, hydroxyapatite, zinc oxide, chromia, zeolites, carbon nanotubes, carbon fullerene and any combination thereof.

[0316] The catalysts used in this invention can be prepared using conventional methods known to those in the art. Suitable methods may include, but are not limited to, incipient wetting, evaporative impregnation, chemical vapor deposition, wash-coating, magnetron sputtering techniques, and the like.

[0317] The conditions for which to carry out the hydrogenation reaction will vary based on the type of starting material and the desired products. One of ordinary skill in the art, with the benefit of this disclosure, will recognize the appropriate reaction conditions. In general, the hydrogenation reaction is conducted at temperatures of 80°C to 250°C, and preferably at 90°C to 200°C, and most preferably at 100°C to 150°C. In some embodiments, the hydrogenation reaction is conducted at pressures from 500 KPa to 14000 KPa.

[0318] The hydrogen used in the hydrogenolysis reaction of the current invention may include external hydrogen, recycled hydrogen, in situ generated hydrogen, and any combination thereof. As used herein, the term "external hydrogen" refers to hydrogen that does not originate from the biomass reaction itself, but rather is added to the system from another source.

[0319] In some embodiments of the invention, it is desirable to convert the starting carbohydrate to a smaller molecule that will be more readily converted to desired higher hydrocarbons. One suitable method for this conversion is through a hydrogenolysis reaction. Various processes are known for performing hydrogenolysis of carbohydrates. One suitable method includes contacting a carbohydrate with hydrogen or hydrogen mixed with a suitable gas and a hydrogenolysis catalyst in a hydrogenolysis reactor under conditions sufficient to form a reaction product comprising smaller molecules or polyols. As used herein, the term "smaller molecules or polyols" includes any molecule that has a smaller molecular weight, which can include a smaller number of carbon atoms or oxygen atoms than the starting carbohydrate. In an embodiment, the reaction products include smaller molecules that include polyols and alcohols. Someone of ordinary skill in the art would be able to choose the appropriate method by which to carry out the hydrogenolysis reaction.

[0320] In some embodiments, a 5 and/or 6 carbon sugar or sugar alcohol may be converted to propylene glycol, ethylene glycol, and glycerol using a hydrogenolysis catalyst. The hydrogenolysis catalyst may include Cr, Mo, W, Re, Mn, Cu, Cd, Fe, Co, Ni, Pt, Pd, Rh, Ru, Ir, Os, and alloys or any combination thereof, either alone or with promoters such as Au, Ag, Cr, Zn, Mn, Sn, Bi, B, O, and alloys or any combination thereof. The hydrogenolysis catalyst may also include a carbonaceous pyropolymer catalyst containing transition metals (e.g., chromium, molybdenum, tungsten, rhenium, manganese, copper, cadmium) or Group VIII

metals (e.g., iron, cobalt, nickel, platinum, palladium, rhodium, ruthenium, iridium, and osmium). In certain embodiments, the hydrogenolysis catalyst may include any of the above metals combined with an alkaline earth metal oxide or adhered to a catalytically active support. In certain embodiments, the catalyst described in the hydrogenolysis reaction may include a catalyst support as described above for the hydrogenation reaction.

[0321] The conditions for which to carry out the hydrogenolysis reaction will vary based on the type of starting material and the desired products. One of ordinary skill in the art, with the benefit of this disclosure, will recognize the appropriate conditions to use to carry out the reaction. In general, the hydrogenolysis reaction is conducted at temperatures of 110°C to 300°C, and preferably at 170°C to 220°C, and most preferably at 200°C to 225°C. In some embodiments, the hydrogenolysis reaction is conducted under basic conditions, preferably at a pH of 8 to 13, and even more preferably at a pH of 10 to 12. In some embodiments, the hydrogenolysis reaction is conducted at pressures in a range between 60 KPa and 16500 KPa, and preferably in a range between 1700 KPa and 14000 KPa, and even more preferably between 4800 KPa and 11000 KPa.

[0322] The hydrogen used in the hydrogenolysis reaction of the current invention can include external hydrogen, recycled hydrogen, in situ generated hydrogen, and any combination thereof.

[0323] In some embodiments, the reaction products discussed above may be converted into higher hydrocarbons through a condensation reaction in a condensation reactor (shown schematically as condensation reactor 110 in Figure 1). In such embodiments, condensation of the reaction products occurs in the presence of a catalyst capable of forming higher hydrocarbons. While not intending to be limited by theory, it is believed that the production of higher hydrocarbons proceeds through a stepwise addition reaction including the formation of carbon-carbon, or carbon-oxygen bond. The resulting reaction products include any number of compounds containing these moieties, as described in more detail below.

[0324] In certain embodiments, suitable condensation catalysts include an acid catalyst, a base catalyst, or an acid/base catalyst. As used herein, the term "acid/base catalyst" refers to a catalyst that has both an acid and a base functionality. In some embodiments the condensation catalyst can include, without limitation, zeolites, carbides, nitrides, zirconia, alumina, silica, aluminosilicates, phosphates, titanium oxides, zinc oxides, vanadium oxides, lanthanum oxides, yttrium oxides, scandium oxides, magnesium oxides, cerium oxides, barium oxides, calcium oxides, hydroxides, heteropolyacids, inorganic acids, acid modified resins, base modified resins, and any combination thereof. In some embodiments, the

condensation catalyst can also include a modifier. Suitable modifiers include La, Y, Sc, P, B, Bi, Li, Na, K, Rb, Cs, Mg, Ca, Sr, Ba, and any combination thereof. In some embodiments, the condensation catalyst can also include a metal. Suitable metals include Cu, Ag, Au, Pt, Ni, Fe, Co, Ru, Zn, Cd, Ga, In, Rh, Pd, Ir, Re, Mn, Cr, Mo, W, Sn, Os, alloys, and any combination thereof.

[0325] In certain embodiments, the catalyst described in the condensation reaction may include a catalyst support as described above for the hydrogenation reaction. In certain embodiments, the condensation catalyst is self-supporting. As used herein, the term "self-supporting" means that the catalyst does not need another material to serve as support. In other embodiments, the condensation catalyst is used in conjunction with a separate support suitable for suspending the catalyst. In an embodiment, the condensation catalyst support is silica.

[0326] The conditions under which the condensation reaction occurs will vary based on the type of starting material and the desired products. One of ordinary skill in the art, with the benefit of this disclosure, will recognize the appropriate conditions to use to carry out the reaction. In some embodiments, the condensation reaction is carried out at a temperature at which the thermodynamics for the proposed reaction are favorable. The temperature for the condensation reaction will vary depending on the specific starting polyol or alcohol. In some embodiments, the temperature for the condensation reaction is in a range from 80°C to 500°C, and preferably from 125°C to 450°C, and most preferably from 125°C to 250°C. In some embodiments, the condensation reaction is conducted at pressures in a range between 0 KPa to 9000 KPa, and preferably in a range between 0 KPa and 7000 KPa, and even more preferably between 0 KPa and 5000 KPa.

[0327] The higher alkanes formed by the invention include, but are not limited to, branched or straight chain alkanes that have from 4 to 30 carbon atoms, branched or straight chain alkenes that have from 4 to 30 carbon atoms, cycloalkanes that have from 5 to 30 carbon atoms, cycloalkenes that have from 5 to 30 carbon atoms, aryls, fused aryls, alcohols, and ketones. Suitable alkanes include, but are not limited to, butane, pentane, pentene, 2-methylbutane, hexane, hexene, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutane, 2,3-dimethylbutane, heptane, heptene, octane, octene, 2,2,4-trimethylpentane, 2,3-dimethylhexane, 2,3,4-trimethylpentane, 2,3-dimethylpentane, nonane, nonene, decane, decene, undecane, undecene, dodecane, dodecene, tridecane, tridecene, tetradecane, tetradecene, pentadecane, pentadecene, nonyldecane, nonyldecene, eicosane, eicosene, uneicosane,

uneicosene, doeicosane, doeicosene, trieicosane, trieicosene, tetraeicosane, tetraeicosene, and isomers thereof. Some of these products may be suitable for use as fuels.

[0328] In some embodiments, the cycloalkanes and the cycloalkenes are unsubstituted. In other embodiments, the cycloalkanes and cycloalkenes are mono-substituted. In still other embodiments, the cycloalkanes and cycloalkenes are multi-substituted. In the embodiments comprising the substituted cycloalkanes and cycloalkenes, the substituted group includes, without limitation, a branched or straight chain alkyl having 1 to 12 carbon atoms, a branched or straight chain alkylene having 1 to 12 carbon atoms, a phenyl, and any combination thereof. Suitable cycloalkanes and cycloalkenes include, but are not limited to, cyclopentane, cyclopentene, cyclohexane, cyclohexene, methyl-cyclopentane, methyl-cyclopentene, ethyl-cyclopentane, ethyl-cyclopentene, ethyl-cyclohexane, ethyl-cyclohexene, isomers and any combination thereof.

[0329] In some embodiments, the aryls formed are unsubstituted. In another embodiment, the aryls formed are mono-substituted. In the embodiments comprising the substituted aryls, the substituted group includes, without limitation, a branched or straight chain alkyl having 1 to 12 carbon atoms, a branched or straight chain alkylene having 1 to 12 carbon atoms, a phenyl, and any combination thereof. Suitable aryls for the invention include, but are not limited to, benzene, toluene, xylene, ethyl benzene, para xylene, meta xylene, and any combination thereof.

[0330] The alcohols produced in the invention have from 4 to 30 carbon atoms. In some embodiments, the alcohols are cyclic. In other embodiments, the alcohols are branched. In another embodiment, the alcohols are straight chained. Suitable alcohols for the invention include, but are not limited to, butanol, pentanol, hexanol, heptanol, octanol, nonanol, decanol, undecanol, dodecanol, tridecanol, tetradecanol, pentadecanol, hexadecanol, heptyldecanol, octyldecanol, nonyldecanol, eicosanol, uneicosanol, doeicosanol, trieicosanol, tetraeicosanol, and isomers thereof.

[0331] The ketones produced in the invention have from 4 to 30 carbon atoms. In an embodiment, the ketones are cyclic. In another embodiment, the ketones are branched. In another embodiment, the ketones are straight chained. Suitable ketones for the invention include, but are not limited to, butanone, pentanone, hexanone, heptanone, octanone, nonanone, decanone, undecanone, dodecanone, tridecanone, tetradecanone, pentadecanone, hexadecanone, heptyldecanone, octyldecanone, nonyldecanone, eicosanone, uneicosanone, doeicosanone, trieicosanone, tetraeicosanone, and isomers thereof.

[0332] Another such chemical modification is interesterification. Naturally produced glycerolipids do not have a uniform distribution of fatty acid constituents. In the context of oils, interesterification refers to the exchange of acyl radicals between two esters of different glycerolipids. The interesterification process provides a mechanism by which the fatty acid constituents of a mixture of glycerolipids can be rearranged to modify the distribution pattern. Interesterification is a well-known chemical process, and generally comprises heating (to about 200°C) a mixture of oils for a period (e.g., 30 minutes) in the presence of a catalyst, such as an alkali metal or alkali metal alkylate (e.g., sodium methoxide). This process can be used to randomize the distribution pattern of the fatty acid constituents of an oil mixture, or can be directed to produce a desired distribution pattern. This method of chemical modification of lipids can be performed on materials provided herein, such as microbial biomass with a percentage of dry cell weight as lipid at least 20%.

[0333] Directed interesterification, in which a specific distribution pattern of fatty acids is sought, can be performed by maintaining the oil mixture at a temperature below the melting point of some TAGs which might occur. This results in selective crystallization of these TAGs, which effectively removes them from the reaction mixture as they crystallize. The process can be continued until most of the fatty acids in the oil have precipitated, for example. A directed interesterification process can be used, for example, to produce a product with a lower calorie content via the substitution of longer-chain fatty acids with shorter-chain counterparts. Directed interesterification can also be used to produce a product with a mixture of fats that can provide desired melting characteristics and structural features sought in food additives or products (e.g., margarine) without resorting to hydrogenation, which can produce unwanted trans isomers.

[0334] Interesterification of oils produced by the methods described herein can be performed in conjunction with one or more of the methods and/or materials, or to produce products, as reported in the following: US Patent Nos. 6,080,853 (Nondigestible fat substitutes); 4,288,378 (Peanut butter stabilizer); 5,391,383 (Edible spray oil); 6,022,577 (Edible fats for food products); 5,434,278 (Edible fats for food products); 5,268,192 (Low calorie nut products); 5,258,197 (Reduce calorie edible compositions); 4,335,156 (Edible fat product); 7,288,278 (Food additives or medicaments); 7,115,760 (Fractionation process); 6,808,737 (Structural fats); 5,888,947 (Engine lubricants); 5,686,131 (Edible oil mixtures); and 4,603,188 (Curable urethane compositions).

[0335] In one embodiment in accordance with the invention, transesterification of the oil, as described above, is followed by reaction of the transesterified product with polyol, as

reported in US Patent No. 6,465,642, to produce polyol fatty acid polyesters. Such an esterification and separation process may comprise the steps as follows: reacting a lower alkyl ester with polyol in the presence of soap; removing residual soap from the product mixture; water-washing and drying the product mixture to remove impurities; bleaching the product mixture for refinement; separating at least a portion of the unreacted lower alkyl ester from the polyol fatty acid polyester in the product mixture; and recycling the separated unreacted lower alkyl ester.

[0336] Transesterification can also be performed on microbial biomass with short chain fatty acid esters, as reported in U.S. Patent 6,278,006. In general, transesterification may be performed by adding a short chain fatty acid ester to an oil in the presence of a suitable catalyst and heating the mixture. In some embodiments, the oil comprises about 5% to about 90% of the reaction mixture by weight. In some embodiments, the short chain fatty acid esters can be about 10% to about 50% of the reaction mixture by weight. Non-limiting examples of catalysts include base catalysts, sodium methoxide, acid catalysts including inorganic acids such as sulfuric acid and acidified clays, organic acids such as methane sulfonic acid, benzenesulfonic acid, and toluenesulfonic acid, and acidic resins such as Amberlyst 15. Metals such as sodium and magnesium, and metal hydrides also are useful catalysts.

[0337] Another such chemical modification is hydroxylation, which involves the addition of water to a double bond resulting in saturation and the incorporation of a hydroxyl moiety. The hydroxylation process provides a mechanism for converting one or more fatty acid constituents of a glycerolipid to a hydroxy fatty acid. Hydroxylation can be performed, for example, via the method reported in US Patent No. 5,576,027. Hydroxylated fatty acids, including castor oil and its derivatives, are useful as components in several industrial applications, including food additives, surfactants, pigment wetting agents, defoaming agents, water proofing additives, plasticizing agents, cosmetic emulsifying and/or deodorant agents, as well as in electronics, pharmaceuticals, paints, inks, adhesives, and lubricants. One example of how the hydroxylation of a glyceride may be performed is as follows: fat may be heated, preferably to about 30-50°C combined with heptane and maintained at temperature for thirty minutes or more; acetic acid may then be added to the mixture followed by an aqueous solution of sulfuric acid followed by an aqueous hydrogen peroxide solution which is added in small increments to the mixture over one hour; after the aqueous hydrogen peroxide, the temperature may then be increased to at least about 60°C and stirred for at least six hours; after the stirring, the mixture is allowed to settle and a lower aqueous layer formed

by the reaction may be removed while the upper heptane layer formed by the reaction may be washed with hot water having a temperature of about 60°C; the washed heptane layer may then be neutralized with an aqueous potassium hydroxide solution to a pH of about 5 to 7 and then removed by distillation under vacuum; the reaction product may then be dried under vacuum at 100°C and the dried product steam-deodorized under vacuum conditions and filtered at about 50° to 60°C using diatomaceous earth.

[0338] Hydroxylation of microbial oils produced by the methods described herein can be performed in conjunction with one or more of the methods and/or materials, or to produce products, as reported in the following: US Patent Nos. 6,590,113 (Oil-based coatings and ink); 4,049,724 (Hydroxylation process); 6,113,971 (Olive oil butter); 4,992,189 (Lubricants and lube additives); 5,576,027 (Hydroxylated milk); and 6,869,597 (Cosmetics).

[0339] Hydroxylated glycerolipids can be converted to estolides. Estolides consist of a glycerolipid in which a hydroxylated fatty acid constituent has been esterified to another fatty acid molecule. Conversion of hydroxylated glycerolipids to estolides can be carried out by warming a mixture of glycerolipids and fatty acids and contacting the mixture with a mineral acid, as described by Isbell et al., *JAACS* 71(2):169-174 (1994). Estolides are useful in a variety of applications, including without limitation those reported in the following: US Patent Nos. 7,196,124 (Elastomeric materials and floor coverings); 5,458,795 (Thickened oils for high-temperature applications); 5,451,332 (Fluids for industrial applications); 5,427,704 (Fuel additives); and 5,380,894 (Lubricants, greases, plasticizers, and printing inks).

[0340] Other chemical reactions that can be performed on microbial oils include reacting triacylglycerols with a cyclopropanating agent to enhance fluidity and/or oxidative stability, as reported in U.S. Patent 6,051,539; manufacturing of waxes from triacylglycerols, as reported in U.S. Patent 6,770,104; and epoxidation of triacylglycerols, as reported in "The effect of fatty acid composition on the acrylation kinetics of epoxidized triacylglycerols", *Journal of the American Oil Chemists' Society*, 79:1, 59-63, (2001) and *Free Radical Biology and Medicine*, 37:1, 104-114 (2004).

[0341] The generation of oil-bearing microbial biomass for fuel and chemical products as described above results in the production of delipidated biomass meal. Delipidated meal is a byproduct of preparing algal oil and is useful as animal feed for farm animals, e.g., ruminants, poultry, swine and aquaculture. The resulting meal, although of reduced oil content, still contains high quality proteins, carbohydrates, fiber, ash, residual oil and other nutrients appropriate for an animal feed. Because the cells are predominantly lysed by the oil separation process, the delipidated meal is easily digestible by such animals. Delipidated

meal can optionally be combined with other ingredients, such as grain, in an animal feed. Because delipidated meal has a powdery consistency, it can be pressed into pellets using an extruder or expander or another type of machine, which are commercially available.

[0342] The invention, having been described in detail above, is exemplified in the following examples, which are offered to illustrate, but not to limit, the claimed invention.

VII. EXAMPLES

[0343] EXAMPLE 1: Methods for Culturing *Prototheca*

[0344] *Prototheca* strains were cultivated to achieve a high percentage of oil by dry cell weight. Cryopreserved cells were thawed at room temperature and 500 ul of cells were added to 4.5 ml of medium (4.2 g/L K_2HPO_4 , 3.1 g/L NaH_2PO_4 , 0.24 g/L $MgSO_4 \cdot 7H_2O$, 0.25 g/L Citric Acid monohydrate, 0.025 g/L $CaCl_2 \cdot 2H_2O$, 2g/L yeast extract) plus 2% glucose and grown for 7 days at 28°C with agitation (200 rpm) in a 6-well plate. Dry cell weights were determined by centrifuging 1 ml of culture at 14,000 rpm for 5 min in a pre-weighed Eppendorf tube. The culture supernatant was discarded and the resulting cell pellet washed with 1 ml of deionized water. The culture was again centrifuged, the supernatant discarded, and the cell pellets placed at -80°C until frozen. Samples were then lyophilized for 24 hrs and dry cell weights calculated. For determination of total lipid in cultures, 3 ml of culture was removed and subjected to analysis using an Ankom system (Ankom Inc., Macedon, NY) according to the manufacturer's protocol. Samples were subjected to solvent extraction with an Amkom XT10 extractor according to the manufacturer's protocol. Total lipid was determined as the difference in mass between acid hydrolyzed dried samples and solvent extracted, dried samples. Percent oil dry cell weight measurements are shown in Table 8.

[0345] Table 8. Percent oil by dry cell weight

Species	Strain	% Oil
<i>Prototheca stagnora</i>	UTEX 327	13.14
<i>Prototheca moriformis</i>	UTEX 1441	18.02
<i>Prototheca moriformis</i>	UTEX 1435	27.17

[0346] Microalgae samples from the strains listed in Table 22 above were genotyped. Genomic DNA was isolated from algal biomass as follows. Cells (approximately 200 mg) were centrifuged from liquid cultures 5 minutes at 14,000 x g. Cells were then resuspended in sterile distilled water, centrifuged 5 minutes at 14,000 x g and the supernatant discarded. A single glass bead ~2mm in diameter was added to the biomass and tubes were placed at -80°C for at least 15 minutes. Samples were removed and 150 µl of grinding buffer (1% Sarkosyl, 0.25 M Sucrose, 50 mM NaCl, 20 mM EDTA, 100 mM Tris-HCl, pH 8.0, RNase A 0.5

ug/ul) was added. Pellets were resuspended by vortexing briefly, followed by the addition of 40 μ l of 5M NaCl. Samples were vortexed briefly, followed by the addition of 66 μ l of 5% CTAB (Cetyl trimethylammonium bromide) and a final brief vortex. Samples were next incubated at 65°C for 10 minutes after which they were centrifuged at 14,000 x g for 10 minutes. The supernatant was transferred to a fresh tube and extracted once with 300 μ l of Phenol:Chloroform:Isoamyl alcohol 12:12:1, followed by centrifugation for 5 minutes at 14,000 x g. The resulting aqueous phase was transferred to a fresh tube containing 0.7 vol of isopropanol (~190 μ l), mixed by inversion and incubated at room temperature for 30 minutes or overnight at 4°C. DNA was recovered via centrifugation at 14,000 x g for 10 minutes. The resulting pellet was then washed twice with 70% ethanol, followed by a final wash with 100% ethanol. Pellets were air dried for 20-30 minutes at room temperature followed by resuspension in 50 μ l of 10mM TrisCl, 1mM EDTA (pH 8.0).

[0347] Five μ l of total algal DNA, prepared as described above, was diluted 1:50 in 10 mM Tris, pH 8.0. PCR reactions, final volume 20 μ l, were set up as follows. Ten μ l of 2 x iProof HF master mix (BIO-RAD) was added to 0.4 μ l primer SZ02613 (5'-TGTTGAAGAATGAGCCGCGAC-3' (SEQ ID NO:9) at 10mM stock concentration). This primer sequence runs from position 567-588 in Gen Bank accession no. L43357 and is highly conserved in higher plants and algal plastid genomes. This was followed by the addition of 0.4 μ l primer SZ02615 (5'-CAGTGAGCTATTACGCACTC-3' (SEQ ID NO:10) at 10 mM stock concentration). This primer sequence is complementary to position 1112-1093 in Gen Bank accession no. L43357 and is highly conserved in higher plants and algal plastid genomes. Next, 5 μ l of diluted total DNA and 3.2 μ l dH₂O were added. PCR reactions were run as follows: 98°C, 45''; 98°C, 8''; 53°C, 12''; 72°C, 20'' for 35 cycles followed by 72°C for 1 min and holding at 25°C. For purification of PCR products, 20 μ l of 10 mM Tris, pH 8.0, was added to each reaction, followed by extraction with 40 μ l of Phenol:Chloroform:isoamyl alcohol 12:12:1, vortexing and centrifuging at 14,000 x g for 5 minutes. PCR reactions were applied to S-400 columns (GE Healthcare) and centrifuged for 2 minutes at 3,000 x g. Purified PCR products were subsequently TOPO cloned into PCR8/GW/TOPO and positive clones selected for on LB/Spec plates. Purified plasmid DNA was sequenced in both directions using M13 forward and reverse primers. In total, twelve *Prototheca* strains were selected to have their 23S rRNA DNA sequenced and the sequences are listed in the Sequence Listing. A summary of the strains and Sequence Listing Numbers is included below. The sequences were analyzed for overall divergence from the UTEX 1435 (SEQ ID NO: 15) sequence. Two pairs emerged (UTEX 329/UTEX 1533 and UTEX

329/UTEX 1440) as the most divergent. In both cases, pairwise alignment resulted in 75.0% pairwise sequence identity. The percent sequence identity to UTEX 1435 is also included below.

<u>Species</u>	<u>Strain</u>	<u>% nt identity</u>	<u>SEQ ID NO.</u>
<i>Prototheca kruegeri</i>	UTEX 329	75.2	SEQ ID NO: 11
<i>Prototheca wickerhamii</i>	UTEX 1440	99	SEQ ID NO: 12
<i>Prototheca stagnora</i>	UTEX 1442	75.7	SEQ ID NO: 13
<i>Prototheca moriformis</i>	UTEX 288	75.4	SEQ ID NO: 14
<i>Prototheca moriformis</i>	UTEX 1439; 1441; 1435; 1437	100	SEQ ID NO: 15
<i>Prototheca wickerhamii</i>	UTEX 1533	99.8	SEQ ID NO: 16
<i>Prototheca moriformis</i>	UTEX 1434	75.9	SEQ ID NO: 17
<i>Prototheca zopfii</i>	UTEX 1438	75.7	SEQ ID NO: 18
<i>Prototheca moriformis</i>	UTEX 1436	88.9	SEQ ID NO: 19

[0348] Lipid samples from a subset of the above-listed strains were analyzed for lipid profile using HPLC. Results are shown below in Table 9.

[0349] Table 9. Diversity of lipid chains in microalgal species

<u>Strain</u>	<u>C14:0</u>	<u>C16:0</u>	<u>C16:1</u>	<u>C18:0</u>	<u>C18:1</u>	<u>C18:2</u>	<u>C18:3</u>	<u>C20:0</u>	<u>C20:1</u>
UTEX 327	0	12.01	0	0	50.33	17.14	0	0	0
UTEX 1441	1.41	29.44	0.70	3.05	57.72	12.37	0.97	0.33	0
UTEX 1435	1.09	25.77	0	2.75	54.01	11.90	2.44	0	0

[0350] Algal plastid transit peptides were identified through the analysis of UTEX 1435 (*Prototheca moriformis*) or UTEX 250 (*Chlorella protothecoides*) cDNA libraries as described in Examples 12 and Example 11 below. cDNAs encoding potentially plastid targeted proteins based upon BLAST hit homology to other known plastid targeted proteins were subjected to further analysis by the software programs PSORT (<http://psort.ims.u-tokyo.ac.jp/form.html>), ChloroP (<http://www.cbs.dtu.dk/services/ChloroP/>) or TargetP (<http://www.cbs.dtu.dk/services/TargetP/>). Candidate plastid transit peptides identified through at least one of these three programs were then PCR amplified from the appropriate genomic DNA. Below is a summary of the amino acid sequences algal plastid targeting sequences (PTS) that were identified from this screen. Also included are the amino acid sequences of plant fatty acyl-ACP thioesterases that are used in the heterologous expression Examples below.

<u>cDNA</u>	<u>SEQ ID NO.</u>
<i>P.moriformis</i> isopentenyl diphosphate synthase PTS	SEQ ID NO: 127
<i>P.moriformis</i> delta 12 fatty acid desaturase PTS	SEQ ID NO: 128

<i>P.moriformis</i> stearoyl ACP desaturase PTS	SEQ ID NO: 129
<i>C.protothecoides</i> stearoyl ACP desaturase PTS	SEQ ID NO: 130
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (C8-10)	SEQ ID NO: 131
<i>Umbellularia californica</i> fatty acyl-ACP thioesterase (C12)	SEQ ID NO: 132
<i>Cinnamomum camphora</i> fatty acyl-ACP thioesterase (C14)	SEQ ID NO: 133

[0351] EXAMPLE 2: Culturing *Prototheca* on Various Feedstocks

A. Sorghum

[0352] The following strains were shown to be capable of utilizing sorghum as a sole carbon source: *Prototheca moriformis* strains UTEX 1435, UTEX 1437, UTEX 288, UTEX 1439, UTEX 1441 and UTEX 1434, and *Prototheca stagnora* strain UTEX 1442. The “UTEX” designation indicates the strain number from the algal culture collection of the University of Texas, 1 University State A6700, Austin, Texas 78712-0183.

[0353] Pure sorghum was purchased from Maasdam Sorghum Mills (Lynnville, Iowa) with a sugar profile of fructose 21.0% w/w, dextrose 28.0% w/w, sucrose 16.0% w/w and maltose <0.5%w/w. The cultures were grown in liquid medium containing 2%, 5%, or 7% (v/v) pure sorghum (diluted from the pure stock) as the sole carbon source and the cultures were grown heterotrophically in the dark, agitating at ~ 350 rpm. Samples from the cultures were pulled at 24, 40, 48, 67 and 89 hours and growth was measured using A750 readings on a spectrophotometer. Growth was observed for each of the strains tested as shown in Figures 1-2.

B. Cellulose

[0354] Wet, exploded corn stover, *Miscanthus*, forage sorghum, beet pulp and sugar cane bagasse were prepared by The National Renewable Energy Laboratory (Golden, CO) by cooking in a 1.4% sulfuric acid solution and dewatering the resultant slurry. Percent solids were determined gravimetrically by drying and were as follows: corn stover, 25% solids; *Miscanthus*, 28.7% solids; forage sorghum, 26.7% solids; and sugar cane bagasse, 26% solids.

[0355] 100 gram wet samples of exploded cellulosic materials (corn stover or switch grass) were resuspended in deionized water to a final volume of 420 mL and the pH was adjusted to 4.8 using 10N NaOH. For beet pulp, 9.8 grams dry solids were brought to 350 mL with deionized water and pH was adjusted to 4.8 with 10 N NaOH. For all of the above feedstocks, Accellerase 1000 (Genencor, New York) was used at a ratio of 0.25 ml enzyme per gram of dry biomass for saccharification of the cellulosic materials. Samples were incubated with

agitation (110 rpm) at 50°C for 72 hours. The pH of each of the samples was adjusted to 7.0 with NaOH (with negligible volume change), filter sterilized through a 0.22 µm filter and used in the processes detailed below. For larger scale processes, the same procedure for saccharification was followed except an additional step of tangential flow filtration (TFF) or microfiltration step was performed to aid in filter sterilization of feedstocks. A sample from each of the feedstocks prepared was reserved for determination of glucose and xylose concentration using an HPLC/ELSD-based system or a hexokinase-based kit (Sigma). Additionally, for beet pulp, the material was initially brought to volume as with the other feedstocks, the pH was then adjusted to 4.0 and a pectinase treatment was carried out at 50°C for 24 hours. The pH was then adjusted to 4.8 if no washing steps were conducted or 5.3 if washing steps were conducted. Enzymatic saccharification was then performed with the same procedure used for the other feedstocks as described above.

[0356] Microalgae *Prototheca moriformis* strain UTEX 1435 was assessed for its ability to grow on a series of cellulosic feedstocks prepared as described above (corn stover, beet pulp, sorghum cane, *Miscanthus* and glucose control). The microalgae culture was grown in conditions described in Example 1 above with the exception of the carbon source. The carbon source was either 4% glucose (for control conditions) or 4% glucose as measured by available glucose in the cellulosic materials. Growth was assessed by A750 readings and the culturing time was 168 hours, with A750 readings at 48, 72, 96, 120, 144 and 168 hours after initiation of the culture. As can be seen in Figure 7a, the *Prototheca moriformis* culture grew best in corn stover. The other cellulosic feedstocks used, *Miscanthus*, sorghum cane and beet pulp, all exhibited inhibition of growth.

[0357] Based on the above results with corn stover derived cellulosic sugars, lipid accumulation was also assessed in *Prototheca moriformis* using different levels of corn stover derived cellulosic sugars and reagent glucose as a control. Cultures were grown in 18g/L glucose that was completely from corn stover derived cellulosic sugars (100% corn stover condition in Figure 7b), 9g/L glucose from corn stover derived cellulosic sugars supplemented with 9g/L reagent glucose (50% corn stover supplemented with glucose to 18g/L condition in Figure 7b), 9g/L glucose from corn stover derived cellulosic sugars (50% corn stover, not supplemented; glucose at 9g/L condition in Figure 7b) and a control culture of 42g/L reagent glucose and 13 g/L reagent xylose for osmolarity control. All cultures were fed with cellulosic sugars to maintain the glucose concentration at 20 g/L, except for the control culture, which was fed with reagent glucose to maintain the glucose concentration at 20 g/L. Growth was measured based on the dry cell weight of the culture and lipid

productivity was determined as a percent dry cell weight. Total lipids were determined gravimetrically using an Ankom acid hydrolysis/solvent extraction system as described in Example 1 above.

[0358] As can be seen in Figure 7b, based on biomass accumulation (as measured by DCW), all concentrations of the corn stover derived cellulosics out-performed (higher DCW) the control media that was fed glucose alone. Lipid production as a percentage of DCW was also calculated for all of the conditions. In addition to the higher biomass accumulation seen for growth on corn stover, lipid accumulation was also higher in the corn stover derived cellulosics conditions as compared to the glucose control condition. These data demonstrate that, in addition to providing cellulosic derived sugars, corn stover provides additional nutrients/components that contribute to an increased biomass accumulation (growth) and increased product yield.

[0359] Because the cellulosic feedstocks contain components in addition to glucose, some of these additional components can accumulate to undesirable levels during culture as more cellulosic derived sugars are fed into the culture as the main carbon source (usually, but not limited to, glucose) is consumed. For example, the xylose present in the cellulosic derived sugar feedstock may build up during the high density cultivation of microalgae to levels inhibitory to growth and end product production. To test the effects of xylose build up during *Prototheca* cultivation, cultures were grown with 4% glucose in the media and supplemented with 0, 10 g/L, 25 g/L, 50 g/L and 100 g/L xylose. After 6 days of culture, growth and lipid accumulation were assessed using the methods described above. As seen in Figure 7c, surprisingly, the highest concentrations of xylose tested were not inhibitory to *Prototheca moriformis*' ability to grow and accumulate lipid, and the culture actually grew better and accumulated more lipids at the highest xylose concentrations. To explore this phenomenon, a similar experiment was carried out with sucrose, a carbon source which wild type *Prototheca moriformis* is unable to metabolize. No positive impact was observed with sucrose, suggesting that the increased growth and lipid accumulation seen with xylose is attributable to a mechanism other than the osmotic stress from high concentrations of unmetabolized components in the media and is xylose-specific.

[0360] In addition to non-metabolized sugars, salts may accumulate to inhibitory levels as a result of concentrating lignocellulosic derived sugars. Due to the acid hydrolysis step with H₂SO₄ during the typical preparation of cellulosic materials followed by neutralization of the acid with NaOH, Na₂SO₄ is formed during the generation of lignocellulosic sugars. To assess the impact of salt concentration on growth and lipid production, *Prototheca moriformis*

cultures were grown at Na_2SO_4 concentrations ranging from 0-700 mM in media supplemented with 4% glucose. As shown in Figure 7d, a significant inhibition of growth was observed, as measured by DCW accumulation, where Na_2SO_4 concentrations exceeded 25 mM, specifically at the 80 mM, 240 mM and 700 mM concentrations. In addition, the impact of antifoam P2000 was assessed in the same test. The antifoam compound had a significant, positive impact on biomass productivity. Lipid productivity was also assessed for each condition, and Na_2SO_4 concentrations above 80 mM, specifically 240 mM and 700 mM, were inhibitory while the addition of antifoam P2000 significantly increased lipid productivity. Thus, in one embodiment, the culturing steps of the methods of the present invention include culturing in media containing an antifoaming agent.

[0361] Based on the results discussed above and summarized in Figure 7a, inhibitors were likely present in the cellulosic feedstocks exhibiting poor growth. The present invention provides means of removing such compounds by washing the materials with hot water (hydrothermal treatment). Figure 8 summarizes the growth results, as measured by A750, using sugar derived from cellulosic feedstock with a single hot water wash. The culture conditions were identical to those used in the processes summarized in Figure 7a. Compared to the results shown in Figure 7a, after just one hot water wash, *Prototheca moriformis* cultures grew better in all cellulosic feedstocks tested, specifically sugar cane bagasse, sorghum cane, *Miscanthus* and beet pulp, as compared to glucose control. Lipid productivity was also assessed in each of the conditions. Except for the beet pulp condition, which was comparable to the glucose control, cultures grown in sugars derived from cellulosic materials subjected to one hot water wash exhibited better lipid productivity than the glucose control.

[0362] One potential impact of hydrothermal treatment (hot water washing) of cellulosic biomass is the removal of furfurals and hydroxymethyl furfurals released by acid explosion of the material. The presence of furfurals and hydroxymethyl furfurals may have contributed to limited growth observed in some of the processes summarized in Figure 7a. To assess how hydrothermal treatment affected the levels of furfurals (FA) and hydroxymethyl furfurals (HMF), supernatants resulting from one to three washes of cellulosic biomass derived from sugarcane bagasse (B), sorghum cane (S), *Miscanthus* (M) or beet pulp (BP) were assayed for FA and HMF by HPLC. As shown in Figure 8, FA and HMF levels decrease significantly with each washing step. This result is consistent with the observation that FA and HMF can be inhibitory to microalgal growth (as seen in Figure 7a) and that hydrothermal treatment removes these compounds and results in improved microalgal growth, even better than the growth in the control glucose conditions (as seen in Figure 8).

[0363] The impact on the lipid profile of *Prototheca moriformis* cultures grown on the various hydrothermally treated lignocellulosic derived sugars was assessed. *Prototheca moriformis* cultures were grown on the following 4x-washed cellulosic feedstocks: *Miscanthus*, sugar cane bagasse and sorghum cane, with glucose levels maintained at 20 g/L through feeding of the cellulosic sugars. At the conclusion of the culturing, microalgae biomass from each condition was analyzed for lipid profile using the methods described in Example 1. The results of the lipid profile analysis (expressed in Area %) are summarized in Table 10 below. Each condition was tested in duplicates, and the results from each of the duplicate test conditions are included. Growth on cellulosic feedstocks resulted in a significant re-distribution in the lipid profile as compared to the glucose control. For example, there was a significant increase in C18:0 Area % in all of the cellulosic feedstock conditions as compared to the glucose control condition.

[0364] Table 10. Lipid profile of *Prototheca moriformis* grown on glucose and cellulosics derived sugars.

	glucose 1 (ctrl)	glucose 2 (ctrl)	bagasse 1	bagasse 2	sorgh 1	sorgh 2	Miscan 1	Miscan 2
C10:0	n.d.	n.d.	0.03	0.02	n.d.	n.d.	n.d.	n.d.
C12:0	0.04	0.05	0.04	0.04	0.05	0.04	0.04	0.04
C14:0	1.64	1.64	1.07	1.10	1.17	1.14	1.08	1.12
C14:1	0.03	0.04	0.04	0.04	0.06	0.06	0.03	0.03
C15:0	0.04	0.05	0.07	0.05	0.08	0.08	0.06	0.06
C16:0	26.80	26.81	22.32	22.81	22.09	22.19	23.45	23.62
C16:1	0.75	0.82	1.68	1.70	1.92	2.12	1.38	1.23
C17:0	0.14	0.16	0.28	0.17	0.29	0.27	0.21	0.19
C17:1	0.07	0.06	0.10	0.10	0.13	0.12	0.10	0.09
C18:0	3.56	3.64	15.88	10.40	15.30	12.37	10.15	8.69
C18:1	54.22	54.01	49.87	53.87	49.35	50.80	54.05	55.26
C18:2	11.23	11.11	6.54	7.91	7.47	8.80	7.71	7.88
C18:3 alpha	0.84	0.85	0.39	0.56	0.47	0.53	0.56	0.60
C20:0	0.31	0.30	0.85	0.63	0.76	0.69	0.63	0.56
C20:1	0.15	0.15	0.33	0.28	0.32	0.32	0.27	0.25
C20:3	0.06	0.06	0.13	0.12	0.14	0.12	0.11	0.11
C24:0	0.12	0.12	0.22	0.19	0.22	0.20	0.18	0.15

n.d. denotes none detected

[0365] Cellulosic sugar stream was generated from exploded corn stover, saccharified using Accellerase enzyme and concentrated using vacuum evaporation. This sugar stream was tested in *Prototheca moriformis* growth assays at a 4% glucose concentration. The results of the growth assays showed very poor growth and the cellulosic sugar stream was tested for conductivity (salt content). The conductivity was very high, far greater than 700 mM sodium equivalents, a level that was shown to be inhibitory to growth as described above and shown in Figure 7d. Methods of the invention include methods in which salt is reduced or removed

from lignocellulosic derived sugars prior to utilizing these feedstocks in the production of lignocellulosic derived microalgal oil. Surprisingly, however, one cannot use resins to desalt concentrated sugar streams, one must first dilute the concentrated sugar stream. To demonstrate this embodiment of the invention, cellulosic sugars derived from corn stover material were diluted eight-fold prior to removing contaminating salts with the resin. The initial conductivity of the concentrated starting material was 87 mS/cm while that of the eight-fold diluted stream was 10990 μ S/cm at a pH of 5.61. Previous studies had indicated that failure to dilute the concentrated sugar stream prior to de-ionization resulted in an inability to remove salts quantitatively as well as a significant loss of glucose from the sugar stream. Three different bed volumes of IEX resin (DOWEX Marathon MR3) were used (1:2, 1:4 and 1:10). Table 11 summarizes results demonstrating the ability of a mixed bed ion exchange (IEX) resin to reduce salts (as measured by conductivity) significantly in a previously concentrated corn stover derived cellulosic sugar stream in diluted feedstocks.

[0366] Table 11. Ability of IEX resin to reduce salts.

Bed volume resin: cellulosics	pH post-deionization	Conductivity post-deionization (μ S/cm)	Calculated conductivity post deionization and 8x re-concentration (μ S/cm)	Na ⁺ equivalents (based on std curve) in mM
1:2	3.1	74	592	7.42
1:4	3.1	97	776	9.7
1:10	5.25	6320	50560	634

[0367] A process employing a 1:4 bed volume:cellulosic feedstock and re-concentration of the material eight-fold would result in a sodium concentration is well within the range for normal biomass and lipid accumulation. Alternatively, deionization or salt removal can be performed prior to saccharification or after saccharification, but before concentration of the sugar stream. If salt removal is performed before the concentration of the sugar stream, a dilution step of the sugar stream before salt removal would likely not be necessary.

[0368] This example demonstrates the efficacy of washing of exploded cellulosic material for the use in cellulosic oil production. As described above, concentration of cellulosically derived sugars without the removal of salts (inherent to the production of exploded cellulosic material and subsequent treatment) results in less than optimal fermentations. The materials treated in the process described below were of the appropriate pH for subsequent saccharification. In addition, the conductivity of this material was significantly reduced (over 100 fold) from the starting feedstock. Therefore, the subsequent concentrated sugars to be used in fermentations were not inhibitory due to the presence of excessive salts. An

additional advantage is seen by the removal of furfurals from the cellulosic material. Any xylose or glucose removed in the hemicellulosic fraction can either be discarded or preferably re-concentrated to be used in fermentations.

[0369] Wet, exploded sugar cane bagasse (NREL, Colorado) with an initial starting mass of 65 kg wet weight and conductivity of 15,000 $\mu\text{S}/\text{cm}$, pH 2.4 was brought to 128 kg with deionized water and the pH adjusted to 4.6 with 10 N NaOH, making the resulting conductivity 6,800 $\mu\text{S}/\text{cm}$. The percent solids were assessed by removal of an aliquot of the suspended materials to a tared (weight = t) aluminum pan, recording the wet weight (weight = w) followed by drying for three hours at 110°C. After drying samples were removed to a desiccator and allowed to come to room temperature (25 °C) at which point, they were weighed again (weight = d). Percent solids were calculated as: % solids = $[(d-t/w-t)] \times 100$. Conductivities were measured on a Thermo Electron Orion 3 Star Conductivity meter.

[0370] The sugar cane bagasse was washed in a semi-continuous fashion by continuously mixing the cellulosic slurry (initial percent solids of 8.2%) at a temperature of 50°C in a stainless steel reactor (150L capacity). Cellulosics were discharged from the reactor vessel via a rotary load pump at a flow rate of 1.9-3.8 kg/min to a Sharples Model 660 decanter centrifuge. Liquid permeate was retained batch wise (ca. 35-175 kg aliquots, see Table 12 below) and homogenous aliquots removed for assessment of total sugars (glucose and xylose) and percent solids as described in Table 12. Conductivity and pH of the cellulosic material were controlled via the addition of de-ionized water and 10 N NaOH, respectively. Samples 1-10 in Table 12 represent decanted centrifuge permeate, and as such, solids and sugars present in these fractions are removed from the final, washed cellulosic materials. A mass balance calculation of total solids compared to solids removed minus solids lost plus final solids for saccharification, resulted in a 99% recovery in the above process. Figure 8 summarizes the furfural and hydroxymethyl furfurals concentration (mg/L) in each of the 11 centrifuge permeates collected and described in Table 12. These data demonstrate a clear removal of furfurals and hydroxymethyl furfurals from the sugar cane bagasse.

[0371] Table 12. Mass balance for semi-continuous hydrothermal treatment of sugar cane bagasse.

Sample	kg (wet)	kg (dry)	pH	Conductivity $\mu\text{S}/\text{cm}$	total xylose removed (g)	total glucose removed (g)
1 (initial material)	128	10.50	4.60	6,880	0	0
2	81.8	2.03		3,280	1030.68	286.3
3	76.5	0.49		2,500	298.35	76.50
4	106	0.41			254.40	63.60
5	173.9	0.30	3.74	1,260	226.07	69.56

6	101.8	0.08	4.40	791	71.26	20.36
7	110.6	0.04	4.86	327	44.24	0
8	77.2	0			0	0
9	108.6	0.02	4.7	221	0	0
10	101.5	0			0	0
11	34.8	0	4.7	146	0	0
Solids removed (samples 1-10) lost in process		3.37				
Total xylose removed					1925.00	
Total glucose removed						516.32
Final solids for saccharification	7.03					

[0372] In another demonstration of the ability of *Prototheca* to utilize cellulosic-derived feedstock, *Prototheca moriformis* (UTEX 1435) was cultivated in three-liter bioreactors using cellulosic derived sugar as a fixed carbon feedstock. The inoculum was prepared from cryopreserved cells, which were thawed at room temperature and 1 mL of cells were added to 300 mL of inoculum medium based on the basal microalgae medium described in Example 1 with 1 g/L (NH₄)₂SO₄, 4 g/L yeast extract and a trace element solution, plus 4% glucose and grown for 1 day at 28°C with agitation (200 rpm). This culture was used to inoculate a three-liter bioreactor containing 1L medium plus 0.26mL of Antifoam 204 (Sigma, USA). The fermentor was controlled at 28°C and pH was maintained at 6.8 by addition of KOH. Dissolved oxygen was maintained at 30% saturation by cascading agitation and airflow. Cellulosic sugar feedstock from corn stover was fed to the culture to maintain 0-10g/L glucose. Desalination of cellulosic sugar feedstocks to less than 300 mM salt was essential to assure similar dry cell weight and lipid accumulation performance as compared to purified sugar feedstock controls. Desalination of the cellulosic sugar feedstock was performed using the methods described above. Fermentor samples were removed to monitor fermentation performance. Cell mass accumulation was monitored by optical density and dry cell weight. Glucose, xylose, ammonia, potassium, sodium and furfural concentrations were also determined and monitored throughout the fermentation time course. Lipid concentration was determined by gravimetric methods discussed above.

[0373] **EXAMPLE 3: Methods for Transforming *Prototheca***

A. General Method for Biolistic transformation of *Prototheca*

[0374] S550d gold carriers from Seashell Technology were prepared according to the protocol from manufacturer. Linearized plasmid (20 µg) was mixed with 50 µl of binding buffer and 60 µl (30 mg) of S550d gold carriers and incubated in ice for 1 min. Precipitation

buffer (100 µl) was added, and the mixture was incubated in ice for another 1 min. After vortexing, DNA-coated particles were pelleted by spinning at 10,000 rpm in an Eppendorf 5415C microfuge for 10 seconds. The gold pellet was washed once with 500 µl of cold 100% ethanol, pelleted by brief spinning in the microfuge, and resuspended with 50 µl of ice-cold ethanol. After a brief (1-2 sec) sonication, 10 µl of DNA-coated particles were immediately transferred to the carrier membrane.

[0375] *Prototheca* strains were grown in proteose medium (2g/L yeast extract, 2.94mM NaNO₃, 0.17mM CaCl₂•2H₂O, 0.3mM MgSO₄•7H₂O, 0.4mM K₂HPO₄, 1.28mM KH₂PO₄, 0.43mM NaCl) on a gyratory shaker until it reaches a cell density of 2x10⁶ cells/ml. The cells were harvested, washed once with sterile distilled water, and resuspended in 50 µl of medium. 1 x 10⁷ cells were spread in the center third of a non-selective proteose media plate. The cells were bombarded with the PDS-1000/He Biolistic Particle Delivery system (Bio-Rad). Rupture disks (1100 and 1350 psi) were used, and the plates are placed 9 and 12 cm below the screen/macrocarrier assembly. The cells were allowed to recover at 25°C for 12–24 h. Upon recovery, the cells were scraped from the plates with a rubber spatula, mixed with 100 µl of medium and spread on plates containing the appropriate antibiotic selection. After 7-10 days of incubation at 25°C, colonies representing transformed cells were visible on the plates from 1100 and 1350 psi rupture discs and from 9 and 12 cm distances. Colonies were picked and spotted on selective agar plates for a second round of selection.

B. Transformation of *Prototheca* with G418 Resistance Gene

[0376] *Prototheca moriformis* and other *Prototheca* strains sensitive to G418 can be transformed using the methods described below. G418 is an aminoglycoside antibiotic that inhibits the function of 80S ribosomes and thereby inhibits protein synthesis. The corresponding resistance gene functions through phosphorylation, resulting in inactivation of G418. *Prototheca* strains UTEX 1435, UTEX 1439 and UTEX 1437 were selected for transformation. All three *Prototheca* strains were genotyped using the methods described above. All three *Prototheca* strains had identical 23s rRNA genomic sequences (SEQ ID NO:15).

[0377] All transformation cassettes were cloned as EcoRI-SacI fragments into pUC19. Standard molecular biology techniques were used in the construction of all vectors according to Sambrook and Russell, 2001. The *C. reinhardtii* beta-tubulin promoter/5'UTR was obtained from plasmid pHyg3 (Berthold *et al.*, (2002) Protist: 153(4), pp 401-412) by PCR as an EcoRI-AscI fragment. The *Chlorella vulgaris* nitrate reductase 3'UTR was obtained

from genomic DNA isolated from UTEX strain 1803 via PCR using the following primer pairs:

Forward:

5' TGACCTAGGTGATTAATTAAGCTCGAGGCAGCAGCAGCTCGGATAGTATCG 3'

(SEQ ID NO:35)

Reverse:

5' CTACGAGCTCAAGCTTTCCATTTGTGTTC CCATCCCACTACTTCC 3'

(SEQ ID NO:36)

[0378] The *Chlorella sorokiniana* glutamate dehydrogenase promoter/UTR was obtained via PCR of genomic DNA isolated from UTEX strain 1230 via PCR using the following primer pairs:

Forward: 5' GATCAGAATTCCGCCTGCAACGCAAGG GCAGC 3' (SEQ ID NO:37)

Reverse: 5' GCATACTAGTGGCGGGACGGAGAGA GGGCG 3' (SEQ ID NO:38)

[0379] Codon optimization was based on the codons in Table 1 for *Prototheca moriformis*. The sequence of the non-codon optimized neomycin phosphotransferase (nptII) cassette was synthesized as an AscI-XhoI fragment and was based on upon the sequence of Genbank Accession No. YP_788126. The codon optimized nptII cassette was also based on this Genbank Accession number.

[0380] The three *Prototheca* strains were transformed using biolistic methods described above. Briefly, the *Prototheca* strains were grown heterophically in liquid medium containing 2% glucose until they reached the desired cell density (1×10^7 cells/mL to 5×10^7 cells/mL). The cells were harvested, washed once with sterile distilled water and resuspended at 1×10^8 cells/mL. 0.5mL of cells were then spread out on a non-selective solid media plate and allowed to dry in a sterile hood. The cells were bombarded with the PDS-1000/He Biolistic Particle Delivery System (BioRad). The cells were allowed to recover at 25° C for 24 hours. Upon recovery, the cells were removed by washing plates with 1 mL of sterile media and transferring to fresh plates containing 100 µg/mL G418. Cells were allowed to dry in a sterile hood and colonies were allowed to form on the plate at room temperature for up to three weeks. Colonies of UTEX 1435, UTEX 1439 and UTEX 1437 were picked and spotted on selective agar plates for a second round of selection.

[0381] A subset of colonies that survived a second round of selection described above, were cultured in small volume and genomic DNA and RNA were extracted using standard molecular biology methods. Southern blots were done on genomic DNA extracted from untransformed (WT), the transformants and plasmid DNA. DNA from each sample was run

on 0.8% agarose gels after the following treatments: undigested (U), digested with AvrII (A), digested with NcoI (N), digested with SacI (S). DNA from these gels was blotted on Nylon+ membranes (Amersham). These membranes were probed with a fragment corresponding to the entire coding region of the nptII gene (NeoR probe). Figure 4 shows maps of the cassettes used in the transformations. Figure 5 shows the results of Southern blot analysis on three transformants (all generated in UTEX strain 1435) (1, 2, and 3) transformed with either the beta-tubulin::neo::nit (SEQ ID NO: 39) (transformants 1 and 2) or glutamate dehydrogenase::neo::nit (SEQ ID NO: 40) (transformant 3). The glutamate dehydrogenase::neo::nit transforming plasmid was run as a control and cut with both NcoI and SacI. AvrII does not cut in this plasmid. Genomic DNA isolated from untransformed UTEX strain 1435 shows no hybridization to the NeoR probe.

[0382] Additional transformants containing the codon-optimized glutamate dehydrogenase::neo::nit (SEQ ID NO: 41) and codon-optimized β -tubulin::neo::nit (SEQ ID NO: 42) constructs were picked and analyzed by Southern blot analysis. As expected, only digests with SacI show linearization of the transforming DNA. These transformation events are consistent with integration events that occur in the form of oligomers of the transforming plasmid. Only upon digestion with restriction enzymes that cut within the transforming plasmid DNA do these molecules collapse down the size of the transforming plasmid.

[0383] Southern blot analysis was also performed on transformants generated upon transformation of *Prototheca* strains UTEX 1437 and UTEX 1439 with the glutamate dehydrogenase::neo::nit cassette. The blot was probed with the NeoR probe and the results are similar to the UTEX 1435 transformants. The results are indicative of integration events characterized by oligomerization and integration of the transforming plasmid. This type of integration event is known to occur quite commonly in *Dictyostelium discoideum* (see, for example, Kuspa, A. and Loomis, W. (1992) *PNAS*, 89:8803-8807 and Morio *et al.*, (1995) *J. Plant Res.* 108:111-114).

[0384] To further confirm expression of the transforming plasmid, Northern blot analysis and RT-PCR analysis were performed on selected transformants. RNA extraction was performed using Trizol Reagent according to manufacturer's instructions. Northern blot analysis were run according to methods published in Sambrook and Russel, 2001. Total RNA (15 μ g) isolated from five UTEX 1435 transformants and untransformed UTEX 1435 (control lanes) was separated on 1% agarose-formaldehyde gel and blotted on nylon membrane. The blot was hybridized to the neo-non-optimized probe specific for transgene sequences in transformants 1 and 3. The two other transformants RNAs express the codon-optimized

version of the neo-transgene and, as expected, based on the sequence homology between the optimized and non-optimized neo genes, showed significantly lower hybridization signal.

[0385] RNA (1 µg) was extracted from untransformed *Prototheca* strain UTEX 1435 and two representative UTEX 1435 transformants and reverse transcribed using an oligo dT primer or a gene specific primer. Subsequently these cDNAs (in duplicate) were subjected to qPCR analysis on ABI Veriti Thermocycler using SYBR-Green qPCR chemistry using the following primers (nptII):

Forward: 5' GCCGCGACTGGCTGCTGCTGG 3' (SEQ ID NO:43)

Reverse: 5' AGGTCCTCGCCGTCGGGCATG 3' (SEQ ID NO:44)

[0386] Possible genomic DNA contamination was ruled out by a no reverse transcriptase negative control sample. The results indicated that the NeoR genes used to transform these strains is actively transcribed in the transformants.

C. Transformation of *Prototheca* with Secreted Heterologous Sucrose

Invertase

[0387] All of the following experiments were performed using liquid medium/agar plates based on the basal medium described in Ueno et al., (2002) *J Bioscience and Bioengineering* 94(2):160-65, with the addition of trace minerals described in US Patent No. 5,900,370, and 1x DAS Vitamin Cocktail (1000x solution): tricine: 9g, thiamine HCL: 0.67g, biotin: 0.01g, cyannocobalamin (vitamin B12): 0.008g, calcium pantothenate: 0.02g and p-aminobenzoic acid: 0.04g).

[0388] Two plasmid constructs were assembled using standard recombinant DNA techniques. The yeast sucrose invertase genes (one codon optimized and one non-codon optimized), suc2, were under the control of the *Chlorella reinhardtii* beta-tubulin promoter/5'UTR and had the *Chlorella vulgaris* nitrate reductase 3'UTR. The sequences (including the 5'UTR and 3'UTR sequences) for the non-codon optimized (Crβ-tub::NCO-suc2::CvNitRed) construct, SEQ ID NO: 57, and codon optimized (Crβ-tub::CO-suc2::CvNitRed) construct, SEQ ID NO: 58, are listed in the Sequence Listing. Codon optimization was based on Table 1 for *Prototheca* sp. Figure 6 shows a schematic of the two constructs with the relevant restriction cloning sites and arrows indicating the direction of transcription. Selection was provided by Neo R (codon optimized using Table 1).

[0389] Preparation of the DNA/gold microcarrier: DNA/gold microcarriers were prepared immediately before use and stored on ice until applied to macrocarriers. The plasmid DNA (in TE buffer) was added to 50 µl of binding buffer. Saturation of the gold beads was achieved at 15 µg plasmid DNA for 3 mg gold carrier. The binding buffer and DNA were

mixed well via vortexing. The DNA and binding buffer should be pre-mix prior to gold addition to ensure uniformed plasmid binding to gold carrier particles. 60 μ l of S550d (Seashell Technologies, San Diego, CA) gold carrier was added to the DNA/binding buffer mixture. For a gold stock at 50 mg/ml, addition of 60 μ l results in an optimal ratio of 15 μ g DNA/3 mg gold carrier. The gold carrier/DNA mixture was allowed to incubate on ice for 1 minute and then 100 μ l of precipitation buffer was added. The mixture was allowed to incubate again on ice for 1 minute and then briefly vortexed and centrifuged at 10,000 rpm at room temperature for 10 seconds to pellet the gold carrier. The supernatant was carefully removed with a pipette and the pellet was washed with 500 μ l of ice cold 100% ethanol. The gold particles were re-pelleted by centrifuging again at 10,000 rpm for 10 seconds. The ethanol was removed and 50 μ l of ice cold ethanol was added to the gold mixture. Immediately prior to applying the gold to macrocarriers, the gold/ethanol was resuspended with a brief 1-2 second pulse at level 2 on a MISONIX sonicator using the micro tip. Immediately after resuspension, 10 μ l of the dispersed gold particles was transferred to the macrocarrier and allowed to dry in a sterile hood.

[0390] The two *Prototheca moriformis* strains (UTEX 1435 and 1441) were grown heterotrophically in liquid medium containing 2% glucose from cryopreserved vials. Each strain was grown to a density of 10^7 cells/ml. This seed culture was then diluted with fresh media to a density of 10^5 cells/ml and allowed to grow for 12-15 hours to achieve a final cell density of approximately 10^6 cells/ml. The microalgae were aliquoted into 50 ml conical tubes and centrifuged for 10 minutes at 3500 rpm. The cells were washed with fresh medium and centrifuged again for 10 minutes at 3500 rpm. The cells were then resuspended at a density of 1.25×10^8 cells/ml in fresh medium.

[0391] In a sterile hood, 0.4ml of the above-prepared cells were removed and placed directly in the center of an agar plate (without selection agent). The plate was gently swirled with a level circular motion to evenly distribute the cells to a diameter of no more than 3cm. The cells were allowed to dry onto the plates in the sterile hood for approximately 30-40 minutes and then were bombarded at a rupture disk pressure of 1350 psi and a plate to macrocarrier distance of 6 cm. The plates were then covered and wrapped with parafilm and allowed to incubate under low light for 24 hours.

[0392] After the 24 hour recovery, 1ml of sterile medium (with no glucose) was added to the lawn of cells. The cells were resuspended using a sterile loop, applied in a circular motion to the lawn of cells and the resuspended cells were collected using a sterile pipette. The cells were then plated onto a fresh agar plate with 2% glucose and 100 μ g/ml G418. The

appearance of colonies occurred 7-12 days after plating. Individual colonies were picked and grown in selective medium with 2% glucose and 100 µg/ml G418. The wildtype (untransformed) and transgenic cells were then analyzed for successful introduction, integration and expression of the transgene.

[0393] Genomic DNA from transformed *Prototheca moriformis* UTEX 1435 and 1441 and their wildtype (untransformed) counterparts were isolated using standard methods. Briefly, the cells were centrifuged for 5 minutes at 14,000 rpm in a standard table top Eppendorf centrifuge (model 5418) and flash frozen prior to DNA extraction. Cell pellets were lysed by adding 200 µL of Lysis buffer (100 mM Tris HCl, pH 8.0, 1% Lauryl Sarcosine, 50 mM NaCl, 20 mM EDTA, 0.25 M sucrose, 0.5 mg/ml RNase A) for every 100-200 mg of cells (wet weight) and vortexing for 30-60 seconds. Cetyl trimethylammonium bromide (CTAB) and NaCl were brought to 1% and 1 M, respectively, and cell extracts were incubated at 60-65°C for 10 minutes. Subsequently, extracts were clarified via centrifugation at 14,000 rpm for 10 minutes and the resulting supernatant was extracted with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1). Samples were then centrifuged for 5 minutes at 14,000 rpm and the aqueous phase removed. DNA was precipitated with 0.7 volumes of isopropanol. DNA was pelleted via centrifugation at 14,000 rpm for 10 minutes and washed twice with 80% ethanol, and once with ethanol. After drying, DNA was resuspended in 10 mM Tris HCl, pH 8.0 and DNA concentrations were determined by using PicoGreen fluorescence quantification assay (Molecular Probes).

[0394] RNA from transformed *Prototheca moriformis* UTEX 1435 and 1441 and their wildtype (untransformed) counterparts were isolated using standard methods. Briefly, the cells were centrifuged for 5 minutes at 14,000 rpm in a standard table top Eppendorf centrifuge (model 5418) and flash frozen before RNA extraction. Cell pellets were lysed by addition of 1 mL of Trizol reagent (Sigma) for every 100 mg of cells (wet weight) and by vortexing for 1-2 minutes. Samples were incubated at room temperature for 5 minutes and subsequently adjusted with 200 µL of chloroform per 1 mL of Trizol reagent. After extensive shaking, cells were incubated at room temperature for 15 minutes and then subjected to centrifugation at 14000 rpm for 15 minutes in a refrigerated table top microcentrifuge. RNA partitioning to the upper aqueous phase was removed and precipitated by addition of isopropanol (500 µL per 1ml of Trizol reagent). RNA was collected by centrifugation for 10 minutes and the resulting pellet washed twice with 1 mL of 80% ethanol, dried, and resuspended in RNase free water. RNA concentration was estimated by RiboGreen fluorescence quantification assay (Molecular Probes).

[0395] Expression of neomycin phosphotransferase gene conferring G418 antibiotic resistance and yeast invertase was assayed in non-transformed *Prototheca moriformis* UTEX 1435 and 1441 and transformants T98 (UTEX 1435 transformant) and T97 (UTEX 1441 transformant) using reverse transcription quantitative PCR analysis (RT-qPCR). 20 ng total RNA (isolated as described above) was subjected to one step RT-qPCR analysis using iScript SYBR Green RT-PCR kit (BioRad Laboratories) and primer pairs targeting the neomycin resistance gene (forward primer 5'CCGCCGTGCTGGACGTGGTG 3' and reverse primer 5'GGTGGCGGGGTCCAGGGTGT 3'; SEQ ID NOs: 65 and 66, respectively) and *suc2* invertase transcripts (forward primer 5' CGGCCGGCGGCTCCTTCAAC 3' and reverse primer 5' GCGCTCCCGTAGGTCGGGT 3'; SEQ ID NO: 67 and 68, respectively). Endogenous beta-tubulin transcripts served as an internal positive control for PCR amplification and as a normalization reference to estimate relative transcript levels.

[0396] Both codon optimized and non-codon optimized constructs were transformed into UTEX 1435 and 1441 *Prototheca moriformis* cells as described above. Initially, transformants were obtained with both constructs and the presence of the transgene was verified by Southern blot analysis followed by RTPCR to confirm the presence of the DNA and mRNA from the transgene. For the Southern blot analysis, genomic DNA isolated as described above was electrophoresed on 0.7% agarose gels in 1x TAE buffer. Gels were processed as described in Sambrook et al. (Molecular Cloning; A Laboratory Manual, 2nd Edition. Cold Spring Harbor Laboratory Press, 1989). Probes were prepared by random priming and hybridizations carried out as described in Sambrook et al. Transformants from both the codon optimized and the non-codon optimized constructs showed the presence of the invertase cassette, while the non-transformed control was negative. Invertase mRNA was also detected in transformants with both the codon optimized and non-codon optimized constructs.

[0397] To confirm that the transformants were expressing an active invertase protein, the transformants were plated on sucrose plates. The transformants containing the non-codon optimized cassette failed to grow on the sucrose containing plates, indicating that, while the gene and the mRNA encoding the SUC2 protein were present, the protein was either (1) not being translated, or (2) being translated, but not accumulating to levels sufficient to allow for growth on sucrose as the sole carbon source. The transformants with the codon optimized cassette grew on the sucrose containing plates. To assess the levels of invertase being expressed by these transformants, two clones (T98 and T97) were subjected to an invertase assay of whole cells scraped from solid medium and direct sampling and quantitation of

sugars in the culture supernatants after 48 hours of growth in liquid medium containing 2% sucrose as the sole carbon source.

[0398] For the invertase assay, the cells (T98 and T97) were grown on plates containing 2% sucrose, scraped off and assayed for invertase activity. 10 μ l of the scraped cells was mixed with 40 μ l of 50mM NaOAc pH 5.1. 12.5 μ l of 0.5M sucrose was added to the cell mixture and incubated at 37°C for 10-30 minutes. To stop the reaction, 75 μ l of 0.2M K_2HPO_4 was added. To assay for glucose liberated, 500 μ l of reconstituted reagent (glucose oxidase/peroxidase + o-Dianisidine) from Sigma (GAGO-20 assay kit) was added to each tube and incubated at 37°C for 30 minutes. A glucose standard curve was also created at this time (range: 25 μ g to 0.3 μ g glucose). After incubation, 500 μ l of 6N HCl was added to stop the reaction and to develop the color. The samples were read at 540nm. The amount of glucose liberated was calculated from the glucose standard curve using the formula $y=mx+c$, where y is the 540nm reading, and x is μ g of glucose. Weight of glucose was converted to moles of glucose, and given the equimolar relationship between moles of sucrose hydrolyzed to moles of glucose generated, the data was expressed as nmoles of sucrose hydrolyzed per unit time. The assay showed that both T98 and T97 clones were able to hydrolyze sucrose, indicating that a functional sucrose invertase was being produced and secreted by the cells.

[0399] For the sugar analysis on liquid culture media after 48 hours of algal growth, T97 and T98 cells were grown in 2% sucrose containing medium for 48 hours and the culture media were processed for sugar analysis. Culture broths from each transformant (and negative non-transformed cell control) were centrifuged at 14,000 rpm for 5 minutes. The resulting supernatant was removed and subjected to HPLC/ELSD (evaporative light scattering detection). The amount of sugar in each sample was determined using external standards and liner regression analysis. The sucrose levels in the culture media of the transformants were very low (less than 1.2g/L, and in most cases 0g/L). In the negative controls, the sucrose levels remained high, at approximately 19g/L after 48 hours of growth.

[0400] These results were consistent with the invertase activity results, and taken together, indicated that the codon optimized transformants, T97 and T98, secreted an active sucrose invertase that allowed the microalgae to utilize sucrose as the sole carbon source in contrast to (1) the non-codon optimized transformants and (2) the non-transformed wildtype microalgae, both of which could not utilize sucrose as the sole carbon source in the culture medium.

[0401] *Prototheca moriformis* strains, T98 and T97, expressing a functional, secreted sucrose invertase (SUC2) transgene were assayed for growth and lipid production using sucrose as the sole carbon source.

[0402] Wild type (untransformed), T98 and T97 strains were grown in growth media (as described above) containing either 4% glucose or 4% sucrose as the sole carbon source under heterotrophic conditions for approximately 6 days. Growth, as determined by A750 optical density readings were taken of all four samples every 24 hours and the dry cell weight of the cultures and lipid profiles were determined after the 6 days of growth. The optical density readings of the transgenic strains grown in both the glucose and sucrose conditions were comparable to the wildtype strains grown in the glucose conditions. These results indicate that the transgenic strains were able to grow on either glucose or sucrose as the sole carbon source at a rate equal to wildtype strains in glucose conditions. The non-transformed, wildtype strains did not grow in the sucrose-only condition.

[0403] The biomass for the wildtype strain grown on glucose and T98 strain grown on sucrose was analyzed for lipid profile. Lipid samples were prepared from dried biomass (lyophilized) using an Acid Hydrolysis System (Ankom Technology, NY) according to manufacturer's instructions. Lipid profile determinations were carried as described in Example 4. The lipid profile for the non-transformed *Prototheca moriformis* UTEX 1435 strain, grown on glucose as the sole carbon source and two clonal T98 strains (UTEX 1435 transformed with a sucrose invertase transgene), grown on sucrose as the sole carbon source, are disclosed in Table 13 (wildtype UTEX 1435 and T98 clone 8 and clone 11 below. C:19:0 lipid was used as an internal calibration control.

[0404] Table 13. Lipid profile of wildtype UTEX 1435 and UTEX 1435 clones with *suc2* transgene.

Name	wildtype (Area % - ISTD)	T98 clone 11 (Area % - ISTD)	T98 clone 8 (Area % - ISTD)
C 12:0	0.05	0.05	0.05
C 14:0	1.66	1.51	1.48
C 14:1	0.04	nd	nd
C 15:0	0.05	0.05	0.04
C 16:0	27.27	26.39	26.50
C 16:1	0.86	0.80	0.84
C 17:0	0.15	0.18	0.14
C 17:1	0.05	0.07	0.05
C 18:0	3.35	4.37	4.50
C 18:1	53.05	54.48	54.50
C 18:2	11.79	10.33	10.24
C 19:0 (ISTD)	--	--	--
C 18:3 alpha	0.90	0.84	0.81
C 20:0	0.32	0.40	0.38

C 20:1	0.10	0.13	0.12
C 20:1	0.04	0.05	0.04
C 22:0	0.12	0.16	0.12
C 20:3	0.07	0.08	0.07
C 24:0	0.12	0.11	0.10
nd - denotes none detected			

[0405] Oil extracted from wildtype *Prototheca moriformis* UTEX 1435 (via solvent extraction or using an expeller press (see methods in Example 44 above) was analyzed for carotenoids, chlorophyll, tocopherols, other sterols and tocotrienols. The results are summarized below in Table 14.

[0406] Table 14. Carotenoid, chlorophyll, tocopherol/sterols and tocotrienol analysis in oil extracted from *Prototheca moriformis* (UTEX 1435).

	Pressed oil (mcg/ml)	Solvent extracted oil (mcg/ml)
cis-Lutein	0.041	0.042
trans-Lutein	0.140	0.112
trans-Zeaxanthin	0.045	0.039
cis-Zeaxanthin	0.007	0.013
t-alpha-Cryptoxanthin	0.007	0.010
t-beta-Cryptoxanthin	0.009	0.010
t-alpha-Carotene	0.003	0.001
c-alpha-Carotene	none detected	none detected
t-beta-Carotene	0.010	0.009
9-cis-beta-Carotene	0.004	0.002
Lycopene	none detected	none detected
Total Carotenoids	0.267	0.238
Chlorophyll	<0.01 mg/kg	<0.01 mg/kg
Tocopherols and Sterols		
	Pressed oil (mg/100g)	Solvent extracted oil (mg/100g)
gamma Tocopherol	0.49	0.49
Campesterol	6.09	6.05
Stigmasterol	47.6	47.8
Beta-sitosterol	11.6	11.5
Other sterols	445	446
Tocotrienols		
	Pressed oil (mg/g)	Solvent extracted oil (mg/g)
alpha Tocotrienol	0.26	0.26
beta Tocotrienol	<0.01	<0.01
gamma Tocotrienol	0.10	0.10
delta Tocotrienol	<0.01	<0.01
Total Tocotrienols	0.36	0.36

[0407] The ability of using sucrose as the sole carbon source as the selection factor for clones containing the *suc2* transgene construct instead of G418 (or another antibiotic) was assessed using the positive *suc2* gene transformants. A subset of the positive transformants was grown on plates containing sucrose as the sole carbon source and without antibiotic

selection for 24 doublings. The clones were then challenged with plates containing glucose as the sole carbon source and G418. There was a subset of clones that did not grow on the glucose + G418 condition, indicating a loss of expression of the transgene. An additional experiment was performed using a plate containing sucrose as the sole carbon source and no G418 and streaking out a *suc2* transgene expressing clone on one half of the plate and wild-type *Prototheca moriformis* on the other half of the plate. Growth was seen with both the wild-type and transgene-containing *Prototheca moriformis* cells. Wild-type *Prototheca moriformis* has not demonstrated the ability to grow on sucrose, therefore, this result shows that unlike antibiotic resistance, the use of sucrose/invertase selection is not cell-autonomous. It is very likely that the transformants were secreting enough sucrose invertase into the plate/media to support wildtype growth as the sucrose was hydrolyzed into fructose and glucose.

[0408] EXAMPLE 4: Recombinant *Prototheca* with Exogenous TE Gene

[0409] As described above, *Prototheca* strains can be transformed with exogenous genes. *Prototheca moriformis* (UTEX 1435) was transformed, using methods described above, with either *Umbellularia californica* C12 thioesterase gene or *Cinnamomum camphora* C14 thioesterase gene (both codon optimized according to Table 1). Each of the transformation constructs contained a *Chlorella sorokiniana* glutamate dehydrogenase promoter/5'UTR region (SEQ ID NO: 69) to drive expression of the thioesterase transgene. The thioesterase transgenes coding regions of *Umbellularia californica* C12 thioesterase (SEQ ID NO: 70) or *Cinnamomum camphora* C14 thioesterase (SEQ ID NO: 71), each with the native putative plastid targeting sequence. Immediately following the thioesterase coding sequence is the coding sequence for a c-terminal 3x-FLAG tag (SEQ ID NO: 72), followed by the *Chlorella vulgaris* nitrate reductase 3'UTR (SEQ ID NO: 73). A diagram of the thioesterase constructs that were used in the *Prototheca moriformis* transformations is shown in Figure 9.

[0410] Preparation of the DNA, gold microcarrier and *Prototheca moriformis* (UTEX 1435) cells were performed using the methods described above in Example 3. The microalgae were bombarded using the gold microcarrier—DNA mixture and plated on selection plates containing 2% glucose and 100µg/ml G418. The colonies were allowed to develop for 7 to 12 days and colonies were picked from each transformation plate and screened for DNA construct incorporation using Southern blots assays and expression of the thioesterase constructs were screened using RT-PCR.

[0411] Positive clones were picked from both the C12 and C14 thioesterase transformation plates and screened for construct incorporation using Southern blot assays. Southern blot

assays were carried out using standard methods (and described above in Example 3) using an optimized c probes, based on the sequence in SEQ ID NO: 70 and SEQ ID NO: 71.

Transforming plasmid DNA was run as a positive control. Out of the clones that were positive for construct incorporation, a subset was selected for reverse transcription quantitative PCR (RT-qPCR) analysis for C12 thioesterase and C14 thioesterase expression.

[0412] RNA isolation was performed using methods described in Example 3 above and RT-qPCR of the positive clones were performed using 20 ng of total RNA from each clone using the below-described primer pair and iScript SYBR Green RT-PCR kit (Bio-Rad Laboratories) according to manufacturer's protocol. Wildtype (non-transformed) *Prototheca moriformis* total RNA was included as a negative control. mRNA expression was expressed as relative fold expression (RFE) as compared to negative control. . The primers that were used in the C12 thioesterase transformation RT-qPCR screening were:

[0413] *U. californica* C12 thioesterase PCR primers:

Forward: 5' CTGGGCGACGGCTTCGGCAC 3' (SEQ ID NO: 74)

Reverse: 5' AAGTCGCGGCGCATGCCGTT 3' (SEQ ID NO: 75)

[0414] The primers that were used in the C14 thioesterase transformation RT-qPCR screening were:

[0415] *Cinnamomum camphora* C14 thioesterase PCR primers:

Forward: 5' TACCCCGCCTGGGGCGACAC 3' (SEQ ID NO: 76)

Reverse: 5' CTTGCTCAGGCGGCGGGTGC 3' (SEQ ID NO: 77)

[0416] RT-qPCR results for C12 thioesterase expression in the positive clones showed an increased RFE of about 40 fold to over 2000 fold increased expression as compared to negative control. Similar results were seen with C14 thioesterase expression in the positive clones with an increase RFE of about 60-fold to over 1200 fold increased expression as compared to negative control.

[0417] A subset of the positive clones from each transformation (as screened by Southern blotting and RT-qPCR assays) were selected and grown under nitrogen-replete conditions and analyzed for total lipid production and profile. Lipid samples were prepared from dried biomass from each clone. 20-40 mg of dried biomass from each transgenic clone was resuspended in 2 mL of 3% H₂SO₄ in MeOH, and 200ul of toluene containing an appropriate amount of a suitable internal standard (C19:0) was added. The mixture was sonicated briefly to disperse the biomass, then heated at 65-70°C for two hours. 2 mL of heptane was added to extract the fatty acid methyl esters, followed by addition of 2 mL of 6% K₂CO₃ (aq) to neutralize the acid. The mixture was agitated vigorously, and a portion of the upper layer

was transferred to a vial containing Na₂SO₄ (anhydrous) for gas chromatography analysis using standard FAME GC/FID (fatty acid methyl ester gas chromatography flame ionization detection) methods. Lipid profile (expressed as Area %) of the positive clones as compared to wildtype negative control are summarized in Tables 15 and 16 below. As shown in Table 15, the fold increase of C12 production in the C12 transformants ranged from about a 5-fold increase (clone C12-5) to over 11-fold increase (clone C12-1). Fold increase of C14 production in the C14 transformants ranged from about a 1.5 fold increase to about a 2.5 fold increase.

[0418] Table 15. Summary of total lipid profile of the *Prototheca moriformis* C12 thioesterase transformants.

	Wildtype	C12-1	C12-2	C12-3	C12-4	C12-5	C12-6	C12-7	C12-8
C6:0	0.03	nd	nd	nd	nd	nd	nd	nd	nd
C8:0	0.11	0.09	nd	0.11	nd	nd	nd	nd	nd
C10:0	nd	nd	nd	0.01	0.01	nd	nd	0.01	nd
C12:0	0.09	1.04	0.27	0.72	0.71	0.50	0.67	0.61	0.92
C14:0	2.77	2.68	2.84	2.68	2.65	2.79	2.73	2.56	2.69
C14:1	0.01	nd	nd	0.02	nd	nd	nd	0.01	nd
C15:0	0.30	0.09	0.10	0.54	0.19	0.09	0.13	0.97	0.09
C15:1	0.05	nd	nd	0.02	nd	nd	nd	nd	nd
C16:0	24.13	23.12	24.06	22.91	22.85	23.61	23.14	21.90	23.18
C16:1	0.57	0.62	0.10	0.52	0.69	0.63	0.69	0.49	0.63
C17:0	0.47	0.24	0.27	1.02	0.36	0.17	0.26	2.21	0.19
C17:1	0.08	nd	0.09	0.27	0.10	0.05	0.09	0.80	0.05
C18:0	nd	nd	2.14	1.75	2.23	2.16	2.38	1.62	2.47
C18:1	22.10	23.15	24.61	21.90	23.52	19.30	22.95	20.22	22.85
C18:1	nd	0.33	0.24	nd	nd	0.09	0.09	nd	0.11
C18:2	37.16	34.71	35.29	35.44	35.24	36.29	35.54	36.01	35.31
C18:3 alpha	11.68	11.29	9.26	11.62	10.76	13.61	10.64	11.97	10.81
C20:0	0.15	0.16	0.19	0.16	0.16	0.14	0.18	0.14	0.18
C20:1	0.22	0.17	0.19	0.20	0.21	0.19	0.21	0.20	0.21
C20:2	0.05	nd	0.04	0.05	0.05	0.05	0.04	0.05	0.04
C22:0	nd	nd	nd	0.01	nd	nd	nd	0.02	nd
C22:1	nd	nd	nd	nd	nd	0.01	nd	0.01	nd
C20:3	0.05	nd	0.07	0.06	0.06	0.10	0.07	0.05	0.06
C20:4	nd	nd	nd	nd	nd	0.02	nd	nd	nd
C24:0	nd	nd	0.24	0.01	0.20	0.19	0.19	0.14	0.20

[0419] Table 16. Summary of total lipid profile of the *Prototheca moriformis* C14 thioesterase transformants.

	Wildtype	C14-1	C14-2	C14-3	C14-4	C14-5	C14-6	C14-7
C6:0	0.03	nd	nd	nd	nd	nd	nd	nd
C8:0	0.11	nd	nd	nd	nd	nd	nd	nd
C10:0	nd	0.01	nd	0.01	nd	0.01	nd	nd
C12:0	0.09	0.20	0.16	0.25	0.21	0.19	0.40	0.17
C14:0	2.77	4.31	4.76	4.94	4.66	4.30	6.75	4.02
C14:1	0.01	nd	0.01	nd	nd	0.01	nd	nd
C15:0	0.30	0.43	0.45	0.12	0.09	0.67	0.10	0.33
C15:1	0.05	nd	nd	nd	nd	nd	nd	nd

C16:0	24.13	22.85	23.20	23.83	23.84	23.48	24.04	23.34
C16:1	0.57	0.65	0.61	0.60	0.60	0.47	0.56	0.67
C17:0	0.47	0.77	0.76	0.21	0.19	1.11	0.18	0.54
C17:1	0.08	0.23	0.15	0.06	0.05	0.24	0.05	0.12
C18:0	nd	1.96	1.46	2.48	2.34	1.84	2.50	2.06
C18:1	22.10	22.25	19.92	22.36	20.57	19.50	20.63	22.03
C18:1	nd	nd	nd	nd	nd	nd	0.10	nd
C18:2	37.16	34.97	36.11	34.35	35.70	35.49	34.03	35.60
C18:3	11.68	10.71	12.00	10.15	11.03	12.08	9.98	10.47
alpha								
C20:0	0.15	0.16	0.19	0.17	0.17	0.14	0.18	0.16
C20:1	0.22	0.20	0.12	0.19	0.19	0.19	0.17	0.20
C20:2	0.05	0.04	0.02	0.03	0.04	0.05	0.03	0.04
C22:0	nd	nd	nd	nd	0.02	0.01	nd	nd
C22:1	nd	0.01	nd	nd	nd	nd	nd	0.01
C20:3	0.05	0.08	0.03	0.06	0.09	0.05	0.05	0.07
C20:4	nd	0.01	nd	nd	nd	nd	0.02	nd
C24:0	nd	0.17	0.14	0.19	0.20	0.16	0.22	0.17

[0420] The above-described experiments indicate the successful transformation of *Prototheca moriformis* (UTEX 1435) with transgene constructs of two different thioesterases (C12 and C14), which involved not only the successful expression of the transgene, but also the correct targeting of the expressed protein to the plastid and a functional effect (the expected change in lipid profile) as a result of the transformation. The same transformation experiment was performed using an expression construct containing a codon-optimized (according to Table 1) *Cuphea hookeriana* C8-10 thioesterase coding region with the native plastid targeting sequence (SEQ ID NO: 78) yielded no change in lipid profile. While the introduction of the *Cuphea hookeriana* C8-10 transgene into *Prototheca moriformis* (UTEX 1435) was successful and confirmed by Southern blot analysis, no change in C8 or C10 fatty acid production was detected in the transformants compared to the wildtype strain.

[0421] EXAMPLE 5: Generation of *Prototheca moriformis* strain with exogenous plant TE with algal plastid targeting sequence

[0422] In order to investigate whether the use of algal chloroplast/plastid targeting sequences would improve medium chain (C8-C14) thioesterase expression and subsequent medium chain lipid production in *Prototheca moriformis* (UTEX 1435), several putative algal plastid targeting sequences were cloned from *Chlorella protothecoides* and *Prototheca moriformis*. Thioesterase constructs based on *Cuphea hookeriana* C8-10 thioesterase, *Umbellularia californica* C12 thioesterase, and *Cinnamomum camphora* C14 thioesterase were made using made with a *Chlorella sorokiniana* glutamate dehydrogenase promoter/5'UTR and a *Chlorella vulgaris* nitrate reductase 3'UTR. The thioesterase coding sequences were modified by removing the native plastid targeting sequences and replacing

them with plastid targeting sequences from the *Chlorella protothecoides* and the *Prototheca moriformis* genomes. The thioesterase expression constructs and their corresponding sequence identification numbers are listed below. Each transformation plasmid also contained a Neo resistance construct that was identical to the ones described in Example 3 above. Additionally, another algal-derived promoter, the *Chlamydomonas reinhardtii* β -tubulin promoter, was also tested in conjunction with the thioesterase constructs. "Native" plastid targeting sequence refers to the higher plant thioesterase plastid targeting sequence. A summary of the constructs used in these experiments is provided below:

Construct Name	Promoter/ 5'UTR	Plastid targeting seq	Gene	3'UTR	SEQ ID NO.
Construct 1	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>C. protothecoides</i> stearoyl ACP desaturase	<i>Cuphea</i> <i>hookeriana</i> C8-10 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 79
Construct 2	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>P. moriformis</i> delta 12 fatty acid desaturase	<i>Cuphea</i> <i>hookeriana</i> C8-10 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 80
Construct 3	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>P. moriformis</i> isopentenyl diphosphate synthase	<i>Cuphea</i> <i>hookeriana</i> C8-10 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 81
Construct 4	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>P. moriformis</i> isopentenyl diphosphate synthase	<i>Umbellularia</i> <i>californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 82
Construct 5	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>P. moriformis</i> stearoyl ACP desaturase	<i>Umbellularia</i> <i>californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 83
Construct 6	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>C. protothecoides</i> stearoyl ACP desaturase	<i>Umbellularia</i> <i>californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 84
Construct 7	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>P. moriformis</i> delta 12 fatty acid desaturase	<i>Umbellularia</i> <i>californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 85
Construct 8	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>C. protothecoides</i> stearoyl ACP desaturase	<i>Cinnamomum</i> <i>camphora</i> C14 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 86
Construct 9	<i>Chlamydomonas</i> <i>reinhardtii</i> β -tubulin	Native	<i>Cuphea</i> <i>hookeriana</i> C8-10 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 113
Construct 10	<i>Chlamydomonas</i> <i>reinhardtii</i> β -tubulin	<i>P. moriformis</i> isopentenyl diphosphate synthase	<i>Cuphea</i> <i>hookeriana</i> C8-10 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 114
Construct 11	<i>Chlamydomonas</i>	<i>P. moriformis</i>	<i>Cuphea</i>	<i>C. vulgaris</i>	SEQ ID NO: 115

	<i>reinhardtii</i> β -tubulin	delta 12 fatty acid desaturase	<i>hookeriana</i> C8-10 TE	nitrate reductase	
Construct 12	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>C. protothecoides</i> stearoyl ACP desaturase	<i>Cuphea hookeriana</i> C8-10 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 116
Construct 13	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>P. moriformis</i> stearoyl ACP desaturase	<i>Cuphea hookeriana</i> C8-10 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 117
Construct 14	<i>Chlamydomonas reinhardtii</i> β -tubulin	Native	<i>Umbellularia californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 118
Construct 15	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>P. moriformis</i> isopentenyl diphosphate	<i>Umbellularia californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 119
Construct 16	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>P. moriformis</i> delta 12 fatty acid desaturase	<i>Umbellularia californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 120
Construct 17	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>C. protothecoides</i> stearoyl ACP desaturase	<i>Umbellularia californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 121
Construct 18	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>P. moriformis</i> stearoyl ACP desaturase	<i>Umbellularia californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 122
Construct 19	<i>Chlamydomonas reinhardtii</i> β -tubulin	Native	<i>Cinnamomum camphora</i> C14 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 123
Construct 20	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>P. moriformis</i> isopentenyl diphosphate synthase	<i>Cinnamomum camphora</i> C14 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 124
Construct 21	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>P. moriformis</i> delta 12 fatty acid desaturase	<i>Cinnamomum camphora</i> C14 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO:
Construct 22	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>C. protothecoides</i> stearoyl ACP desaturase	<i>Cinnamomum camphora</i> C14 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 87
Construct 23	<i>Chlamydomonas reinhardtii</i> β -tubulin	<i>P. moriformis</i> stearoyl ACP desaturase	<i>Cinnamomum camphora</i> C14 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 88

[0423] Each construct was transformed into *Prototheca moriformis* (UTEX 1435) and selection was performed using G418 using the methods described in Example 4 above. Several positive clones from each transformation were picked and screened for the presence thioesterase transgene using Southern blotting analysis. Expression of the thioesterase

transgene was confirmed using RT-PCR. A subset of the positive clones (as confirmed by Southern blotting analysis and RT-PCR) from each transformation was selected and grown for lipid profile analysis. Lipid samples were prepared from dried biomass samples of each clone and lipid profile analysis was performed using acid hydrolysis methods described in Example 4. Changes in area percent of the fatty acid corresponding to the thioesterase transgene were compared to wildtype levels, and clones transformed with a thioesterase with the native plastid targeting sequence.

[0424] As mentioned in Example 4, the clones transformed with *Cuphea hookeriana* C8-10 thioesterase constructs with the native plastid targeting sequence had the same level of C8 and C10 fatty acids as wildtype. The clones transformed with *Cuphea hookeriana* C8-10 thioesterase constructs (Constructs 1-3) with algal plastid targeting sequences had over a 10-fold increase in C10 fatty acids for Construct 3 and over 40-fold increase in C10 fatty acids for Constructs 1 and 2 (as compared to wildtype). The clones transformed with *Umbellularia californica* C12 thioesterase constructs with the native plastid targeting sequence had a modest 6-8 fold increase in C12 fatty acid levels as compared to wildtype. The clones transformed with the *Umbellularia californica* C12 thioesterase constructs with the algal plastid targeting constructs (Constructs 4-7) had over an 80-fold increase in C12 fatty acid level for Construct 4, about an 20-fold increase in C12 fatty acid level for Construct 6, about a 10-fold increase in C12 fatty acid level for Construct 7 and about a 3-fold increase in C12 fatty acid level for Construct 5 (all compared to wildtype). The clones transformed with *Cinnamomum camphora* C14 thioesterase with either the native plastid targeting sequence or the construct 8 (with the *Chlorella protothecoides* stearoyl ACP desaturase plastid targeting sequence) had about a 2-3 fold increase in C14 fatty acid levels as compared to wildtype. In general clones transformed with an algal plastid targeting sequence thioesterase constructs had a higher fold increase in the corresponding chain-length fatty acid levels than when using the native higher plant targeting sequence.

A. *Chlamydomonas reinhardtii* β -tubulin promoter

[0425] Additional heterologous thioesterase expression constructs were prepared using the *Chlamydomonas reinhardtii* β -tubulin promoter instead of the *C. sorokinana* glutamate dehydrogenase promoter. The construct elements and sequence of the expression constructs are listed above. Each construct was transformed into *Prototheca moriformis* UTEX 1435 host cells using the methods described above. Lipid profiles were generated from a subset of positive clones for each construct in order to assess the success and productivity of each construct. The lipid profiles compare the fatty acid levels (expressed in area %) to wildtype

host cells. The "Mean" column represents the numerical average of the subset of positive clones. The "Sample" column represents the best positive clone that was screened (best being defined as the sample that produced the greatest change in area % of the corresponding chain-length fatty acid production). The "low-high" column represents the lowest area % and the highest area % of the fatty acid from the clones that were screened. The lipid profiles results of Constructs 9-23 are summarized below.

Construct 9. <i>Cuphea hookeriana</i> C8-10 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 8:0	0	0.05	0.30	0-0.29
C 10:0	0.01	0.63	2.19	0-2.19
C 12:0	0.03	0.06	0.10	0-0.10
C 14:0	1.40	1.50	1.41	1.36-3.59
C 16:0	24.01	24.96	24.20	
C 16:1	0.67	0.80	0.85	
C 17:0	0	0.16	0.16	
C 17:1	0	0.91	0	
C 18:0	4.15	17.52	3.19	
C 18:1	55.83	44.81	57.54	
C 18:2	10.14	7.58	8.83	
C 18:3 α	0.93	0.68	0.76	
C 20:0	0.33	0.21	0.29	
C 24:0	0	0.05	0.11	

Construct 10. <i>Cuphea hookeriana</i> C8-10 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 8:0	0	0.01	0.02	0-0.03
C 10:0	0	0.16	0.35	0-0.35
C 12:0	0.04	0.05	0.07	0-0.07
C 14:0	1.13	1.62	1.81	0-0.05
C 14:1	0	0.04	0.04	
C 15:0	0.06	0.05	0.05	
C 16:0	19.94	26.42	28.08	
C 16:1	0.84	0.96	0.96	
C 17:0	0.19	0.14	0.13	
C 17:1	0.10	0.06	0.05	
C 18:0	2.68	3.62	3.43	
C 18:1	63.96	54.90	53.91	
C 18:2	9.62	9.83	9.11	
C 18:3 γ	0	0.01	0	
C 18:3 α	0.63	0.79	0.73	
C 20:0	0.26	0.35	0.33	
C 20:1	0.06	0.08	0.09	
C 20:1	0.08	0.06	0.07	
C 22:0	0	0.08	0.09	
C 24:0	0.13	0.13	0.11	

Construct 11. <i>Cuphea hookeriana</i> C8-10 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 8:0	0	0.82	1.57	0-1.87
C 10:0	0	3.86	6.76	0-6.76

C 12:0	0.04	0.13	0.20	0.03-0.20
C 14:0	1.13	1.80	1.98	1.64-2.05
C 14:1	0	0.04	0.04	
C 15:0	0.06	0.06	0.06	
C 16:0	19.94	25.60	25.44	
C 16:1	0.84	1.01	1.02	
C 17:0	0.19	0.13	0.11	
C 17:1	0.10	0.06	0.05	
C 18:0	2.68	2.98	2.38	
C 18:1	63.96	51.59	48.85	
C 18:2	9.62	9.85	9.62	
C18:3 γ	0	0.01	0	
C 18:3 α	0.63	0.91	0.92	
C 20:0	0.26	0.29	0.26	
C 20:1	0.06	0.06	0	
C 20:1	0.08	0.06	0.03	
C 22:0	0	0.08	0.08	
C 24:0	0.13	0.06	0	

Construct 12. <i>Cuphea hookeriana</i> C8-10 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 8:0	0	0.31	0.85	0-0.85
C 10:0	0	2.16	4.35	0.20-4.35
C 12:0	0.04	0.10	0.15	0-0.18
C 14:0	1.13	1.96	1.82	1.66-2.97
C 14:1	0	0.03	0.04	
C 15:0	0.06	0.07	0.07	
C 16:0	19.94	26.08	25.00	
C 16:1	0.84	1.04	0.88	
C 17:0	0.19	0.16	0.16	
C 17:1	0.10	0.05	0.07	
C 18:0	2.68	3.02	3.19	
C 18:1	63.96	51.08	52.15	
C 18:2	9.62	11.44	9.47	
C18:3 γ	0	0.01	0	
C 18:3 α	0.63	0.98	0.90	
C 20:0	0.26	0.30	0.28	
C 20:1	0.06	0.06	0.05	
C 20:1	0.08	0.04	0	
C 22:0	0	0.07	0	
C 24:0	0.13	0.05	0	

Construct 14. <i>Umbellularia californica</i> C12 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0.01	0.02	0.03	0.02-0.03
C 12:0	0.03	2.62	3.91	0.04-3.91
C 14:0	1.40	1.99	2.11	1.83-2.19
C 16:0	24.01	27.64	27.01	
C 16:1	0.67	0.92	0.92	

C 18:0	4.15	2.99	2.87	
C 18:1	55.83	53.22	52.89	
C 18:2	10.14	8.68	8.41	
C 18:3 α	0.93	0.78	0.74	
C 20:0	0.33	0.29	0.27	

Construct 15. <i>Umbellularia californica</i> C12 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0	0.05	0.08	0-0.08
C 12:0	0.04	8.12	12.80	4.35-12.80
C 13:0	0	0.02	0.03	0-0.03
C 14:0	1.13	2.67	3.02	2.18-3.37
C 14:1	0	0.04	0.03	0.03-0.10
C 15:0	0.06	0.07	0.06	
C 16:0	19.94	25.26	23.15	
C 16:1	0.84	0.99	0.86	
C 17:0	0.19	0.14	0.14	
C 17:1	0.10	0.05	0.05	
C 18:0	2.68	2.59	2.84	
C 18:1	63.96	46.91	44.93	
C 18:2	9.62	10.59	10.01	
C 18:3 α	0.63	0.92	0.83	
C 20:0	0.26	0.27	0.24	
C 20:1	0.06	0.06	0.06	
C 20:1	0.08	0.05	0.04	
C 22:0	0	0.07	0.09	
C 24:0	0.13	0.13	0.12	

Construct 16. <i>Umbellularia californica</i> C12 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0	0.03	0.04	0.02-0.04
C 12:0	0.04	2.43	5.32	0.98-5.32
C 13:0	0	0.01	0.02	0-0.02
C 14:0	1.13	1.77	1.93	1.62-1.93
C 14:1	0	0.03	0.02	0.02-0.04
C 15:0	0.06	0.06	0.05	
C 16:0	19.94	24.89	22.29	
C 16:1	0.84	0.91	0.82	
C 17:0	0.19	0.16	0.15	
C 17:1	0.10	0.06	0.06	
C 18:0	2.68	3.81	3.67	
C 18:1	63.96	53.19	52.82	
C 18:2	9.62	10.38	10.57	
C 18:3 α	0.63	0.80	0.77	
C 20:0	0.26	0.35	0.32	
C 20:1	0.06	0.06	0.07	
C 20:1	0.08	0.07	0.08	
C 22:0	0	0.08	0.07	
C 24:0	0.13	0.15	0.14	

Construct 17. <i>Umbellularia californica</i> C12 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0	0.04	0.07	0.03-0.08
C 12:0	0.04	7.02	14.11	4.32-14.11
C 13:0	0	0.03	0.04	0.01-0.04
C 14:0	1.13	2.25	3.01	1.95-3.01
C 14:1	0	0.03	0.03	0.02-0.03
C 15:0	0.06	0.06	0.06	
C 16:0	19.94	23.20	21.46	
C 16:1	0.84	0.82	0.77	
C 17:0	0.19	0.15	0.14	
C 17:1	0.10	0.06	0.06	
C 18:0	2.68	3.47	2.93	
C 18:1	63.96	50.30	45.17	
C 18:2	9.62	10.33	9.98	
C18:3 γ	0	0.01	0	
C 18:3 α	0.63	0.84	0.86	
C 20:0	0.26	0.32	0.27	
C 20:1	0.06	0.07	0.06	
C 20:1	0.08	0.06	0.06	
C 22:0	0	0.08	0.09	
C 24:0	0.13	0.14	0.13	

Construct 18. <i>Umbellularia californica</i> C12 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0	0.03	0.05	0.01-0.05
C 12:0	0.04	5.06	7.77	0.37-7.77
C 13:0	0	0.02	0	0-0.03
C 14:0	1.13	2.11	2.39	1.82-2.39
C 14:1	0	0.03	0.03	0.02-0.05
C 15:0	0.06	0.06	0.06	
C 16:0	19.94	24.60	23.95	
C 16:1	0.84	0.86	0.83	
C 17:0	0.19	0.15	0.14	
C 17:1	0.10	0.06	0.05	
C 18:0	2.68	3.31	2.96	
C 18:1	63.96	51.26	49.70	
C 18:2	9.62	10.18	10.02	
C18:3 γ	0	0.01	0.02	
C 18:3 α	0.63	0.86	0.86	
C 20:0	0.26	0.32	0.29	
C 20:1	0.06	0.05	0.05	
C 20:1	0.08	0.07	0.04	
C 22:0	0	0.08	0.08	
C 24:0	0.13	0.13	0.13	

Construct 19. <i>Cinnamomum camphora</i> C14 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0.02	0.01	0.01	0.01-0.02
C 12:0	0.05	0.27	0.40	0.08-0.41
C 14:0	1.52	4.47	5.81	2.10-5.81
C 16:0	25.16	28.14	28.55	
C 16:1	0.72	0.84	0.82	
C 18:0	3.70	3.17	2.87	
C 18:1	54.28	51.89	51.01	
C 18:2	12.24	9.36	8.62	
C 18:3 α	0.87	0.74	0.75	
C 20:0	0.33	0.33	0.31	

Construct 20. <i>Cinnamomum camphora</i> C14 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0.01	0.01	0.02	0.01-0.02
C 12:0	0.03	0.39	0.65	0.08-0.65
C 13:0	0	0.01	0.01	0.01-0.02
C 14:0	1.40	5.61	8.4	2.1-8.4
C 14:1	0	0.03	0.03	0.02-0.03
C 15:0	0	0.06	0.07	
C 16:0	24.01	25.93	25.57	
C 16:1	0.67	0.75	0.71	
C 17:0	0	0.13	0.12	
C 17:1	0	0.05	0.05	
C 18:0	4.15	3.30	3.23	
C 18:1	55.83	51.00	48.48	
C 18:2	10.14	10.38	10.35	
C 18:3 α	0.93	0.91	0.88	
C 20:0	0.33	0.35	0.32	
C 20:1	0	0.08	0.08	
C 20:1	0	0.07	0.07	
C 22:0	0	0.08	0.08	
C 24:0	0	0.14	0.13	

Construct 21. <i>Cinnamomum camphora</i> C14 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0.01	0.01	0.01	0-0.01
C 12:0	0.03	0.10	0.27	0.04-0.27
C 14:0	1.40	2.28	4.40	1.47-4.40
C 16:0	24.01	26.10	26.38	
C 16:1	0.67	0.79	0.73	
C 17:0	0	0.15	0.16	
C 17:1	0	0.06	0.06	
C 18:0	4.15	3.59	3.51	
C 18:1	55.83	53.53	50.86	
C 18:2	10.14	10.83	11.11	

C 18:3 α	0.93	0.97	0.87	
C 20:0	0.33	0.36	0.37	
C 20:1	0	0.09	0.08	
C 20:1	0	0.07	0.07	
C 22:0	0	0.09	0.09	

Construct 22. <i>Cinnamomum camphora</i> C14 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0.01	0.02	0.02	0.02-0.02
C 12:0	0.03	1.22	1.83	0.59-1.83
C 13:0	0	0.02	0.03	0.01-0.03
C 14:0	1.40	12.77	17.33	7.97-17.33
C 14:1	0	0.02	0.02	0.02-0.04
C 15:0	0	0.07	0.08	
C 16:0	24.01	24.79	24.22	
C 16:1	0.67	0.64	0.58	
C 17:0	0	0.11	0.10	
C 17:1	0	0.04	0.04	
C 18:0	4.15	2.85	2.75	
C 18:1	55.83	45.16	41.23	
C 18:2	10.14	9.96	9.65	
C 18:3 α	0.93	0.91	0.85	
C 20:0	0.33	0.30	0.30	
C 20:1	0	0.07	0.06	
C 20:1	0	0.06	0.05	
C 22:0	0	0.08	0.08	

Construct 23. <i>Cinnamomum camphora</i> C14 TE				
Fatty Acid	wildtype	Mean	Sample	low/high
C 10:0	0.01	0.01	0.02	0-0.02
C 12:0	0.05	0.57	1.08	0.16-1.08
C 13:0	0	0.02	0.02	0-0.02
C 14:0	1.45	7.18	11.24	2.96-11.24
C 14:1	0.02	0.03	0.03	0.02-0.03
C 15:0	0.06	0.07	0.07	
C 16:0	24.13	25.78	25.21	
C 16:1	0.77	0.72	0.66	
C 17:0	0.19	0.13	0.11	
C 17:1	0.08	0.05	0.04	
C 18:0	3.53	3.35	3.12	
C 18:1	56.15	49.65	46.35	
C 18:2	11.26	10.17	9.72	
C 18:3 α	0.84	0.95	0.83	
C 20:0	0.32	0.34	0.32	
C 20:1	0.09	0.08	0.09	
C 20:1	0.07	0.05	0.06	
C 22:0	0.07	0.08	0.08	
C 24:0	0.13	0.13	0.12	

[0426] Constructs 9-13 were expression vectors containing the *Cuphea hookeriana* C8-10 thioesterase construct. As can be seen in the data summaries above, the best results were seen with Construct 11, with the Sample C8 fatty acid being 1.57 Area % (as compared to 0 in wildtype) and C10 fatty acid being 6.76 Area % (as compared to 0 in wildtype). There was also a modest increase in C12 fatty acids (approximately 2-5 fold increase). While the native plastid targeting sequence produced no change when under the control of the *C.sorokinana* glutamate dehydrogenase promoter, the same expression construct driven by the *C.reinhardtii* β -tubulin promoter produced significant changes in C8-10 fatty acids in the host cell. This is further evidence of the idiosyncrasies of heterologous expression of thioesterases in *Prototheca* species. All of the clones containing the *C.reinhardtii* β -tubulin promoter C8-10 thioesterase construct had greater increases in C8-10 fatty acids than the clones containing the *C.sorokinana* glutamate dehydrogenase promoter C8-10 thioesterase construct. Lipid profile data for Construct 13 was not obtained and therefore, not included above.

[0427] Constructs 14-18 were expression vectors containing the *Umbellularia californica* C12 thioesterase construct. As can be seen in the data summaries above, the best results were seen with Constructs 15 (*P.moriformis* isopentenyl diphosphate synthase plastid targeting sequence) and 17 (*C.protothecoides* stearoyl ACP desaturase plastid targeting sequence). The greatest change in C12 fatty acid production was seen with Construct 17, with C12 fatty acids levels of up to 14.11 area %, as compared to 0.04 area % in wildtype. Modest changes (about 2-fold) were also seen with C14 fatty acid levels. When compared to the same constructs with the *C.sorokinana* glutamate dehydrogenase promoter, the same trends were true with the *C.reinhardtii* β -tubulin promoter—the *C.protothecoides* stearoyl ACP desaturase and *P.moriformis* isopentenyl diphosphate synthase plastid targeting sequences produced the greatest change in C12 fatty acid levels with both promoters.

[0428] Constructs 19-23 were expression vectors containing the *Cinnamomum camphora* C14 thioesterase construct. As can be seen in the data summaries above, the best results were seen with Constructs 22 and Construct 23. The greatest change in C14 fatty acid production was seen with Construct 22, with C14 fatty acid levels of up to 17.35 area % (when the values for C140 and C141 are combined), as compared to 1.40% in wildtype. Changes in C12 fatty acids were also seen (5-60 fold). When compared to the same constructs with the *C.sorokinana* glutamate dehydrogenase promoter, the same trends were true with the *C.reinhardtii* β -tubulin promoter—the *C.protothecoides* stearoyl ACP desaturase and *P.moriformis* stearoyl ACP desaturase plastid targeting sequences produced the greatest

change in C14 fatty acid levels with both promoters. Consistently with all thioesterase expression constructs, the *C.reinhardtii* β -tubulin promoter constructs produced greater changes in C8-14 fatty acid levels than the *C.sorokiniana* glutamate dehydrogenase [0429] Two positive clones from the Construct 22 were selected and grown under high selective pressure (50mg/L G418). After 6 days in culture, the clones were harvested and their lipid profile was determined using the methods described above. The lipid profile data is summarized below and is expressed in area %.

Construct 22 clones + 50mg/L G418		
Fatty Acid	Construct 22 A	Construct 22 B
C 12:0	3.21	3.37
C 14:0	27.55	26.99
C 16:0	25.68	24.37
C 16:1	0.99	0.92
C 18:0	1.37	1.23
C 18:1	28.35	31.07
C 18:2	11.73	11.05
C 18:3 α	0.92	0.81
C 20:0	0.16	0.17

[0430] Both clones, when grown under constant, high selective pressure, produced an increased amount of C14 and C12 fatty acids, about double the levels seen with Construct 22 above. These clones yielded over 30 area % of C12-14 fatty acids, as compared to 1.5 area % of C12-14 fatty acids seen in wildtype cells.

[0431] **EXAMPLE 6: Heterologous Expression of *Cuphea palustris* and *Ulmus americana* Thioesterase in *Prototheca***

[0432] Given the success of the above-described heterologous expression thioesterases in *Prototheca* species, expression cassettes containing codon-optimized (according to Table 1) sequences encoding fatty acyl-ACP thioesterases from *Cuphea palustris* and *Ulmus americana* were constructed and described below.

Construct Name	Promoter/ 5'UTR	Plastid targeting seq	Gene	3'UTR	SEQ ID NO.
Construct 27	<i>C.reinhardtii</i> β -tubulin	<i>C.protothecoides</i> stearoyl ACP desaturase	<i>Cuphea palustris</i> thioesterase	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 107

[0433] The *Ulmus americana* (codon-optimized coding sequence) can be inserted into the expression cassette. The codon-optimized coding sequence without the native plastid targeting sequence for the *Ulmus americana* thioesterase is listed as SEQ ID NO: 108 and can be fused any desired plastid targeting sequence and expression element (i.e., promoter/5'UTR and 3'UTR).

[0434] These expression cassettes can be transformed in to *Prototheca* species using the methods described above. Positive clones can be screened with the inclusion of an antibiotic resistance gene (e.g, neoR) on the expression construct and screened on G418-containing plates/media. Positive clones can be confirmed using Southern blot assays with probes specific to the heterologous thioesterase coding region and expression of the construct can also be confirmed using RT-PCR and primers specific to the coding region of the heterologous thioesterase. Secondary confirmation of positive clones can be achieved by looking for changes in levels of fatty acids in the host cell's lipid profile. As seen in the above Examples, heterologous expression in *Prototheca* species of thioesterase can be idiosyncratic to the particular thioesterase. Promoter elements and plastid targeting sequences (and other expression regulatory elements) can be interchanged until the expression of the thioesterase (and the subsequent increase in the corresponding fatty acid) reaches a desired level.

[0435] EXAMPLE 7: Dual Transformants—Simultaneous Expression of Two Heterologous Proteins

[0436] Microalgae strain *Prototheca moriformis* (UTEX 1435) was transformed using the above disclosed methods with a expression construct containing the yeast sucrose invertase *suc2* gene encoding the secreted form of the *S. cerevisiae* invertase. Successful expression of this gene and targeting to the periplasm results in the host cell's ability to grow on (and utilize) sucrose as a sole carbon source in heterotrophic conditions (as demonstrated in Example 3 above). The second set of genes expressed are thioesterases which are responsible for the cleavage of the acyl moiety from the acyl carrier protein. Specifically, thioesterases from *Cuphea hookeriana* (a C8-10 preferring thioesterase), *Umbellularia californica* (a C12 preferring thioesterase), and *Cinnamomum camphora* (a C14 preferring thioesterase). These thioesterase expression cassettes were cloned as fusions with N-terminal microalgal plastid targeting sequences from either *Prototheca moriformis* or *Chlorella protothecoides*, which have been shown (in the above Examples) to be more optimal than the native higher plant plastid targeting sequences. The successful expression of the thioesterase genes and the targeting to the plastid resulted in measurable changes in the fatty acid profiles within the host cell. These changes in profiles are consistent with the enzymatic specificity or preference of each thioesterase. Below is a summary of dual expression constructs that were assembled and transformed into *Prototheca moriformis* (UTEX 1435). Each construct contained the yeast *suc2* gene under the control of the *C. reinhardtii* β -tubulin 5'UTR/promoter and contained the *C. vulgaris* nitrate reductase 3'UTR and a higher plant thioesterase with a

microalgal plastid targeting sequence replacing the native sequence under the control of *C. sorokiniana* glutamate dehydrogenase 5'UTR and contained the *C. vulgaris* nitrate reductase 3'UTR. Below is a summary of the thioesterase portion of the constructs that were assembled and transformed into *Prototheca moriformis* (UTEX 1435). The entire dual expression cassette with the *suc2* gene and the thioesterase gene and the is listed in the Sequence Identification Listing.

Construct Name	Promoter/ 5'UTR	Plastid targeting seq	Gene	3'UTR	SEQ ID NO.
Construct 24	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>C. protothecoides</i> stearoyl ACP desaturase	<i>Cuphea hookeriana</i> C8-10 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 109
Construct 25	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>P. moriformis</i> isopentenyl diphosphate synthase	<i>Umbellularia californica</i> C12 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 110
Construct 26	<i>C. sorokiniana</i> glutamate dehydrogenase	<i>C. protothecoides</i> stearoyl ACP desaturase	<i>Cinnamomum camphora</i> C14 TE	<i>C. vulgaris</i> nitrate reductase	SEQ ID NO: 111

Similar dual expression constructs with the thioesterase cassettes described in Example 5 (e.g., under the control of a different promoter such as *C. reinhardtii* β -tubulin promoter/5'UTR) can also be generated using standard molecular biology methods and methods described herein.

[0437] Positive clones containing each of expression constructs were screened using their ability to grow on sucrose-containing plates, where sucrose is the sole-carbon source, as the selection factor. A subset of these positive clones from each construct transformation was selected and the presence of the expression construct was confirmed using Southern blot assays. The function of the yeast sucrose invertase was also confirmed using a sucrose hydrolysis assay. Positive clones were selected and grown in media containing sucrose as the sole carbon source at a starting concentration of 40g/L. A negative control of wildtype *Prototheca moriformis* (UTEX 1435) grown in media containing glucose as the sole carbon source at the same 40 g/L starting concentration was also included. Utilization of sucrose was measured throughout the course of the experiment by measuring the level of sucrose in the media using a YSI 2700 Biochemistry Analyzer with a sucrose-specific membrane. After six days in culture, the cultures were harvested and processed for lipid profile using the same methods as described above. The lipid profile results are summarized below in Table 17 and are show in area %.

[0438] Table 17. Lipid profiles of dual transformants with *suc2* sucrose invertase and thioesterase.

Fatty Acid	Wt	C24 A	C24 B	C24 C	C25 A	C25 B	C25 C	C26 A	C26 B	C26 C
C 10:0	0.01	0.03	0.04	0.08	0.01	0.01	0.01	0.01	0.01	0.0
C 12:0	0.04	0.04	0.04	0.04	0.28	0.40	0.10	0.04	0.04	0.13
C 14:0	1.6	1.55	1.53	1.56	1.59	1.59	1.60	1.65	1.56	2.69
C 14:1	0.03	0.03	0.03	0.02	0.03	0.03	0.03	0.03	0.03	0.03
C 15:0	0.04	0.03	0.03	0.04	0.04	0.03	0.03	0.03	0.03	0.04
C 16:0	29.2	29.1	29.0	28.6	28.9	28.6	29.0	28.8	29.5	27.5
C 16:1	0.86	0.80	0.79	0.82	0.77	0.81	0.82	0.79	0.79	0.86
C 17:0	0.1	0.08	0.08	0.09	0.09	0.08	0.09	0.08	0.08	0.09
C 17:1	0.04	0.03	0.03	0.04	0.03	0.03	0.03	0.03	0.03	0.04
C 18:0	3.26	3.33	3.37	3.27	3.36	3.28	3.18	3.33	3.36	3.03
C 18:1	54.5	53.9	54.1	53.9	53.5	53.7	53.5	54.2	53.9	52.7
C 18:2	8.72	9.35	9.22	9.45	9.68	9.65	9.87	9.31	9.06	10.8
C 18:3 alpha	0.63	0.71	0.69	0.73	0.74	0.73	0.75	0.71	0.66	0.83
C 20:0	0.29	0.31	0.31	0.31	0.32	0.32	0.31	0.32	0.31	0.29

[0439] All of the positive clones selected for the sucrose utilization assay were able to hydrolyze the sucrose in the media and at the end of the 6 day culture period, there were no measurable levels of sucrose in the media. This data, in addition to the successful use of sucrose as a selection tool for positive clones, indicates that the exogenous yeast *suc2* sucrose invertase gene was targeted correctly and expressed in the transformants. As show in Table 17 above, the clones expressing Construct 24 (C8-10 thioesterase) had a measurable increase in C10 fatty acids (as high as an eight-fold increase). Likewise there were measurable increases in clones expressing Construct 25 (C12 thioesterase) and Construct 26 (C14 thioesterase) in the corresponding medium chain fatty acids. Taken together, the data shows the successful simultaneous expression in *Prototheca moriformis* two recombinant proteins (e.g., sucrose invertase and a fatty acid acyl-ACP thioesterase), both of which confer useful and quantifiable phenotypic changes on the host organism.

[0440] EXAMPLE 8: Effects of glycerol on C10-C14 fatty acid production in C14 thioesterase transformants

[0441] Clones from all the thioesterase transformations were selected and further evaluated. One clone expressing Construct 8 (*Cinnamomum camphora* C14 TE) was grown heterotrophically using different carbon sources: glucose only, fructose only and glycerol only. The glucose only condition resulted in higher cell growth and total lipid production when compared to the fructose only and glycerol only conditions. However, the proportion of C12-14 fatty acids produced in the glycerol only condition was two-fold higher than that attained in the glucose only condition.

[0442] EXAMPLE 9: Expression of *Arabidopsis thaliana* invertase in *Prototheca moriformis*

[0443] Microalgae strain *Prototheca moriformis* (UTEX 1435) was transformed using methods described above, with an expression construct containing a codon-optimized (according to Table 1) cell wall associated invertase from *Arabidopsis thaliana*. The *Arabidopsis* invertase sequence was modified to include the the N-terminal 39 amino acids from yeast invertase (SUC2 protein) to ensure efficient targeting to the ER and ultimately the periplasm. To aid detection, a Flag epitope was added to the C-terminus of the recombinant protein. The transgene was cloned into an expression vector with a *Chlorella sorokiniana* glutamate dehydrogenase promoter/5'UTR region and a *Chlorella vulgaris* nitrate reductase 3'UTR region. The DNA sequence of this transgene cassette is listed as SEQ ID NO: 89 and the translated amino acid sequence is listed as SEQ ID NO: 90. Positive clones were screened and selected using sucrose-containing media/plates. A subset of the positive clones were confirmed for the presence of the transgene and expression of invertase using Southern blot analysis and Western blot analysis for the Flag-tagged invertase. From these screens, 10 positive clones were chosen for lipid productivity and sucrose utilization assays. All 10 clones were grown on media containing sucrose as the sole carbon source and a positive control suc2 invertase transformant was also included. The negative control, wildtype *Prototheca moriformis*, was also grown but on glucose containing media. After six days, the cells were harvested and dried and the total percent lipid by dry cell weight was determined. The media was also analyzed for total sucrose consumption.

[0444] All ten positive clones were able to hydrolyze sucrose, however, most clones grew about half as well as either wildtype or the positive control suc2 yeast invertase transformant as determined by dry cell weight at the end of the experiment. Similarly, all ten positive clones produced about half as much total lipid when compared to wildtype or the positive control transformant. This data demonstrate the successful heterologous expression of diverse sucrose invertases in *Prototheca*.

[0445] EXAMPLE 10: Heterologous expression of yeast invertase (suc2) in *Prototheca krugani*, *Prototheca stagnora* and *Prototheca zopfii*

[0446] To test the general applicability of the transformation methods for use in species of the genus *Prototheca*, three other *Prototheca* species were selected: *Prototheca krugani* (UTEX 329), *Prototheca stagnora* (UTEX 1442) and *Prototheca zopfii* (UTEX 1438). These three strains were grown in the media and conditions described in Example 1 and their lipid

profiles were determined using the above described methods. A summary of the lipid profiles from the three *Prototheca* strains are summarized below in Area %.

Fatty Acid	<i>P. krugani</i> (UTEX 329)	<i>P. stagnora</i> (UTEX 1442)	<i>P. zopfii</i> (UTEX 1438)
C 10:0	0.0	0.0	0.0
C 10:1	0.0	0.0	0.0
C 12:0	1.5	0.8	2.1
C 14:0	1.2	0.9	1.7
C 16	15.1	17.1	19.7
C 18:0	3.3	4.1	5.4
C 18:1	66.0	61.5	53.8
C 18:2	12.9	15.6	17.3

[0447] These three strains were transformed with a yeast invertase (suc2) expression cassette (SEQ ID NO: 58) using the methods described in Example 3 above. This yeast invertase (suc2) expression cassette has been demonstrated to work in *Prototheca moriformis* (UTEX 1435) above in Example 3. The transformants were screened using sucrose containing plates/media. A subset of the positive clones for each *Prototheca* species was selected and the presence of the transgene was confirmed by Southern blot analysis. Ten of confirmed positive clones from each species were selected for sucrose hydrolysis analysis and lipid productivity. The clones were grown in media containing sucrose as the sole carbon source and compared to its wildtype counterpart grown on glucose. After 6 days, the cultures were harvested and dried and total percent lipid and dry cell weight was assessed. The media from each culture was also analyzed for sucrose hydrolysis using a YSI2700 Biochemistry Analyzer for sucrose content over the course of the experiment. Clones from all three species were able to hydrolyze sucrose, with *Prototheca stagnora* and *Prototheca zopfii* transformants being able to hydrolyze sucrose more efficiently than *Prototheca krugani*. Total lipid production and dry cell weight of the three species of transformants were comparable to their wildtype counterpart grown on glucose. This data demonstrates the successful transformation and expression exogenous genes in multiple species of the genus *Prototheca*.

[0448] EXAMPLE 11: Algal-derived Promoters and Genes for Use in Microalgae

A. 5'UTR and Promoter Sequences from *Chlorella protothecoides*

[0449] A cDNA library was generated from mixotrophically grown *Chlorella protothecoides* (UTEX 250) using standard techniques. Based upon the cDNA sequences, primers were designed in certain known housekeeping genes to "walk" upstream of the coding regions using Seegene's DNA Walking kit (Rockville, MD). Sequences isolated include an actin (SEQ ID NO:31) and elongation factor-1a (EF1a) (SEQ ID NO:32)

promoter/UTR, both of which contain introns (as shown in the lower case) and exons (upper case italicized) and the predicted start site (in bold) and two beta-tubulin promoter/UTR elements: Isoform A (SEQ ID NO:33) and Isoform B (SEQ ID NO:34).

B. Lipid Biosynthesis Enzyme and Plastid Targeting Sequences from *C. protothecoides*

[0450] From the cDNA library described above, three cDNAs encoding proteins functional in lipid metabolism in *Chlorella protothecoides* (UTEX 250) were cloned using the same methods as described above. The nucleotide and amino acid sequences for an acyl ACP desaturase (SEQ ID NOs: 45 and 46) and two geranyl geranyl diphosphate synthases (SEQ ID NOs:47-50) are included in the Sequence Listing below. Additionally, three cDNAs with putative signal sequences targeting to the plastid were also cloned. The nucleotide and amino acid sequences for a glyceraldehyde-3-phosphate dehydrogenase (SEQ ID NOs:51 and 52), an oxygen evolving complex protein OEE33 (SEQ ID NOs:53 and 54) and a Clp protease (SEQ ID NOs:55 and 56) are included in the Sequence Listing below. The putative plastid targeting sequence has been underlined in both the nucleotide and amino acid sequence. The plastid targeting sequences can be used to target the products of transgenes to the plastid of microbes, such as lipid modification enzymes.

[0451] EXAMPLE 12: 5'UTR/promoters that are nitrogen responsive from *Prototheca moriformis*

[0452] A cDNA library was generated from *Prototheca moriformis* (UTEX 1435) using standard techniques. The *Prototheca moriformis* cells were grown for 48 hours under nitrogen replete conditions. Then a 5% innoculum (v/v) was then transferred to low nitrogen and the cells were harvested every 24 hours for seven days. After about 24 hours in culture, the nitrogen supply in the media was completely depleted. The collected samples were immediately frozen using dry ice and isopropanol. Total RNA was subsequently isolated from the frozen cell pellet samples and a portion from each sample was held in reserve for RT-PCR studies. The rest of the total RNA harvested from the samples was subjected to polyA selection. Equimolar amounts of polyA selected RNA from each condition was then pooled and used to generate a cDNA library in vector pcDNA 3.0 (Invitrogen). Roughly 1200 clones were randomly picked from the resulting pooled cDNA library and subjected to sequencing on both strands. Approximately 68 different cDNAs were selected from among these 1200 sequences and used to design cDNA-specific primers for use in real-time RT-PCR studies.

[0453] RNA isolated from the cell pellet samples that were held in reserve was used as substrate in the real time RT-PCR studies using the cDNA-specific primer sets generated above. This reserved RNA was converted into cDNA and used as substrate for RT-PCR for each of the 68 gene specific primer sets. Threshold cycle or C_T numbers were used to indicate relative transcript abundance for each of the 68 cDNAs within each RNA sample collected throughout the time course. cDNAs showing significant increase (greater than three fold) between nitrogen replete and nitrogen-depleted conditions were flagged as potential genes whose expression was up-regulated by nitrogen depletion. As discussed in the specification, nitrogen depletion/limitation is a known inducer of lipogenesis in oleaginous microorganisms.

[0454] In order to identify putative promoters/5'UTR sequences from the cDNAs whose expression was upregulated during nitrogen depletion/limitation, total DNA was isolated from *Prototheca moriformis* (UTEX 1435) grown under nitrogen replete conditions and were then subjected to sequencing using 454 sequencing technology (Roche). cDNAs flagged as being up-regulated by the RT-PCR results above were compared using BLAST against assembled contigs arising from the 454 genomic sequencing reads. The 5' ends of cDNAs were mapped to specific contigs, and where possible, greater than 500bp of 5' flanking DNA was used to putatively identify promoters/UTRs. The presence of promoters/5'UTR were subsequently confirmed and cloned using PCR amplification of genomic DNA. Individual cDNA 5' ends were used to design 3' primers and 5' end of the 454 contig assemblies were used to design 5' gene-specific primers.

[0455] As a first screen, one of the putative promoter, the 5'UTR/promoter isolated from Aat2 (Ammonium transporter, SEQ ID NO: 99), was cloned into the *Cinnamomum camphora* C14 thioesterase construct with the *Chlorella protothecoides* stearoyl ACP desaturase transit peptide described in Example 5 above, replacing the *C.sorokinana* glutamate dehydrogenase promoter. This construct is listed as SEQ ID NO: 112. To test the putative promoter, the thioesterase construct is transformed into *Prototheca moriformis* cells to confirm actual promoter activity by screening for an increase in C14/C12 fatty acids under low/no nitrogen conditions, using the methods described above. Similar testing of the putative nitrogen-regulated promoters isolated from the cDNA/genomic screen can be done using the same methods.

[0456] Other putative nitrogen-regulated promoters/5'UTRs that were isolated from the cDNA/genomic screen were:

<u>Promoter/5'UTR</u>	<u>SEQ ID NO.</u>	<u>Fold increased</u>
-----------------------	-------------------	-----------------------

FatB/A promoter/5'UTR	SEQ ID NO: 91	n/a
NRAMP metal transporter promoter/5'UTR	SEQ ID NO: 92	9.65
Flap Flagellar-associated protein promoter/5'UTR	SEQ ID NO: 93	4.92
SulfRed Sulfite reductase promoter/5'UTR	SEQ ID NO: 94	10.91
SugT Sugar transporter promoter/5'UTR	SEQ ID NO: 95	17.35
Amt03-Ammonium transporter 03 promoter/5'UTR	SEQ ID NO: 96	10.1
Amt02-Ammonium transporter 02 promoter/5'UTR	SEQ ID NO: 97	10.76
Aat01-Amino acid transporter 01 promoter/5'UTR	SEQ ID NO: 98	6.21
Aat02-Amino acid transporter 02 promoter/5'UTR	SEQ ID NO: 99	6.5
Aat03-Amino acid transporter 03 promoter/5'UTR	SEQ ID NO: 100	7.87
Aat04-Amino acid transporter 04 promoter/5'UTR	SEQ ID NO: 101	10.95
Aat05-Amino acid transporter 05 promoter/5'UTR	SEQ ID NO: 102	6.71

Fold increase refers to the fold increase in cDNA abundance after 24 hours of culture in low nitrogen medium.

[0457] EXAMPLE 13: Homologous Recombination in *Prototheca* species

[0458] Homologous recombination of transgenes has several advantages over the transformation methods described in the above Examples. First, the introduction of transgenes without homologous recombination can be unpredictable because there is no control over the number of copies of the plasmid that gets introduced into the cell. Also, the introduction of transgenes without homologous recombination can be unstable because the plasmid may remain episomal and is lost over subsequent cell divisions. Another advantage of homologous recombination is the ability to “knock-out” gene targets, introduce epitope tags, switch promoters of endogenous genes and otherwise alter gene targets (e.g., the introduction of point mutations).

[0459] Two vectors were constructed using a specific region of the *Prototheca moriformis* (UTEX 1435) genome, designated KE858. KE858 is a 1.3 kb, genomic fragment that encompasses part of the coding region for a protein that shares homology with the transfer RNA (tRNA) family of proteins. Southern blots have shown that the KE858 sequence is present in a single copy in the *Prototheca moriformis* (UTEX 1435) genome. The first type of vector that was constructed, designated SZ725 (SEQ ID NO: 103), consisted of the entire 1.3 kb KE858 fragment cloned into a pUC19 vector backbone that also contains the optimized yeast invertase (*suc2*) gene used in Example 3 above. The KE858 fragment contains an unique SnaB1 site that does not occur anywhere else in the targeting construct. The second type of vector that was constructed, designated SZ726 (SEQ ID NO: 126),

consisted of the KE858 sequence that had been disrupted by the insertion of the yeast invertase gene (*suc2*) at the SnaB1 site within the KE858 genomic sequence. The entire DNA fragment containing the KE858 sequences flanking the yeast invertase gene can be excised from the vector backbone by digestion with EcoRI, which cuts at either end of the KE858 region.

[0460] Both vectors were used to direct homologous recombination of the yeast invertase gene (*suc2*) into the corresponding KE858 region of the *Prototheca moriformis* (UTEX 1435) genome. The linear DNA ends homologous to the genomic region that was being targeted for homologous recombination were exposed by digesting the vector construct SZ725 with SnaB1 and vector construct SZ726 with EcoRI. The digested vector constructs were then introduced into *Prototheca moriformis* cultures using methods described above in Example 3. Transformants from each vector construct were then selected using sucrose plates. Ten independent, clonally pure transformants from each vector transformation were analyzed for successful recombination of the yeast invertase gene into the desired genomic location (using Southern blots) and for transgene stability.

[0461] Southern blot analysis of the SZ725 transformants showed that 4 out of the 10 transformants picked for analysis contained the predicted recombinant bands, indicating that a single crossover event had occurred between the KE858 sequences on the vector and the KE858 sequences in the genome. In contrast, all ten of the SZ726 transformants contained the predicted recombinant bands, indicating that double crossover events had occurred between the EcoRI fragment of pSZ726 carrying KE858 sequence flanking the yeast invertase transgene and the corresponding KE858 region of the genome.

[0462] Sucrose invertase expression and transgene stability were assessed by growing the transformants for over 15 generations in the absence of selection. The four SZ725 transformants and the ten SZ726 transformants that were positive for the transgene by Southern blotting were selected and 48 single colonies from each of the transformants were grown serially: first without selection in glucose containing media and then with selection in media containing sucrose as the sole carbon source. All ten SZ726 transformants (100%) retained their ability to grow on sucrose after 15 generations, whereas about 97% of the SZ725 transformants retained their ability to grow on sucrose after 15 generations. Transgenes introduced by a double crossover event (SZ726 vector) have extremely high stability over generation doublings. In contrast, transgenes introduced by a single cross over event (SZ725 vector) can result in some instability over generation doublings because is

tandem copies of the transgenes were introduced, the repeated homologous regions flanking the transgenes may recombine and excise the transgenic DNA located between them.

[0463] These experiments demonstrate the successful use of homologous recombination to generate *Prototheca* transformants containing a heterologous sucrose invertase gene that is stably integrated into the nuclear chromosomes of the organism. The success of the homologous recombination enables other genomic alterations in *Prototheca*, including gene deletions, point mutations and epitope tagging a desired gene product. These experiments also demonstrate the first documented system for homologous recombination in the nuclear genome of an eukaryotic microalgae.

A. Use of Homologous Recombination to Knock-out an Endogenous

Prototheca moriformis gene

[0464] In the *Prototheca moriformis* cDNA/genomic screen described in Example 11 above, an endogenous stearyl ACP desaturase (SAPD) cDNA was identified. Stearyl ACP desaturase enzymes are part of the lipid synthesis pathway and they function to introduce double bonds into the fatty acyl chains. In some cases, it may be advantages to knock-out or reduce the expression of lipid pathway enzymes in order to alter a fatty acid profile. A homologous recombination construct was created to assess whether the expression of an endogenous stearyl ACP desaturase enzyme can be reduced (or knocked out) and if a corresponding reduction in unsaturated fatty acids can be observed in the lipid profile of the host cell. An approximately 1.5kb coding sequence of a stearyl ACP desaturase gene from *Prototheca moriformis* (UTEX 1435) was identified and cloned (SEQ ID NO: 104). The homologous recombination construct was constructed using 0.5kb of the SAPD coding sequence at the 5' end (5' targeting site), followed by the *Chlamydomonas reinhardtii* β -tubulin promoter driving a codon-optimized yeast sucrose invertase *suc2* gene with the *Chlorella vulgaris* 3'UTR. The rest (~1kb) of the *Prototheca moriformis* SAPD coding sequence was then inserted after the *C. vulgaris* 3'UTR to make up the 3' targeting site. The sequence for this homologous recombination cassette is listed in SEQ ID NO: 105. As shown above, the success-rate for integration of the homologous recombination cassette into the nuclear genome can be increased by linearizing the cassette before transforming the microalgae, leaving exposed ends. The homologous recombination cassette targeting an endogenous SAPD enzyme in *Prototheca moriformis* is linearized and then transformed into the host cell (*Prototheca moriformis*, UTEX 1435). A successful integration will eliminate the endogenous SAPD enzyme coding region from the host genome via a double reciprocal recombination event, while expression of the newly inserted *suc2* gene will be regulated by

the *C.reinhardtii* β -tubulin promoter. The resulting clones can be screened using plates/media containing sucrose as the sole carbon source. Clones containing a successful integration of the homologous recombination cassette will have the ability to grow on sucrose as the sole carbon source and changes in overall saturation of the fatty acids in the lipid profile will serve as a secondary confirmation factor. Additionally, Southern blotting assays using a probe specific for the yeast sucrose invertase *suc2* gene and RT-PCR can also confirm the presence and expression of the invertase gene in positive clones. As an alternative, the same construct without the β -tubulin promoter can be used to excise the endogenous SAPD enzyme coding region. In this case, the newly inserted yeast sucrose invertase *suc2* gene will be regulated by the endogenous SAPD promoter/5'UTR.

[0465] EXAMPLE 14: Fuel Production

A. Extraction of oil from microalgae using an expeller press and a press aid

[0466] Microalgal biomass containing 38% oil by DCW was dried using a drum dryer resulting in resulting moisture content of 5-5.5%. The biomass was fed into a French L250 press. 30.4 kg (67 lbs.) of biomass was fed through the press and no oil was recovered. The same dried microbial biomass combined with varying percentage of switchgrass as a press aid was fed through the press. The combination of dried microbial biomass and 20% w/w switchgrass yielded the best overall percentage oil recovery. The pressed cakes were then subjected to hexane extraction and the final yield for the 20% switchgrass condition was 61.6% of the total available oil (calculated by weight). Biomass with above 50% oil dry cell weight did not require the use of a pressing aid such as switchgrass in order to liberate oil.

B. Monosaccharide Composition of Delipidated *Prototheca moriformis* biomass

[0467] *Prototheca moriformis* (UTEX 1435) was grown in conditions and nutrient media (with 4% glucose) as described in Example 45 above. The microalgal biomass was then harvested and dried using a drum dryer. The dried algal biomass was lysed and the oil extracted using an expeller press as described in Example 44 above. The residual oil in the pressed biomass was then solvent extracted using petroleum ether. Residual petroleum ether was evaporated from the delipidated meal using a Rotovapor (Buchi Labortechnik AG, Switzerland). Glycosyl (monosaccharide) composition analysis was then performed on the delipidated meal using combined gas chromatography/mass spectrometry (GC/MS) of the per-O-trimethylsilyl (TMS) derivatives of the monosaccharide methyl glycosides produced from the sample by acidic methanolysis. A sample of delipidated meal was subjected to methanolysis in 1M HCl in methanol at 80°C for approximately 20 hours, followed by re-N-

acetylation with pyridine and acetic anhydride in methanol (for detection of amino sugars). The samples were then per-O-trimethylsilylated by treatment with Tri-Sil (Pierce) at 80°C for 30 minutes (see methods in Merkle and Poppe (1994) *Methods Enzymol.* 230: 1-15 and York et al., (1985) *Methods Enzymol.* 118:3-40). GC/MS analysis of the TMS methyl glycosides was performed on an HP 6890 GC interfaced to a 5975b MSD, using a All Tech EC-1 fused silica capillary column (30m x 0.25 mm ID). The monosaccharides were identified by their retention times in comparison to standards, and the carbohydrate character of these are authenticated by their mass spectra. 20 micrograms per sample of inositol was added to the sample before derivatization as an internal standard. The monosaccharide profile of the delipidated *Prototheca moriformis* (UTEX 1435) biomass is summarized in Table 18 below. The total percent carbohydrate from the sample was calculated to be 28.7%.

[0468] Table 18. Monosaccharide (glycosyl) composition analysis of *Prototheca moriformis* (UTEX 1435) delipidated biomass.

	Mass (µg)	Mole % (of total carbohydrate)
Arabinose	0.6	1.2
Xylose	n.d.	n.d.
Galacturonic acid (GalUA)	n.d.	n.d.
Mannose	6.9	11.9
Galactose	14.5	25.2
Glucose	35.5	61.7
N Acetyl Galactosamine (GalNAc)	n.d.	n.d.
N Acetyl Glucosamine (GlcNAc)	n.d.	n.d.
Heptose	n.d.	n.d.
3 Deoxy-2-manno-2 Octulonic acid (KDO)	n.d.	n.d.
Sum	57	100

n.d. = none detected

[0469] The carbohydrate content and monosaccharide composition of the delipidated meal makes it suitable for use as an animal feed or as part of an animal feed formulation. Thus, in one aspect, the present invention provides delipidated meal having the product content set forth in the table above.

C. Production of biodiesel from *Prototheca* oil

[0470] Degummed oil from *Prototheca moriformis* UTEX 1435, produced according to the methods described above, was subjected to transesterification to produce fatty acid methyl esters. Results are shown below:

The lipid profile of the oil was:

C10:0 0.02
C12:0 0.06
C14:0 1.81
C14:1 0.07

C16:0 24.53
 C16:1 1.22
 C18:0 2.34
 C18:1 59.21
 C18:2 8.91
 C18:3 0.28
 C20:0 0.23
 C20:1 0.10
 C20:1 0.08
 C21:0 0.02
 C22:0 0.06
 C24:0 0.10

[0471] Table 19. Biodiesel profile from *Prototheca moriformis* triglyceride oil.

Method	Test		Result	Units
ASTM D6751 A1	Cold Soak Filterability of Biodiesel Blend Fuels	Filtration Time	120	sec
		Volume Filtered	300	ml
ASTM D93	Pensky-Martens Closed Cup Flash Point	Procedure Used	A	
		Corrected Flash Point	165.0	°C
ASTM D2709	Water and Sediment in Middle Distillate Fuels (Centrifuge Method)	Sediment and Water	0.000	Vol %
EN 14538	Determination of Ca and Mg Content by ICP OES	Sum of (Ca and Mg)	<1	mg/kg
EN 14538	Determination of Ca and Mg Content by ICP OES	Sum of (Na and K)	<1	mg/kg
ASTM D445	Kinematic / Dynamic Viscosity	Kinematic Viscosity @ 104 °F/ 40 °C	4.873	mm ² /s
ASTM D874	Sulfated Ash from Lubricating Oils and Additives	Sulfated Ash	< 0.005	Wt %
ASTM D5453	Determination of Total Sulfur in Light Hydrocarbons, Spark Ignition Engine Fuel, Diesel Engine Fuel, and Engine Oil by Ultraviolet Fluorescence.	Sulfur, mg /kg	1.7	mg/kg
ASTM D130	Corrosion - Copper Strip	Biodiesel-Cu Corrosion 50°C (122°F)/3 hr	1a	
ASTM D2500	Cloud Point	Cloud Point	6	°C
ASTM D4530	Micro Carbon Residue	Average Micro Method Carbon Residue	< 0.10	Wt %
ASTM D664	Acid Number of Petroleum Products by Potentiometric Titration	Procedure Used	A	
		Acid Number	0.20	mg KOH/g
ASTM	Determination of Free and	Free Glycerin	< 0.005	Wt %

Method	Test		Result	Units
D6584	Total Glycerin in B-100 Biodiesel Methyl Esters By Gas Chromatography	Total Glycerin	0.123	Wt %
ASTM D4951	Additive Elements in Lubricating Oils by ICP-AES	Phosphorus	0.000200	Wt %
ASTM D1160	Distillation of Petroleum Products at Reduced Pressure	IBP	248	°C
		AET @ 5% Recovery	336	°C
		AET @ 10% Recovery	338	°C
		AET @ 20% Recovery	339	°C
		AET @ 30% Recovery	340	°C
		AET @ 40% Recovery	342	°C
		AET @ 50% Recovery	344	°C
		AET @ 60% Recovery	345	°C
		AET @ 70% Recovery	347	°C
		AET @ 80% Recovery	349	°C
		AET @ 90% Recovery	351	°C
		AET @ 95% Recovery	353	°C
		FBP	362	°C
		% Recovered	98.5	%
		% Loss	1.5	%
		% Residue	0.0	%
		Cold Trap Volume	0.0	ml
			IBP	248
EN 14112	Determination of Oxidation Stability (Accelerated Oxidation Test)	Oxidation Stability	> 12	hr
		Operating Temp (usually 110 deg C)	110	°C
ASTM D4052	Density of Liquids by Digital Density Meter	API Gravity @ 60°F	29.5	°API
ASTM D 6890	Determination of Ignition Delay (ID) and Derived Cetane Number (DCN)	Derived Cetane Number (DCN)	> 61.0	

[0472] The lipid profile of the biodiesel was highly similar to the lipid profile of the feedstock oil. Other oils provided by the methods and compositions of the invention can be subjected to transesterification to yield biodiesel with lipid profiles including (a) at least 4%

C8-C14; (b) at least 0.3% C8; (c) at least 2% C10; (d) at least 2% C12; and (3) at least 30% C8-C14.

[0473] The Cold Soak Filterability by the ASTM D6751 A1 method of the biodiesel produced was 120 seconds for a volume of 300ml. This test involves filtration of 300 ml of B100, chilled to 40°F for 16 hours, allowed to warm to room temp, and filtered under vacuum using 0.7 micron glass fiber filter with stainless steel support. Oils of the invention can be transesterified to generate biodiesel with a cold soak time of less than 120 seconds, less than 100 seconds, and less than 90 seconds.

D. Production of Renewable Diesel

[0474] Degummed oil from *Prototheca moriformis* UTEX 1435, produced according to the methods described above and having the same lipid profile as the oil used to make biodiesel in Example X above, was subjected to transesterification to produce renewable diesel.

[0475] The oil was first hydrotreated to remove oxygen and the glycerol backbone, yielding n-paraffins. The n-paraffins were then subjected to cracking and isomerization. A chromatogram of the material is shown in Figure 13. The material was then subjected to cold filtration, which removed about 5% of the C18 material. Following the cold filtration the total volume material was cut to flash point and evaluated for flash point, ASTM D-86 distillation distribution, cloud point and viscosity. Flash point was 63°C; viscosity was 2.86 cSt (centistokes); cloud point was 4°C. ASTM D86 distillation values are shown in Table 20:

[0476] Table 20. Readings in °C:

Volume	Temperature
IBP	173
5	217.4
10	242.1
15	255.8
20	265.6
30	277.3
40	283.5
50	286.6
60	289.4
70	290.9
80	294.3
90	300
95	307.7
FBP	331.5

[0477] The T10-T90 of the material produced was 57.9°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to

generate renewable diesel compositions with other T10-T90 ranges, such as 20, 25, 30, 35, 40, 45, 50, 60 and 65°C using triglyceride oils produced according to the methods disclosed herein.

[0478] The T10 of the material produced was 242.1°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other T10 values, such as T10 between 180 and 295, between 190 and 270, between 210 and 250, between 225 and 245, and at least 290.

[0479] The T90 of the material produced was 300°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein can be employed to generate renewable diesel compositions with other T90 values, such as T90 between 280 and 380, between 290 and 360, between 300 and 350, between 310 and 340, and at least 290.

[0480] The FBP of the material produced was 300°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other FBP values, such as FBP between 290 and 400, between 300 and 385, between 310 and 370, between 315 and 360, and at least 300.

[0481] Other oils provided by the methods and compositions of the invention can be subjected to combinations of hydrotreating, isomerization, and other covalent modification including oils with lipid profiles including (a) at least 4% C8-C14; (b) at least 0.3% C8; (c) at least 2% C10; (d) at least 2% C12; and (3) at least 30% C8-C14.

[0482] **EXAMPLE 15: Utilization of Sucrose by *Chlorella luteoviridis***

A. SAG 2214 Growth on Glucose and Sucrose

[0483] SAG 2214 (designated as *Chlorella luteoviridis*) was tested for growth in the dark on media containing either glucose or sucrose. Heterotrophic liquid cultures were initiated using inoculum from a frozen vial in either media containing 4% glucose or 4% sucrose as the sole carbon source. Cultures were grown in the dark, shaking at 200 rpm. Samples from the cultures were taken at 0, 24, 48 and 72 hour timepoints and growth was measured by relative absorbance at 750nm (UV Mini1240, Shimadzu). SAG 2214 grew equally well on glucose as on sucrose, showing that this microalgae can utilize sucrose as effectively as glucose as a sole carbon source. The result of this experiment is represented graphically in Figure 3.

B. Lipid Productivity and Fatty Acid Profile for SAG 2214

[0484] Microalgal strain SAG 2214 was cultivated in liquid medium containing either glucose or sucrose as the sole carbon source in similar conditions as described in Example 32 above. After 7 days, cells were harvested for dry cell weight calculation. Cells were centrifuged and lyophilized for 24 hours. The dried cell pellets were weighed and the dry cell weight per liter was calculated. Cells for lipid analysis were also harvested and centrifuged at 4000 x g for 10 minutes at room temperature. The supernatant was discarded and the samples were processed for lipid analysis and fatty acid profile using standard gas chromatography (GC/FID) procedures. The results are summarized below in Tables 21 and 22.

[0485] Table 21. Lipid productivity and DCW for SAG 2214.

Sample	Lipid (g/L)	DCW (g/L)	% Lipid DCW
SAG 2214 glucose	2.43	5.73	42.44%
SAG 2214 sucrose	0.91	2.00	45.56%

[0486] Table 22. Fatty acid profile for SAG 2214.

Fatty Acid	Percent (w/w)
C:16:0	21
C:18:1	38
C:18:2	41

C. Genomic Comparison of SAG 2214 to other *Chlorella luteoviridis* strains

[0487] Microalgal strain SAG 2214 proved to be of general interest due to its ability to grow on sucrose as a carbon source (illustrated above). In addition to the growth characteristics of this strain, its taxonomic relationship to other microalgal species was also of interest. Designated by the SAG collection as a *Chlorella luteoviridis* strain, the 23s rRNA gene of SAG 2214 was sequenced and compared to the 23s rRNA genomic sequence of nine other strains also identified by the SAG and UTEX collections as *Chlorella luteoviridis*. These strains were UTEX 21, 22, 28, 257 and 258, and SAG strains 2133, 2196, 2198 and 2203. The DNA genotyping methods used were the same as the methods described above in Example 1. Sequence alignments and unrooted trees were generated using Geneious DNA analysis software. Out of the nine other strains that were genotypes, UTEX 21, 22, 28 and 257 had identical 23s rRNA DNA sequence (SEQ ID NO: 106). The other five *Chlorella luteoviridis* strains had 23s rRNA sequences that were highly homologous to UTEX 21, 22, 28, and 257.

[0488] The 23s rRNA gene sequence from SAG 2214 (SEQ ID NO: 30) is decidedly different from that of the other nine *C. luteoviridis* strains, having a large insertion that was not found in the other strains. Further analysis of this 23s rRNA gene sequence using BLAST indicated that it shared the greatest homology with members of the genus *Leptosira* and *Trebouxia* (members of phycobiont portion of lichens). These results indicate that SAG 2214 may not be *Chlorella luteoviridis* strain as categorized by the strain collection, but instead shares significant 23S rRNA nucleotide identity to algal symbionts found in lichen. The genomic analysis along with the growth characteristics indicate that SAG 2214 may be a source for genes and proteins involved in the metabolism of sucrose, as well as signaling and transit peptides responsible for the correct localization of such enzymes. SAG 2214 and other strains with a high degree of genomic similarity may also be strains useful for oil production using sucrose as a source of fixed carbon.

[0489] Although this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.

[0490] All references cited herein, including patents, patent applications, and publications, are hereby incorporated by reference in their entireties, whether previously specifically incorporated or not. The publications mentioned herein are cited for the purpose of describing and disclosing reagents, methodologies and concepts that may be used in connection with the present invention. Nothing herein is to be construed as an admission that these references are prior art in relation to the inventions described herein. In particular, the following patent applications are hereby incorporated by reference in their entireties for all purposes: US Provisional Application No. 60/941,581, filed June 1, 2007, entitled "Production of Hydrocarbons in Microorganisms"; US Provisional Application No. 60/959,174, filed July 10, 2007, entitled "Production of Hydrocarbons in Microorganisms"; US Provisional Application No. 60/968,291, filed August 27, 2007, entitled "Production of Hydrocarbons in Microorganisms"; US Provisional Application No. 61/024,069, filed January 28, 2008, entitled "Production of Hydrocarbons in Microorganisms"; PCT Application No. PCT/US08/65563, filed June 2, 2008, entitled "Production of Oil in Microorganisms"; US Patent Application No. 12/131,783, filed June 2, 2008, entitled "Use of Cellulosic Material for Cultivation of Microorganisms"; US Patent Application No. 12/131,773, filed June 2,

2008, entitled "Renewable Diesel and Jet Fuel from Microbial Sources"; US Patent Application No. 12/131,793, filed June 2, 2008, entitled "Sucrose Feedstock Utilization for Oil-Based Fuel Manufacturing"; US Patent Application No. 12/131,766, filed June 2, 2008, entitled "Glycerol Feedstock Utilization for Oil-Based Fuel Manufacturing"; US Patent Application No. 12/131,804, filed June 2, 2008, entitled "Lipid Pathway Modification in Oil-Bearing Microorganisms"; US Patent Application No. 61/118,590, filed November 28, 2008, entitled "Production of Oil in Microorganisms"; US Provisional Patent Application No. 61/118,994, filed December 1, 2008, entitled "Production of Oil in Microorganisms"; US Provisional Patent Application No. 61/174,357, filed April 3, 2009, entitled "Production of Oil in Microorganisms"; US Provisional Patent Application No. 61/219,525, filed June 23, 2009, entitled "Production of Oil in Microorganisms"; and PCT Application No. _____ [[Attorney Docket No. 026172-005020PC]] , filed November 30, 2009, entitled "Manufacturing of Tailored Oils in Recombinant Heterotrophic Microorganisms".

CLAIMS:

1. A method of manufacturing a chemical, the method comprising:
 - (a) providing a triglyceride oil isolated from a cultivated oleaginous microorganism, wherein the oleaginous microorganism comprises an exogenous fatty acyl-ACP thioesterase gene that encodes a fatty acyl-ACP thioesterase having hydrolysis activity towards one or more fatty acyl-ACP substrates of chain length 8 to 18 carbon atoms, and produces triglyceride oil enriched in the chain lengths for which the thioesterase is specific;
 - (b) performing one or more chemical reactions on the triglyceride oil to produce the chemical; and
 - (c) separating the chemical from the reaction mixture after performing step (b).
2. The method of claim 1, wherein the oleaginous microorganism further comprises an exogenous invertase gene and the oleaginous microorganism is cultivated in a medium comprising sucrose.
3. The method of claim 1, wherein the fatty acyl-ACP thioesterase gene is from *Umbellularia*, *Cinnamomum*, *Myristica*, *Elaeis*, *Populus*, *Arabidopsis*, *Gossypium*, *Cuphea*, *Vitis*, *Garcinia*, *Iris*, *Brassica*, *Madhuca*, *Oryza*, or *Ulmus*.
4. The method of claim 3, wherein the fatty acyl-ACP thioesterase gene is from *Umbellularia*, *Cinnamomum*, *Myristica*, *Elaeis*, *Populus*, *Cuphea*, or *Iris*.
5. The method of claim 3, wherein the fatty acyl-ACP thioesterase gene is from *Elaeis*, *Arabidopsis*, *Gossypium*, *Vitis*, *Garcinia*, *Brassica*, *Madhuca*, *Oryza*, or *Ulmus*.
6. The method of claim 1, wherein the one or more chemical reactions comprise amination, ozonolysis, transesterification, hydrogenation, hydrocracking, hydroprocessing, hydrotreating, fluid catalytic cracking, hydrodeoxygenation, hydrodesulfurization, epoxidation, deoxygenation, isomerization, interestification, directed interestification, hydroxylation and/or hydrolysis.
7. The method of claim 1, wherein the chemical comprises a fatty acid, a fatty acid methyl ester, a fatty nitrile, an ester, a dimer acid, a quat, a surfactant, a fatty alkanolamide, a fatty alcohol sulfate, a resin, an emulsifier, a fatty alcohol, an olefin, a higher alkane, a linear alkylbenzyl sulfonate, or a sulfated fatty acid.

8. The method of claim 1, wherein the triglyceride oil is blended with at least one of the following oils before performing the one or more chemical reactions: soy, rapeseed, canola, palm, palm kernel, coconut, corn, waste vegetable, Chinese tallow, olive, sunflower, cotton seed, chicken fat, beef tallow, porcine tallow, microalgal, macroalgal, *Cuphea*, flax, peanut, choice white grease, lard, *Camelina sativa*, mustard seed, cashew nut, oats, lupine kenaf, calendula, hemp, coffee, hazelnut, euphorbia, pumpkin seed, coriander, camellia, sesame, safflower, rice, tung tree, cocoa, copra, plum poppy, castor bean, pecan, jojoba, macademia, Brazil nut, avocado, petroleum, or a distillate fraction of any of the proceeding oils.

9. The method of claim 8, wherein the chemical comprises a fatty acid, a fatty acid methyl ester, a fatty nitrile, an ester, a dimer acid, a quat, a surfactant, a fatty alkanolamide, a fatty alcohol sulfate, a resin, an emulsifier, a fatty alcohol, an olefin, a higher alkane, a linear alkylbenzyl sulfonate, or a sulfated fatty acid.

10. The method of claim 1, wherein the oleaginous microorganism is an obligate heterotroph.

11. The method of claim 1, wherein the oleaginous microorganism is a microalga.

12. The method of claim 11, wherein the microalga is an obligate heterotroph.

13. The method of claim 11, wherein the microalga is of the genus *Prototheca* or *Chlorella*.

14. The method of claim 13, wherein the microalga is of the species *Prototheca moriformis*.

15. The method of claim 11, wherein the one or more chemical reactions comprise amination.

16. The method of claim 11, wherein the one or more chemical reactions comprise ozonolysis.

17. The method of claim 11, wherein the one or more chemical reactions comprise transesterification.

18. The method of claim 11, wherein the one or more chemical reactions comprise hydrogenation.

19. The method of claim 11, wherein the one or more chemical reactions comprise hydrocracking.

20. The method of claim 11, wherein the one or more chemical reactions comprise hydroprocessing.

21. The method of claim 11, wherein the one or more chemical reactions comprise hydrotreating.

22. The method of claim 11, wherein the one or more chemical reactions comprise fluid catalytic cracking.

23. The method of claim 11, wherein the one or more chemical reactions comprise hydrodeoxygenation

24. The method of claim 11, wherein the one or more chemical reactions comprise hydrodesulfurization.

25. The method of claim 11, wherein the one or more chemical reactions comprise epoxidation.

26. The method of claim 11, wherein the one or more chemical reactions comprise deoxygenation.

27. The method of claim 11, wherein the one or more chemical reactions comprise isomerization.

28. The method of claim 11, wherein the one or more chemical reactions comprise interestification.

29. The method of claim 11, wherein the one or more chemical reactions comprise directed interestification.

30. The method of claim 11, wherein the one or more chemical reactions comprise hydroxylation.

31. The method of claim 11, wherein the one or more chemical reactions comprise hydrolysis.
32. The method of claim 31, wherein the one or more chemical reactions comprise saponification.
33. The method of claim 1, wherein the fatty acyl-ACP thioesterase gene is from *Cinnamomum camphora*.
34. The method of claim 1, wherein the fatty acyl-ACP thioesterase gene is from *Cuphea palustris*.
35. The method of claim 1, wherein the triglyceride oil comprises at least 4% by weight of fatty acids having a chain length of 8 to 14 carbons (C8-C14).

026172-005010PC - Sequence Listing_1.TXT
SEQUENCE LISTING

<110> SOLAZYME, INC.
<120> PRODUCTION OF TAILORED OILS IN HETEROTROPHIC MICROORGANISMS
<130> 026172-005010PC
<140> PCT/US2009/066142
<141> 2009-11-30
<150> 61/219,525
<151> 2009-06-23
<150> 61/174,357
<151> 2009-04-30
<150> 61/118,994
<151> 2008-12-01
<150> 61/118,590
<151> 2008-11-28
<160> 143
<170> PatentIn version 3.5
<210> 1
<211> 1187
<212> DNA
<213> Chlorella sp.

<400> 1
gatcagacgg gcctgacctg cgagataatc aagtgctcgt aggcaaccaa ctcagcagct 60
gcttggtggtt ggggtctgcag gatagtgttg cagggcccca aggacagcag ggggaacttac 120
accttggtccc cgacccagtt ttatggagtg cattgcctca agagcctagc cggagcgcta 180
ggctacatac ttgccgcacc ggtatgaggg gatatagtagc tcgcactgctg ctgtctagtgt 240
agatgggcag tgctgcccac aaacaactgg ctgctcagcc atttgttggc ggaccattct 300
ggggggggcca gcaatgcctg actttcgggt aggggtgaaaa ctgaacaaag actacaaaaa 360
cagaatttct tcctccttgg aggtaagcgc aggccggccc gcctgcgccc acatggcgct 420
ccgaacacct ccatagctgt aaggggcgaa acatggccgg actgttgtca gcactctttc 480
atggccatac aagggtcatgt cgagattagt gctgagtag acactatcac cccatgttctg 540
attgaagccg tgacttcatg ccaacctgcc cctgggcgta gcagacgtat gccatcatga 600
ccactagccg acatgcgctg tcttttgcca ccaaaacaac tggtagaccg ctcgaagtcg 660
tgccgcacac ctccgggagt gagtccggcg actcctcccc ggcgggccgc ggccctacct 720
gggtaggggtc gccatacgcc cacgacaaa cgacgcagga ggggattggg gtagggaatc 780
ccaaccagcc taaccaagac ggcacctata ataataggtg gggggactaa cagccctata 840
tcgcaagctt tgggtgccta tcttgagaag cacgagttgg agtggctgtg tacggctcgac 900
cctaagggtg gtgtgccgca gcctgaaaca aagcgtctag cagctgcttc tataatgtgt 960
cagccgttgt gtttcagtta tattgtatgc tattgtttgt tcgtgctagg gtggcgagc 1020
cccacctact gtggcgggcc attggttggg gcttgaattg cctcaccatc taaggctctga 1080

026172-005010PC - Sequence Listing_1.TXT

acgctcactc aaacgccttt gtacaactgc agaactttcc ttggcgctgc aactacagtg 1140
tgcaaaccag cacatagcac tcccttacat caccagcag tacaaca 1187

<210> 2
<211> 1414
<212> DNA
<213> *Chlorella ellipsoidea*

<400> 2
cgctgcgcac cagggccgcc agctcgctga tgctcgctcca aatgcggtcc cccgattttt 60
tgttcttcat cttctccacc ttggtggcct tcttggccag ggccttcagc tgcattgcgc 120
cagaccgttg agctcctgat cagcatcctc aggaggccct ttgacaagca agcccctgtg 180
caagcccatt cacggggtag cagtgggtgct gaggtagatg ggtttgaaaa ggattgctcg 240
gtcgattgct gctcatggaa ttggcatgtg catgcatgtt cacaatatgc caccaggctt 300
tggagcaaga gagcatgaat gccttcaggc aggttgaaaag ttcctggggg tgaagaggca 360
gggcccagga ttggaggagg aaagcatcaa gtcgtcgctc atgctcatgt tttcagtcag 420
agtttgccaa gctcacagga gcagagacaa gactggctgc tcagggtgtg catcgtgtgt 480
gtggtggggg gggggggggt aatacggtag gaaatgcact tggaaattccc acctcatgcc 540
agcggaccca catgcttgaa ttcgaggcct gtgggggtgag aaatgctcac tctgccctcg 600
ttgctgaggt acttcaggcc gctgagctca aagtcgatgc cctgctcgtc tatcagggcc 660
tgcacctctg ggctgaccgg ctacgcctcc ttcgcgggca tggagtaggc gccggcagcg 720
ttcatgtccg ggcccagggc agcgggtggtg ccataaatgt cgggtgatgtt ggggaggggg 780
gccgtcgcca caccattgcc gttgctggct gacgcatgca catgtggcct ggctggcacc 840
ggcagcactg gtctccagcc agccagcaag tggctgttca ggaaagcggc catgtttgtt 900
gtccctgcgc atgtaattcc ccagatcaaa ggagggaaca gcttggattt gatgtagtgc 960
ccaaccggac tgaatgtgcg atggcaggtc cctttgagtc tcccgaatta ctagcagggc 1020
actgtgacct aacgcagcat gccaaaccga aaaaaatgat tgacagaaaa tgaagcgggtg 1080
tgtcaatatt tgctgtattt attcgtttta atcagcaacc aagttcgaaa cgcaactatc 1140
gtggtgatca agtgaacctc atcagactta cctcgttcgg caaggaaacg gaggcaccaa 1200
attccaattt gatattatcg cttgccaagc tagagctgat ctttgggaaa ccaactgcca 1260
gacagtggac tgtgatggag tgccccgagt ggtggagcct cttcgattcg gttagtcatt 1320
actaacgtga accctcagtg aagggacat cagaccagaa agaccagatc tcctcctcga 1380
caccgagaga gtgttgccgc agtaggacga caag 1414

<210> 3
<211> 512
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown: Yeast sequence
Page 2

026172-005010PC - Sequence Listing_1.TXT

<400> 3

Met Thr Asn Glu Thr Ser Asp Arg Pro Leu Val His Phe Thr Pro Asn
1 5 10 15

Lys Gly Trp Met Asn Asp Pro Asn Gly Leu Trp Tyr Asp Glu Lys Asp
20 25 30

Ala Lys Trp His Leu Tyr Phe Gln Tyr Asn Pro Asn Asp Thr Val Trp
35 40 45

Gly Thr Pro Leu Phe Trp Gly His Ala Thr Ser Asp Asp Leu Thr Asn
50 55 60

Trp Glu Asp Gln Pro Ile Ala Ile Ala Pro Lys Arg Asn Asp Ser Gly
65 70 75 80

Ala Phe Ser Gly Ser Met Val Val Asp Tyr Asn Asn Thr Ser Gly Phe
85 90 95

Phe Asn Asp Thr Ile Asp Pro Arg Gln Arg Cys Val Ala Ile Trp Thr
100 105 110

Tyr Asn Thr Pro Glu Ser Glu Glu Gln Tyr Ile Ser Tyr Ser Leu Asp
115 120 125

Gly Gly Tyr Thr Phe Thr Glu Tyr Gln Lys Asn Pro Val Leu Ala Ala
130 135 140

Asn Ser Thr Gln Phe Arg Asp Pro Lys Val Phe Trp Tyr Glu Pro Ser
145 150 155 160

Gln Lys Trp Ile Met Thr Ala Ala Lys Ser Gln Asp Tyr Lys Ile Glu
165 170 175

Ile Tyr Ser Ser Asp Asp Leu Lys Ser Trp Lys Leu Glu Ser Ala Phe
180 185 190

Ala Asn Glu Gly Phe Leu Gly Tyr Gln Tyr Glu Cys Pro Gly Leu Ile
195 200 205

Glu Val Pro Thr Glu Gln Asp Pro Ser Lys Ser Tyr Trp Val Met Phe
210 215 220

Ile Ser Ile Asn Pro Gly Ala Pro Ala Gly Gly Ser Phe Asn Gln Tyr
225 230 235 240

Phe Val Gly Ser Phe Asn Gly Thr His Phe Glu Ala Phe Asp Asn Gln
245 250 255

Ser Arg Val Val Asp Phe Gly Lys Asp Tyr Tyr Ala Leu Gln Thr Phe
260 265 270

026172-005010PC - Sequence Listing_1.TXT

Phe Asn Thr Asp Pro Thr Tyr Gly Ser Ala Leu Gly Ile Ala Trp Ala
275 280 285

Ser Asn Trp Glu Tyr Ser Ala Phe Val Pro Thr Asn Pro Trp Arg Ser
290 295 300

Ser Met Ser Leu Val Arg Lys Phe Ser Leu Asn Thr Glu Tyr Gln Ala
305 310 315 320

Asn Pro Glu Thr Glu Leu Ile Asn Leu Lys Ala Glu Pro Ile Leu Asn
325 330 335

Ile Ser Asn Ala Gly Pro Trp Ser Arg Phe Ala Thr Asn Thr Thr Leu
340 345 350

Thr Lys Ala Asn Ser Tyr Asn Val Asp Leu Ser Asn Ser Thr Gly Thr
355 360 365

Leu Glu Phe Glu Leu Val Tyr Ala Val Asn Thr Thr Gln Thr Ile Ser
370 375 380

Lys Ser Val Phe Ala Asp Leu Ser Leu Trp Phe Lys Gly Leu Glu Asp
385 390 395 400

Pro Glu Glu Tyr Leu Arg Met Gly Phe Glu Val Ser Ala Ser Ser Phe
405 410 415

Phe Leu Asp Arg Gly Asn Ser Lys Val Lys Phe Val Lys Glu Asn Pro
420 425 430

Tyr Phe Thr Asn Arg Met Ser Val Asn Asn Gln Pro Phe Lys Ser Glu
435 440 445

Asn Asp Leu Ser Tyr Tyr Lys Val Tyr Gly Leu Leu Asp Gln Asn Ile
450 455 460

Leu Glu Leu Tyr Phe Asn Asp Gly Asp Val Val Ser Thr Asn Thr Tyr
465 470 475 480

Phe Met Thr Thr Gly Asn Ala Leu Gly Ser Val Asn Met Thr Thr Gly
485 490 495

Val Asp Asn Leu Phe Tyr Ile Asp Lys Phe Gln Val Arg Glu Val Lys
500 505 510

<210> 4

<211> 20

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown: Yeast sequence

<400> 4

Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
1 5 10 15

Ile Ser Ala Ser
20

<210> 5

<211> 18

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown: Higher plant secretion signal

<400> 5

Met Ala Asn Lys Ser Leu Leu Leu Leu Leu Leu Gly Ser Leu Ala
1 5 10 15

Ser Gly

<210> 6

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic consensus sequence

<400> 6

Met Ala Arg Leu Pro Leu Ala Ala Leu Gly
1 5 10

<210> 7

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 7

Met Ala Asn Lys Leu Leu Leu Leu Leu Leu Leu Leu Leu Leu Pro Leu
1 5 10 15

Ala Ala Ser Gly
20

<210> 8

<211> 2615

<212> DNA

<213> Saccharomyces cerevisiae

<400> 8

gaattcccca acatggtgga gcacgacact ctcgtctact ccaagaatat caaagataca

60

026172-005010PC - Sequence Listing_1.TXT

gtctcagaag accaaagggc tattgagact tttcaacaaa gggtaatatc gggaaacctc	120
ctcggattcc attgcccagc tatctgtcac ttcacaaaaa ggacagtaga aaaggaaggt	180
ggcacctaca aatgccatca ttgcgataaa ggaaaggcta tcgttcaaga tgcctctgcc	240
gacagtgggtc ccaaagatgg acccccaccc acgaggagca tcgtggaaaa agaagacgtt	300
ccaaccacgt cttcaaagca agtggattga tgtgaacatg gtggagcacg acactctcgt	360
ctactccaag aatatcaaag atacagtctc agaagaccaa agggctattg agacttttca	420
acaaagggta atatcgggaa acctcctcgg attccattgc ccagctatct gtcacttcat	480
caaaaggaca gtagaaaagg aaggtggcac ctacaaatgc catcattgcg ataaaggaaa	540
ggctatcggt caagatgcct ctgccgacag tggccccaaa gatggacccc caccacgag	600
gagcatcggt gaaaaagaag acgttccaac cagctcttca aagcaagtgg attgatgtga	660
tatctccact gacgtaaggg atgacgcaca atcccactat ctttcgcaag acccttcctc	720
tatataagga agttcatttc atttgagag gacacgctga aatcaccagt ctctctctac	780
aaatctatct ctggcgcgcc atatcaatgc ttcttcaggc ctttcttttt cttcttgctg	840
gttttgctgc caagatcagc gcctctatga cgaacgaaac ctcggataga ccacttgctc	900
actttacacc aaacaagggc tggatgaatg accccaatgg actgtggtac gacgaaaaag	960
atgccaagtg gcatctgtac tttcaatata acccgaacga tactgtctgg gggacgccat	1020
tgttttgggg ccacgccacg tccgacgacc tgaccaattg ggaggaccaa ccaatagcta	1080
tcgctccgaa gaggaacgac tccggagcat tctcgggttc catggtggtt gactacaaca	1140
atacttccgg ctttttcaac gataccattg acccgagaca acgctgcgtg gccatatgga	1200
cttacaacac accggagtcc gaggagcagt acatctcgta tagcctggac ggtggataca	1260
cttttacaga gtatcagaag aaccctgtgc ttgctgcaaa ttcgactcag ttccgagatc	1320
cgaagggtctt ttggtacgag ccctcgcaga agtggatcat gacagcggca aagtcacagg	1380
actacaagat cgaaatttac tcgtctgacg accttaaadc ctggaagctc gaatccgcgt	1440
tcgcaaacga gggctttctc ggctaccaat acgaatgccc aggcctgata gaggtcccaa	1500
cagagcaaga tcccagcaag tcctactggg tgatgtttat ttccattaat ccaggagcac	1560
cggcaggagg ttcttttaat cagtacttcg tcggaagctt taacggaact ctttctgagg	1620
catttgataa ccaatcaaga gtagttgatt ttggaaagga ctactatgcc ctgcagactt	1680
tcttcaatac tgacccgacc tatgggagcg ctcttggcat tgcgtgggct tctaactggg	1740
agtattccgc attcgttcct acaaaccctt ggaggtcctc catgtcgtc gtgaggaaat	1800
tctctctcaa cactgagtac caggccaacc cggaaccga actcataaac ctgaaagccg	1860
aaccgatcct gaacattagc aacgctggcc cctggagccg gtttgcaacc aacaccacgt	1920
tgacgaaagc caacagctac aacgtcgatc tttcgaatag caccggtaca cttgaatttg	1980
aactggtgta tgccgtcaat accacccaaa cgatctcgaa gtcggtgttc gcggacctct	2040
ccctctgggt taaaggcctg gaagaccccg aggagtacct cagaatgggt ttcgaggttt	2100

026172-005010PC - Sequence Listing_1.TXT

ctgcgtcctc cttcttcctt gatcgcgga acagcaaagt aaaatttggt aaggagaacc	2160
catattttac caacaggatg agcgtaaca accaaccatt caagagcgaa aacgacctgt	2220
cgtactacaa agtgtatggt ttgcttgatc aaaatatcct ggaactctac ttcaacgatg	2280
gtgatgtcgt gtccaccaac acatacttca tgacaaccgg gaacgcactg ggctccgtga	2340
acatgacgac ggggtgtggat aacctgttct acatcgacaa attccagggtg aggggaagtca	2400
agtgagatct gtcgatcgac aagctcgagt ttctccataa taatgtgtga gtagttccca	2460
gataagggaa ttaggggttcc tataagggtt cgctcatgtg ttgagcatat aagaaaccct	2520
tagtatgtat ttgtatttgt aaaatacttc tatcaataaa atttctaatt cctaaaacca	2580
aaatccagta ctaaaatcca gatccccga attaa	2615

<210> 9
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 9	
tgttgaagaa tgagccggcg ac	22

<210> 10
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 10	
cagtgaagctt ttacgcactc	20

<210> 11
 <211> 541
 <212> DNA
 <213> Prototheca kruegani

<400> 11	
tgttgaagaa tgagccggcg agttaaaaag agtggcatgg ttaaagaaaa tactctggag	60
ccatagcgaa agcaagttta gtaagcttag gtcattcttt ttagaccgga aaccgagtga	120
tctacccatg atcaggggtga agtggttagta aaataacatg gaggcccgaa ccgactaatg	180
ttgaaaaatt agcggatgaa ttgtgggtag gggcgaaaaa ccaatcgaac tcggagttag	240
ctggttcttc ccgaaatgag tttaggcgca gcagtagcag taaaaataga ggggttaaagc	300
actgtttctt ttgtgggctt cgaaagtgtg acctcaaagt ggcaaactct gaatactcta	360
tttagatatc tactagttag accttggggg ataagctcct tggtaaaaag ggaaacagcc	420
cagatcacca gttaaggccc caaaatgaaa atgatagtga ctaaggatgt gggtagtgca	480
aaacctccag cagggttagct tagaagcagc aatcctttca agagtgcgta atagctcact	540

g 541

<210> 12
 <211> 573
 <212> DNA
 <213> *Prototheca wickerhamii*

<400> 12
 tgttgaagaa tgagccggcg acttaaaata aatggcaggc taagagattt aataactcga 60
 aacctaagcg aaagcaagtc ttaatagggc gtcaatttaa caaaacttta aataaattat 120
 aaagtcattt attttagacc cgaacctgag tgatctaacc atggtcagga tgaaacttgg 180
 gtgacaccaa gtggaagtcc gaaccgaccg atgttgaaaa atcggcggat gaactgtggt 240
 tagtggtgaa ataccagtcg aactcagagc tagctggttc tccccgaaat gcgttgaggc 300
 gcagcaatat atctcgtcta tctaggggta aagcactggt tcggtgcggg ctatgaaaat 360
 ggtaccaa at cgtggcaaac tctgaatact agaaatgacg atatattagt gagactatgg 420
 gggataagct ccatagtcga gagggaaaca gccagacca ccagttaagg ccccaaatg 480
 ataatgaagt ggtaaaggag gtgaaaatgc aaatacaacc aggaggttgg cttagaagca 540
 gccatccttt aaagagtgcg taatagctca ctg 573

<210> 13
 <211> 541
 <212> DNA
 <213> *Prototheca stagnora*

<400> 13
 tgttgaagaa tgagccggcg agttaaaaaa aatggcatgg ttaaagatat ttctctgaag 60
 ccatagcgaa agcaagtttt acaagctata gtcatttttt ttagaccgga aaccgagtga 120
 tctacccatg atcaggggtga agtggtggtc aaataacatg gagggccgaa ccgactaatg 180
 gtgaaaaatt agcggatgaa ttgtgggtag gggcgaaaaa ccaatcgaac tcggagttag 240
 ctggttctcc ccgaaatgcg tttaggcgca gcagtagcaa cacaataga ggggtaaagc 300
 actgtttctt ttgtgggctt cgaaagtgtg acctcaaagt ggcaaactct gaatactcta 360
 tttagatatc tactagttag accttggggg ataagctcct tgggtcaaaag ggaaacagcc 420
 cagatcacca gttaaggccc caaaatgaaa atgatagtga ctaaggacgt gagtatgtca 480
 aaacctccag caggtttagt tagaagcagc aatcctttca agagtgcgta atagctcact 540
 g 541

<210> 14
 <211> 541
 <212> DNA
 <213> *Prototheca moriformis*

<400> 14
 tgttgaagaa tgagccggcg agttaaaaag agtggcatgg ttaaagataa ttctctggag 60
 ccatagcgaa agcaagttta acaagctaaa gtcacccttt ttagaccgga aaccgagtga 120

026172-005010PC - Sequence Listing_1.TXT

tctacccatg atcaggggtga agtggttggtg aaataacatg gagggcccgaa ccgactaatg	180
gtgaaaaatt agcggatgaa ttgtgggtag gggcgaaaaa ccaatcgaac tcggaggttag	240
ctggttctcc ccgaaatgcg tttaggcgca gcagtagcaa cacaaataga ggggtaaagc	300
actgtttctt ttgtgggctt cgaaagttgt acctcaaagt ggcaaactct gaatactcta	360
tttagatatc tactagttag accttggggg ataagctcct tgggtcaaaag ggaaacagcc	420
cagatcacca gttaaggccc caaaatgaaa atgatagtga ctaaggatgt gggatatgta	480
aaacctccag caggttagct tagaagcagc aatcctttca agagtgcgta atagctcact	540
g	541

<210> 15
 <211> 573
 <212> DNA
 <213> *Prototheca moriformis*

<400> 15	
tggtgaagaa tgagccggcg acttaaaata aatggcaggc taagagaatt aataactcga	60
aacctaaagcg aaagcaagtc ttaatagggc gctaatttaa caaaacatta aataaaatct	120
aaagtcattt attttagacc cgaacctgag tgatctaacc atggtcagga tgaaacttgg	180
gtgacaccaa gtggaagtcc gaaccgaccg atgttgaaaa atcggcggat gaactgtggt	240
tagtggtgaa ataccagtcg aactcagagc tagctgggtc tccccgaaat gcgttgaggc	300
gcagcaatat atctcgtcta tctaggggta aagcactggt tcggtgcggg ctatgaaaat	360
ggtaccaa at cgtggcaaac tctgaatact agaaatgacg atatattagt gagactatgg	420
gggataagct ccatagtcga gagggaaaca gcccagacca ccagttaagg ccccaaatg	480
ataatgaagt ggtaaaggag gtgaaaatgc aaatacaacc aggagggttg cttagaagca	540
gccatccttt aaagagtgcg taatagctca ctg	573

<210> 16
 <211> 573
 <212> DNA
 <213> *Prototheca wickerhamii*

<400> 16	
tggtgaagaa tgagccgtcg acttaaaata aatggcaggc taagagaatt aataactcga	60
aacctaaagcg aaagcaagtc ttaatagggc gctaatttaa caaaacatta aataaaatct	120
aaagtcattt attttagacc cgaacctgag tgatctaacc atggtcagga tgaaacttgg	180
gtgacaccaa gtggaagtcc gaaccgaccg atgttgaaaa atcggcggat gaactgtggt	240
tagtggtgaa ataccagtcg aactcagagc tagctgggtc tccccgaaat gcgttgaggc	300
gcagcaatat atctcgtcta tctaggggta aagcactggt tcggtgcggg ctatgaaaat	360
ggtaccaa at cgtggcaaac tctgaatact agaaatgacg atatattagt gagactatgg	420
gggataagct ccatagtcga gagggaaaca gcccagacca ccagttaagg ccccaaatg	480
ataatgaagt ggtaaaggag gtgaaaatgc aaatacaacc aggagggttg cttagaagca	540

gccatccttt aaagagtgcg taatagctca ctg

573

<210> 17
 <211> 541
 <212> DNA
 <213> Prototheca moriformis

<400> 17
 tgttgaagaa tgagccggcg agttaaaaag agtggcgtgg ttaaagaaaa ttctctggaa 60
 ccatagcgaa agcaagttta acaagcttaa gtcacttttt ttagacccga aaccgagtga 120
 tctacccatg atcaggggtga agtggttgga aaataacatg gagggccgaa ccgactaatg 180
 gtgaaaaatt agcggatgaa ttgtgggtag gggcgaaaaa ccaatcgaac tcggagttag 240
 ctggttctcc ccgaaatgcg tttaggcgca gcagtagcaa cacaaataga ggggtaaagc 300
 actgtttctt ttgtgggctc cgaaagttgt acctcaaagt ggcaaactct gaatactcta 360
 tttagatata tactagttag accttggggg ataagctcct tggtcgaaag ggaaacagcc 420
 cagatcacca gttaaggccc caaaatgaaa atgatatgta ctaaggatgt gagtatgtca 480
 aaacctccag caggtttagct tagaagcagc aatcctttca agagtgcgta atagctcact 540
 g 541

<210> 18
 <211> 541
 <212> DNA
 <213> Prototheca zopfii

<400> 18
 tgttgaagaa tgagccggcg agttaaaaag agtggcatgg ttaaagaaaa ttctctggag 60
 ccatagcgaa agcaagttta acaagcttaa gtcacttttt ttagacccga aaccgagtga 120
 tctacccatg atcaggggtga agtggttgga aaataacatg gagggccgaa ccgactaatg 180
 gtgaaaaatt agcggatgaa ttgtgggtag gggcgaaaaa ccaatcgaac tcggagttag 240
 ctggttctcc ccgaaatgcg tttaggcgca gcagtagcaa cacaaataga ggggtaaagc 300
 actgtttctt tcgtgggctt cgaaagttgt acctcaaagt ggcaaactct gaatactcta 360
 tttagatata tactagttag accttggggg ataagctcct tggtcgaaag ggaaacagcc 420
 cagatcacca gttaaggccc caaaatgaaa atgatatgta ctaaggatgt gagtatgtca 480
 aaacctccag caggtttagct tagaagcagc aatcctttca agagtgcgta atagctcact 540
 g 541

<210> 19
 <211> 565
 <212> DNA
 <213> Prototheca moriformis

<400> 19
 tgttgaagaa tgagccggcg acttagaaaa ggtggcatgg ttaaggaaat attccgaagc 60
 cgtagcaaaa gcgagtctga atagggcgat aaaatatatt aatattttaga atctagtcac 120
 tttttctaga cccgaacccg ggtgatctaa ccatgaccag gatgaagctt ggggtgatacc 180

026172-005010PC - Sequence Listing_1.TXT

```

aagtgaaggt ccgaaccgac cgatgttgaa aaatcggcgg atgagttgtg gttagcgggtg      240
aaataaccagt cgaacccgga gctagctggt tctccccgaa atgcgttgag gcgcagcagt      300
acatctagtc tatctagggg taaagcactg tttcgggtgcg ggctgtgaga acggtaccaa      360
atcgtggcaa actctgaata ctagaaatga cgatgtagta gtgagactgt gggggataag      420
ctccattgtc aagagggaaa cagcccagac caccagctaa ggccccaaaa tggtaatgta      480
gtgacaaagg aggtgaaaat gcaaatacaa ccaggagggtt ggcttagaag cagccatcct      540
ttaaagagtg cgtaatatgt cactg      565

```

<210> 20
 <211> 550
 <212> PRT
 <213> Cichorium intybus

<400> 20

Met Ser Asn Ser Ser Asn Ala Ser Glu Ser Leu Phe Pro Ala Thr Ser
 1 5 10 15

Glu Gln Pro Tyr Arg Thr Ala Phe His Phe Gln Pro Pro Gln Asn Trp
 20 25 30

Met Asn Asp Pro Asn Gly Pro Met Cys Tyr Asn Gly Val Tyr His Leu
 35 40 45

Phe Tyr Gln Tyr Asn Pro Phe Gly Pro Leu Trp Asn Leu Arg Met Tyr
 50 55 60

Trp Ala His Ser Val Ser His Asp Leu Ile Asn Trp Ile His Leu Asp
 65 70 75 80

Leu Ala Phe Ala Pro Thr Glu Pro Phe Asp Ile Asn Gly Cys Leu Ser
 85 90 95

Gly Ser Ala Thr Val Leu Pro Gly Asn Lys Pro Ile Met Leu Tyr Thr
 100 105 110

Gly Ile Asp Thr Glu Asn Arg Gln Val Gln Asn Leu Ala Val Pro Lys
 115 120 125

Asp Leu Ser Asp Pro Tyr Leu Arg Glu Trp Val Lys His Thr Gly Asn
 130 135 140

Pro Ile Ile Ser Leu Pro Glu Glu Ile Gln Pro Asp Asp Phe Arg Asp
 145 150 155 160

Pro Thr Thr Thr Trp Leu Glu Glu Asp Gly Thr Trp Arg Leu Leu Val
 165 170 175

Gly Ser Gln Lys Asp Lys Thr Gly Ile Ala Phe Leu Tyr His Ser Gly
 180 185 190

026172-005010PC - Sequence Listing_1.TXT

Asp Phe Val Asn Trp Thr Lys Ser Asp Ser Pro Leu His Lys Val Ser
195 200 205

Gly Thr Gly Met Trp Glu Cys Val Asp Phe Phe Pro Val Trp Val Asp
210 215 220

Ser Thr Asn Gly Val Asp Thr Ser Ile Ile Asn Pro Ser Asn Arg Val
225 230 235 240

Lys His Val Leu Lys Leu Gly Ile Gln Asp His Gly Lys Asp Cys Tyr
245 250 255

Leu Ile Gly Lys Tyr Ser Ala Asp Lys Glu Asn Tyr Val Pro Glu Asp
260 265 270

Glu Leu Thr Leu Ser Thr Leu Arg Leu Asp Tyr Gly Met Tyr Tyr Ala
275 280 285

Ser Lys Ser Phe Phe Asp Pro Val Lys Asn Arg Arg Ile Met Thr Ala
290 295 300

Trp Val Asn Glu Ser Asp Ser Glu Ala Asp Val Ile Ala Arg Gly Trp
305 310 315 320

Ser Gly Val Gln Ser Phe Pro Arg Ser Leu Trp Leu Asp Lys Asn Gln
325 330 335

Lys Gln Leu Leu Gln Trp Pro Ile Glu Glu Ile Glu Met Leu His Gln
340 345 350

Asn Glu Val Ser Phe His Asn Lys Lys Leu Asp Gly Gly Ser Ser Leu
355 360 365

Glu Val Leu Gly Ile Thr Ala Ser Gln Ala Asp Val Lys Ile Ser Phe
370 375 380

Lys Leu Ala Asn Leu Glu Glu Ala Glu Glu Leu Asp Pro Ser Trp Val
385 390 395 400

Asp Pro Gln Leu Ile Cys Ser Glu Asn Asp Ala Ser Lys Lys Gly Lys
405 410 415

Phe Gly Pro Phe Gly Leu Leu Ala Leu Ala Ser Ser Asp Leu Arg Glu
420 425 430

Gln Thr Ala Ile Phe Phe Arg Val Phe Arg Lys Asn Gly Arg Tyr Val
435 440 445

Val Leu Met Cys Ser Asp Gln Ser Arg Ser Ser Met Lys Asn Gly Ile
450 455 460

026172-005010PC - Sequence Listing_1.TXT

Glu Lys Arg Thr Tyr Gly Ala Phe Val Asp Ile Asp Pro Gln Gln Asp
465 470 475 480

Glu Ile Ser Leu Arg Thr Leu Ile Asp His Ser Ile Val Glu Ser Phe
485 490 495

Gly Gly Arg Gly Lys Thr Cys Ile Thr Thr Arg Val Tyr Pro Thr Leu
500 505 510

Ala Ile Gly Glu Gln Ala Arg Leu Phe Ala Phe Asn His Gly Thr Glu
515 520 525

Ser Val Glu Ile Ser Glu Leu Ser Ala Trp Ser Met Lys Lys Ala Gln
530 535 540

Met Lys Val Glu Glu Pro
545 550

<210> 21
<211> 581
<212> PRT
<213> Schizosaccharomyces pombe

<400> 21
Met Phe Leu Lys Tyr Ile Leu Ala Ser Gly Ile Cys Leu Val Ser Leu
1 5 10 15

Leu Ser Ser Thr Asn Ala Ala Pro Arg His Leu Tyr Val Lys Arg Tyr
20 25 30

Pro Val Ile Tyr Asn Ala Ser Asn Ile Thr Glu Val Ser Asn Ser Thr
35 40 45

Thr Val Pro Pro Pro Pro Phe Val Asn Thr Thr Ala Pro Asn Gly Thr
50 55 60

Cys Leu Gly Asn Tyr Asn Glu Tyr Leu Pro Ser Gly Tyr Tyr Asn Ala
65 70 75 80

Thr Asp Arg Pro Lys Ile His Phe Thr Pro Ser Ser Gly Phe Met Asn
85 90 95

Asp Pro Asn Gly Leu Val Tyr Thr Gly Gly Val Tyr His Met Phe Phe
100 105 110

Gln Tyr Ser Pro Lys Thr Leu Thr Ala Gly Glu Val His Trp Gly His
115 120 125

Thr Val Ser Lys Asp Leu Ile His Trp Glu Asn Tyr Pro Ile Ala Ile
130 135 140

026172-005010PC - Sequence Listing_1.TXT

Tyr Pro Asp Glu His Glu Asn Gly Val Leu Ser Leu Pro Phe Ser Gly
 145 150 155 160
 Ser Ala Val Val Asp Val His Asn Ser Ser Gly Leu Phe Ser Asn Asp
 165 170 175
 Thr Ile Pro Glu Glu Arg Ile Val Leu Ile Tyr Thr Asp His Trp Thr
 180 185 190
 Gly Val Ala Glu Arg Gln Ala Ile Ala Tyr Thr Thr Asp Gly Gly Tyr
 195 200 205
 Thr Phe Lys Lys Tyr Ser Gly Asn Pro Val Leu Asp Ile Asn Ser Leu
 210 215 220
 Gln Phe Arg Asp Pro Lys Val Ile Trp Asp Phe Asp Ala Asn Arg Trp
 225 230 235 240
 Val Met Ile Val Ala Met Ser Gln Asn Tyr Gly Ile Ala Phe Tyr Ser
 245 250 255
 Ser Tyr Asp Leu Ile His Trp Thr Glu Leu Ser Val Phe Ser Thr Ser
 260 265 270
 Gly Tyr Leu Gly Leu Gln Tyr Glu Cys Pro Gly Met Ala Arg Val Pro
 275 280 285
 Val Glu Gly Thr Asp Glu Tyr Lys Trp Val Leu Phe Ile Ser Ile Asn
 290 295 300
 Pro Gly Ala Pro Leu Gly Gly Ser Val Val Gln Tyr Phe Val Gly Asp
 305 310 315 320
 Trp Asn Gly Thr Asn Phe Val Pro Asp Asp Gly Gln Thr Arg Phe Val
 325 330 335
 Asp Leu Gly Lys Asp Phe Tyr Ala Ser Ala Leu Tyr His Ser Ser Ser
 340 345 350
 Ala Asn Ala Asp Val Ile Gly Val Gly Trp Ala Ser Asn Trp Gln Tyr
 355 360 365
 Thr Asn Gln Ala Pro Thr Gln Val Phe Arg Ser Ala Met Thr Val Ala
 370 375 380
 Arg Lys Phe Thr Leu Arg Asp Val Pro Gln Asn Pro Met Thr Asn Leu
 385 390 395 400
 Thr Ser Leu Ile Gln Thr Pro Leu Asn Val Ser Leu Leu Arg Asp Glu
 405 410 415

026172-005010PC - Sequence Listing_1.TXT

Thr Leu Phe Thr Ala Pro Val Ile Asn Ser Ser Ser Ser Leu Ser Gly
420 425 430

Ser Pro Ile Thr Leu Pro Ser Asn Thr Ala Phe Glu Phe Asn Val Thr
435 440 445

Leu Ser Ile Asn Tyr Thr Glu Gly Cys Thr Thr Gly Tyr Cys Leu Gly
450 455 460

Arg Ile Ile Ile Asp Ser Asp Asp Pro Tyr Arg Leu Gln Ser Ile Ser
465 470 475 480

Val Asp Val Asp Phe Ala Ala Ser Thr Leu Val Ile Asn Arg Ala Lys
485 490 495

Ala Gln Met Gly Trp Phe Asn Ser Leu Phe Thr Pro Ser Phe Ala Asn
500 505 510

Asp Ile Tyr Ile Tyr Gly Asn Val Thr Leu Tyr Gly Ile Val Asp Asn
515 520 525

Gly Leu Leu Glu Leu Tyr Val Asn Asn Gly Glu Lys Thr Tyr Thr Asn
530 535 540

Asp Phe Phe Phe Leu Gln Gly Ala Thr Pro Gly Gln Ile Ser Phe Ala
545 550 555 560

Ala Phe Gln Gly Val Ser Phe Asn Asn Val Thr Val Thr Pro Leu Lys
565 570 575

Thr Ile Trp Asn Cys
580

<210> 22
<211> 550
<212> PRT
<213> Pichia anomala

<400> 22
Met Ile Gln Leu Ser Pro Leu Leu Leu Leu Pro Leu Phe Ser Val Phe
1 5 10 15

Asn Ser Ile Ala Asp Ala Ser Thr Glu Tyr Leu Arg Pro Gln Ile His
20 25 30

Leu Thr Pro Asp Gln Gly Trp Met Asn Asp Pro Asn Gly Met Phe Tyr
35 40 45

Asp Arg Lys Asp Lys Leu Trp His Val Tyr Phe Gln His Asn Pro Asp
50 55 60

Lys Lys Ser Ile Trp Ala Thr Pro Val Thr Trp Gly His Ser Thr Ser
65 70 75 80

026172-005010PC - Sequence Listing_1.TXT

Lys Asp Leu Leu Thr Trp Asp Tyr His Gly Asn Ala Leu Glu Pro Glu
85 90 95

Asn Asp Asp Glu Gly Ile Phe Ser Gly Ser Val Val Val Asp Arg Asn
100 105 110

Asn Thr Ser Gly Phe Phe Asn Asp Ser Thr Asp Pro Glu Gln Arg Ile
115 120 125

Val Ala Ile Tyr Thr Asn Asn Ala Gln Leu Gln Thr Gln Glu Ile Ala
130 135 140

Tyr Ser Leu Asp Lys Gly Tyr Ser Phe Ile Lys Tyr Asp Gln Asn Pro
145 150 155 160

Val Ile Asn Val Asn Ser Ser Gln Gln Arg Asp Pro Lys Val Leu Trp
165 170 175

His Asp Glu Ser Asn Gln Trp Ile Met Val Val Ala Lys Thr Gln Glu
180 185 190

Phe Lys Val Gln Ile Tyr Gly Ser Pro Asp Leu Lys Lys Trp Asp Leu
195 200 205

Lys Ser Asn Phe Thr Ser Asn Gly Tyr Leu Gly Phe Gln Tyr Glu Cys
210 215 220

Pro Gly Leu Phe Lys Leu Pro Ile Glu Asn Pro Leu Asn Asp Thr Val
225 230 235 240

Thr Ser Lys Trp Val Leu Leu Leu Ala Ile Asn Pro Gly Ser Pro Leu
245 250 255

Gly Gly Ser Ile Asn Glu Tyr Phe Ile Gly Asp Phe Asp Gly Thr Thr
260 265 270

Phe His Pro Asp Asp Gly Ala Thr Arg Phe Met Asp Ile Gly Lys Asp
275 280 285

Phe Tyr Ala Phe Gln Ser Phe Asp Asn Thr Glu Pro Glu Asp Gly Ala
290 295 300

Leu Gly Leu Ala Trp Ala Ser Asn Trp Gln Tyr Ala Asn Thr Val Pro
305 310 315 320

Thr Glu Asn Trp Arg Ser Ser Met Ser Leu Val Arg Asn Tyr Thr Leu
325 330 335

Lys Tyr Val Asp Val Asn Pro Glu Asn Tyr Gly Leu Thr Leu Ile Gln
340 345 350

026172-005010PC - Sequence Listing_1.TXT

Lys Pro Val Tyr Asp Thr Lys Glu Thr Arg Leu Asn Glu Thr Leu Lys
355 360 365

Thr Leu Glu Thr Ile Asn Glu Tyr Glu Val Asn Asp Leu Lys Leu Asp
370 375 380

Lys Ser Ser Phe Val Ala Thr Asp Phe Asn Thr Glu Arg Asn Ala Thr
385 390 395 400

Gly Val Phe Glu Phe Asp Leu Lys Phe Thr Gln Thr Asp Leu Lys Met
405 410 415

Gly Tyr Ser Asn Met Thr Thr Gln Phe Gly Leu Tyr Ile His Ser Gln
420 425 430

Thr Val Lys Gly Ser Gln Glu Thr Leu Gln Leu Val Phe Asp Thr Leu
435 440 445

Ser Thr Thr Trp Tyr Ile Asp Arg Thr Thr Gln His Ser Phe Gln Arg
450 455 460

Asn Ser Pro Val Phe Thr Glu Arg Ile Ser Thr Tyr Val Glu Lys Ile
465 470 475 480

Asp Thr Thr Asp Gln Gly Asn Val Tyr Thr Leu Tyr Gly Val Val Asp
485 490 495

Arg Asn Ile Leu Glu Leu Tyr Phe Asn Asp Gly Ser Ile Ala Met Thr
500 505 510

Asn Thr Phe Phe Phe Arg Glu Gly Lys Ile Pro Thr Ser Phe Glu Val
515 520 525

Val Cys Asp Ser Glu Lys Ser Phe Ile Thr Ile Asp Glu Leu Ser Val
530 535 540

Arg Glu Leu Ala Arg Lys
545 550

<210> 23

<211> 533

<212> PRT

<213> Debaryomyces occidentalis

<400> 23

Met Val Gln Val Leu Ser Val Leu Val Ile Pro Leu Leu Thr Leu Phe
1 5 10 15

Phe Gly Tyr Val Ala Ser Ser Ser Ile Asp Leu Ser Val Asp Thr Ser
20 25 30

026172-005010PC - Sequence Listing_1.TXT

Glu Tyr Asn Arg Pro Leu Ile His Phe Thr Pro Glu Lys Gly Trp Met
 35 40 45

Asn Asp Pro Asn Gly Leu Phe Tyr Asp Lys Thr Ala Lys Leu Trp His
 50 55 60

Leu Tyr Phe Gln Tyr Asn Pro Asn Ala Thr Ala Trp Gly Gln Pro Leu
 65 70 75 80

Tyr Trp Gly His Ala Thr Ser Asn Asp Leu Val His Trp Asp Glu His
 85 90 95

Glu Ile Ala Ile Gly Pro Glu His Asp Asn Glu Gly Ile Phe Ser Gly
 100 105 110

Ser Ile Val Val Asp His Asn Asn Thr Ser Gly Phe Phe Asn Ser Ser
 115 120 125

Ile Asp Pro Asn Gln Arg Ile Val Ala Ile Tyr Thr Asn Asn Ile Pro
 130 135 140

Asp Leu Gln Thr Gln Asp Ile Ala Phe Ser Leu Asp Gly Gly Tyr Thr
 145 150 155 160

Phe Thr Lys Tyr Glu Asn Asn Pro Val Ile Asp Val Ser Ser Asn Gln
 165 170 175

Phe Arg Asp Pro Lys Val Phe Trp His Glu Arg Phe Lys Ser Met Asp
 180 185 190

His Gly Cys Ser Glu Ile Ala Arg Val Lys Ile Gln Ile Phe Gly Ser
 195 200 205

Ala Asn Leu Lys Asn Trp Val Leu Asn Ser Asn Phe Ser Ser Gly Tyr
 210 215 220

Tyr Gly Asn Gln Tyr Gly Met Ser Arg Leu Ile Glu Val Pro Ile Glu
 225 230 235 240

Asn Ser Asp Lys Ser Lys Trp Val Met Phe Leu Ala Ile Asn Pro Gly
 245 250 255

Ser Pro Leu Gly Gly Ser Ile Asn Gln Tyr Phe Val Gly Asp Phe Asp
 260 265 270

Gly Phe Gln Phe Val Pro Asp Asp Ser Gln Thr Arg Phe Val Asp Ile
 275 280 285

Gly Lys Asp Phe Tyr Ala Phe Gln Thr Phe Ser Glu Val Glu His Gly
 290 295 300

026172-005010PC - Sequence Listing_1.TXT

Val Leu Gly Leu Ala Trp Ala Ser Asn Trp Gln Tyr Ala Asp Gln Val
305 310 315 320

Pro Thr Asn Pro Trp Arg Ser Ser Thr Ser Leu Ala Arg Asn Tyr Thr
325 330 335

Leu Arg Tyr Val Ile Gln Met Leu Lys Leu Thr Ala Asn Ile Asp Lys
340 345 350

Ser Val Leu Pro Asp Ser Ile Asn Val Val Asp Lys Leu Lys Lys Lys
355 360 365

Asn Val Lys Leu Thr Asn Lys Lys Pro Ile Lys Thr Asn Phe Lys Gly
370 375 380

Ser Thr Gly Leu Phe Asp Phe Asn Ile Thr Phe Lys Val Leu Asn Leu
385 390 395 400

Asn Val Ser Pro Gly Lys Thr His Phe Asp Ile Leu Ile Asn Ser Gln
405 410 415

Glu Leu Asn Ser Ser Val Asp Ser Ile Lys Ile Gly Phe Asp Ser Ser
420 425 430

Gln Ser Leu Phe Tyr Ile Asp Arg His Ile Pro Asn Val Glu Phe Pro
435 440 445

Arg Lys Gln Phe Phe Thr Asp Lys Leu Ala Ala Tyr Leu Glu Pro Leu
450 455 460

Asp Tyr Asp Gln Asp Leu Arg Val Phe Ser Leu Tyr Gly Ile Val Asp
465 470 475 480

Lys Asn Ile Ile Glu Leu Tyr Phe Asn Asp Gly Thr Val Ala Met Thr
485 490 495

Asn Thr Phe Phe Met Gly Glu Gly Lys Tyr Pro His Asp Ile Gln Ile
500 505 510

Val Thr Asp Thr Glu Glu Pro Leu Phe Glu Leu Glu Ser Val Ile Ile
515 520 525

Arg Glu Leu Asn Lys
530

<210> 24
<211> 654
<212> PRT
<213> Oryza sativa

<400> 24
Met Ala Thr Ser Arg Leu Thr Pro Ala Tyr Asp Leu Lys Asn Ala Ala
1 5 10 15

026172-005010PC - Sequence Listing_1.TXT

Ala Ala Val Tyr Thr Pro Leu Pro Glu Gln Pro His Ser Ala Glu Val
20 25 30

Glu Ile Arg Asp Arg Lys Pro Phe Lys Ile Ile Ser Ala Ile Ile Leu
35 40 45

Ser Ser Leu Leu Leu Leu Ala Leu Ile Leu Val Ala Val Asn Tyr Gln
50 55 60

Ala Pro Pro Ser His Ser Ser Gly Asp Asn Ser Gln Pro Ala Ala Val
65 70 75 80

Met Pro Pro Ser Arg Gly Val Ser Gln Gly Val Ser Glu Lys Ala Phe
85 90 95

Arg Gly Ala Ser Gly Ala Gly Asn Gly Val Ser Phe Ala Trp Ser Asn
100 105 110

Leu Met Leu Ser Trp Gln Arg Thr Ser Tyr His Phe Gln Pro Val Lys
115 120 125

Asn Trp Met Asn Asp Pro Asn Gly Pro Leu Tyr Tyr Lys Gly Trp Tyr
130 135 140

His Leu Phe Tyr Gln Tyr Asn Pro Asp Ser Ala Val Trp Gly Asn Ile
145 150 155 160

Thr Trp Gly His Ala Val Ser Thr Asp Leu Ile Asn Trp Leu His Leu
165 170 175

Pro Phe Ala Met Val Pro Asp Gln Trp Tyr Asp Val Asn Gly Val Trp
180 185 190

Thr Gly Ser Ala Thr Ile Leu Pro Asp Gly Arg Ile Val Met Leu Tyr
195 200 205

Thr Gly Asp Thr Asp Asp Tyr Val Gln Asp Gln Asn Leu Ala Phe Pro
210 215 220

Ala Asn Leu Ser Asp Pro Leu Leu Val Asp Trp Val Lys Tyr Pro Asn
225 230 235 240

Asn Pro Val Ile Tyr Pro Pro Pro Gly Ile Gly Val Lys Asp Phe Arg
245 250 255

Asp Pro Thr Thr Ala Gly Thr Ala Gly Met Gln Asn Gly Gln Arg Leu
260 265 270

Val Thr Ile Gly Ser Lys Val Gly Lys Thr Gly Ile Ser Leu Val Tyr
275 280 285

026172-005010PC - Sequence Listing_1.TXT

Glu Thr Thr Asn Phe Thr Thr Phe Lys Leu Leu Tyr Gly Val Leu His
290 295 300

Ala Val Pro Gly Thr Gly Met Trp Glu Cys Val Asp Leu Tyr Pro Val
305 310 315 320

Ser Thr Thr Gly Glu Asn Gly Leu Asp Thr Ser Val Asn Gly Leu Gly
325 330 335

Val Lys His Val Leu Lys Thr Ser Leu Asp Asp Asp Lys His Asp Tyr
340 345 350

Tyr Ala Leu Gly Thr Tyr Asp Pro Val Lys Asn Lys Trp Thr Pro Asp
355 360 365

Asn Pro Asp Leu Asp Val Gly Ile Gly Leu Arg Leu Asp Tyr Gly Lys
370 375 380

Tyr Tyr Ala Ala Arg Thr Phe Tyr Asp Gln Asn Lys Gln Arg Arg Ile
385 390 395 400

Leu Trp Gly Trp Ile Gly Glu Thr Asp Leu Glu Ala Val Asp Leu Met
405 410 415

Lys Gly Trp Ala Ser Leu Gln Ala Ile Pro Arg Thr Ile Val Phe Asp
420 425 430

Lys Lys Thr Gly Thr Asn Val Leu Gln Arg Pro Glu Glu Glu Val Glu
435 440 445

Ser Trp Ser Ser Gly Asp Pro Ile Thr Gln Arg Arg Ile Phe Glu Pro
450 455 460

Gly Ser Val Val Pro Ile His Val Ser Gly Ala Thr Gln Leu Asp Ile
465 470 475 480

Thr Ala Ser Phe Glu Val Asp Glu Thr Leu Leu Glu Thr Thr Ser Glu
485 490 495

Ser His Asp Ala Gly Tyr Asp Cys Ser Asn Ser Gly Gly Ala Gly Thr
500 505 510

Arg Gly Ser Leu Gly Pro Phe Gly Leu Leu Val Val Ala Asp Glu Lys
515 520 525

Leu Ser Glu Leu Thr Pro Val Tyr Leu Tyr Val Ala Lys Gly Gly Asp
530 535 540

Gly Lys Ala Lys Ala His Leu Cys Ala Tyr Gln Thr Arg Ser Ser Met
545 550 555 560

026172-005010PC - Sequence Listing_1.TXT

Ala Ser Gly Val Glu Lys Glu Val Tyr Gly Ser Ala Val Pro Val Leu
565 570 575

Asp Gly Glu Asn Tyr Ser Ala Arg Ile Leu Ile Asp His Ser Ile Val
580 585 590

Glu Ser Phe Ala Gln Ala Gly Arg Thr Cys Val Arg Ser Arg Asp Tyr
595 600 605

Pro Thr Lys Asp Ile Tyr Gly Ala Ala Arg Cys Phe Phe Phe Asn Asn
610 615 620

Ala Thr Glu Ala Ser Val Arg Ala Ser Leu Lys Ala Trp Gln Met Lys
625 630 635 640

Ser Phe Ile Arg Pro Tyr Pro Phe Ile Pro Asp Gln Lys Ser
645 650

<210> 25
<211> 690
<212> PRT
<213> Allium cepa

<400> 25
Met Ser Ser Asp Asp Leu Glu Ser Pro Pro Ser Ser Tyr Leu Pro Ile
1 5 10 15

Pro Pro Ser Asp Glu Phe His Asp Gln Pro Pro Pro Leu Arg Ser Trp
20 25 30

Leu Arg Leu Leu Ser Ile Pro Leu Ala Leu Met Phe Leu Leu Phe Leu
35 40 45

Ala Thr Phe Leu Ser Asn Leu Glu Ser Pro Pro Ser Asp Ser Gly Leu
50 55 60

Val Ser Asp Pro Val Thr Phe Asp Val Asn Pro Ala Val Val Arg Arg
65 70 75 80

Gly Lys Asp Ala Gly Val Ser Asp Lys Thr Ser Gly Val Asp Ser Gly
85 90 95

Phe Val Leu Asp Pro Val Ala Val Asp Ala Asn Ser Val Val Val His
100 105 110

Arg Gly Lys Asp Ala Gly Val Ser Asp Lys Thr Ser Gly Val Asp Ser
115 120 125

Gly Leu Leu Lys Asp Ser Pro Leu Gly Pro Tyr Pro Trp Thr Asn Gln
130 135 140

026172-005010PC - Sequence Listing_1.TXT

Met Leu Ser Trp Gln Arg Thr Gly Phe His Phe Gln Pro Val Lys Asn
 145 150 155 160

Trp Met Asn Asp Pro Asn Gly Pro Leu Tyr Tyr Lys Gly Trp Tyr His
 165 170 175

Phe Phe Tyr Gln Tyr Asn Pro Glu Gly Ala Val Trp Gly Asn Ile Ala
 180 185 190

Trp Gly His Ala Val Ser Arg Asp Leu Val His Trp Thr His Leu Pro
 195 200 205

Leu Ala Met Val Pro Asp Gln Trp Tyr Asp Ile Asn Gly Val Trp Thr
 210 215 220

Gly Ser Ala Thr Ile Leu Pro Asp Gly Gln Ile Val Met Leu Tyr Thr
 225 230 235 240

Gly Ala Thr Asn Glu Ser Val Gln Val Gln Asn Leu Ala Val Pro Ala
 245 250 255

Asp Gln Ser Asp Thr Leu Leu Leu Arg Trp Lys Lys Ser Glu Ala Asn
 260 265 270

Pro Ile Leu Val Pro Pro Pro Gly Ile Gly Asp Lys Asp Phe Arg Asp
 275 280 285

Pro Thr Thr Ala Trp Tyr Glu Pro Ser Asp Asp Thr Trp Arg Ile Val
 290 295 300

Ile Gly Ser Lys Asp Ser Ser His Ser Gly Ile Ala Ile Val Tyr Ser
 305 310 315 320

Thr Lys Asp Phe Ile Asn Tyr Lys Leu Ile Pro Gly Ile Leu His Ala
 325 330 335

Val Glu Arg Val Gly Met Trp Glu Cys Val Asp Phe Tyr Pro Val Ala
 340 345 350

Thr Ala Asp Ser Ser His Ala Asn His Gly Leu Asp Pro Ser Ala Arg
 355 360 365

Pro Ser Pro Ala Val Lys His Val Leu Lys Ala Ser Met Asp Asp Asp
 370 375 380

Arg His Asp Tyr Tyr Ala Ile Gly Thr Tyr Asp Pro Ala Gln Asn Thr
 385 390 395 400

Trp Val Pro Asp Asp Ala Ser Val Asp Val Gly Ile Gly Leu Arg Tyr
 405 410 415

026172-005010PC - Sequence Listing_1.TXT

Asp Trp Gly Lys Phe Tyr Ala Ser Lys Thr Phe Tyr Asp His Ala Lys
 420 425 430

Lys Arg Arg Ile Leu Trp Ser Trp Ile Gly Glu Thr Asp Ser Glu Thr
 435 440 445

Ala Asp Ile Ala Lys Gly Trp Ala Ser Leu Gln Gly Val Pro Arg Thr
 450 455 460

Val Leu Leu Asp Val Lys Thr Gly Ser Asn Leu Ile Thr Trp Pro Val
 465 470 475 480

Val Glu Ile Glu Ser Leu Arg Thr Arg Pro Arg Asp Phe Ser Gly Ile
 485 490 495

Thr Val Asp Ala Gly Ser Thr Phe Lys Leu Asp Val Gly Gly Ala Ala
 500 505 510

Gln Leu Asp Ile Glu Ala Glu Phe Lys Ile Ser Ser Glu Glu Leu Glu
 515 520 525

Ala Val Lys Glu Ala Asp Val Ser Tyr Asn Cys Ser Ser Ser Gly Gly
 530 535 540

Ala Ala Glu Arg Gly Val Leu Gly Pro Phe Gly Leu Leu Val Leu Ala
 545 550 555 560

Asn Gln Asp Leu Thr Glu Gln Thr Ala Thr Tyr Phe Tyr Val Ser Arg
 565 570 575

Gly Met Asp Gly Gly Leu Asn Thr His Phe Cys Gln Asp Glu Lys Arg
 580 585 590

Ser Ser Lys Ala Ser Asp Ile Val Lys Arg Ile Val Gly His Ser Val
 595 600 605

Pro Val Leu Asp Gly Glu Ser Phe Ala Leu Arg Ile Leu Val Asp His
 610 615 620

Ser Ile Val Glu Ser Phe Ala Gln Gly Gly Arg Ala Ser Ala Thr Ser
 625 630 635 640

Arg Val Tyr Pro Thr Glu Ala Ile Tyr Asn Asn Ala Arg Val Phe Val
 645 650 655

Phe Asn Asn Ala Thr Gly Ala Lys Val Thr Ala Gln Ser Leu Lys Val
 660 665 670

Trp His Met Ser Thr Ala Ile Asn Glu Ile Tyr Asp Pro Ala Thr Ser
 675 680 685

Val Met
690

<210> 26
<211> 501
<212> PRT
<213> Beta vulgaris

<220>
<221> MOD_RES
<222> (382)..(382)
<223> Any amino acid

<400> 26
Leu Phe Tyr Gln Tyr Asn Pro Asn Gly Val Ile Trp Gly Pro Pro Val
1 5 10 15

Trp Gly His Ser Thr Ser Lys Asp Leu Val Asn Trp Val Pro Gln Pro
20 25 30

Leu Thr Met Glu Pro Glu Met Ala Ala Asn Ile Asn Gly Ser Trp Ser
35 40 45

Gly Ser Ala Thr Ile Leu Pro Gly Asn Lys Pro Ala Ile Leu Phe Thr
50 55 60

Gly Leu Asp Pro Lys Tyr Glu Gln Val Gln Val Leu Ala Tyr Pro Lys
65 70 75 80

Asp Thr Ser Asp Pro Asn Leu Lys Glu Trp Phe Leu Ala Pro Gln Asn
85 90 95

Pro Val Met Phe Pro Thr Pro Gln Asn Gln Ile Asn Ala Thr Ser Phe
100 105 110

Arg Asp Pro Thr Thr Ala Trp Arg Leu Pro Asp Gly Val Trp Arg Leu
115 120 125

Leu Ile Gly Ser Lys Arg Gly Gln Arg Gly Leu Ser Leu Leu Phe Arg
130 135 140

Ser Arg Asp Phe Val His Trp Val Gln Ala Lys His Pro Leu Tyr Ser
145 150 155 160

Asp Lys Leu Ser Gly Met Trp Glu Cys Pro Asp Phe Phe Pro Val Tyr
165 170 175

Ala Asn Gly Asp Gln Met Gly Val Asp Thr Ser Ile Ile Gly Ser His
180 185 190

Val Lys His Val Leu Lys Asn Ser Leu Asp Ile Thr Lys His Asp Ile
195 200 205

026172-005010PC - Sequence Listing_1.TXT

Tyr Thr Ile Gly Asp Tyr Asn Ile Lys Lys Asp Ala Tyr Thr Pro Asp
 210 215 220
 Ile Gly Tyr Met Asn Asp Ser Ser Leu Arg Tyr Asp Tyr Gly Lys Tyr
 225 230 235 240
 Tyr Ala Ser Lys Thr Phe Phe Asp Asp Ala Lys Lys Glu Arg Ile Leu
 245 250 255
 Leu Gly Trp Ala Asn Glu Ser Ser Ser Val Glu Asp Asp Ile Lys Lys
 260 265 270
 Gly Trp Ser Gly Ile His Thr Ile Pro Arg Lys Ile Trp Leu Asp Lys
 275 280 285
 Leu Gly Lys Gln Leu Ile Gln Trp Pro Ile Ala Asn Ile Glu Lys Leu
 290 295 300
 Arg Gln Lys Pro Val Asn Ile Tyr Arg Lys Val Leu Lys Gly Gly Ser
 305 310 315 320
 Gln Ile Glu Val Ser Gly Ile Thr Ala Ala Gln Ala Asp Val Glu Ile
 325 330 335
 Ser Phe Lys Ile Lys Asp Leu Lys Asn Val Glu Lys Phe Asp Ala Ser
 340 345 350
 Trp Thr Ser Pro Gln Leu Leu Cys Ser Lys Lys Gly Ala Ser Val Lys
 355 360 365
 Gly Gly Leu Gly Pro Phe Gly Leu Leu Thr Leu Ala Ser Xaa Gly Leu
 370 375 380
 Glu Glu Tyr Thr Ala Val Phe Phe Arg Ile Phe Lys Ala Tyr Asp Asn
 385 390 395 400
 Lys Phe Val Val Leu Met Cys Ser Asp Gln Ser Arg Ser Ser Leu Asn
 405 410 415
 Pro Thr Asn Asp Lys Thr Thr Tyr Gly Thr Phe Val Asp Val Asn Pro
 420 425 430
 Ile Arg Glu Gly Leu Ser Leu Arg Val Leu Ile Asp His Ser Val Val
 435 440 445
 Glu Ser Phe Gly Ala Lys Gly Lys Asn Val Ile Thr Ala Arg Val Tyr
 450 455 460
 Pro Thr Leu Ala Ile Asn Glu Lys Ala His Leu Tyr Val Phe Asn Arg
 465 470 475 480

026172-005010PC - Sequence Listing_1.TXT

Gly Thr Ser Asn Val Glu Ile Thr Gly Leu Thr Ala Trp Ser Met Lys
485 490 495

Lys Ala Asn Ile Ala
500

<210> 27
<211> 518
<212> PRT
<213> Bifidobacterium breve

<400> 27
Met Thr Asp Phe Thr Pro Glu Thr Pro Val Leu Thr Pro Ile Arg Asp
1 5 10 15

His Ala Ala Glu Leu Ala Lys Ala Glu Ala Gly Val Ala Glu Met Ala
20 25 30

Ala Lys Arg Asn Asn Arg Trp Tyr Pro Lys Tyr His Ile Ala Ser Asn
35 40 45

Gly Gly Trp Ile Asn Asp Pro Asn Gly Leu Cys Phe Tyr Lys Gly Arg
50 55 60

Trp His Val Phe Tyr Gln Leu His Pro Tyr Gly Thr Gln Trp Gly Pro
65 70 75 80

Met His Trp Gly His Val Ser Ser Thr Asp Met Leu Asn Trp Lys Arg
85 90 95

Glu Pro Ile Met Phe Ala Pro Ser Leu Glu Gln Glu Lys Asp Gly Val
100 105 110

Phe Ser Gly Ser Ala Val Ile Asp Asp Asn Gly Asp Leu Arg Phe Tyr
115 120 125

Tyr Thr Gly His Arg Trp Ala Asn Gly His Asp Asn Thr Gly Gly Asp
130 135 140

Trp Gln Val Gln Met Thr Ala Leu Pro Asp Asn Asp Glu Leu Thr Ser
145 150 155 160

Ala Thr Lys Gln Gly Met Ile Ile Asp Cys Pro Thr Asp Lys Val Asp
165 170 175

His His Tyr Arg Asp Pro Lys Val Trp Lys Thr Gly Asp Thr Trp Tyr
180 185 190

Met Thr Phe Gly Val Ser Ser Glu Asp Lys Arg Gly Gln Met Trp Leu
195 200 205

Phe Ser Ser Lys Asp Met Val Arg Trp Glu Tyr Glu Arg Val Leu Phe
210 215 220

026172-005010PC - Sequence Listing_1.TXT

Gln His Pro Asp Pro Asp Val Phe Met Leu Glu Cys Pro Asp Phe Phe
 225 230 235 240

Pro Ile Lys Asp Lys Asp Gly Asn Glu Lys Trp Val Ile Gly Phe Ser
 245 250 255

Ala Met Gly Ser Lys Pro Ser Gly Phe Met Asn Arg Asn Val Asn Asn
 260 265 270

Ala Gly Tyr Met Ile Gly Thr Trp Glu Pro Gly Gly Glu Phe Lys Pro
 275 280 285

Glu Thr Glu Phe Arg Leu Trp Asp Cys Gly His Asn Tyr Tyr Ala Pro
 290 295 300

Gln Ser Phe Asn Val Asp Gly Arg Gln Ile Val Tyr Gly Trp Met Ser
 305 310 315 320

Pro Phe Val Gln Pro Ile Pro Met Glu Asp Asp Gly Trp Cys Gly Gln
 325 330 335

Leu Thr Leu Pro Arg Glu Ile Thr Leu Asp Asp Asp Gly Asp Val Val
 340 345 350

Thr Ala Pro Val Ala Glu Met Glu Gly Leu Arg Glu Asp Thr Leu Asp
 355 360 365

His Gly Ser Ile Thr Leu Asp Met Asp Gly Glu Gln Val Ile Ala Asp
 370 375 380

Asp Ala Glu Ala Val Glu Ile Glu Met Thr Ile Asp Leu Ala Ala Ser
 385 390 395 400

Thr Ala Asp Arg Ala Gly Leu Lys Ile His Ala Thr Glu Asp Gly Ala
 405 410 415

Tyr Thr Tyr Val Ala Tyr Asp Asp Gln Ile Gly Arg Val Val Val Asp
 420 425 430

Arg Gln Ala Met Ala Asn Gly Asp His Gly Tyr Arg Ala Ala Pro Leu
 435 440 445

Thr Asp Ala Glu Leu Ala Ser Gly Lys Leu Asp Leu Arg Val Phe Val
 450 455 460

Asp Arg Gly Ser Val Glu Val Tyr Val Asn Gly Gly His Gln Val Leu
 465 470 475 480

Ser Ser Tyr Ser Tyr Ala Ser Glu Gly Pro Arg Ala Ile Lys Leu Val
 485 490 495

026172-005010PC - Sequence Listing_1.TXT

Ala Glu Phe Gly Asn Leu Lys Val Glu Ser Leu Lys Leu His His Met
500 505 510

Lys Ser Ile Gly Leu Glu
515

<210> 28

<211> 532

<212> PRT

<213> Saccharomyces cerevisiae

<400> 28

Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
1 5 10 15

Ile Ser Ala Ser Met Thr Asn Glu Thr Ser Asp Arg Pro Leu Val His
20 25 30

Phe Thr Pro Asn Lys Gly Trp Met Asn Asp Pro Asn Gly Leu Trp Tyr
35 40 45

Asp Glu Lys Asp Ala Lys Trp His Leu Tyr Phe Gln Tyr Asn Pro Asn
50 55 60

Asp Thr Val Trp Gly Thr Pro Leu Phe Trp Gly His Ala Thr Ser Asp
65 70 75 80

Asp Leu Thr Asn Trp Glu Asp Gln Pro Ile Ala Ile Ala Pro Lys Arg
85 90 95

Asn Asp Ser Gly Ala Phe Ser Gly Ser Met Val Val Asp Tyr Asn Asn
100 105 110

Thr Ser Gly Phe Phe Asn Asp Thr Ile Asp Pro Arg Gln Arg Cys Val
115 120 125

Ala Ile Trp Thr Tyr Asn Thr Pro Glu Ser Glu Glu Gln Tyr Ile Ser
130 135 140

Tyr Ser Leu Asp Gly Gly Tyr Thr Phe Thr Glu Tyr Gln Lys Asn Pro
145 150 155 160

Val Leu Ala Ala Asn Ser Thr Gln Phe Arg Asp Pro Lys Val Phe Trp
165 170 175

Tyr Glu Pro Ser Gln Lys Trp Ile Met Thr Ala Ala Lys Ser Gln Asp
180 185 190

Tyr Lys Ile Glu Ile Tyr Ser Ser Asp Asp Leu Lys Ser Trp Lys Leu
195 200 205

026172-005010PC - Sequence Listing_1.TXT

Glu Ser Ala Phe Ala Asn Glu Gly Phe Leu Gly Tyr Gln Tyr Glu Cys
 210 215 220

Pro Gly Leu Ile Glu Val Pro Thr Glu Gln Asp Pro Ser Lys Ser Tyr
 225 230 235 240

Trp Val Met Phe Ile Ser Ile Asn Pro Gly Ala Pro Ala Gly Gly Ser
 245 250 255

Phe Asn Gln Tyr Phe Val Gly Ser Phe Asn Gly Thr His Phe Glu Ala
 260 265 270

Phe Asp Asn Gln Ser Arg Val Val Asp Phe Gly Lys Asp Tyr Tyr Ala
 275 280 285

Leu Gln Thr Phe Phe Asn Thr Asp Pro Thr Tyr Gly Ser Ala Leu Gly
 290 295 300

Ile Ala Trp Ala Ser Asn Trp Glu Tyr Ser Ala Phe Val Pro Thr Asn
 305 310 315 320

Pro Trp Arg Ser Ser Met Ser Leu Val Arg Lys Phe Ser Leu Asn Thr
 325 330 335

Glu Tyr Gln Ala Asn Pro Glu Thr Glu Leu Ile Asn Leu Lys Ala Glu
 340 345 350

Pro Ile Leu Asn Ile Ser Asn Ala Gly Pro Trp Ser Arg Phe Ala Thr
 355 360 365

Asn Thr Thr Leu Thr Lys Ala Asn Ser Tyr Asn Val Asp Leu Ser Asn
 370 375 380

Ser Thr Gly Thr Leu Glu Phe Glu Leu Val Tyr Ala Val Asn Thr Thr
 385 390 395 400

Gln Thr Ile Ser Lys Ser Val Phe Ala Asp Leu Ser Leu Trp Phe Lys
 405 410 415

Gly Leu Glu Asp Pro Glu Glu Tyr Leu Arg Met Gly Phe Glu Val Ser
 420 425 430

Ala Ser Ser Phe Phe Leu Asp Arg Gly Asn Ser Lys Val Lys Phe Val
 435 440 445

Lys Glu Asn Pro Tyr Phe Thr Asn Arg Met Ser Val Asn Asn Gln Pro
 450 455 460

Phe Lys Ser Glu Asn Asp Leu Ser Tyr Tyr Lys Val Tyr Gly Leu Leu
 465 470 475 480

026172-005010PC - Sequence Listing_1.TXT

Asp Gln Asn Ile Leu Glu Leu Tyr Phe Asn Asp Gly Asp Val Val Ser
485 490 495

Thr Asn Thr Tyr Phe Met Thr Thr Gly Asn Ala Leu Gly Ser Val Asn
500 505 510

Met Thr Thr Gly Val Asp Asn Leu Phe Tyr Ile Asp Lys Phe Gln Val
515 520 525

Arg Glu Val Lys
530

<210> 29

<211> 512

<212> PRT

<213> *Zymomonas mobilis*

<400> 29

Met Glu Ser Pro Ser Tyr Lys Asn Leu Ile Lys Ala Glu Asp Ala Gln
1 5 10 15

Lys Lys Ala Gly Lys Arg Leu Leu Ser Ser Glu Trp Tyr Pro Gly Phe
20 25 30

His Val Thr Pro Leu Thr Gly Trp Met Asn Asp Pro Asn Gly Leu Ile
35 40 45

Phe Phe Lys Gly Glu Tyr His Leu Phe Tyr Gln Tyr Tyr Pro Phe Ala
50 55 60

Pro Val Trp Gly Pro Met His Trp Gly His Ala Lys Ser Arg Asp Leu
65 70 75 80

Val His Trp Glu Thr Leu Pro Val Ala Leu Ala Pro Gly Asp Leu Phe
85 90 95

Asp Arg Asp Gly Cys Phe Ser Gly Cys Ala Val Asp Asn Asn Gly Val
100 105 110

Leu Thr Leu Ile Tyr Thr Gly His Ile Val Leu Ser Asn Asp Ser Pro
115 120 125

Asp Ala Ile Arg Glu Val Gln Cys Met Ala Thr Ser Ile Asp Gly Ile
130 135 140

His Phe Gln Lys Glu Gly Ile Val Leu Glu Lys Ala Pro Met Pro Gln
145 150 155 160

Val Ala His Phe Arg Asp Pro Arg Val Trp Lys Glu Asn Asp His Trp
165 170 175

Phe Met Val Val Gly Tyr Arg Thr Asp Asp Glu Lys His Gln Gly Ile
180 185 190

026172-005010PC - Sequence Listing_1.TXT

Gly His Val Ala Leu Tyr Arg Ser Glu Asn Leu Lys Asp Trp Ile Phe
195 200 205

Val Lys Thr Leu Leu Gly Asp Asn Ser Gln Leu Pro Leu Gly Lys Arg
210 215 220

Ala Phe Met Trp Glu Cys Pro Asp Phe Phe Ser Leu Gly Asn Arg Ser
225 230 235 240

Val Leu Met Phe Ser Pro Gln Gly Leu Lys Ala Ser Gly Tyr Lys Asn
245 250 255

Arg Asn Leu Phe Gln Asn Gly Tyr Ile Leu Gly Lys Trp Gln Ala Pro
260 265 270

Gln Phe Thr Pro Glu Thr Ser Phe Gln Glu Leu Asp Tyr Gly His Asp
275 280 285

Phe Tyr Ala Ala Gln Arg Phe Glu Ala Lys Asp Gly Arg Gln Ile Leu
290 295 300

Ile Ala Trp Phe Asp Met Trp Glu Asn Gln Lys Pro Ser Gln Arg Asp
305 310 315 320

Gly Trp Ala Gly Cys Met Thr Leu Pro Arg Lys Leu Asp Leu Ile Asp
325 330 335

Asn Lys Ile Val Met Thr Pro Val Arg Glu Met Glu Ile Leu Arg Gln
340 345 350

Ser Glu Lys Ile Glu Ser Val Val Thr Leu Ser Asp Ala Glu His Pro
355 360 365

Phe Thr Met Asp Ser Pro Leu Gln Glu Ile Glu Leu Ile Phe Asp Leu
370 375 380

Glu Lys Ser Ser Ala Tyr Gln Ala Gly Leu Ala Leu Arg Cys Asn Gly
385 390 395 400

Lys Gly Gln Glu Thr Leu Leu Tyr Ile Asp Arg Ser Gln Asn Arg Ile
405 410 415

Ile Leu Asp Arg Asn Arg Ser Gly Gln Asn Val Lys Gly Ile Arg Ser
420 425 430

Cys Pro Leu Pro Asn Thr Ser Lys Val Arg Leu His Ile Phe Leu Asp
435 440 445

Arg Ser Ser Ile Glu Ile Phe Val Gly Asp Asp Gln Thr Gln Gly Leu
450 455 460

026172-005010PC - Sequence Listing_1.TXT

Tyr Ser Ile Ser Ser Arg Ile Phe Pro Asp Lys Asp Ser Leu Lys Gly
465 470 475 480

Arg Leu Phe Ala Ile Glu Gly Tyr Ala Val Phe Asp Ser Phe Lys Arg
485 490 495

Trp Thr Leu Gln Asp Ala Asn Leu Ala Ala Phe Ser Ser Asp Ala Cys
500 505 510

<210> 30

<211> 987

<212> DNA

<213> *Chlorella luteoviridis*

<400> 30

tggtgaagaa tgagccggcg acttatagga agtggcttgg ttaaggatac tttccgaagc	60
ctaagcgaaa gcaagttgta acaatagcga tatacctctt tgtaggtcag tcacttctta	120
tggacccgaa cccgggtgat ctaaccatga ccaggatgaa gcttgggtaa caccaagtga	180
aggtccgaac tcttcgatct ttaaaaatcg tgagatgagt tatgggtagg ggtaaactctg	240
gcagttttgc cccgcaaaag ggtaaccttt tgtaattact gactcataac ggtgaagcct	300
aaggcgtag ctatggtaat accgtgggaa gtttcaatac cttcttgcatt attttttatt	360
tgcaccttta gtgcaaacag tgtaaagaaa gcgttttgaa accccttaac gactaatttt	420
ttgcttttgc aagaacgtca gcactcacca atacactttc cgtttttttc ttttattaat	480
taaagcaaca taaaaatata ttttatagct ttaatcataa aactatgtta gcacttcgtg	540
ctaattgtgct aatgtgctaa tcaaatgaaa agtggttctta aaagtgtggt gaaggtagag	600
tctaattcttg cctgaaaggg caagctgcac attttttttt gaatgtgcaa caatggaaat	660
gccaatcgaa ctcgagagcta gctggttctc cccgaaatgt gttgaggcgc agcgattcat	720
gattagtacg gtgtaggggt aaagcactgt ttcggtgcgg gctgtgaaaa cggtagcaaa	780
tcgtggcaaa ctaagaatac tacgcttgta taccatggat cagtgtgact atgggggata	840
agctccatag tcaagagggg aacagcccag atcaccagtt aaggcccaaa aatgacagct	900
aagtggcaaa ggaggtgaaa gtgcagaaac aaccaggagg ttgcccaga agcagccatc	960
ctttaagag tgcgtaatag ctactg	987

<210> 31

<211> 1412

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 31

gaattcgagt ttaggtccag cgtccgtggg gggggacggg ctgggagctt gggccgggaa	60
gggcaagacg atgcagtccc tctggggagt cacagccgac tgtgtgtgtt gcactgtgcg	120

026172-005010PC - Sequence Listing_1.TXT

gccccgagca ctcacacgca aaatgcctgg ccgacaggca ggccctgtcc agtgcaacat	180
ccacgggtccc tctcatcagg ctcaccttgc tcattgacat aacggaatgc gtaccgctct	240
ttcagatctg tccatccaga gaggggagca ggctccccac cgacgctgtc aaacttgctt	300
cctgcccac cgaaaacatt attgtttgag gggggggggg gggggggcaga ttgcatggcg	360
ggatatctcg tgaggaacat cactgggaca ctgtggaaca cagtgagtgc agtatgcaga	420
gcatgtatgc taggggtcag cgcaggaagg gggcctttcc cagtctccca tgccactgca	480
ccgtatccac gactcaccag gaccagcttc ttgatcggct tccgctcccg tggacaccag	540
tgtgtagcct ctggactcca ggtatgcgtg caccgcaaag gccagccgat cgtgccgatt	600
cctgggggtgg aggatatgag tcagccaact tggggctcag agtgcacact ggggcacgat	660
acgaaacaac atctacaccg tgtcctccat gctgacacac cacagcttcg ctccacctga	720
atgtggggcg atggggccga atcacagcca atgtcgtgc tgccataatg tgatccagac	780
cctctccgcc cagatgccga gcggtcgtg ggcgtgaat agattcctgt ttcgatcact	840
gtttgggtcc tttccttttc gtctcggatg cgcgtctcga aacaggctgc gtcgggcttt	900
cggatccctt ttgctccctc cgtcaccatc ctgcgcgcgg gcaagttgct tgaccctggg	960
ctggtaccag ggttgaggag tattaccgcg tcaggccatt ccagcccgg attcaattca	1020
aagtctgggc caccaccctc cgccgctctg tctgatcact ccacattcgt gcatacacta	1080
cgttcaagtc ctgatccagg cgtgtctcgg gacaagggtg gcttgagttt gaatctcaag	1140
gaccactcc agcacagctg ctggttgacc ccgccctgc aactccctac catgtctgct	1200
ggtaggtcca gggatctttg ccatgcacac aggaccccg ttgtgggggt ccccggtgca	1260
tgctgtcgt gtgcaggcgc cgggtgtggg cctgggcccc gcgggagctc aactcctccc	1320
catatgcctg ccgtccctcc caccaccgc gacctggccc cttttgcaga ggaaggcgaa	1380
gtcagcgcca tcgtgtgcga taatggatcc gg	1412

<210> 32

<211> 1627

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 32

gaattcgcgc ttgagtttag gtccagcgtc cgtggggggg gcgtgagact cccccctgac	60
cttcgtatgg cagggactcc tacttgccaa gtaatcagtt gacaatgcc cttcaatgct	120
cgttggtgta cactgacgcg ggtctaacat actgggaagc atgaattgcc gacatggact	180
cagttggaga cagtaacagc tctttgtgtt ctatcttcag gaacacattt ggcagcgcac	240
ccatacagtg gcgcacacgc agctgtacct gatgtggctc tattcccaca tgtttcaact	300
tgatccaaaa gtcactcaga ctctcagcag ctagacttga tcgcatcttt ggccatgaag	360

026172-005010PC - Sequence Listing_1.TXT

atgcttgatgcg aactctagga atgggacgag aaaagagcct gctctgatcg gatatttcca	420
ttctctggat gggactgaga tgattctgaa gaaatgctgc tcgacttatt tggaagaaca	480
gcacctgacg catgctttga ggctgctgtg gctgggatgt gctgtatttg tcagcattga	540
gcatctacgg gtagatggcc ataaccacgc gctgcctatc atgcggtggg ttgtgtggaa	600
aacgtacaat ggacagaaat caatcccatt gcgagcctag cgtgcagcca tgcgctccct	660
ctgtagcccc gctccaagac aaagccagcc aatgccagaa cccacataga gagggatatct	720
tcctaatagac ctgcgccatc atttctcca aattaactat aatgccttga ttgtggagtt	780
ggctttggct tgcagctgct cgcgctggca cttttgtagg cagcacaggg tatgccagcg	840
ccgaactttg tgcccttgag caggccacaa gggcacaaga ctacaccatg cagctggtat	900
acttggaaact gataccattc ttaccaagca aggacagca cagcctgcac cgactcactt	960
tgcttgagcg gggcacagcg ccgcgactga tcctgcgagc tgtggggagt tccgactgtt	1020
ctggacctcg gtctctgaaa gatgtgtacg atgggatcaa gtcattcaag tatgtcttc	1080
acatgagcaa tcgggggaga cacggtggcc ctaaagggtg tcatctgatt caagtgtagt	1140
ggggggggtgc tgtttgtccc ggggcgcccc ccgctccccg accccggaga agggccccag	1200
aggactcggc cgccacaga ggaataaccg ggcgtggctc ggccctgcgc ctccctcttt	1260
caatatttca cctggtgttc agtgcacgga cacgtaaaga actagataca atggccgagg	1320
gaaagacggt gagagcttgg cgttggtgga ccgggcagca tcagaaactc ctcttccccg	1380
cccgccttga aactcactgt aactccctcc tcttccccct cgcagcatct gtctatcgtt	1440
atcgtgagtg aaagggactg ccatgtgtcg ggctggtgac cacggctcggc tcgggcgctg	1500
ctgcccgcgt cgccaacgtt ccctgcaaac gccgcgcagc cgtccctttt tctgccgccg	1560
ccccaccccc tcgctcccc cttcaatcac accgcagtgc ggacatgtcg attccggcaa	1620
gtccacc	1627

<210> 33

<211> 570

<212> DNA

<213> Chlorella protothecoides

<400> 33

gaattccctg caggaagaag gccggcagca gctggtactt gtccttcacc tccttgatcg	60
gctgggtgag cttggccggg tcgcagtcgt cgatgccggc atcgcccagc acgctgtgcg	120
gggagccggc atcgacaacc ttggcactgc tcaccttggc caccggcatg gggcatggc	180
gctgcagacc agcggcctgt cagcatgctg caggcatctg tgttttgtag tagatacttt	240
ctgatgcac accacacgtt tggaagggtc ccaagcccct tcaacagtct cgacatatga	300
cactcgcgcc ctcttcctcg tcccgtggcc tgatgagggt acgcaggtac cgcagctgcg	360
ccccgtccc ccagttgccc tggccccgcc gggccaatc tgttcattgc cgctccctgg	420
cagccgtgaa cttcacacta ccgctctctg tgaccttcag cacagcagga atcgccattt	480
caccggcggc cgttgctgcg gagcctcagc tgatctcgcc tgcgagaccc cacagtttga	540

atttgcggtc cccacacaac ctctgacgcc 570

<210> 34
 <211> 568
 <212> DNA
 <213> Chlorella protothecoides

<220>
 <221> modified_base
 <222> (133)..(133)
 <223> a, c, t, g, unknown or other

<400> 34
 gaattccctc aggaagaagg ccggcagcag ctggtacttg tccttcacct ccttgatcgg 60
 ctgggtgagc ttcgcaggat cgcagtcgtc gatgccggca tcgcccagca cgctgtgcgg 120
 ggagccggca tcnacaacct tggcactgct ccccttgggtc accggcatgg ggtcatggcg 180
 ctgcagccca gcggcctgtc agcatgctgc aggcattctgt gtattgtagt aggtacttcc 240
 tgatgcatca acacacgttt ggaagctccc caagcccctt caacagtctc gacgtatgac 300
 actcgcgccc tcttcctcgc cccgtggcct gatgagggta cgcaggtacc acagctgcgc 360
 cccgtcccgc cagttgccct ggcccggccg ggcccaatct gttcattgcc gctccctggc 420
 agccgtgaac tcacattacc gctctctgtg accttcagca cagcaggaat cgccatttca 480
 ccggcggtcg ttgctgcgga gcctcagctg atctcgcctg cgagacccca cagtttgaat 540
 ttgcggtccc cacacaacct ctgacgcc 568

<210> 35
 <211> 50
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 35
 tgacctaggt gattaattaa ctcgaggcag cagcagctcg gatagtatcg 50

<210> 36
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 36
 ctacgagctc aagctttcca tttgtgttcc catcccacta ctcc 45

<210> 37
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 37

gatcagaatt ccgcctgcaa cgcaagggca gc

32

<210> 38

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 38

gcatactagt ggcgggacgg agagagggcg

30

<210> 39

<211> 1568

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 39

gaattccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	60
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	120
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	180
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	240
cacaggccac tcgagcttgt gatcgactc cgctaagggg ggcctcttc ctcttcgttt	300
cagtcacaac ccgcaaacgg cgcgccatat caatgattga acaagatgga ttgcacgcag	360
gttctccggc cgcttgggtg gagaggctat tcggctatga ctgggcacaa cagacaatcg	420
gctgctctga tgccgccgtg ttccggctgt cagcgcaggg gcgcccgggt ctttttgtca	480
agaccgacct gtccgggtgcc ctgaatgaac tgcaggacga ggcagcgcg ctatcgtggc	540
tggccacgac gggcgttcct tgcgcagctg tgctcgacgt tgtcactgaa gcgggaaggg	600
actggctgct attgggcgaa gtgccggggc aggatctcct gtcactcac cttgctcctg	660
ccgagaaagt atccatcatg gctgatgcaa tgcggcggct gcatacgctt gatccggcta	720
cctgcccatt cgaccaccaa gcgaaacatc gcatcgagcg agcacgtact cggatggaag	780
ccggtcttgt cgatcaggat gatctggacg aagagcatca ggggctcgcg ccagccgaac	840
tgttcgccag gctcaaggcg cgcattgccg acggcgagga tctcgtcgtg acccatggcg	900
atgcctgctt gccgaatatc atggtggaaa atggccgctt ttctggattc atcgactgtg	960
gccggctggg tgtggcggac cgctatcagg acatagcgtt ggctaccctg gatattgctg	1020
aagagcttgg cggcgaatgg gctgaccgct tcctcgtgct ttacggtatc gccgctcccg	1080
attcgcagcg catcgcttc tatcgcttc ttgacgagtt cttctaagat ctgtcgatcg	1140

026172-005010PC - Sequence Listing_1.TXT

acaagtgact cgaggcagca gcagctcgga tagtatcgac acactctgga cgctgggtcgt	1200
gtgatggact gttgccgcca cacttgctgc cttgacctgt gaatatccct gccgctttta	1260
tcaaacagcc tcagtgtgtt tgatcttgtg tgtacgcgct tttgcgagtt gctagctgct	1320
tgtgctatatt gcgaataacca ccccagcat ccccttcctt cgtttcatat cgcttgcatc	1380
ccaaccgcaa cttatctacg ctgtcctgct atccctcagc gctgctcctg ctcctgctca	1440
ctgcccctcg cacagccttg gtttgggctc cgctgtatt ctcctggtag tgcaacctgt	1500
aaaccagcac tgcaatgctg atgcacggga agtagtggga tgggaacaca aatggaaagc	1560
ttgagctc	1568

<210> 40

<211> 2571

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<221> modified_base

<222> (997)..(999)

<223> a, c, t, g, unknown or other

<400> 40

gaattccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgctgccgc atgcttgctg tggtagggct gggcagtgct	120
gccatgctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgcat	180
gccgggcaat gcgcatgggt gcaagagggc ggcagcactt gctggacgtg ccgcggtgcc	240
tccagggtgg tcaatcgcgg cagccagagg gatttcagat gatcgcgct acaggttgag	300
cagcagtgct agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcatgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaactaac catagctgat caaactgca atcatcggcg gctgatgcaa	540
gcctcctgca agacacatgc tgtgcgatgc tgcgctgctg cctgctgcgc acgccgttga	600
gttggcagca gctcagccat gcactggatc aggctgggct gccactgcaa tgtggtggat	660
aggatgcaag tggagcgaat accaaaccct ctggctgctt gctgggttgc atggcatcgc	720
accatcagca ggagcgcgtg cgaagggact ggcccatgc acgccatgcc aaaccggagc	780
gcaccgagtg tccacactgt caccaggccc gcaagctttg cagaaccatg ctcattggacg	840
catgtagcgc tgacgtccct tgacggcgct cctctcgggt gtgggaaacg caatgcagca	900
caggcagcag aggcggcggc agcagagcgg cggcagcagc ggccggggcc acccttcttg	960
cggggctcgc cccagccag cggtagtgcg ctgatcnnc caaacgagtt cacattcatt	1020

026172-005010PC - Sequence Listing_1.TXT

tcgagcctgg agaagcgagg ctggggcctt tgggctggtg cagcccgcaa tggaatgcgg	1080
gaccgccagg ctagcagcaa aggcgcctcc cctactccgc atcgatgttc catagtgcac	1140
tggactgcat ttgggtgggg cgcccggtg tttctttcgt gttgcaaaac gcgccacgtc	1200
agcaacctgt cccgtgggtc ccccgtgccg atgaaatcgt gtgcacgccg atcagctgat	1260
tgcccggctc gcgaagtagg cgccctcttt ctgctcgccc tctctccgtc ccgccactag	1320
tggcgcgcca tatcaatgat tgaacaagat ggattgcacg caggttctcc ggccgcttgg	1380
gtggagagggc tattcggcta tgactgggca caacagacaa tcggctgctc tgatgccgcc	1440
gtgttcgggc tgtcagcgca gggcgccccg gttctttttg tcaagaccga cctgtccggt	1500
gccctgaatg aactgcagga cgaggcagcg cggctatcgt ggctggccac gacgggcgtt	1560
ccttgcgag ctgtgctcga cgttgtcact gaagcgggaa gggactggct gctattgggc	1620
gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa agtatccatc	1680
atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgcc attcgaccac	1740
caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct tgtcgatcag	1800
gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc caggctcaag	1860
gcgcgcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg cttgccgaat	1920
atcatggtgg aaaatggccg cttttctgga ttcacgact gtggccggct ggggtgtggc	1980
gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct tggcggcgaa	2040
tgggctgacc gcttcctcgt gctttacggc atcgccgctc ccgattcgca gcgcatcgcc	2100
ttctatcgcc ttcttgacga gttctttctaa gatctgtcga tcgacaagt actcgaggca	2160
gcagcagctc ggatagtatc gacacactct ggacgctggc cgtgtgatgg actgttgccg	2220
ccacacttgc tgccttgacc tgtgaatatc cctgccgctt ttatcaaaca gcctcagtgt	2280
gtttgatctt gtgtgtacgc gcttttgca gttgctagct gcttgtgcta tttgcgaata	2340
ccacccccag catccccctt cctcgtttca tatcgcttgc atcccaaccg caacttatct	2400
acgctgtcct gctatccctc agcgtgctc ctgctcctgc tcaactgccc tcgcacagcc	2460
ttggtttggg ctccgcctgt attctcctgg tactgcaacc tgtaaaccag cactgcaatg	2520
ctgatgcacg ggaagtagtg ggatgggaac acaaatggaa agcttgagct c	2571

<210> 41

<211> 2550

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<221> modified_base

<222> (997)..(999)

<223> a, c, t, g, unknown or other

026172-005010PC - Sequence Listing_1.TXT

<400> 41

gaattccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgcctgccgc atgcttgtgc tggtagaggct gggcagtgt	120
gccatgctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgc	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggacgtg ccgcggtgcc	240
tccagggtgg tcaatcgcg gaggcagagg gatttcagat gatcgcgct acagggtgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaactaac catagctgat caacactgca atcatcggcg gctgatgcaa	540
gcattctgca agacacatgc tgtgcgatgc tgcgctgctg cctgctgcgc acgccgttga	600
gttggcagca gctcagccat gcactggatc aggctgggct gccactgcaa tgtggtggat	660
aggatgcaag tggagcgaat accaaaccct ctggctgctt gctgggttgc atggcatcgc	720
accatcagca ggagcgcatg cgaagggact ggccccatgc acgccatgcc aaaccggagc	780
gcaccgagtg tccacactgt caccaggccc gcaagctttg cagaaccatg ctcatggacg	840
catgtagcgc tgacgtccct tgacggcgct cctctcgggt gtgggaaacg caatgcagca	900
caggcagcag aggcggcggc agcagagcgg cggcagcagc ggcggggggc acccttcttg	960
cggggtcgcg cccagccag cggatgatgc ctgacnnnc caaacgagtt cacattcatt	1020
tgcagcctgg agaagcgagg ctggggcctt tgggtggtg cagcccgaat tggaatgcgg	1080
gaccgccagg ctagcagcaa aggcgcctcc cctactccgc atcgatgttc catagtgc	1140
tggactgcat ttgggtgggg cggccggctg tttctttcgt gttgcaaac gcgccacgtc	1200
agcaacctgt cccgtgggtc ccccgctgcc atgaaatcgt gtgcacgccg atcagctgat	1260
tgcccggtc gcgaagtagg cgccctctt ctgctcgc tctctccgtc ccgccactag	1320
tggcgcgcca tatcaatgat cgagcaggac ggcctccacg ccggtcccc cgccgcctgg	1380
gtggagcgcc tgttcggcta cgactgggccc cagcagacca tcggctgctc cgacgccgcc	1440
gtgttccgcc tgtccgcccc gggccgcccc gtgctgttcg tgaagaccga cctgtccggc	1500
gccctgaacg agctgcagga cgaggccgc cgctgtcct ggctggccac caccggcgtg	1560
ccctgcgcg ccgtgctgga cgtggtgacc gaggccggcc gcgactggct gctgctgggc	1620
gagggtgccc gccaggacct gctgtcctcc cacctggccc ccgccagaa ggtgtccatc	1680
atggccgacg ccatgcgcgc cctgcacacc ctggacccc ccacctgccc cttcgaccac	1740
caggccaagc accgcatcga gcgcgccccg acccgcatgg aggcggcct ggtggaccag	1800
gacgacctgg acgaggagca ccagggcctg gccccgcgc agctgttcgc ccgcctgaag	1860
gccccgatgc ccgacggcga ggacctggtg gtgaccacg gcgacgcctg cctgcccac	1920
atcatggtgg agaacggccg cttctccggc ttcacgact gcggccgcct gggcggtggc	1980
gaccgctacc aggacatcgc cctggccacc cgcgacatcg ccgaggagct gggcggcgag	2040

026172-005010PC - Sequence Listing_1.TXT

tgggccgacc gcttcctggt gctgtacggc atcgccgccc cgcactccca gcgcatcgcc	2100
ttctaccgcc tgctggacga gttcttctga ctcgaggcag cagcagctcg gatagtatcg	2160
acacactctg gacgctggtc gtgtgatgga ctgttgccgc cacacttgct gccttgacct	2220
gtgaatatcc ctgccgcttt tatcaaacag cctcagtgtg tttgatcttg tgtgtacgcg	2280
cttttgcgag ttgctagctg cttgtgctat ttgcgaatac cccccccagc atcccccttc	2340
ctcgtttcat atcgcttgca tcccaaccgc aacttatcta cgctgtcctg ctatccctca	2400
gcgctgctcc tgctcctgct cactgcccct cgcacagcct tggtttgggc tccgcctgta	2460
ttctcctggt actgcaacct gtaaaccagc actgcaatgc tgatgcacgg gaagtagtgg	2520
gatgggaaca caaatggaaa gcttgagctc	2550

<210> 42

<211> 1547

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 42

gaattccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	60
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	120
atgggcgctc cgatgccgct ccagggcgag cgctgtttta atagccaggc ccccgattgc	180
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	240
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	300
cagtcacaac ccgcaaacgg cgcgccatat caatgatcga gcaggacggc ctccacgccc	360
gctccccgcg cgcttggtg gagcgctgt tcggctacga ctgggcccag cagaccatcg	420
gctgctccga cgccgccgtg ttccgcctgt ccgcccaggg ccgccccgtg ctgttcgtga	480
agaccgacct gtccggcgcc ctgaacgagc tgcaggacga ggccgcccgc ctgtcctggc	540
tggccaccac cggcgtgccc tgcgccgccc tgctggacgt ggtgaccgag gccggccgcg	600
actggctgct gctgggcgag gtgcccggcc aggacctgct gtcctccac ctggcccccg	660
ccgagaaggt gtccatcatg gccgacgcca tgcgccgcct gcacaccctg gaccccgcca	720
cctgccccct cgaccaccag gccaagcacc gcatcgagcg cgcccgacc cgcattggagg	780
ccggcctggt ggaccaggac gacctggacg aggagcacca gggcctggcc cccgccgagc	840
tgttcgcccc cctgaaggcc cgcattgccc acggcgagga cctggtggtg acccacggcg	900
acgcctgcct gcccaacatc atggtggaga acggccgctt ctccggcttc atcgactgcg	960
gccgcctggg cgtggccgac cgctaccagg acatcgccct ggccaccgcg gacatcgccg	1020
aggagctggg cggcgagtgg gccgaccgct tcctggtgct gtacggcatc gccgcccccg	1080
actcccagcg catcgcttc taccgcctgc tggacgagtt cttctgactc gaggcagcag	1140

026172-005010PC - Sequence Listing_1.TXT

cagctcggat agtatcgaca cactctggac gctggtcgtg tgatggactg ttgccgccac	1200
acttgctgcc ttgacctgtg aatatccctg ccgcttttat caaacagcct cagtgtgttt	1260
gatcttgtgt gtacgcgctt ttgcgagttg ctagctgctt gtgctatttg cgaataccac	1320
ccccagcatc cccttccttc gtttcataatc gcttgcatcc caaccgcaac ttatctacgc	1380
tgtcctgcta tccctcagcg ctgctcctgc tcctgctcac tgcccctcgc acagccttgg	1440
tttgggctcc gcctgtattc tcctgggtact gcaacctgta aaccagcact gcaatgctga	1500
tgcacgggaa gtagtgggat gggaacacaa atggaaagct tgagctc	1547

<210> 43
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 43	
gccgcgactg gctgctgctg g	21

<210> 44
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 44	
aggtcctcgc cgtcgggcat g	21

<210> 45
 <211> 1292
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 45	
atcaaaggca tagattcaca tttgttggca ttgcagagca atcatcgcgaggacgaaca	60
tcgctcacca agcacgtact gggcatccgg aggcctccgc aaattcctgc aacaggactc	120
gctgatcagt tcgccaagg tctacgacgc tccctatcgg cgctagactt caacacatat	180
ttcactgtca cagcctcggc atgcatcagg cctcagtctc caccatgaag accatccagt	240
ctcggcacgc cggtcccatc ggacatgtgc agtcgggtcg ccgatcggcg gggcgcgcg	300
gatcccgcat ggcgacccc gtggccgcag ctaccgtcgc agcccctcgc tcggccctca	360
acctctccc caccatcatt cgacaggagg tgctccactc cgccagcgcc cagcaactag	420
actgcgtggc ctccctggcg cccgtcttcg agtcccagat cctccccctc ctgacgccc	480
tggacgagat gtggcagccc accgacttcc tccccgctc gaactcggag gcattcttcg	540

026172-005010PC - Sequence Listing_1.TXT

```

accagatcgg cgacctgagg ggcgatcgg cggccatccc cgacgacctg ctgggtctgcc      600
tggtggggga catgatcacg gaggaggccc tgcccaccta catggccatg ctgaacaccc      660
tggacgtcgt ggcgatgag acagggcaca gccagcaccc ctacgccaag tggaccaggg      720
cttgatcgc ggaggagaac cgccatggcg acctgctgaa caagtacatg tggctgacgg      780
ggcgggtggg acatgctggc ggtggagcgc accatccagc catgctggcg gtggagcgca      840
ccatccagcg cctcatctca tcgggcatgg acccgggcac ggagaaccac ccctaccacg      900
cctttgtgtt caccagcttc caggagcgcg ccaccaagct gagccacggc tccaccgccc      960
gcctggcggg cgccgccggg gacgaggccc tggccaagat ctgcgggacc attgcgcggg     1020
acgagtcgcg ccacgaggcg gcgtacacgc ggaccatgga tgccatcttc cagcgcgacc     1080
ccagcggggc catggtggcg tttgcgcaca tgatgatgcy caagatcacc atgcccgcgc     1140
acctcatgga cgacggccag cacggcgcgc gcaacggggg ggcgcaactt gttcgacgac     1200
tttgcggcag tggcggagcg ggcaggggtg tacaccgccg gcgactacat cggcatcctg     1260
cgccacctca tccggcgctg ggacgtggag gg                                     1292

```

<210> 46

<211> 364

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 46

Met His Gln Ala Ser Val Ser Thr Met Lys Thr Ile Gln Ser Arg His
1 5 10 15

Ala Gly Pro Ile Gly His Val Gln Ser Gly Arg Arg Ser Ala Gly Arg
20 25 30

Ala Gly Ser Arg Met Ala Thr Pro Val Ala Ala Ala Thr Val Ala Ala
35 40 45

Pro Arg Ser Ala Leu Asn Leu Ser Pro Thr Ile Ile Arg Gln Glu Val
50 55 60

Leu His Ser Ala Ser Ala Gln Gln Leu Asp Cys Val Ala Ser Leu Ala
65 70 75 80

Pro Val Phe Glu Ser Gln Ile Leu Pro Leu Leu Thr Pro Val Asp Glu
85 90 95

Met Trp Gln Pro Thr Asp Phe Leu Pro Ala Ser Asn Ser Glu Ala Phe
100 105 110

Phe Asp Gln Ile Gly Asp Leu Arg Ala Arg Ser Ala Ala Ile Pro Asp
115 120 125

026172-005010PC - Sequence Listing_1.TXT

Asp Leu Leu Val Cys Leu Val Gly Asp Met Ile Thr Glu Glu Ala Leu
130 135 140

Pro Thr Tyr Met Ala Met Leu Asn Thr Leu Asp Val Val Arg Asp Glu
145 150 155 160

Thr Gly His Ser Gln His Pro Tyr Ala Lys Trp Thr Arg Ala Trp Ile
165 170 175

Ala Glu Glu Asn Arg His Gly Asp Leu Leu Asn Lys Tyr Met Trp Leu
180 185 190

Thr Gly Arg Val Gly His Ala Gly Gly Gly Ala His His Pro Ala Met
195 200 205

Leu Ala Val Glu Arg Thr Ile Gln Arg Leu Ile Ser Ser Gly Met Asp
210 215 220

Pro Gly Thr Glu Asn His Pro Tyr His Ala Phe Val Phe Thr Ser Phe
225 230 235 240

Gln Glu Arg Ala Thr Lys Leu Ser His Gly Ser Thr Ala Arg Leu Ala
245 250 255

Val Ala Ala Gly Asp Glu Ala Leu Ala Lys Ile Cys Gly Thr Ile Ala
260 265 270

Arg Asp Glu Ser Arg His Glu Ala Ala Tyr Thr Arg Thr Met Asp Ala
275 280 285

Ile Phe Gln Arg Asp Pro Ser Gly Ala Met Val Ala Phe Ala His Met
290 295 300

Met Met Arg Lys Ile Thr Met Pro Ala His Leu Met Asp Asp Gly Gln
305 310 315 320

His Gly Ala Arg Asn Gly Gly Ala Gln Leu Val Arg Arg Leu Cys Gly
325 330 335

Ser Gly Gly Ala Gly Arg Gly Val His Arg Arg Arg Leu His Arg His
340 345 350

Pro Ala Pro Pro His Pro Ala Leu Gly Arg Gly Gly
355 360

<210> 47

<211> 1395

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

```

<400> 47
attatacatc ggcacgtctt caggtttcac gatctgcatg ctatctatgg gactgtgact      60
ccgccggcca ggttgtggtg cgcgagaatc ctccccgctc ctgccttctc atttccctga    120
cgggagtcgc cgctgagcac cgggcgatc atgggcgctg gcacactcca aaccccatat    180
acatgtggtc gtgcattcac gcatagcgca cggtatgtcc cgcgacgcgc ggctcgaagc    240
cgtggccatc cgacgcgctg cacggccgag gtgagggcac gcccctccgc caatggcgcg    300
cagcccatga ccgccttcga cttccggcag tacatgcagc agcgcgccgc gctggtggac    360
gcagcgctgg acctggcagt gccgctgcag taccgccaga agatcaacga ggccatgcgg    420
tacagcctgc tggccggggg caagcgctg cgccccgcgc tctgcctcgc tgctgcgag    480
ctcgtgggcg gccccctgga ggcggccatg cccgcccgtt gcgccatgga gatgatccac    540
accatgagcc tcattccacga cgacctcccc gccatggaca acgacgactt ccggcgcggc    600
cagcccgcga accacaaggc ctatggcgag gagattgcga tcctggcggg cgacgcgctg    660
ctgtcgctga gctttgagca catcgcgcgc gagacgcgag gcgtggaccc ggtgcgcgtc    720
ctggccgcca tctcggagtg gcgcgcggtg ggcagccgcg ggctggtggc ggggcaggtg    780
gtggacctgg gtttcgaggg cggcggcgctg gggctggccc cgctgcgcta catccacgag    840
cacaaaaccg cggcgctgct ggaggcgggc gtggtgtccg gcgcgctgct gggcggcgcg    900
gaggaggcgg acctggagcg cctgcgcacc tacaaccgcg ccatcggcct cgctttccag    960
gtggtggggg acatcctgga catcccgggg accagcgagg agctgggcaa gaccgcgggc   1020
aaggacctga gtccccccaa aacccccctac ccgtccctgg tggggctggc caggtccaaa   1080
aaaattgcgg acgaactgat tgaggacgcg aaaacccaac tcaccagta cgagccggcc   1140
cgagcggcgc ccctcgtaac cctggccgaa aacatttgaa accggaagaa ctgactgggg   1200
gccccccctg cccccagata cggcggggct cctccatcca gttttgggat gggaggagcg   1260
acaaccgacc ccgtaaccct gtgacgcgtt tgccttgcat acgtacgcat gccttgaaac   1320
ccatccatga ccctcaacaa tacctggttg tgtgtagctt ggtcctgaaa aaaaaaaaaa   1380
aaaaaaaaaa aaaaaa                                     1395

```

<210> 48

<211> 342

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 48

```

Met Gly Val Gly Thr Leu Gln Thr Pro Tyr Thr Cys Gly Arg Ala Phe
1           5           10          15

```

```

Thr His Ser Ala Arg Tyr Val Pro Arg Arg Ala Ala Arg Ser Arg Gly

```


290

295

300

Gly Leu Ala Arg Ser Lys Lys Ile Ala Asp Glu Leu Ile Glu Asp Ala
 305 310 315 320

Lys Thr Gln Leu Thr Gln Tyr Glu Pro Ala Arg Ala Ala Pro Leu Val
 325 330 335

Thr Leu Ala Glu Asn Ile
 340

<210> 49

<211> 833

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 polynucleotide

<400> 49

cagatgccat gcgccctcgg gccgcgggcc tgaggggtcca cgcagcgtcc tcggtggccc	60
agacgcacca ggccgcccc cggcgggaca ggagggttcga cgactaccag ccccgaccg	120
ccatcctctt ccccgccag ggcgcgcaga gcgtgggcat ggcgggagag ctggcgaagg	180
ccgtccccgc cgccgcggcg ctgttcgacg ccgcctccga ccagctcggc tatgacctgc	240
tccgcgtgtg cgttgagggc cccaaggcgc gcctggacag caccgccgtc agccagccc	300
ccatctacgt ggccagcctg gcggcggtgg agaagctgcg cgcggagggc ggggaggagg	360
cactggccgc catcgacgtc gctgccggtc tgccttgagg cgagtacacc gcgctggcct	420
ttgccggcgc cttctccttc gccgacgggc tgcgcctggt ggccctgcgc ggcgcagca	480
tgcaggccgc cgccgacgcc gcacctcgg gcattggtctc cgtcatcggc ctgccctccg	540
acgcggtggc cgcgctgtgc gagggccgcca acgcgcaggc ggcccccgac caggccgtgc	600
gcatcgccaa ctacctctgc gacggcaact acgccgtcag cgggtgggctg gagggctgcg	660
cggcggtgga gggcctggcc aaggcccaca aggcgcgcac gacggtgcgc ctggcggtgg	720
cgggcgcctt ccacaccccc ttcattgcagc cggcggtgga ggcgctgagc gcgggcgctg	780
gcggacacgc cgctggctgc gccgcgcac cccgtggtca gcaacgggac gcc	833

<210> 50

<211> 275

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 polypeptide

<400> 50

Met Arg Pro Arg Ala Ala Gly Leu Arg Val His Ala Ala Ser Ser Val
 1 5 10 15

026172-005010PC - Sequence Listing_1.TXT

Ala Gln Thr His Gln Ala Ala Pro Pro Ala Asp Arg Arg Phe Asp Asp
20 25 30

Tyr Gln Pro Arg Thr Ala Ile Leu Phe Pro Gly Gln Gly Ala Gln Ser
35 40 45

Val Gly Met Ala Gly Glu Leu Ala Lys Ala Val Pro Ala Ala Ala Ala
50 55 60

Leu Phe Asp Ala Ala Ser Asp Gln Leu Gly Tyr Asp Leu Leu Arg Val
65 70 75 80

Cys Val Glu Gly Pro Lys Ala Arg Leu Asp Ser Thr Ala Val Ser Gln
85 90 95

Pro Ala Ile Tyr Val Ala Ser Leu Ala Ala Val Glu Lys Leu Arg Ala
100 105 110

Glu Gly Gly Glu Glu Ala Leu Ala Ala Ile Asp Val Ala Ala Gly Leu
115 120 125

Ser Leu Gly Glu Tyr Thr Ala Leu Ala Phe Ala Gly Ala Phe Ser Phe
130 135 140

Ala Asp Gly Leu Arg Leu Val Ala Leu Arg Gly Ala Ser Met Gln Ala
145 150 155 160

Ala Ala Asp Ala Ala Pro Ser Gly Met Val Ser Val Ile Gly Leu Pro
165 170 175

Ser Asp Ala Val Ala Ala Leu Cys Glu Ala Ala Asn Ala Gln Val Ala
180 185 190

Pro Asp Gln Ala Val Arg Ile Ala Asn Tyr Leu Cys Asp Gly Asn Tyr
195 200 205

Ala Val Ser Gly Gly Leu Glu Gly Cys Ala Ala Val Glu Gly Leu Ala
210 215 220

Lys Ala His Lys Ala Arg Met Thr Val Arg Leu Ala Val Ala Gly Ala
225 230 235 240

Phe His Thr Pro Phe Met Gln Pro Ala Val Glu Ala Leu Ser Ala Gly
245 250 255

Ala Gly Gly His Ala Ala Gly Arg Ala Ala His Pro Arg Gly Gln Gln
260 265 270

Arg Asp Ala
275

026172-005010PC - Sequence Listing_1.TXT

<210> 51
 <211> 787
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 51
 tgtccatctc cccccaccct ccaccaacc atcgctgacg gcatgcaggc gctgtgttct 60
 cccccgcgt ccctcacggc gcgtgcggtta ccccatgggc gggccagccc agcacagcgg 120
 gtgtccagcg ccggcccggc ctacaccggc ctgtcccggc acaccctggg ctgccccagc 180
 acccccaccc tccagtcccg cgccgcggtc cagaccgcg gctcctcctc cggctccacc 240
 acgcgcatga ccaccaccgc ccagcgcaag atcaagggtg ccaccaacgg gttcggccgc 300
 atcggccgcc agttcctgcg ctgcgtggag gggcgcgagg actcgctgct ggagatcgtg 360
 gccgtgaacg actccggcgg cgtgaagcag gccagccacc tgctcaagta cgactccacc 420
 atgggcacct tcaacgccga catcaagatc tcgggcgagg gcaccttctc cgtcaacggc 480
 cgcgacatcc gcgtcgtctc ctcccgcgac cccctggccc tgccctgggg cgagctgggc 540
 gtggacctgg tgatcgaggg gacgggagtg tttgtggacc gcaagggtgc cagcaagcac 600
 ctgcaggcgg gggccaagaa ggtcatcatc accgcgccgg ccaagggctc cgacgtgccc 660
 acctacgtca tgggcgtgaa cgcggaccag tactccaact ccgacgacat catctccaac 720
 gcctcctgca ccaccaactg cctggcgccc tttgtcaagg tgctcaacga ccgcttcggc 780
 atcgtga 787

<210> 52
 <211> 248
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 52
 Met Gln Ala Leu Cys Ser His Pro Ala Ser Leu Thr Ala Arg Ala Val
 1 5 10 15
 Pro His Gly Arg Ala Ser Pro Ala Gln Arg Val Ser Ser Ala Gly Pro
 20 25 30
 Ala Tyr Thr Gly Leu Ser Arg His Thr Leu Gly Cys Pro Ser Thr Pro
 35 40 45
 Thr Leu Gln Ser Arg Ala Ala Val Gln Thr Arg Gly Ser Ser Ser Gly
 50 55 60
 Ser Thr Thr Arg Met Thr Thr Thr Ala Gln Arg Lys Ile Lys Val Ala
 65 70 75 80

026172-005010PC - Sequence Listing_1.TXT

Ile Asn Gly Phe Gly Arg Ile Gly Arg Gln Phe Leu Arg Cys Val Glu
85 90 95

Gly Arg Glu Asp Ser Leu Leu Glu Ile Val Ala Val Asn Asp Ser Gly
100 105 110

Gly Val Lys Gln Ala Ser His Leu Leu Lys Tyr Asp Ser Thr Met Gly
115 120 125

Thr Phe Asn Ala Asp Ile Lys Ile Ser Gly Glu Gly Thr Phe Ser Val
130 135 140

Asn Gly Arg Asp Ile Arg Val Val Ser Ser Arg Asp Pro Leu Ala Leu
145 150 155 160

Pro Trp Gly Glu Leu Gly Val Asp Leu Val Ile Glu Gly Thr Gly Val
165 170 175

Phe Val Asp Arg Lys Gly Ala Ser Lys His Leu Gln Ala Gly Ala Lys
180 185 190

Lys Val Ile Ile Thr Ala Pro Ala Lys Gly Ser Asp Val Pro Thr Tyr
195 200 205

Val Met Gly Val Asn Ala Asp Gln Tyr Ser Asn Ser Asp Asp Ile Ile
210 215 220

Ser Asn Ala Ser Cys Thr Thr Asn Cys Leu Ala Pro Phe Val Lys Val
225 230 235 240

Leu Asn Asp Arg Phe Gly Ile Val
245

<210> 53

<211> 860

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 53

gatgttgaga atagtagctt gctgccttgt cgccatgcag agcgtgtgcg cgcagtcggt	60
ttcatgcaag ggggccttca ccagtcctt gcggaacccc cgatgcagca ggagccagct	120
cgtctgccgg gctgatggca aggccggagc cttcatcaag accgtaaaga gcggtgctgc	180
cgctctggct gcctccctcc tcctgtctgg ggggtgcgggc gcaactgacct ttgatgagct	240
gcagggcctg acctacctgc aggtgaaggg ctctggcatc gccaacacct gccccacct	300
gtctggcggc tcctccaaca tcaaggacct gaagagcggg acctactccg tcaacaagat	360
gtgcctggag cccacgtcct tcaagggtcaa ggaggaggca cagttcaaga acggcgaggg	420

026172-005010PC - Sequence Listing_1.TXT

```

cgactttgtg cccaccaagc tcgtcacgcg tctgacctac accctggacg agatctctgg      480
ccagatgaag atcgacggca gcgggcgcggt ggagttcaag gaggaggatg gcatcgacta      540
tgctgcagtc accgtgcagc ttccggggcg ggagcgcggtg cccttcctct tcaccatcaa      600
ggagcttgac gccaaagggga ctgccgacgg cttcaagggc gagttcaccg tgccctccta      660
ccgtgggtcc tccttcctgg accccaaggg ccgcggcgcc tccaccggct acgacaacgc      720
cgtggccctg cccgccgccc gcgattccga ggagttggag aaggagaaca acaagtccac      780
caaggctctg aagggggagg ccattctctc catcgccaag gtggacgccg ggacagggga      840
ggtagcgggc atctttgagt                                         860

```

<210> 54

<211> 275

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 54

Met Gln Ser Val Cys Ala Gln Ser Val Ser Cys Lys Gly Ala Phe Thr
1 5 10 15

Gln Ser Leu Arg Thr Pro Arg Cys Ser Arg Ser Gln Leu Val Cys Arg
20 25 30

Ala Asp Gly Lys Ala Gly Ala Phe Ile Lys Thr Val Lys Ser Gly Ala
35 40 45

Ala Ala Leu Ala Ala Ser Leu Leu Leu Ser Gly Gly Ala Gly Ala Leu
50 55 60

Thr Phe Asp Glu Leu Gln Gly Leu Thr Tyr Leu Gln Val Lys Gly Ser
65 70 75 80

Gly Ile Ala Asn Thr Cys Pro Thr Leu Ser Gly Gly Ser Ser Asn Ile
85 90 95

Lys Asp Leu Lys Ser Gly Thr Tyr Ser Val Asn Lys Met Cys Leu Glu
100 105 110

Pro Thr Ser Phe Lys Val Lys Glu Glu Ala Gln Phe Lys Asn Gly Glu
115 120 125

Ala Asp Phe Val Pro Thr Lys Leu Val Thr Arg Leu Thr Tyr Thr Leu
130 135 140

Asp Glu Ile Ser Gly Gln Met Lys Ile Asp Gly Ser Gly Gly Val Glu
145 150 155 160

026172-005010PC - Sequence Listing_1.TXT

Phe Lys Glu Glu Asp Gly Ile Asp Tyr Ala Ala Val Thr Val Gln Leu
165 170 175

Pro Gly Gly Glu Arg Val Pro Phe Leu Phe Thr Ile Lys Glu Leu Asp
180 185 190

Ala Lys Gly Thr Ala Asp Gly Phe Lys Gly Glu Phe Thr Val Pro Ser
195 200 205

Tyr Arg Gly Ser Ser Phe Leu Asp Pro Lys Gly Arg Gly Ala Ser Thr
210 215 220

Gly Tyr Asp Asn Ala Val Ala Leu Pro Ala Ala Gly Asp Ser Glu Glu
225 230 235 240

Leu Glu Lys Glu Asn Asn Lys Ser Thr Lys Ala Leu Lys Gly Glu Ala
245 250 255

Ile Phe Ser Ile Ala Lys Val Asp Ala Gly Thr Gly Glu Val Ala Gly
260 265 270

Ile Phe Glu
275

<210> 55
<211> 818
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 55
ataatcggaa cccagctgca cgcaccatca gtgcggcagc atgcagaccg tcgcagccag 60
ctatggcgta ttggcgccct ccggctccag cgtgacccgg ggctcgacca gcagcaagca 120
gcacttcacc accctcactc ccttttccgg cttcaggcgc ctgaatcatg tggatcgggc 180
ggggcaggcg gggctctggga gccccagac cctgcagcag gccgtgggca aggccgtgcg 240
ccggctcgcg ggccgcacca ccagcgccgt gcgcgtgacc cgcattgatgt ttgagcgggt 300
caccgagaag gccatcaagg tggctcatgct cgcgcaggag gaggctcgcc gtctgggcca 360
caacttcgtg gggacggagc aaatcctgct ggggttgatt ggggagtcca caggcatcgc 420
cgccaaggtc ctcaagtcga tgggcgtcac gctgaaagat gcgcgtgtgg aggtcgagaa 480
gatcatcggc cgggggagcg gctttgtggc cgtggagatc cccttcaccc cccgcgccaa 540
gcgtgtgctg gagctgtccc tggaggaggc tcgccagctc ggccacaact acattggcac 600
ggagcacatc ctgctggggc tgctgcgcga gggtgagggc gtggcctccc gcgtgctgga 660
gaccctgggc gccgaccccc agaagatccg cactcagggtg gtacgcatgg tgggtgagtc 720
gcaggagccc gtgggcacca cgggtggcgagg aggtccacc ggctccaaca agatgcccac 780

cctggaggag tacggcacca acctgaccgc ccaggccg

<210> 56

<211> 259

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 56

Met Gln Thr Val Ala Ala Ser Tyr Gly Val Leu Ala Pro Ser Gly Ser
1 5 10 15Ser Val Thr Arg Gly Ser Thr Ser Ser Lys Gln His Phe Thr Thr Leu
20 25 30Thr Pro Phe Ser Gly Phe Arg Arg Leu Asn His Val Asp Arg Ala Gly
35 40 45Gln Ala Gly Ser Gly Ser Pro Gln Thr Leu Gln Gln Ala Val Gly Lys
50 55 60Ala Val Arg Arg Ser Arg Gly Arg Thr Thr Ser Ala Val Arg Val Thr
65 70 75 80Arg Met Met Phe Glu Arg Phe Thr Glu Lys Ala Ile Lys Val Val Met
85 90 95Leu Ala Gln Glu Glu Ala Arg Arg Leu Gly His Asn Phe Val Gly Thr
100 105 110Glu Gln Ile Leu Leu Gly Leu Ile Gly Glu Ser Thr Gly Ile Ala Ala
115 120 125Lys Val Leu Lys Ser Met Gly Val Thr Leu Lys Asp Ala Arg Val Glu
130 135 140Val Glu Lys Ile Ile Gly Arg Gly Ser Gly Phe Val Ala Val Glu Ile
145 150 155 160Pro Phe Thr Pro Arg Ala Lys Arg Val Leu Glu Leu Ser Leu Glu Glu
165 170 175Ala Arg Gln Leu Gly His Asn Tyr Ile Gly Thr Glu His Ile Leu Leu
180 185 190Gly Leu Leu Arg Glu Gly Glu Gly Val Ala Ser Arg Val Leu Glu Thr
195 200 205Leu Gly Ala Asp Pro Gln Lys Ile Arg Thr Gln Val Val Arg Met Val
210 215 220

026172-005010PC - Sequence Listing_1.TXT

Gly Glu Ser Gln Glu Pro Val Gly Thr Thr Val Gly Gly Gly Ser Thr
225 230 235 240

Gly Ser Asn Lys Met Pro Thr Leu Glu Glu Tyr Gly Thr Asn Leu Thr
245 250 255

Ala Gln Ala

<210> 57
<211> 2357
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 57
ctttcttgcg ctatgacact tccagcaaaa ggtagggcgg gctgcgagac ggcttcccgg 60
cgctgcatgc aacaccgatg atgcttcgac cccccgaagc tccttcgggg ctgcatgggc 120
gctccgatgc cgctccaggg cgagcgctgt ttaaatagcc agggccccga ttgcaaagac 180
attatagcga gctaccaaag ccatattcaa acacctagat cactaccact tctacacagg 240
ccactcgagc ttgtgatcgc actccgctaa gggggcgcct cttcctcttc gtttcagtca 300
caaccgcga acggcgcgcc atatcaatgc ttcttcaggc ctttcttttt cttcttgctg 360
gttttgctgc caagatcagc gcctctatga cgaacgaaac ctcggataga ccacttgctg 420
actttacacc aaacaagggc tggatgaatg accccaatgg actgtggtac gacgaaaaag 480
atgccaagtg gcatctgtac tttcaataca acccgaaacga tactgtctgg gggacgccat 540
tgttttgggg ccacgccacg tccgacgacc tgaccaattg ggaggaccaa ccaatagcta 600
tcgctccgaa gaggaacgac tccggagcat tctcgggttc catggtggtt gactacaaca 660
atacttccgg ctttttcaac gataccattg acccgagaca acgctgcgtg gccatatgga 720
cttacaacac accggagtcc gaggagcagt acatctcgta tagcctggac ggtggataca 780
cttttacaga gtatcagaag aaccctgtgc ttgctgcaaa ttcgactcag ttccgagatc 840
cgaaggtcct ttggtacgag ccctcgcaga agtggatcat gacagcggca aagtcacagg 900
actacaagat cgaaatttac tcgtctgacg accttaaadc ctggaagctc gaatccgcgt 960
tcgcaaacga gggctttctc ggctaccaat acgaatgcc aggctgata gaggtcccaa 1020
cagagcaaga tcccagcaag tcctactggg tgatgtttat ttccattaat ccaggagcac 1080
cggcaggagg ttcttttaac cagtacttcg tcggaagctt taacggaact catttcgagg 1140
catttgataa ccaatcaaga gtagttgatt ttggaaagga ctactatgcc ctgcagactt 1200
tcttcaatac tgaccgcacc tatgggagcg ctcttggcat tgcgtgggct tctaactggg 1260
agtattccgc attcgttcct acaaaccctt ggaggtcctc catgtcgctc gtgaggaaat 1320
tctctctcaa cactgagtac caggccaacc cggaaaccga actcataaac ctgaaagccg 1380

026172-005010PC - Sequence Listing_1.TXT

aaccgatcct gaacattagc aacgctggcc cctggagccg gtttgcaacc aacaccacgt	1440
tgacgaaagc caacagctac aacgtcgatc tttcgaatag caccgggtaca cttgaatttg	1500
aactggtgta tgccgtcaat accacccaaa cgatctcgaa gtcggtgttc gcggacctct	1560
ccctctggtt taaaggcctg gaagaccccg aggagtacct cagaatgggt ttcgaggttt	1620
ctgcgctctc cttcttcctt gatcgcgggg acagcaaagt aaaatttggt aaggagaacc	1680
catattttac caacaggatg agcgttaaca accaaccatt caagagcgaa aacgacctgt	1740
cgtactacaa agtgtatggt ttgcttgatc aaaatatcct ggaactctac ttcaacgatg	1800
gtgatgtcgt gtccaccaac acatacttca tgacaaccgg gaacgcactg ggctccgtga	1860
acatgacgac ggggtgtggat aacctgttct acatcgacaa attccagggtg aggggaagtca	1920
agtgagatct gtcgatcgac aagctcgagg cagcagcagc tcggatagta tcgacacact	1980
ctggacgctg gtcgtgtgat ggactgttgc cgccacactt gctgccttga cctgtgaata	2040
tccctgccgc ttttatcaaa cagcctcagt gtgtttgatc ttgtgtgtac gcgcttttgc	2100
gagttgctag ctgcttgtgc tatttgcgaa taccaccccc agcatcccct tccctcgttt	2160
catatcgctt gcaccccaac cgcaacttat ctacgctgtc ctgctatccc tcagcgctgc	2220
tcctgctcct gctcactgcc cctcgcacag ccttggtttg ggctccgcct gtattctcct	2280
ggtactgcaa cctgtaaacc agcactgcaa tgctgatgca cgggaagtag tgggatggga	2340
acacaaatgg aaagctt	2357

<210> 58

<211> 2335

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 58

ctttcttgcg ctatgacact tccagcaaaa ggtagggcgg gctgcgagac ggcttcccgg	60
cgctgcatgc aacaccgatg atgcttcgac cccccgaagc tccttcgggg ctgcatgggc	120
gctccgatgc cgctccaggg cgagcgctgt taaatagcc agggccccga ttgcaaagac	180
attatagcga gctaccaaag ccatattcaa acacctagat cactaccact tctacacagg	240
ccactcgagc ttgtgatcgc actccgctaa gggggcgcct cttcctcttc gtttcagtca	300
caaccgcgaa acggcgcgcc atgctgctgc aggccttcct gttcctgctg gccggcttcg	360
ccgccaagat cagcgctcc atgacgaacg agacgtccga ccgccccctg gtgcacttca	420
cccccaacaa gggctggatg aacgacccca acggcctgtg gtacgacgag aaggacgcca	480
agtggcacct gtacttccag tacaacccga acgacaccgt ctgggggacg cccttggttct	540
ggggccacgc cacgtccgac gacctgacca actgggagga ccagcccatc gccatcgccc	600
cgaagcgcaa cgactccggc gccttctccg gctccatggt ggtggactac aacaacacct	660

026172-005010PC - Sequence Listing_1.TXT

ccggcttctt caacgacacc atcgacccgc gccagcgctg cgtggccatc tggacctaca	720
acaccccgga gtccgaggag cagtacatct cctacagcct ggacggcggc tacaccttca	780
ccgagtacca gaagaacccc gtgctggccg ccaactccac ccagttccgc gacccgaagg	840
tcttctggta cgagccctcc cagaagtgga tcatgaccgc ggccaagtcc caggactaca	900
agatcgagat ctactcctcc gacgacctga agtcctggaa gctggagtcc gcgttcgcca	960
acgagggctt cctcggctac cagtacgagt gccccggcct gatcgaggtc cccaccgagc	1020
aggaccccag caagtcctac tgggtgatgt tcatctccat caaccccggc gccccggccg	1080
gcggctcctt caaccagtac ttcgtcggca gcttcaacgg caccacttc gaggccttcg	1140
acaaccagtc ccgcgtggtg gacttcggca aggactacta cgccctgcag accttcttca	1200
acaccgaccc gacctacggg agcgccctgg gcatcgctg ggccccaac tgggagtact	1260
ccgccttcgt gcccaccaac ccctggcgct cctccatgtc cctcgtgcgc aagttctccc	1320
tcaacaccga gtaccaggcc aacccggaga cggagctgat caacctgaag gccgagccga	1380
tcctgaacat cagcaacgcc ggccccctgga gccggttcgc caccaacacc acgttgacga	1440
aggccaacag ctacaacgtc gacctgtcca acagcaccgg caccctggag ttcgagctgg	1500
tgtacgccgt caacaccacc cagacgatct ccaagtccgt gttcgcggac ctctccctct	1560
ggttcaaggg cctggaggac cccgaggagt acctccgcat gggcttcgag gtgtccgcgt	1620
cctccttctt cctggaccgc gggaacagca aggtgaagtt cgtgaaggag aacccctact	1680
tcaccaaccg catgagcgtg aacaaccagc cttcaagag cgagaacgac ctgtcctact	1740
acaagggtgta cggcttgctg gaccagaaca tcctggagct gtacttcaac gacggcgacg	1800
tcgtgtccac caacacctac ttcatgacca ccgggaacgc cctgggctcc gtgaacatga	1860
cgacgggggt ggacaacctg ttctacatcg acaagttcca ggtgcgcgag gtcaagtgat	1920
taattaactc gaggcagcag cagctcggat agtatcgaca cactctggac gctggctgtg	1980
tgatggactg ttgccgccac acttgctgcc ttgacctgtg aatatccctg ccgcttttat	2040
caaacagcct cagtgtgttt gatcttgtgt gtacgcgctt ttgcgagttg ctagctgctt	2100
gtgctatttg cgaataccac ccccagcatc cccttcctc gtttcatatc gcttgcaccc	2160
caaccgcaac ttatctacgc tgcctgcta tccctcagcg ctgctcctgc tcctgctcac	2220
tgccccctgc acagccttgg tttgggctcc gcctgtattc tcctgggtact gcaacctgta	2280
aaccagcact gcaatgctga tgcacgggaa gtagtgggat gggaacacaa atgga	2335

<210> 59

<211> 382

<212> PRT

<213> Cinnamomum camphorum

<400> 59

Met	Ala	Thr	Thr	Ser	Leu	Ala	Ser	Ala	Phe	Cys	Ser	Met	Lys	Ala	Val
1				5				10						15	

Met Leu Ala Arg Asp Gly Arg Gly Met Lys Pro Arg Ser Ser Asp Leu

20

25

30

Gln Leu Arg Ala Gly Asn Ala Gln Thr Ser Leu Lys Met Ile Asn Gly
 35 40 45

Thr Lys Phe Ser Tyr Thr Glu Ser Leu Lys Lys Leu Pro Asp Trp Ser
 50 55 60

Met Leu Phe Ala Val Ile Thr Thr Ile Phe Ser Ala Ala Glu Lys Gln
 65 70 75 80

Trp Thr Asn Leu Glu Trp Lys Pro Lys Pro Asn Pro Pro Gln Leu Leu
 85 90 95

Asp Asp His Phe Gly Pro His Gly Leu Val Phe Arg Arg Thr Phe Ala
 100 105 110

Ile Arg Ser Tyr Glu Val Gly Pro Asp Arg Ser Thr Ser Ile Val Ala
 115 120 125

Val Met Asn His Leu Gln Glu Ala Ala Leu Asn His Ala Lys Ser Val
 130 135 140

Gly Ile Leu Gly Asp Gly Phe Gly Thr Thr Leu Glu Met Ser Lys Arg
 145 150 155 160

Asp Leu Ile Trp Val Val Lys Arg Thr His Val Ala Val Glu Arg Tyr
 165 170 175

Pro Ala Trp Gly Asp Thr Val Glu Val Glu Cys Trp Val Gly Ala Ser
 180 185 190

Gly Asn Asn Gly Arg Arg His Asp Phe Leu Val Arg Asp Cys Lys Thr
 195 200 205

Gly Glu Ile Leu Thr Arg Cys Thr Ser Leu Ser Val Met Met Asn Thr
 210 215 220

Arg Thr Arg Arg Leu Ser Lys Ile Pro Glu Glu Val Arg Gly Glu Ile
 225 230 235 240

Gly Pro Ala Phe Ile Asp Asn Val Ala Val Lys Asp Glu Glu Ile Lys
 245 250 255

Lys Pro Gln Lys Leu Asn Asp Ser Thr Ala Asp Tyr Ile Gln Gly Gly
 260 265 270

Leu Thr Pro Arg Trp Asn Asp Leu Asp Ile Asn Gln His Val Asn Asn
 275 280 285

Ile Lys Tyr Val Asp Trp Ile Leu Glu Thr Val Pro Asp Ser Ile Phe
 Page 57

290

295

300

Glu Ser His His Ile Ser Ser Phe Thr Ile Glu Tyr Arg Arg Glu Cys
305 310 315 320

Thr Met Asp Ser Val Leu Gln Ser Leu Thr Thr Val Ser Gly Gly Ser
325 330 335

Ser Glu Ala Gly Leu Val Cys Glu His Leu Leu Gln Leu Glu Gly Gly
340 345 350

Ser Glu Val Leu Arg Ala Lys Thr Glu Trp Arg Pro Lys Leu Thr Asp
355 360 365

Ser Phe Arg Gly Ile Ser Val Ile Pro Ala Glu Ser Ser Val
370 375 380

<210> 60

<211> 1240

<212> DNA

<213> Cinnamomum camphorum

<400> 60

```

ggcgcgccat ggccaccacc tccctggcct ccgccttctg cagcatgaag gccgtgatgc      60
tggccccgca cggccgcggc atgaagcccc gctccagcga cctgcagctg cgcgccggca      120
acgcccagac ctccctgaag atgatcaacg gcaccaagtt ctctacacc gagagcctga      180
agaagctgcc cgactggtcc atgctgttcg ccgtgatcac caccatcttc tccgccgccg      240
agaagcagtg gaccaacctg gagtggaaag ccaagcccaa cccccccag ctgctggacg      300
accacttcgg cccccacggc ctggtgttcc gccgcacctt cgccatccgc agctacgagg      360
tgggccccga ccgctccacc agcatcgtgg ccgtgatgaa ccacctgcag gaggccgccc      420
tgaaccacgc caagtccgtg ggcacctctg gcgacggctt cggcaccacc ctggagatgt      480
ccaagcgcca cctgatctgg gtggtgaagc gcacccacgt ggccgtggag cgctaccccg      540
cctggggcga caccgtggag gtggagtgtt ggggtggcgc ctccggcaac aacggccgcc      600
gccacgactt cctggtgcgc gactgcaaga ccggcgagat cctgaccgcg tgcacctccc      660
tgagcgtgat gatgaacacc cgcacccgcc gcctgagcaa gatccccgag gaggtgcgcg      720
gcgagatcgg ccccgccctt atcgacaacg tggccgtgaa ggacgaggag atcaagaagc      780
cccagaagct gaacgactcc accgccgact acatccaggg cggcctgacc ccccgctgga      840
acgacctgga catcaaccag cacgtgaaca acatcaagta cgtggactgg atcctggaga      900
ccgtgcccga cagcatcttc gagagccacc acatctcttc cttcaccatc gagtaccgcc      960
gcgagtgcac catggacagc gtgctgcagt ccctgaccac cgtgagcggc ggctcctccg     1020
aggccggcct ggtgtgcgag cacctgctgc agctggaggg cggcagcgag gtgctgcgcg     1080
ccaagaccga gtggcgcccc aagctgaccg actccttcgg cggcatcagc gtgatccccg     1140
ccgagtccag cgtgatggac tacaaggacc acgacggcga ctacaaggac cacgacatcg     1200

```

actacaagga cgacgacgac aagtgactcg agttaattaa

1240

<210> 61

<211> 415

<212> PRT

<213> Cuphea hookeriana

<400> 61

Met Val Ala Ala Ala Ser Ser Ala Phe Phe Pro Val Pro Ala Pro
1 5 10 15Gly Ala Ser Pro Lys Pro Gly Lys Phe Gly Asn Trp Pro Ser Ser Leu
20 25 30Ser Pro Ser Phe Lys Pro Lys Ser Ile Pro Asn Gly Gly Phe Gln Val
35 40 45Lys Ala Asn Asp Ser Ala His Pro Lys Ala Asn Gly Ser Ala Val Ser
50 55 60Leu Lys Ser Gly Ser Leu Asn Thr Gln Glu Asp Thr Ser Ser Ser Pro
65 70 75 80Pro Pro Arg Thr Phe Leu His Gln Leu Pro Asp Trp Ser Arg Leu Leu
85 90 95Thr Ala Ile Thr Thr Val Phe Val Lys Ser Lys Arg Pro Asp Met His
100 105 110Asp Arg Lys Ser Lys Arg Pro Asp Met Leu Val Asp Ser Phe Gly Leu
115 120 125Glu Ser Thr Val Gln Asp Gly Leu Val Phe Arg Gln Ser Phe Ser Ile
130 135 140Arg Ser Tyr Glu Ile Gly Thr Asp Arg Thr Ala Ser Ile Glu Thr Leu
145 150 155 160Met Asn His Leu Gln Glu Thr Ser Leu Asn His Cys Lys Ser Thr Gly
165 170 175Ile Leu Leu Asp Gly Phe Gly Arg Thr Leu Glu Met Cys Lys Arg Asp
180 185 190Leu Ile Trp Val Val Ile Lys Met Gln Ile Lys Val Asn Arg Tyr Pro
195 200 205Ala Trp Gly Asp Thr Val Glu Ile Asn Thr Arg Phe Ser Arg Leu Gly
210 215 220Lys Ile Gly Met Gly Arg Asp Trp Leu Ile Ser Asp Cys Asn Thr Gly
225 230 235 240

026172-005010PC - Sequence Listing_1.TXT

Glu Ile Leu Val Arg Ala Thr Ser Ala Tyr Ala Met Met Asn Gln Lys
245 250 255

Thr Arg Arg Leu Ser Lys Leu Pro Tyr Glu Val His Gln Glu Ile Val
260 265 270

Pro Leu Phe Val Asp Ser Pro Val Ile Glu Asp Ser Asp Leu Lys Val
275 280 285

His Lys Phe Lys Val Lys Thr Gly Asp Ser Ile Gln Lys Gly Leu Thr
290 295 300

Pro Gly Trp Asn Asp Leu Asp Val Asn Gln His Val Ser Asn Val Lys
305 310 315 320

Tyr Ile Gly Trp Ile Leu Glu Ser Met Pro Thr Glu Val Leu Glu Thr
325 330 335

Gln Glu Leu Cys Ser Leu Ala Leu Glu Tyr Arg Arg Glu Cys Gly Arg
340 345 350

Asp Ser Val Leu Glu Ser Val Thr Ala Met Asp Pro Ser Lys Val Gly
355 360 365

Val Arg Ser Gln Tyr Gln His Leu Leu Arg Leu Glu Asp Gly Thr Ala
370 375 380

Ile Val Asn Gly Ala Thr Glu Trp Arg Pro Lys Asn Ala Gly Ala Asn
385 390 395 400

Gly Ala Ile Ser Thr Gly Lys Thr Ser Asn Gly Asn Ser Val Ser
405 410 415

<210> 62
<211> 1339
<212> DNA
<213> Cuphea hookeriana

<400> 62
ggcgcgccat ggtggccgcc gccgcctcca gcgccttctt ccccgtagcc gcccccggcg 60
cctcccccaa gcccggcaag ttcggcaact ggccctccag cctgagcccc tccttcaagc 120
ccaagtccat cccaacggc ggcttccagg tgaaggccaa cgacagcgcc caccccaagg 180
ccaacggctc cgccgtgagc ctgaagagcg gcagcctgaa caccaggag gacacctcct 240
ccagcccccc ccccgccacc ttctgcacc agctgcccga ctggagccgc ctgctgaccg 300
ccatcaccac cgtgttcgtg aagtccaagc gcccgcacat gcacgaccgc aagtccaagc 360
gccccgacat gctggtggac agcttcggcc tggagtccac cgtgcaggac ggcctggtgt 420
tccgccagtc cttctccatc cgctcctacg agatcggcac cgaccgcacc gccagcatcg 480

026172-005010PC - Sequence Listing_1.TXT

```

agaccctgat gaaccacctg caggagacct ccctgaacca ctgcaagagc accggcatcc      540
tgctggacgg cttcggccgc accctggaga tgtgcaagcg cgacctgac tgggtggtga      600
tcaagatgca gatcaaggtg aaccgctacc ccgcctgggg cgacaccgtg gagatcaaca      660
cccgcttcag ccgcctggggc aagatcgcca tgggccgcga ctggctgac tccgactgca      720
acaccggcga gatcctgggtg cgcgccacca gcgcctacgc catgatgaac cagaagaccc      780
gccgcctgtc caagctgccc tacgaggtgc accaggagat cgtgcccctg ttcgtggaca      840
gccccgtgat cgaggactcc gacctgaagg tgcacaagtt caaggtgaag accggcgaca      900
gcatccagaa gggcctgacc cccggctgga acgacctgga cgtgaaccag cacgtgtcca      960
acgtgaagta catcggtcgg atcctggaga gcatgcccac cgaggtgctg gagaccagg    1020
agctgtgctc cctggccctg gactaccgcc gcgagtgcgg ccgcgactcc gtgctggaga    1080
gcgtgaccgc catggacccc agcaaggtgg gcgtgcgctc ccagtaccag cacctgctgc    1140
gcctggagga cggcaccgcc atcgtgaacg gcgccaccga gtggcgcccc aagaacgccg    1200
gcgccaacgg cgccatctcc accggcaaga ccagcaacgg caactccgtg tccatggact    1260
acaaggacca cgacggcgac tacaaggacc acgacatcga ctacaaggac gacgacgaca    1320
agtgactcga gttaattaa                                     1339

```

<210> 63

<211> 382

<212> PRT

<213> Umbellularia sp.

<400> 63

```

Met Ala Thr Thr Ser Leu Ala Ser Ala Phe Cys Ser Met Lys Ala Val
1           5           10           15

```

```

Met Leu Ala Arg Asp Gly Arg Gly Met Lys Pro Arg Ser Ser Asp Leu
          20           25           30

```

```

Gln Leu Arg Ala Gly Asn Ala Pro Thr Ser Leu Lys Met Ile Asn Gly
          35           40           45

```

```

Thr Lys Phe Ser Tyr Thr Glu Ser Leu Lys Arg Leu Pro Asp Trp Ser
          50           55           60

```

```

Met Leu Phe Ala Val Ile Thr Thr Ile Phe Ser Ala Ala Glu Lys Gln
65           70           75           80

```

```

Trp Thr Asn Leu Glu Trp Lys Pro Lys Pro Lys Leu Pro Gln Leu Leu
          85           90           95

```

```

Asp Asp His Phe Gly Leu His Gly Leu Val Phe Arg Arg Thr Phe Ala
          100           105           110

```

```

Ile Arg Ser Tyr Glu Val Gly Pro Asp Arg Ser Thr Ser Ile Leu Ala
          115           120           125

```

026172-005010PC - Sequence Listing_1.TXT

Val Met Asn His Met Gln Glu Ala Thr Leu Asn His Ala Lys Ser Val
130 135 140

Gly Ile Leu Gly Asp Gly Phe Gly Thr Thr Leu Glu Met Ser Lys Arg
145 150 155 160

Asp Leu Met Trp Val Val Arg Arg Thr His Val Ala Val Glu Arg Tyr
165 170 175

Pro Thr Trp Gly Asp Thr Val Glu Val Glu Cys Trp Ile Gly Ala Ser
180 185 190

Gly Asn Asn Gly Met Arg Arg Asp Phe Leu Val Arg Asp Cys Lys Thr
195 200 205

Gly Glu Ile Leu Thr Arg Cys Thr Ser Leu Ser Val Leu Met Asn Thr
210 215 220

Arg Thr Arg Arg Leu Ser Thr Ile Pro Asp Glu Val Arg Gly Glu Ile
225 230 235 240

Gly Pro Ala Phe Ile Asp Asn Val Ala Val Lys Asp Asp Glu Ile Lys
245 250 255

Lys Leu Gln Lys Leu Asn Asp Ser Thr Ala Asp Tyr Ile Gln Gly Gly
260 265 270

Leu Thr Pro Arg Trp Asn Asp Leu Asp Val Asn Gln His Val Asn Asn
275 280 285

Leu Lys Tyr Val Ala Trp Val Phe Glu Thr Val Pro Asp Ser Ile Phe
290 295 300

Glu Ser His His Ile Ser Ser Phe Thr Leu Glu Tyr Arg Arg Glu Cys
305 310 315 320

Thr Arg Asp Ser Val Leu Arg Ser Leu Thr Thr Val Ser Gly Gly Ser
325 330 335

Ser Glu Ala Gly Leu Val Cys Asp His Leu Leu Gln Leu Glu Gly Gly
340 345 350

Ser Glu Val Leu Arg Ala Arg Thr Glu Trp Arg Pro Lys Leu Thr Asp
355 360 365

Ser Phe Arg Gly Ile Ser Val Ile Pro Ala Glu Pro Arg Val
370 375 380

<210> 64
<211> 1240
<212> DNA

<213> Umbellularia sp.

<400> 64

```

ggcgcgccat ggccaccacc agcctggcct ccgccttctg ctccatgaag gccgtgatgc      60
tggcccgcgga cggccgcggc atgaagcccc gcagctccga cctgcagctg cgcgccggca    120
acgccccccac ctccctgaag atgatcaacg gcaccaagtt cagctacacc gagagcctga    180
agcgcctgcc cgactggtcc atgctgttcg ccgtgatcac caccatcttc agcgccgccg    240
agaagcagtg gaccaacctg gagtggaagc ccaagcccaa gctgccccag ctgctggacg    300
accacttcgg cctgcacggc ctggtgttcc gccgcacctt cgccatccgc tcctacgagg    360
tgggccccga ccgcagcacc tccatcctgg ccgtgatgaa ccacatgcag gaggccaccc    420
tgaaccacgc caagagcgtg ggcatcctgg gcgacggctt cggcaccacc ctggagatgt    480
ccaagcgcga cctgatgtgg gtggtgcgcc gacccacgt ggccgtggag cgctacccca    540
cctggggcgga caccgtggag gtggagtgtt ggatcggcgc cagcggcaac aacggcatgc    600
gccgcgactt cctggtgcgc gactgcaaga ccggcgagat cctgaccgcg tgcacctccc    660
tgagcgtgct gatgaacacc cgcacccgcc gcctgagcac catccccgac gaggtgcgcg    720
gcgagatcgg ccccgcttc atcgacaacg tggccgtgaa ggacgacgag atcaagaagc    780
tgcagaagct gaacgactcc accgccgact acatccaggg cggcctgacc ccccgctgga    840
acgacctgga cgtgaaccag cacgtgaaca acctgaagta cgtggcctgg gtgttcgaga    900
ccgtgcccga cagcatcttc gagtcccacc acatcagctc cttaccctg gagtaccgcc    960
gcgagtgcac ccgcgactcc gtgctgcgca gcctgaccac cgtgagcggc ggcagctccg   1020
aggccggcct ggtgtgcgac cacctgctgc agctggaggg cggcagcgag gtgctgcgcg   1080
cccgaccgga gtggcgcccc aagctgaccg actccttccg cggcatcagc gtgatccccg   1140
ccgagccccg cgtgatggac tacaaggacc acgacggcga ctacaaggac cacgacatcg   1200
actacaagga cgacgacgac aagtgactcg agttaaataa                        1240

```

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 65

ccgccgtgct ggacgtggtg 20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

026172-005010PC - Sequence Listing_1.TXT

<400> 66
 ggtggcgggg tccaggggtgt 20

<210> 67
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 67
 cggccggcgg ctccttcaac 20

<210> 68
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 68
 ggcgctcccg taggtcgggt 20

<210> 69
 <211> 1335
 <212> DNA
 <213> *Chlorella sorokiniana*

<400> 69
 cgcctgcaac gcaagggcag ccacagccgc tcccacccgc cgctgaaccg acacgtgctt 60
 gggcgccctgc cgcctgcctg ccgcatgctt gtgctgggtga ggctgggcag tgctgccatg 120
 ctgattgagg cttggttcat cgggtggaag cttatgtgtg tgctgggctt gcatgccggg 180
 caatgcgcat ggtggcaaga gggcggcagc acttgctgga gctgccgcgg tgcctccagg 240
 tggttcaatc gcggcagcca gagggatttc agatgatcgc gcgtacaggt tgagcagcag 300
 tgtcagcaaa ggtagcagtt tgccagaatg atcggttcag ctgttaatca atgccagcaa 360
 gagaaggggt caagtgcaaa cacgggcatg ccacagcacg ggcaccgggg agtggaatgg 420
 caccaccaag tgtgtgagcag ccagcatcgc cgcctggctg tttcagctac aacggcagga 480
 gtcaccaaac gtaaccatga gctgatcaac actgcaatca tcgggcgggc gtgatgcaag 540
 catgcctggc gaagacacat ggtgtgcgga tgctgccggc tgctgcctgc tgcgcacgcc 600
 gttgagttgg cagcaggctc agccatgcac tggatggcag ctgggctgcc actgcaatgt 660
 ggtggatagg atgcaagtgg agcgaatacc aaaccctctg gctgcttgct gggttgcatg 720
 gcatcgacc atcagcagga gcgcatgcga agggactggc cccatgcacg ccatgcaaaa 780
 ccggagcgca ccgagtgtcc aactgtcac caggcccgca agctttgcag aaccatgctc 840
 atggacgcat gtagcgctga cgtcccttga cggcgctcct ctcggtgtg ggaaacgcaa 900
 tgcagcacag gcagcagagg cggcggcagc agagcggcgg cagcagcggc gggggccacc 960

026172-005010PC - Sequence Listing_1.TXT

cttcttgccg ggtcgcgccc cagccagcgg tgatgcgctg atcccaaacg agttcacatt	1020
catttgcatg cctggagaag cgaggctggg gcctttgggc tgggtgcagcc cgcaatggaa	1080
tgcgggaccg ccaggctagc agcaaaggcg cctcccctac tccgcatcga tgttccatag	1140
tgcattggac tgcatttggg tggggcgggc ggctgtttct ttcgtgttgc aaaacgcgcc	1200
agctcagcaa cctgtcccgt ggggtccccc tgccgatgaa atcgtgtgca cgccgatcag	1260
ctgattgccc ggctcgcgaa gtaggcgccc tcctttctgc tcgccctctc tccgtcccg	1320
cactagtggc gcgcc	1335

<210> 70

<211> 1146

<212> DNA

<213> *Umbellularia californica*

<400> 70

atggccacca ccagcctggc ctccgccttc tgctccatga aggccgtgat gctggccccg	60
gacggccgcg gcatgaagcc ccgcagctcc gacctgcagc tgcgcgccgg caacgcccc	120
acctccctga agatgatcaa cggcaccaag ttcagctaca ccgagagcct gaagcgcctg	180
cccgactggt ccatgctgtt cgccgtgatc accaccatct tcagcgccgc cgagaagcag	240
tggaccaacc tggagtggaa gcccagccc aagctgcccc agctgctgga cgaccacttc	300
ggcctgcacg gcctgggtgtt ccgccgcacc ttcgccatcc gctcctacga ggtgggcccc	360
gaccgcagca cctccatcct ggccgtgatg aaccacatgc aggaggccac cctgaaccac	420
gccaagagcg tgggcatcct gggcgacggc ttcggcacca ccctggagat gtccaagcgc	480
gacctgatgt ggggtggtgcg ccgcacccac gtggccgtgg agcgctaccc cacctggggc	540
gacaccgtgg aggtggagtg ctggatcggc gccagcggca acaacggcat gcgccgcgac	600
ttcctggtgc gcgactgcaa gaccggcgag atcctgaccc gctgcacctc cctgagcgtg	660
ctgatgaaca ccgcacccg ccgcctgagc accatccccg acgaggtgcg cggcgagatc	720
ggccccgcct tcatcgacaa cgtggccgtg aaggacgacg agatcaagaa gctgcagaag	780
ctgaacgact ccaccgccga ctacatccag ggcggcctga cccccgctg gaacgacctg	840
gacgtgaacc agcacgtgaa caacctgaag tacgtggcct ggggtgttcga gaccgtgccc	900
gacagcatct tcgagtccca ccacatcagc tccttcaccc tggagtaccg ccgcgagtgc	960
acccgcgact ccgtgctgcg cagcctgacc accgtgagcg gcggcagctc cgaggccggc	1020
ctggtgtgcg accacctgct gcagctggag ggcggcagcg aggtgctgcg cggccgcacc	1080
gagtggcgcc ccaagctgac cgactccttc cgcggcatca gcgtgatccc cgccgagccc	1140
cgcggtg	1146

<210> 71

<211> 1146

<212> DNA

<213> *Cinnamomum camphora*

<400> 71

026172-005010PC - Sequence Listing_1.TXT

atggccacca cctccctggc ctccgccttc tgcagcatga aggccgtgat gctggcccgc	60
gacggccgcg gcatgaagcc ccgctccagc gacctgcagc tgcgcgccgg caacgcccag	120
acctccctga agatgatcaa cggcaccaag ttctcctaca ccgagagcct gaagaagctg	180
cccgactggg ccatgctggt cgccgtgatc accaccatct tctccgccgc cgagaagcag	240
tggaccaacc tggagtggaa gcccagccc aaaaaaaaa agctgctgga cgaccacttc	300
ggcccccacg gcctgggtgtt ccgccgcacc ttcccatcc gcagctacga ggtgggcccc	360
gaccgctcca ccagcatcgt ggccgtgatg aaccacctgc aggaggccgc cctgaaccac	420
gccaagtccg tgggcatcct gggcgacggc ttccggacca ccctggagat gtccaagcgc	480
gacctgatct ggggtggtgaa gcgcacccac gtggccgtgg agcgtaccc cgcttggggc	540
gacaccgtgg aggtggagtg ctgggtgggc gcctccggca acaacggccg ccgccacgac	600
ttcctgggtgc gcgactgcaa gaccggcgag atcctgaccc gctgcacctc cctgagcgtg	660
atgatgaaca ccgcacccg ccgcctgagc aagatccccg aggagggtgcg cggcgagatc	720
ggccccgcct tcatcgacaa cgtggccgtg aaggacgagg agatcaagaa gccccagaag	780
ctgaacgact ccaccgccga ctacatccag ggcggcctga cccccgctg gaacgacctg	840
gacatcaacc agcacgtgaa caacatcaag tacgtggact ggatcctgga gaccgtgccc	900
gacagcatct tcgagagcca ccacatctcc tccttcacca tcgagtaccg ccgcgagtg	960
accatggaca gcgtgctgca gtccctgacc accgtgagcg gcggctcctc cgaggccggc	1020
ctggtgtgcg agcacctgct gcagctggag ggcggcagcg aggtgctgcg cgccaagacc	1080
gagtggcgcc ccaagctgac cgactccttc cgcgcatca gcgtgatccc cgccgagtcc	1140
agcgtg	1146

<210> 72

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 72

atggactaca aggaccacga cggcgactac aaggaccacg acatcgacta caaggacgac	60
gacgacaagt ga	72

<210> 73

<211> 408

<212> DNA

<213> Chlorella vulgaris

<400> 73

ctcgaggcag cagcagctcg gatagtatcg acacactctg gacgctggtc gtgtgatgga	60
ctgttgccgc cacacttgct gccttgacct gtgaatatcc ctgccgcttt tatcaaacag	120
cctcagtgtg tttgatcttg tgtgtacgcg cttttgcgag ttgctagctg cttgtgctat	180

026172-005010PC - Sequence Listing_1.TXT

ttgcgaatac cacccccagc atcccccttc ctcgtttcat atcgcttgca tcccaaccgc	240
aacttatcta cgctgtcctg ctatccctca gcgctgctcc tgctcctgct cactgcccct	300
cgcacagcct tggtttgggc tccgcctgta ttctcctggc actgcaacct gtaaaccagc	360
actgcaatgc tgatgcacgg gaagtagtgg gatgggaaca caaatgga	408

<210> 74
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 74	
ctgggcgacg gcttcggcac	20

<210> 75
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 75	
aagtcgcggc gcatgccgtt	20

<210> 76
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 76	
tacccgcct ggggcgacac	20

<210> 77
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

<400> 77	
cttgctcagg cggcgggtgc	20

<210> 78
 <211> 1317
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Page 67

026172-005010PC - Sequence Listing_1.TXT

polynucleotide

<400> 78

```

atggtggccg ccgcccctc cagcgccttc ttccccgtgc ccgcccccg cgctcccc 60
aagcccggca agttcggcaa ctggccctcc agcctgagcc cctccttcaa gcccagtc 120
atccccaacg gcggcttcca ggtgaaggcc aacgacagcg cccaccccaa ggccaacggc 180
tccgccgtga gcctgaagag cggcagcctg aacacccagg aggacacctc ctccagcccc 240
cccccccgca ccttcctgca ccagctgccc gactggagcc gcctgctgac cgccatcacc 300
accgtgttcg tgaagtccaa gcgccccgac atgcacgacc gcaagtccaa gcgccccgac 360
atgctggtgg acagcttcgg cctggagtcc accgtgcagg acggcctggt gttccgccag 420
tcctttctca tccgtccta cgagatcggc accgaccgca ccgccagcat cgagaccctg 480
atgaaccacc tgcaggagac ctccctgaac cactgcaaga gcaccggcat cctgctggac 540
ggcttcggcc gcaccctgga gatgtgcaag cgcgacctga tctgggtggt gatcaagatg 600
cagatcaagg tgaaccgcta cccgccttg ggcgacaccg tggagatcaa caccgcctc 660
agccgcctgg gcaagatcgg catgggccgc gactggctga tctccgactg caacaccggc 720
gagatcctgg tgcgcgccac cagcgcctac gccatgatga accagaagac ccgccgcctg 780
tccaagctgc cctacgaggt gcaccaggag atcgtgcccc tgttcgtgga cagccccgtg 840
atcgaggact ccgacctgaa ggtgcacaag ttcaaggatga agaccggcga cagcatccag 900
aagggcctga cccccggctg gaacgacctg gacgtgaacc agcacgtgtc caacgtgaag 960
tacatcggct ggatcctgga gagcatgccc accgaggtgc tggagacca ggagctgtgc 1020
tccttgcccc tggagtaccg ccgcgagtgc ggccgcgact ccgtgctgga gagcgtgacc 1080
gccatggacc ccagcaagggt gggcgtgcgc tcccagtacc agcacctgct gcgcctggag 1140
gacggcaccg ccatcgtgaa cggcgccacc gagtggcgcc ccaagaacgc cggcgccaac 1200
ggcgccatct ccaccggcaa gaccagcaac ggcaactccg tgtccatgga ctacaaggac 1260
cacgacggcg actacaagga ccacgacatc gactacaagg acgacgacga caagtga 1317

```

<210> 79

<211> 1170

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 79

```

atggccaccg catccacttt ctggcggttc aatgcccgtc gcggcgacct gcgtcgctcg 60
gcgggctccg ggccccggcg cccagcgagg cccctccccg tgcgcgggcg cgcccagctg 120
cccgactgga gccgcctgct gaccgccatc accaccgtgt tcgtgaagtc caagcgcccc 180
gacatgcacg accgcaagtc caagcgcccc gacatgctgg tggacagctt cggcctggag 240
tccaccgtgc aggacggcct ggtgttccgc cagtccttct ccatccgctc ctacgagatc 300

```

026172-005010PC - Sequence Listing_1.TXT

ggcaccgacc gcaccgccag catcgagacc ctgatgaacc acctgcagga gacctccctg	360
aaccactgca agagcaccgg catcctgctg gacggcttcg gccgcaccct ggagatgtgc	420
aagcgcgacc tgatctgggt ggtgatcaag atgcagatca aggtgaaccg ctaccccgcc	480
tggggcgaca ccgtggagat caacacccgc ttcagccgcc tgggcaagat cggcatgggc	540
cgcgactggc tgatctccga ctgcaacacc ggcgagatcc tgggtgcgcgc caccagcgcc	600
tacgccatga tgaaccagaa gacccgccgc ctgtccaagc tgccctacga ggtgcaccag	660
gagatcgtgc ccctgttcgt ggacagcccc gtgatcgagg actccgacct gaaggtgcac	720
aagttcaagg tgaagaccgg cgacagcatc cagaagggcc tgacccccgg ctggaacgac	780
ctggacgtga accagcacgt gtccaacgtg aagtacatcg gctggatcct ggagagcatg	840
cccaccgagg tgctggagac ccaggagctg tgctccctgg ccctggagta ccgccgcgag	900
tgcggccgcg actccgtgct ggagagcgtg accgccatgg accccagcaa ggtgggcgtg	960
cgctcccagt accagcacct gctgcgcctg gaggacggca ccgccatcgt gaacggcgcc	1020
accgagtggc gcccgaagaa cgccggcgcc aacggcgcca tctccaccgg caagaccagc	1080
aacggcaact ccgtgtccat ggactacaag gaccacgacg gcgactacaa ggaccacgac	1140
atcgactaca aggacgacga cgacaagtga	1170

<210> 80

<211> 1170

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 80

atggctatca agacgaacag gcagcctgtg gagaagcctc cgttcacgat cgggacgctg	60
cgcaaggcca tccccgcgca ctgtttcgag cgctcggcgc ttcgtgggcg cgcccagctg	120
cccgactgga gccgcctgct gaccgccatc accaccgtgt tcgtgaagtc caagcgcccc	180
gacatgcacg accgcaagtc caagcgcccc gacatgctgg tggacagctt cggcctggag	240
tccaccgtgc aggacggcct ggtgttccgc cagtccttct ccatccgctc ctacgagatc	300
ggcaccgacc gcaccgccag catcgagacc ctgatgaacc acctgcagga gacctccctg	360
aaccactgca agagcaccgg catcctgctg gacggcttcg gccgcaccct ggagatgtgc	420
aagcgcgacc tgatctgggt ggtgatcaag atgcagatca aggtgaaccg ctaccccgcc	480
tggggcgaca ccgtggagat caacacccgc ttcagccgcc tgggcaagat cggcatgggc	540
cgcgactggc tgatctccga ctgcaacacc ggcgagatcc tgggtgcgcgc caccagcgcc	600
tacgccatga tgaaccagaa gacccgccgc ctgtccaagc tgccctacga ggtgcaccag	660
gagatcgtgc ccctgttcgt ggacagcccc gtgatcgagg actccgacct gaaggtgcac	720
aagttcaagg tgaagaccgg cgacagcatc cagaagggcc tgacccccgg ctggaacgac	780
ctggacgtga accagcacgt gtccaacgtg aagtacatcg gctggatcct ggagagcatg	840

026172-005010PC - Sequence Listing_1.TXT

cccaccgagg tgctggagac ccaggagctg tgctccctgg ccctggagta ccgccgcgag	900
tgcggccgcg actccgtgct ggagagcgtg accgccatgg accccagcaa ggtgggcgtg	960
cgctcccagt accagcacct gctgcgcctg gaggacggca ccgccatcgt gaacggcgcc	1020
accgagtggc gcccgaagaa cgccggcgcc aacggcgcca tctccaccgg caagaccagc	1080
aacggcaact ccgtgtccat ggactacaag gaccacgacg gcgactacaa ggaccacgac	1140
atcgactaca aggacgacga cgacaagtga	1170

<210> 81

<211> 1167

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 81

atgacgttcg gggtcgccct cccggccatg ggccgcggtg tctcccttcc ccggcccagg	60
gtcgcggtgc gcgcccagtc ggcgagtcag gttttggaga gcgggcgcgc ccagctgccc	120
gactggagcc gcctgctgac cgccatcacc accgtgttcg tgaagtccaa gcgccccgac	180
atgcacgacc gcaagtccaa gcgccccgac atgctggtgg acagcttcgg cctggagtcc	240
accgtgcagg acggcctggt gttccgccag tccttctcca tccgctccta cgagatcggc	300
accgaccgca ccgccagcat cgagaccctg atgaaccacc tgcaggagac ctccctgaac	360
cactgcaaga gcaccggcat cctgctggac ggcttcggcc gcaccctgga gatgtgcaag	420
cgcgacctga tctgggtggt gatcaagatg cagatcaagg tgaaccgcta cccgcctgg	480
ggcgacaccg tggagatcaa caccgcttc agccgcctgg gcaagatcgg catgggcccgc	540
gactggctga tctccgactg caacaccggc gagatcctgg tgcgcgccac cagcgcctac	600
gccatgatga accagaagac ccgccgcctg tccaagctgc cctacgaggt gcaccaggag	660
atcgtgcccc tggtcgtgga cagccccgtg atcgaggact ccgacctgaa ggtgcacaag	720
ttcaagggtga agaccggcga cagcatccag aagggcctga cccccggctg gaacgacctg	780
gacgtgaacc agcacgtgtc caacgtgaag tacatcggct ggatcctgga gagcatgccc	840
accgaggtgc tggagacca ggagctgtgc tccctggccc tggagtaccg ccgcgagtgc	900
ggccgcgact ccgtgctgga gagcgtgacc gccatggacc ccagcaaggt gggcgtgcgc	960
tcccagtacc agcacctgct gcgcctggag gacggcaccg ccacgtgaa cggcgccacc	1020
gagtggcgcc ccaagaacgc cggcgccaac ggcgccatct ccaccggcaa gaccagcaac	1080
ggcaactccg tgtccatgga ctacaaggac cacgacggcg actacaagga ccacgacatc	1140
gactacaagg acgacgacga caagtga	1167

<210> 82

<211> 1149

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 82

```

atgacgttcg gggtcgccct cccggccatg ggccgcggtg tctcccttcc ccggcccagg      60
gtcgcggtgc gcgcccagtc ggcgagtcag gttttggaga gcgggcgcgc ccccgactgg      120
tccatgctgt tcgccgtgat caccaccatc ttcagcgccg ccgagaagca gtggaccaac      180
ctggagtgga agcccaagcc caagctgccc cagctgctgg acgaccactt cggcctgcac      240
ggcctggtgt tccgcgcac cttcgccatc cgctcctacg aggtgggccc cgaccgcagc      300
acctccatcc tggccgtgat gaaccacatg caggaggcca ccctgaacca cgccaagagc      360
gtgggcatcc tgggcgacgg cttcggcacc accctggaga tgtccaagcg cgacctgatg      420
tgggtggtgc gccgcaccca cgtggccgtg gagcgctacc ccacctgggg cgacaccgtg      480
gaggtggagt gctggatcgg cgccagcggc aacaacggca tgcgccgcga cttcctggtg      540
cgcgactgca agaccggcga gaccccgacc cgctgcacct ccctgagcgt gctgatgaac      600
acccgcaccc gccgcctgag caccatcccc gacgaggtgc gcggcgagat cggccccgcc      660
ttcatcgaca acgtggccgt gaaggacgac gagatcaaga agctgcagaa gctgaacgac      720
tccaccgccc actacatcca gggcggcctg accccccgct ggaacgacct ggacgtgaac      780
cagcacgtga acaacctgaa gtacgtggcc tgggtgttcg agaccgtgcc cgacagcatc      840
ttcgagtccc accacatcag ctccctcacc ctggagtacc gccgcgagtg caccgcgcac      900
tccgtgctgc gcagcctgac caccgtgagc ggccggcagct ccgaggccgg cctggtgtgc      960
gaccacctgc tgcagctgga gggcggcagc gaggtgctgc gcgcccgcac cgagtggcgc     1020
cccaagctga ccgactcctt ccgcggcatc agcgtgatcc ccgccgagcc ccgcgtgatg     1080
gactacaagg accacgacgg cgactacaag gaccacgaca tcgactacaa ggacgacgac     1140
gacaagtga                                     1149

```

<210> 83

<211> 1146

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 83

```

atggcttcg cggcattcac catgtcggcg tgccccgcga tgactggcag ggcccctggg      60
gcacgtcgct ccggacggcc agtcgccacc cgctgaggg ggccgcgccc cgactggtcc      120
atgctgttcg ccgtgatcac caccatcttc agcgccgccg agaagcagtg gaccaacctg      180
gagtggaagc ccaagcccaa gctgccccag ctgctggacg accacttcgg cctgcacggc      240
ctggtgttcc gccgcacctt cgccatccgc tcctacgagg tgggccccga ccgcagcacc      300

```

026172-005010PC - Sequence Listing_1.TXT

tccatcctgg ccgtgatgaa ccacatgcag gaggccaccc tgaaccacgc caagagcgtg	360
ggcatcctgg gcgacggctt cggcaccacc ctggagatgt ccaagcgcgga cctgatgtgg	420
gtggtgcgcc gcacccacgt ggccgtggag cgctacccca cctggggcgga caccgtggag	480
gtggagtgtt ggatcggcgc cagcggcaac aacggcatgc gccgcgactt cctggtgcgc	540
gactgcaaga ccggcgagat cctgaccgcg tgcacctccc tgagcgtgct gatgaacacc	600
cgcacccgcc gcctgagcac catccccgac gagggtgcgcg gcgagatcgg ccccgcttc	660
atcgacaacg tggccgtgaa ggacgacgag atcaagaagc tgcagaagct gaacgactcc	720
accgccgact acatccaggg cggcctgacc ccccgctgga acgacctgga cgtgaaccag	780
cacgtgaaca acctgaagta cgtggcctgg gtgttcgaga ccgtgcccga cagcatcttc	840
gagtccacc acatcagctc cttcaccttg gagtaccgcc gcgagtgcac ccgcgactcc	900
gtgctgcgca gcctgaccac cgtgagcggc ggcagctccg aggccggcct ggtgtgcgac	960
cacctgctgc agctggaggg cggcagcgag gtgctgcgcg cccgcaccga gtggcgcccc	1020
aagctgaccg actccttcgc cggcatcagc gtgatccccg ccgagccccg cgtgatggac	1080
tacaaggacc acgacggcga ctacaaggac cagcacatcg actacaagga cgacgacgac	1140
aagtga	1146

<210> 84

<211> 1155

<212> DNA

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 84

atggccaccg catccacttt ctcggcgctt aatgcccgtt gcggcgacct gcgtcgctcg	60
gcggggtccg ggccccggcg cccagcgagg cccctccccg tgcgcgggcg cgccccgac	120
tggatcatgc tgttcgccgt gatcaccacc atcttcagcg ccgccgagaa gcagtggacc	180
aacctggagt ggaagcccaa gcccaagctg cccagctgc tggacgacca cttcggcctg	240
cacggcctgg tgttcgcccg caccttcgcc atccgctcct acgagggtgg ccccgaccgc	300
agcacctcca tcctggccgt gatgaaccac atgcaggagg ccacctgaa ccacgccaag	360
agcgtgggca tcctgggcca cggcttcggc accaccttg agatgtccaa gcgcgacctg	420
atgtgggtgg tgcgccgcac ccacgtggcc gtggagcgct accccacctg gggcgacacc	480
gtggaggtgg agtgcctgat cggcgccagc ggcaacaacg gcatgcgccg cgacttcctg	540
gtgcgcgact gcaagaccgg cgagatcctg acccgctgca cctccctgag cgtgctgatg	600
aacacccgca cccgccgctt gagcaccatc cccgacgagg tgcgcggcga gatcggcccc	660
gccttcacgc acaacgtggc cgtgaaggac gacgagatca agaagctgca gaagctgaac	720
gactccaccg ccgactacat ccagggcggc ctgacccccg gctggaacga cctggacgtg	780
aaccagcacg tgaacaacct gaagtacgtg gcctgggtgt tcgagaccgt gcccgacagc	840

026172-005010PC - Sequence Listing_1.TXT

atcttcgagt cccaccacat cagctccttc accctggagt accgccgcga gtgcacccgc	900
gactccgtgc tgcgcagcct gaccaccgtg agcggcggca gctccgaggc cggcctggtg	960
tgcgaccacc tgctgcagct ggagggcggc agcgaggtgc tgcgcgcccg caccgagtgg	1020
cgccccaagc tgaccgactc cttccgcggc atcagcgtga tccccgccga gccccgcgtg	1080
atggactaca aggaccacga cggcgactac aaggaccacg acatcgacta caaggacgac	1140
gacgacaagt gatga	1155

<210> 85

<211> 1152

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 85

atggctatca agacgaacag gcagcctgtg gagaagcctc cgttcacgat cgggacgctg	60
cgcaaggcca tccccgcgca ctgtttcgag cgctcggcgc ttcgtgggcg cgccccgac	120
tggatccatgc tgttcgccgt gatcaccacc atcttcagcg ccgccgagaa gcagtggacc	180
aacctggagt ggaagcccaa gcccagctg cccagctgc tggacgacca cttcggcctg	240
cacggcctgg tggtccgccc caccttcgcc atccgctcct acgaggtggg ccccgaccgc	300
agcacctcca tcttgccgt gatgaaccac atgcaggagg ccaccctgaa ccacgccaag	360
agcgtgggca tcttgggcga cggcttcggc accaccctgg agatgtccaa gcgcgacctg	420
atgtgggtgg tgcgcgcac ccacgtggcc gtggagcgct accccacctg gggcgacacc	480
gtggaggtgg agtgctggat cggcgccagc ggcaacaacg gcatgcgccg cgacttcctg	540
gtgcgcgact gcaagaccgg cgagatcctg acccgctgca cctccctgag cgtgctgatg	600
aacacccgca cccgccgcct gagcaccatc cccgacgagg tgcgcggcga gatcggcccc	660
gccttcacatg acaacgtggc cgtgaaggac gacgagatca agaagctgca gaagctgaac	720
gactccaccg ccgactacat ccagggcggc ctgaccccc gctggaacga cctggacgtg	780
aaccagcacg tgaacaacct gaagtacgtg gcctgggtgt tcgagaccgt gcccgacagc	840
atcttcgagt cccaccacat cagctccttc accctggagt accgccgcga gtgcacccgc	900
gactccgtgc tgcgcagcct gaccaccgtg agcggcggca gctccgaggc cggcctggtg	960
tgcgaccacc tgctgcagct ggagggcggc agcgaggtgc tgcgcgcccg caccgagtgg	1020
cgccccaagc tgaccgactc cttccgcggc atcagcgtga tccccgccga gccccgcgtg	1080
atggactaca aggaccacga cggcgactac aaggaccacg acatcgacta caaggacgac	1140
gacgacaagt ga	1152

<210> 86

<211> 1155

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 86

```

atggccaccg catccacttt ctcggcggtc aatgcccgtc gcggcgacct gcgtcgctcg      60
gcgggctccg ggccccggcg cccagcgagg cccctccccg tgcgcgggcg cgccccgac      120
tggtccatgc tgttcgccgt gatcaccacc atcttctccg ccgccgagaa gcagtggacc      180
aacctggagt ggaagcccaa gcccaccccc ccccgactgc tggacgacca cttcggcccc      240
cacggccttg tggtccgccc caccttcgcc atccgcagct acgagggtgg ccccgaccgc      300
tccaccagca tcgtggccgt gatgaaccac ctgcaggagg ccgccctgaa ccacgccaag      360
tccgtgggca tcctgggcga cggcttcggc accaccctgg agatgtccaa gcgcgacctg      420
atctgggttg tgaagcgcac ccacgtggcc gtggagcgct accccgcctg gggcgacacc      480
gtggaggttg agtgctgggt gggcgccctc ggcaacaacg gccgccgcca cgacttctcg      540
gtgcgcgact gcaagaccgg cgagatcctg acccgctgca cctccctgag cgtgatgatg      600
aacacccgca cccgccgctt gagcaagatc cccgaggagg tgcgcggcga gatcggcccc      660
gccttcatcg acaacgtggc cgtgaaggac gaggagatca agaagcccca gaagctgaac      720
gactccaccg ccgactacat ccagggcggc ctgacccccg gctggaacga cctggacatc      780
aaccagcacg tgaacaacat caagtacgtg gactggatcc tggagaccgt gcccgcagc      840
atcttcgaga gccaccacat ctctccttc accatcgagt accgccgcga gtgcaccatg      900
gacagcgctg tgcagtcctt gaccaccgtg agcggcggtc cctccgaggc cggcctggtg      960
tgcgagcacc tgctgcagct ggagggcggc agcggaggtg tgcgcgcca gaccgagtg      1020
cgccccaaag tgaccgactc cttccgcggc atcagcgtga tccccgccga gtccagcgtg      1080
atggactaca aggaccacga cggcgactac aaggaccacg acatcgacta caaggacgac      1140
gacgacaagt gatga                                     1155

```

<210> 87

<211> 1893

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 87

```

gaattccttt cttgcgctat gacacttcca gaaaaggta gggcgggctg cgagacggct      60
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagtcctt tcggggctgc      120
atgggcgctc cgatgccgct ccagggcgag cgctgtttta atagccaggc ccccgattgc      180
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta      240
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt      300

```

026172-005010PC - Sequence Listing_1.TXT

cagtcacaac ccgcaaacac tagtatggcc accgcatcca ctttctcggc gttcaatgcc	360
cgctgcgggc acctgcgtcg ctcggggggc tccggggccc ggcgcccagc gaggcccctc	420
cccgtgcgcg ggcgcgcccc cgactgggtcc atgctgttcg ccgtgatcac caccatcttc	480
tccgccgccc agaagcagtg gaccaacctg gagtggaagc ccaagcccaa cccccccag	540
ctgctggacg accacttcgg ccccccacggc ctgggtgttc gccgcacctt cgccatccgc	600
agctacgagg tggggcccga ccgctccacc agcatcgtgg ccgtgatgaa ccacctgcag	660
gaggccgccc tgaaccacgc caagtccgtg ggcacccctg ggcacggcctt cggcaccacc	720
ctggagatgt ccaagcgca cctgatctgg gtggtgaagc gcacccacgt ggccgtggag	780
cgctaccccg cctggggcga caccgtggag gtggagtgtt ggggtgggcgc ctccggcaac	840
aacggccgccc gccacgactt cctgggtgcgc gactgcaaga ccggcgagat cctgacccgc	900
tgcacctccc tgagcgtgat gatgaacacc cgcacccgcc gcctgagcaa gatccccgag	960
gaggtgcgcg gcgagatcgg ccccgccctt atcgacaacg tggccgtgaa ggacgaggag	1020
atcaagaagc cccagaagct gaacgactcc accgccgact acatccaggg cggcctgacc	1080
ccccgctgga acgacctgga catcaaccag cacgtgaaca acatcaagta cgtggactgg	1140
atcctggaga ccgtgcccga cagcatcttc gagagccacc acatctctc cttcaccatc	1200
gagtaccgcc gcgagtgcac catggacagc gtgctgcagt ccctgaccac cgtgagcggc	1260
ggctcctccg aggcgggcct ggtgtgcgag cacctgctgc agctggaggg cggcagcgag	1320
gtgctgcgcg ccaagaccga gtggcgcccc aagctgaccg actccttccg cggcatcagc	1380
gtgatccccg ccgagtccag cgtgatggac tacaaggacc acgacggcga ctacaaggac	1440
cacgacatcg actacaagga cgacgacgac aagtgatgac tcgaggcagc agcagctcgg	1500
atagtatcga cacactctgg acgctggctg tgtgatggac tgttgccgcc acacttgctg	1560
ccttgacctg tgaatatccc tgccgctttt atcaaacagc ctcagtgtgt ttgatcttgt	1620
gtgtacgcgc ttttgcgagt tgctagctgc ttgtgctatt tgcgaatacc acccccagca	1680
tccccctccc tcgtttcata tcgcttgcat cccaaccgca acttatctac gctgtcctgc	1740
tatccctcag cgctgctcct gctcctgctc actgcccctc gcacagcctt ggtttgggct	1800
ccgcctgtat tctcctggta ctgcaacctg taaaccagca ctgcaatgct gatgcacggg	1860
aagtagtggg atgggaacac aaatggaaag ctt	1893

<210> 88

<211> 1887

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 88

gaattccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	60
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	120

026172-005010PC - Sequence Listing_1.TXT

atgggcgctc cgatgccgct ccagggcgag cgctgttttaa atagccaggc ccccgattgc	180
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	240
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	300
cagtcacaac ccgcaaacac tagtatggct tccgcggcat tcaccatgtc ggcgtgcccc	360
gcgatgactg gcagggcccc tggggcacgt cgctccggac ggccagtcgc caccgcctg	420
agggggcgcg ccccgactg gtccatgctg ttccgctga tcaccacat cttctccgcc	480
gccgagaagc agtggaccaa cctggagtgg aagcccaagc ccaaccccc ccagctgctg	540
gacgaccact tcggccccca cggcctggtg ttccgccgca cttcggccat ccgcagctac	600
gaggtgggccc ccgaccgctc caccagcatc gtggccgtga tgaaccacct gcaggaggcc	660
gccctgaacc acgccaagtc cgtgggcac cttggcgacg gcttcggcac caccctggag	720
atgtccaagc gcgacctgat ctgggtggtg aagcgacccc acgtggccgt ggagcgctac	780
cccgcctggg gcgacaccgt ggaggtggag tgctgggtgg gcgcctccgg caacaacggc	840
cgccgccacg acttcctggt gcgcgactgc aagaccggcg agatcctgac ccgctgcacc	900
tccctgagcg tgatgatgaa cccccgcacc cgccgcctga gcaagatccc cgaggaggtg	960
cgcggcgaga tcggccccgc cttcatcgac aacgtggccg tgaaggacga ggagatcaag	1020
aagccccaga agctgaacga ctccaccgcc gactacatcc agggcggcct gacccccgc	1080
tggaacgacc tggacatcaa ccagcacgtg aacaacatca agtacgtgga ctggatcctg	1140
gagaccgtgc ccgacagcat cttcgagagc caccacatct cctccttcac catcgagtac	1200
cgccgcgagt gcacatgga cagcgtgctg cagtcctga ccaccgtgag cggcggtccc	1260
tccgaggccg gcctggtgtg cgagcacctg ctgcagctgg agggcggcag cgaggtgctg	1320
cgcgccaaga ccgagtggcg cccaagctg accgactcct tccgcggcat cagcgtgac	1380
cccgccgagt ccagcgtgat ggactacaag gaccacgacg gcgactaaa ggaccacgac	1440
atcgactaca aggacgacga cgacaagtga tgactcgagg cagcagcagc tcggatagta	1500
tcgacacact ctggacgctg gtcgtgtgat ggactgttgc cgccacactt gctgccttga	1560
cctgtgaata tccctgccgc ttttatcaaa cagcctcagt gtgtttgatc ttgtgtgtac	1620
gcgcttttgc gagttgctag ctgcttgtgc tatttgcgaa taccacccc agcatcccct	1680
tccctcgttt catatcgctt gcatcccaac cgcaacttat ctacgtgtc ctgctatccc	1740
tcagcgctgc tcctgctcct gtcactgcc cctcgcacag ccttggtttg ggctccgcct	1800
gtattctcct ggtactgcaa cctgtaaacc agcactgcaa tgctgatgca cgggaagtag	1860
tgggatggga acacaaatgg aaagctt	1887

<210> 89

<211> 3631

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 89

gaattccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgctgccgc atgcttgtgc tggtagggct gggcagtgc	120
gccatgctga ttgaggcttg gttcatcggg tggaaacctta tgttgtgtgc gggcttgcat	180
gccgggcaat gcgcatgggt gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccaggtggt tcaatcgcg gaggcagagg gatttcagat gatcgcgcg acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaattgatcg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtgc	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaaacactg caatcatcgg gcgggctga	540
tgcaagcatg cctggcgaag acacatgggt tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggtcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcattggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgcat	780
gccaaaccgg agcgaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgtcatgag acgcatgtag cgctgacgtc ccttgacggc gctcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcggg	960
gccacccttc ttgcgggggc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgcctg gagaagcgag gctggggcct ttgggctggt gcagcccgca	1080
atggaatgca ggaccgccag gctagcagca aaggcgctc ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt ccccgctgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcgaagtag gcgcctcct ttctgctgc cctctctccg	1320
tcccgcact agtatgctgc tgcaggcctt cctgttcctg ctggccggct tcgcccga	1380
gatcagcgcc tccatgacga acgagacgtc cgaccgcccc ctggtgcact tcaccccaa	1440
caagggtggt gggcgcgcca gccaccacgt gtacaagcgc ctgaccaga gcaccaacac	1500
caagtcccc agcgtgaacc agccctaccg caccggcttc cacttccagc cccccaagaa	1560
ctggatgaac gacccaacg gcccattgat ctacaagggc atctaccacc tgttctacca	1620
gtggaacccc aaggcgccg tgtggggcaa catcgtgtgg gccactcca ccagaccga	1680
cctgatcaac tgggaccccc accccccgc catcttcccc agcgccccct tcgacatcaa	1740
cggctgctgg tccggcagcg ccaccatcct gcccaacggc aagcccgtga tcctgtacac	1800
cggcatcgac cccaagaacc agcaggtgca gaacatcgcc gagcccaaga acctgtccga	1860
cccctacctg cgcgagtggg agaagagccc cctgaacccc ctgatggccc ccgacgccgt	1920

026172-005010PC - Sequence Listing_1.TXT

gaacggcatc aacgcctcca gcttccgcga cccaccacc gcctggctgg gccaggacaa	1980
gaagtggcgc gtgatcatcg gctccaagat ccaccgccgc ggcctggcca tcacctacac	2040
cagcaaggac ttctgaagt gggagaagtc ccccgagccc ctgcactacg acgacggcag	2100
cggcatgttg gagtgccccg acttcttccc cgtgacccgc ttcggcagca acggcgtgga	2160
gacctccagc ttcggcgagc ccaacgagat cctgaagcac gtgctgaaga tctccctgga	2220
cgacaccaag cagcactact acaccatcgg cacctacgac cgcgtaagg acaagttcgt	2280
gcccgacaac ggcttcaaga tggacggcac cgccccccgc tacgactacg gcaagtacta	2340
cgccagcaag accttcttcg actccgcca gaaccgccgc atcctgtggg gctggaccaa	2400
cgagtcctcc agcgtggagg acgacgtgga gaagggtgg tccggcatcc agaccatccc	2460
ccgcaagatc tggctggacc gcagcggcaa gcagctgac cagtggcccc tgcgcgaggt	2520
ggagcgcctg cgcaccaagc aggtgaagaa cctgcgcaac aagggtgctga agtccggcag	2580
ccgcctggag gtgtacggcg tgaccgccgc ccaggccgac gtggaggtgc tgttcaaggt	2640
gcgcgacctg gagaaggccg acgtgatcga gccctcctgg accgaccccc agctgatctg	2700
cagcaagatg aacgtgtccg tgaagtccgg cctgggcccc ttcggcctga tgggtgctggc	2760
cagcaagaac ctggaggagt acacctccgt gtacttccgc atcttcaagg cccgccagaa	2820
cagcaacaag tacgtggtgc tgatgtgctc cgaccagtcc cgcagctccc tgaaggagga	2880
caacgacaag accacctacg gcgccttcgt ggacatcaac cccaccagc ccctgagcct	2940
gcgcgccctg atcgaccact ccgtgggtgga gagcttcggc ggcaagggcc gcgcctgcat	3000
cacctccgc gtgtacccca agctggccat cggcaagtcc agccacctgt tcgccttcaa	3060
ctacggctac cagtccgtgg acgtgctgaa cctgaacgcc tggagcatga actccgcca	3120
gatcagcatg gactacaagg accacgacgg cgactacaag gaccacgaca tcgactacaa	3180
ggacgacgac gacaagtgat taattaaccg gctcgaggca gcagcagctc ggatagtatc	3240
gacacactct ggacgctggc cgtgtgatgg actgttgccg ccacacttgc tgccttgacc	3300
tgtgaatatc cctgccgctt ttatcaaaca gcctcagtgt gtttgatctt gtgtgtacgc	3360
gcttttgca gttgctagct gcttgtgcta tttgcgaata ccacccccag catccccctc	3420
cctcgtttca tatcgcttgc atcccaaccg caacttatct acgctgtcct gctatccctc	3480
agcgtgctc ctgctcctgc tactgcccc tcgcacagcc ttggtttggg ctccgcctgt	3540
attctcctgg tactgcaacc tgtaaaccag cactgcaatg ctgatgcacg ggaagtagtg	3600
ggatgggaac acaaatggaa agcttgagct c	3631

<210> 90

<211> 621

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

026172-005010PC - Sequence Listing_1.TXT

<400> 90

Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
 1 5 10 15

Ile Ser Ala Ser Met Thr Asn Glu Thr Ser Asp Arg Pro Leu Val His
 20 25 30

Phe Thr Pro Asn Lys Gly Trp Gly Arg Ala Ser His His Val Tyr Lys
 35 40 45

Arg Leu Thr Gln Ser Thr Asn Thr Lys Ser Pro Ser Val Asn Gln Pro
 50 55 60

Tyr Arg Thr Gly Phe His Phe Gln Pro Pro Lys Asn Trp Met Asn Asp
 65 70 75 80

Pro Asn Gly Pro Met Ile Tyr Lys Gly Ile Tyr His Leu Phe Tyr Gln
 85 90 95

Trp Asn Pro Lys Gly Ala Val Trp Gly Asn Ile Val Trp Ala His Ser
 100 105 110

Thr Ser Thr Asp Leu Ile Asn Trp Asp Pro His Pro Pro Ala Ile Phe
 115 120 125

Pro Ser Ala Pro Phe Asp Ile Asn Gly Cys Trp Ser Gly Ser Ala Thr
 130 135 140

Ile Leu Pro Asn Gly Lys Pro Val Ile Leu Tyr Thr Gly Ile Asp Pro
 145 150 155 160

Lys Asn Gln Gln Val Gln Asn Ile Ala Glu Pro Lys Asn Leu Ser Asp
 165 170 175

Pro Tyr Leu Arg Glu Trp Lys Lys Ser Pro Leu Asn Pro Leu Met Ala
 180 185 190

Pro Asp Ala Val Asn Gly Ile Asn Ala Ser Ser Phe Arg Asp Pro Thr
 195 200 205

Thr Ala Trp Leu Gly Gln Asp Lys Lys Trp Arg Val Ile Ile Gly Ser
 210 215 220

Lys Ile His Arg Arg Gly Leu Ala Ile Thr Tyr Thr Ser Lys Asp Phe
 225 230 235 240

Leu Lys Trp Glu Lys Ser Pro Glu Pro Leu His Tyr Asp Asp Gly Ser
 245 250 255

Gly Met Trp Glu Cys Pro Asp Phe Phe Pro Val Thr Arg Phe Gly Ser
 260 265 270

026172-005010PC - Sequence Listing_1.TXT

Asn Gly Val Glu Thr Ser Ser Phe Gly Glu Pro Asn Glu Ile Leu Lys
 275 280 285
 His Val Leu Lys Ile Ser Leu Asp Asp Thr Lys His Asp Tyr Tyr Thr
 290 295 300
 Ile Gly Thr Tyr Asp Arg Val Lys Asp Lys Phe Val Pro Asp Asn Gly
 305 310 315 320
 Phe Lys Met Asp Gly Thr Ala Pro Arg Tyr Asp Tyr Gly Lys Tyr Tyr
 325 330 335
 Ala Ser Lys Thr Phe Phe Asp Ser Ala Lys Asn Arg Arg Ile Leu Trp
 340 345 350
 Gly Trp Thr Asn Glu Ser Ser Ser Val Glu Asp Asp Val Glu Lys Gly
 355 360 365
 Trp Ser Gly Ile Gln Thr Ile Pro Arg Lys Ile Trp Leu Asp Arg Ser
 370 375 380
 Gly Lys Gln Leu Ile Gln Trp Pro Val Arg Glu Val Glu Arg Leu Arg
 385 390 395 400
 Thr Lys Gln Val Lys Asn Leu Arg Asn Lys Val Leu Lys Ser Gly Ser
 405 410 415
 Arg Leu Glu Val Tyr Gly Val Thr Ala Ala Gln Ala Asp Val Glu Val
 420 425 430
 Leu Phe Lys Val Arg Asp Leu Glu Lys Ala Asp Val Ile Glu Pro Ser
 435 440 445
 Trp Thr Asp Pro Gln Leu Ile Cys Ser Lys Met Asn Val Ser Val Lys
 450 455 460
 Ser Gly Leu Gly Pro Phe Gly Leu Met Val Leu Ala Ser Lys Asn Leu
 465 470 475 480
 Glu Glu Tyr Thr Ser Val Tyr Phe Arg Ile Phe Lys Ala Arg Gln Asn
 485 490 495
 Ser Asn Lys Tyr Val Val Leu Met Cys Ser Asp Gln Ser Arg Ser Ser
 500 505 510
 Leu Lys Glu Asp Asn Asp Lys Thr Thr Tyr Gly Ala Phe Val Asp Ile
 515 520 525
 Asn Pro His Gln Pro Leu Ser Leu Arg Ala Leu Ile Asp His Ser Val
 530 535 540

026172-005010PC - Sequence Listing_1.TXT

Val Glu Ser Phe Gly Gly Lys Gly Arg Ala Cys Ile Thr Ser Arg Val
545 550 555 560

Tyr Pro Lys Leu Ala Ile Gly Lys Ser Ser His Leu Phe Ala Phe Asn
565 570 575

Tyr Gly Tyr Gln Ser Val Asp Val Leu Asn Leu Asn Ala Trp Ser Met
580 585 590

Asn Ser Ala Gln Ile Ser Met Asp Tyr Lys Asp His Asp Gly Asp Tyr
595 600 605

Lys Asp His Asp Ile Asp Tyr Lys Asp Asp Asp Asp Lys
610 615 620

<210> 91
<211> 997
<212> DNA
<213> Prototheca moriformis

<400> 91
cctgtcgatc gaagagaagg agacatgtgt acattattgg tgtgagggcg ctgaatcggc 60
catttttttaa aatgatcacg ctcatgccaa tagacgcggc acataacgac gttcaaacc 120
ccgcaaagc cgcggacaac cccatccctc cacaccccc acacaaagaa cccgccaccg 180
cttaccttgc ccacgaggta ggcccttctgt tgcgcaaac cggcctcggg gatgaatgca 240
tgcccgttcc tgacgagcgc tgcccggggc aacacgctct tttgctgcgt ctccctcaggc 300
ttgggggcct ccttgggcctt ggggtgccgc atgatctgcg cgcacagag aaacgttgct 360
ggtaaaaagg agcgcggcgc tgcgcaatat atatataggc atgccaacac agcccaacct 420
cactcgggag cccgtccac ccccccaag tcgctgcct tgacggcata ctgctgcaga 480
agcttcatga gaatgatgcc gaacaagagg ggcacgagga cccaatccc gacatccttg 540
tcgataatga tctcgtgagt ccccatcgtc cgcccgacgc tccggggagc ccgccgatgc 600
tcaagacgag agggccctcg accaggagg gctggcccg gcgggactg gcgtcgaagg 660
tgcgcccgtc gttcgcctgc agtcctatgc caaaaacaa gtcttctgac ggggtgcgtt 720
tgctcccgtg cgggcaggca acagaggat tcaccctggg catggggaga tcggcgatcg 780
agctgggata agagatactt ctggcaagca atgacaact gtcaggaccg gaccgtgcca 840
tatatttctc acctagcgcc gcaaaccta acaatttggg agtcactgtg cactgagtt 900
cgactggtag ctgaatggag tcgctgctcc actaaacgaa ttgtcagcac cgccagccgg 960
ccgaggaccc gagtcatagc gagggtagta gcgcgcc 997

<210> 92
<211> 753
<212> DNA
<213> Prototheca moriformis

<400> 92

026172-005010PC - Sequence Listing_1.TXT

actaattgca atcgtgcagt aatcatcgat atggtcacaa gtagatcccc tactgacacc	60
ctctcgtaca tgtaggcaat gtcacggcg ccgtcctgct gaccgatgcc gacgtagcag	120
agcagacccg ggccgatctg ggatacgagc cggccctcca cctgcgctcg aggtggaatc	180
aagtaaataa ccaatacact ttctgacacc acacagagtt gcacggacgg tggcgtacct	240
ctacgctcgc gctcttcacg cgctggacga ccgcacgcat gagcccggtt ggcttggctt	300
gggctgcaaa aatgcacaac aaacaagtat cagacgctca tggatgcaca cgcgctccca	360
agcacgctca gactaaatat tacagtagct cgtatctgat aagatatcga gacataccgc	420
tcaactcacc cgcaaactgc gccccgccag gtgatgcgca cagggcccca ccatgcgatc	480
catcgcacgc ctctcagagg gcgctatcac gtggccggag agcgttcaca gcgtacgcca	540
ctgtatctgg gcggtatgcg gtccgtcaac atggagacag ataccgcac caccaccttg	600
caagctcttc catattggaa gtagaaaatt gtaattgtat catcgcacga ggggccaact	660
tgccgtcggc gagctgggag acgaacacca cctggacgtt gtcgagactc gctcgtgccg	720
tgcgccgggc cgctgggtat ccagaccgtc gcc	753

<210> 93

<211> 1122

<212> DNA

<213> *Prototheca moriformis*

<400> 93

caacgacaac cagcaggcaa ctcggtcagc gacccaacac gcgagtcaaa ttgttgctg	60
ttcttgccct gtctatttac tgtgatagca agactgtcgg tcagtcaata ccgcggtgcg	120
cacgtcgggg tgccaagcct agcagagcac gggacggctg gtgctgtgcg ccagctcagc	180
tcgcttcgcg accaattgta ggaccggcaa agtcacaaa acatgccagc ggtgcgattc	240
aattggatcat gagctctaca aaattgtttt gtgcgtcgcg caggtatcca acggcgcggc	300
agagaaagtt tgacagctct cgatttcacg tcggaaaaat ggggagaatt tatgacacac	360
aagtgcgcag gcggcccagg cgccagcat attctggcgt gacctgggccc gccacaaaa	420
tgcttgatg cactctaaaa taattatatt tgccatgaac aagggaagag ttaccgcacc	480
cagccctaga cttgggagcc cgagcaaggt tacgtcaagc caccttcgcc catcgcccaa	540
ctccgtattc cccgacagcc gcacgtggcc ctcgccggaa tgaaccctga atcggcatca	600
cgccacgcgt tcgccaatcg ttccgctctc tggcttcacg ggcctgcgcc ttcacgtcgt	660
ggtcacgaca gtgcattcat acttccattt gcacctcggc acacactttt acgcatcgcc	720
tacccttgct gcggcagctt agggtcactt tgcagccatg ggacagtgtt acaccaccgt	780
cgggtgcgcaa agctatttca agtgaaccgt gggcggaata aaggaaatgta cactgtctca	840
accgactcct acaattgttt accatgcaga tcagagctcg acggccatca tcgagcaggt	900
gtggggcctt ggtggcgcgg cgcggggccc cagggcgctg caggcattga tggcactctg	960
agactttcgc acgcgcacga gggaccccat caagagaaga gtgtgtcttt atgtcccat	1020
tcatgatgat gtatcttggt attgtcgcag tttggcaagt ttaaccggat cgccgctcca	1080

026172-005010PC - Sequence Listing_1.TXT

ggtgtggcgt ggcggatttt tctaggggtg cttgagcagt cg 1122

<210> 94
<211> 574
<212> DNA
<213> *Prototheca moriformis*

<400> 94
ggcccagggc cctgcggatg gcccacacca gatctagcct ctcttatgcc atgcccgcct 60
cgctgcccgt cgtatccccc cgccgatccg cgcgtagggg accgcggcct gaccacgcc 120
acgaaagagc tttgctcctc aatttctcgc caacagaacc gtatcaaagc ctcaacgcct 180
atcccgaaca atccgtattc acaccaaatac gagtataccg gactggtttg cctagtcttg 240
aaggaaatga tcccgtccat gctcgggaag gggagcgggc ggaggatcct actcatctct 300
gaaatgggat tgggtccgaag atgggttggg caagcacgtg ccaaacccca gcgagttgct 360
gacgagcagg ctcatccaat cccccggcga atcctccctc acgccccgca tgcatacaag 420
tccctccac acgccccctc ccatccatct tgcctgtggtc cgaacgcgag cggcgctcag 480
gcggaccact tgctccgcag cgccgtcttg gtctccaccc cacagcggct ttgctgccag 540
aggcaccccc cttgccccac ctctcttgc agcc 574

<210> 95
<211> 1096
<212> DNA
<213> *Prototheca moriformis*

<400> 95
ccaggcaggc ggtaggggtg ccgattgctt gagcgaattg gaagatataa tttttgttg 60
tgtccctgga cgctgtttgt ggcgctcctt tttggagaag attgctggg ggagctttcc 120
atgtaccacg ctctcttctg aaaggattct ggccgagtc tgatgagccc aaagaaaaca 180
cctgcctttc agtgctggca ctctgaaaac gtcaacagat gattatacat gtcacaaaag 240
gcagccgatt aggaacggga gctctggccg ttcgtttggc tgcctgggct gattgaagtg 300
atccaccctg ttcgaatgaa ggcggctcag tcgaattatc gaccggagct gtcgggaagg 360
cgtccggggc agagtgaagt gctgcggcct ggttgtcgtt caaaaagacc ccggtagccc 420
aacaatcacg aacgaaagga atataattgc ttgcatacta tacattcagt ttctatgttg 480
cgggtagaca agtctcatgg gcttctaaag gctgtccctt gaaggctact tataaaaact 540
tgctgcgcca tggcacggat cgcgcttgcg caggctgcaa ccctgcgcgc aagggtcaaat 600
acacagcaaa agatactaac agaatttcta aaaacattta aatatttgtt tcgaccagcc 660
aattgtggtc gtaggcacgc aaaagacttt gttttgcgcc caccgagcat ccacgtggc 720
agtcaagcca gtccgatgtg cattgcgtgg cagcatcgag gagcatcaaa aacctcgtgc 780
acgcttttct gtcaatcatc atcaaccact ccaccatgta taccgatgc atcgcggtgc 840
gcagcgcgcc acgcgtccca gaccgccc aaaaaccagc agcggcgaaa gcaaattctc 900
acttgcccga aaccccgagc agcggcattc acacgtgggc gaaaaccca cttgccctaa 960

026172-005010PC - Sequence Listing_1.TXT

caggcgatg tctgctgtca cgatgcctga caacgggtatt atagatatatac actgattaat	1020
gtttgagtgt gtgagagtcg cgaatcagga atgaattgct agtaggcact ccgaccgggc	1080
gggggcccag ggacca	1096

<210> 96
 <211> 1075
 <212> DNA
 <213> Prototheca moriformis

<400> 96	
ggccgacagg acgcgcgtca aagggtgctgg gcgtgtatgc cctggctcggc aggtcgttgc	60
tgttgctgcg ctctgtggttc cgcaaccctg attttggcgt cttattcttg cgtggcaagc	120
gctgacgccc gcgagccggg ccggcgccga tgcggtgtct cacggctgcc gagctccaag	180
ggaggcaaga gcgcccggat cagctgaagg gctttacacg caaggtagc ccgctcctgc	240
aaggctgcgt ggtggacttg aacctgtagg tcctctgctg aagttcctcc actacctcac	300
caggcccgac agaccaaagc acaggctttt cagggtccgtg tcattccactc taaaacactc	360
gactacgacc tactgatggc cctagattct tcattcaaca tgctgagac acttgctcag	420
aattgaaact ccctgaaggg accaccagag gccctgagtt gttccttccc cccgtggcga	480
gctgccagcc aggtgtgacc tgtgatcgag gctggcgcca aaataggctt cgtgtgctca	540
ggtcatggga ggtgcaggac agctcatgaa acgccaacaa tcgcacaatt catgtcaagc	600
taatcagcta tttcctcttc acgagctgta attgtcccaa aattctgggc taccgggggt	660
gattccttctg gtacggggccc ttccctcaac cctaggtatg cgcgcatgcg gtcgccgcgc	720
aactcgcgcg agggccgagg gtttgggacg ggccgtcccc aaatgcagtt gcacccggat	780
gcgcgccgcc tttcttgcca taatttatgc aatggactgc tctgcaaatt tctgggtctg	840
tcgccaaccc taggatcagc ggcgtaggat ttcgtaatca ttcgtcctga tggggagcta	900
ccgactaccc taatatcagc ccggctgcct gacgccagcg tccacttttg cgtacacatt	960
ccattcgtgc ccaagacatt tcattgtggt gcgaagcgtc cccagttacg ctcacctgtt	1020
tcccgacctc cttactgttc tgtcgacaga gcggggccac aggccggctc cagcc	1075

<210> 97
 <211> 772
 <212> DNA
 <213> Prototheca moriformis

<400> 97	
tcaccagcgg acaaagcacc ggtgtatcag gtccgtgtca tccactctaa agagctcgac	60
tacgacctac tgatggccct agattcttca tcaaaaacgc ctgagacact tgcccaggat	120
tgaactccc tgaagggacc accaggggccc ctgagttggt ctttcccccc gtggcgagct	180
gccagccagg ctgtacctgt gatcggggct ggcgggaaaa caggcttcgt gtgctcaggt	240
tatgggaggt gcaggacagc tcattaaacg ccaacaatcg cacaattcat ggcaagctaa	300
tcagttatct cccattaacg agctataatt gtcccaaat tctgggtctac cgggggtgat	360

026172-005010PC - Sequence Listing_1.TXT

ccttcgtgta cgggcccttc cctcaaccct aggtatgcgc acatgcggtc gccgcgcaac	420
gcgcgcgagg gccgaggggt tgggacgggc cgtcccgaaa tgcagttgca cccggatgcg	480
tggcaccttt tttgcgataa tttatgcaat ggactgctct gcaaaattct ggctctgtcg	540
ccaaccctag gatcagcggg gtaggatttc gtaatcattc gtcctgatgg ggagctaccg	600
actgccctag tatcagcccc actgcctgac gccagcgtcc acttttgtgc acacattcca	660
ttcgtgcca agacatttca ttgtggtgcg aagcgtcccc agttacgctc acctgatccc	720
caacctcctt attgttctgt cgacagagtg ggcccagagg ccggtcgcag cc	772

<210> 98

<211> 991

<212> DNA

<213> Protoheca moriformis

<400> 98

cgaaggggtc tgcacgatt cgcgcggtct ggaggccagc gtgactgctc gcgaaaatgc	60
tctgccgtgt cgggctctgg ctggggcggc cagagatctc accgtgccac acgcaactgc	120
cgcaactctgt gcccgccacc tggcgcgcac atgcgacctc ttccccgtca taccctctcc	180
tcatgtgatc tttccacacg agtgacgcag gtgcgcggag tggaggggaat caggacgttt	240
tcaagggtacc tgctcgagcc gtaccaacag ctgccgcccg gcaagggaaga gatcgaggca	300
gagattgccc ggctggaggc ccggataacg gagctcaaga gcaagctgtc cgagtgcagc	360
cgcccagggtg cacgtgtcga ctgcctatga catgtactcg acacaacatg aggaattcat	420
cgaatttgta ggaagcgggc attggtacgg gagtgggaaa gcgaaaaaac ctccctccgg	480
cagtgccatc tgccggagtc gaacgttgat agggttctcg tgacagggtg tgacctctca	540
gccttgcatc aattaaacgc tatagacatt atcagtaacc gtgaatcccg cattggatgc	600
caccgcgcg accattgggg acctgcatta cagatctagg tgagatgaca gcgaggcaac	660
ttcgccccgc ggcccagctt gcggcgccacc aatattgggtc acgggaagcc acacaccgac	720
cataaatgaa tacttgtaag ctatgtcaac cgatcaatgg cgtcgaaagt gtgccacgag	780
gatccatctg gcggggcggc gtggcgcaaca agcgcagtcg caatttctcg gacctctg	840
acctaggccc agcgcgcgg gagaaatccc cggcgggtcc tccacgcagt aaccctaattg	900
agtatcgagc gccgaccatt tacaccatcg cccccgaaat ccttccgaca ttattattat	960
cttttagatc ttggaacaga ctctgccaac c	991

<210> 99

<211> 1347

<212> DNA

<213> Prototheca moriformis

<400> 99

agagagcggg ggtggggttg tgagggtggg ttgctgacca ggagctcgcg tcgccgagcg	60
cgactcgcac acggtccagt tcccccccc tccgccccaa cgcaagcctc ccattctgat	120
gcctttccgg ccacctatac tatttcttag ttcgctgtaa catccagacc gtcctgaata	180

026172-005010PC - Sequence Listing_1.TXT

ataacaatgc cctgtgtcaa gtgcattcct aaaaaaattc tgtcccaacc aacaatccca	240
cctgaaatac caccagccct gcccagtaca ctcttccaat accatctccc tacctccacg	300
cgcaagcgac ccccatgcgc gaccaggctc gaaagtgatt tatgacttga gacgagcgag	360
tggcggcgcg gtcgactgcc ttttcatcac gtgccgtacg tcggcgaccg ctagggcttt	420
gcacggcaac gcacggcttc gccaaaccga ccagccagga cctcgactac tctaccgca	480
attcgctca agaagtgcgc aaatgtgcc aacaccattc cttacagcac tgttcaaact	540
tgatgccaat ttgacattc gggttgctcg ttggctgcgc ccacatcggc cgtgagtga	600
gcaggcggga tcggacacgg aggacgcggc gtcacgcccc gaacgcagcc cgtaactcta	660
catcaacacg acgtgttgcg taatcccgcc cggctgcgca tcgtgccaac ccattcgcga	720
tggatggctg gaaaatggtg tgccaactgc cctgagggag gctctcgcga aacgggcacg	780
tccctgaaac cgaaactgtg gccttgctcg cggccacgca agcacgtgga ccctaaacac	840
caagaaaatc agtaaacaag gttgacatcc tctacgggcg aattgtttgc ccaacccttc	900
atcgcacact gccattataa tgcattctagc tcggcgacaa gtttagaaaa ggcaggctgc	960
attgttccat ttcgccgtgg cggcgtgggt gccatttta cgaggtttg gctcccgggc	1020
agcgaccgag ccaggtcgag tccctctcgc ccgtcgacaa tgttgcaaac cccacaagcg	1080
gctaacaaca acttgatggt acctgtacac tgccaattcc ttcttccccg gccgagggtt	1140
acacgtgatg gccatggctt cgcattcagg ccgacttccc attccgactt tccagagggt	1200
ccgcggacgc tgggggttgg ctgcctgagg cccacccttt gttccccgcg tcccgacaaa	1260
cacaattgcg ttacataagg gggagccgcc cccgttcaga gtgcagaaat ctttcactat	1320
attttccagt cgtcagcgaa atcaagt	1347

<210> 100

<211> 1180

<212> DNA

<213> Prototheca moriformis

<400> 100

gatggtgggg tgtctgcctt gggctgggtg atggaggctg gtggtgcgcg ggtttcctga	60
tgcattctat ctacgcagtg tcatggtgtc cattccacac accagtacac ctttacta	120
aggatccatc cctccttccc tcttcaggac tacatggacc ccacgagcta cgcaccgggc	180
tttctcaaaa acgtcaagggt catgtttgac atgcgggacg tgggtggacga cgtgcaagggt	240
gcgtccggag tgcgcgcaaa tgagcaagtc gggcaatgtg tcggggtggg caccggggct	300
ggagatccgc gatccccgag aaaacgccgt accaccccc gcgctattcc ctcgattgcg	360
cgcagatgtg gtgaccgaca cgggggacaa cctggcggac atggggcgcc ggacctggaa	420
gcacgccaag tcgcacacgg ggaggctcgt gcagtcccc ccacgtacc tcaagggtct	480
ctttggtcgc gatccaaagt acgctggtgg catggcatgc ccgaaatgaa catcatgtgt	540
gatctccgat tgccaatggc cacctccacg gaccaccttg caggcggaag cgcaatccag	600

026172-005010PC - Sequence Listing_1.TXT

ggccccgagcc tgacgaggac ggagactcct cgtccagcgc ggggtccccg acccgacgca	660
gcagccgacc cctgctaacc cggcaacgat cggaccagca accttgctgt agttccgac	720
cgtgatgacg ggcattgccg ccgctcgatc cgctttgatg actgtctatt atttgcgcg	780
agccccctcg gaaccctacc ccgctcttgc aagccccctg catcggagat cctcgtgcgc	840
ccgcatgac cccactggat tgcccaacat ccttctttat cgtgtaaaat gtgattcctc	900
ggctgcaatc gactggcctt cgcttctggc cccaagaggg ctcgaacgtg cggcagcgag	960
ggcgctgaca cacccaagcc ctagggcttt caacgtcggc tgccaggccg gataggggga	1020
tcgcctcctt tccaccaccc acctacgagg gattcgagtc ggcttccagc tcagctattc	1080
ggccgcgccc ccggccctgc agacgtcctc cagtttccga acaggtcgct ctcagaacac	1140
ctgccgcggc tgcgatacgg caggctctca aagcgtcgac	1180

<210> 101

<211> 1263

<212> DNA

<213> *Prototheca moriformis*

<400> 101

cgcgtggagc ggtgctgac gatgccgcgc gcctgccaag gccttttgta tgcctggcct	60
gggaagtgtt ctgactgaag catcttcaag atgctctctc acgaccagcg acaccaacac	120
cgtcactttt tgccccctct gccgcagggt ccactttcta ctttgacgtc ttctccaggc	180
ggtacattgc gggactgagc gccaattcgg ccaagaacag cgctgtcgac ttgaggaggc	240
aggggtccgt cgactctgcc gagtgacacg ccttcgaccc gactgtacta cggcctgctg	300
aagagtgggt ctcgccggcc ggcgtgaccg gccctgtgcc cacaatcgac catctattcg	360
ctccttgatc tctggcgccg tcaattgccc gcgacttgac ggcaactggc tcgatcgagt	420
cgtattgaaa aagcacgttt tgcctacag ggccgcggtc cgttaccaac gtggttctcg	480
ttaggttttc gtcgggcggg ggtgcgcgaa ctgtccgatg ccatcccggc aaacccagc	540
aaggtcgcca gtctggttct gacgcaatag agtgcgtttt gggccagtct aaaaattcgt	600
ctggcatgac gtggctccac atcgtacccg gagcctgcct tggtaatgtg aggcaccggt	660
gccaactcca ttatggcagg catcgagcgc gcagggtgagt acatgacctt ccgtgaattg	720
ggaaggcgag cttgtgtaac gcctgcgatc gtgccagtga ggcatcgtaa actcaaaata	780
ttttgtagaa agtgtctgat gcctggtgag gctgcgtagg gcaagggcaa gcccttgga	840
gatgggtaat ggggccggac ctcaaacag caaccccgcg tcccccttag ggccccctgag	900
gctcgatggc agggccagcg agcccgcggc caaagggcgc catccacgg tcgccccacg	960
actccacggg tcctatacct catcttgaat ggcactaaaa actatagaat atcgggcact	1020
ggtgggcgtc tggggtacag ctggccgagc gcagtggcaa accctagggt ccgcctcaag	1080
ggcgattccc gggtaaatga cacgcaagca agatcacatg gcgcgggtccg cctcgcggct	1140
ccacaccag gccctagttt cgcaacccat aaatatcgcc ccgataccat cataagccag	1200
caaataattt ttatcagag ttccaaacct cctcagctgt gggaaaccag cccactctga	1260

026172-005010PC - Sequence Listing_1.TXT

acg

1263

<210> 102
<211> 1400
<212> DNA
<213> Prototheca moriformis

<400> 102
ccgagcagtt catggccaag tacaaggact agagaccgga ggtcggtagg ctgaatggag 60
ctggcgctcg cgtgcgcgac gtgcacgcga tgcgatacta cgaccccaca aacgcatgcc 120
tcccatcttg atgcctttcc ggccatttat actattttctc atttcgctgt aacatcttga 180
ataatagaat tgccctgtgt caagtggatt ccaagaaata ttctgtccca aaaaaacaac 240
ccaacctgaa aacaacctca aataccacca gccctgcca cctgcccagt acacttttcc 300
aataccatct ccctaccttc acgcgcaagc ggcacccatg cgcgaccagg ctcgaaagga 360
tttcacgact caggacgagc gagtggcggc gcgaccgcct gcctgttcgt cacgtgccgt 420
acgtcggcga ccgctagagc tttgcctggc aacccccggc ttcgtcaacc cggccagcca 480
ggatctcgac cactctaccg cgaaatcgcc tcaagaagtc gccaaaagt ccgtaacca 540
tgcttcgcag cgctgttcaa acttgatgcc aatcttgaca atcaggttgc tcgttggtg 600
cgtccacatc ggccgtgatt gcagcaggcg gggatcggac acggaggacg cggcgtcacg 660
ccgcgaacgc agcccgtaac tctacatcaa cgcgatatgt tgcgtaatcc cgcccggctg 720
cgcattgtga caaccattc gcgatggatg gtcggaaaat ggtgtgcaa ctgccctgag 780
ggactctctc gcgaaacggg cacgtcccgt tatccgaaac tgtggcatgg ccttgctgac 840
cacgcaagca cgtggaccct aacaccacga aaataagtaa aaaaggttga catcctctac 900
gagcgaattg tttgctcgac cttcatcgc aactgtcat tataatgcat ctagctcggc 960
gacaagttta aaaaaggcag gctgcattat tccattttgc cgtggcggca tgggtgcca 1020
ttttatgagg tttgggtctt tgggcagcga ccgagccagg ttgagtcct ctcgcccgtc 1080
gacaacgttc caaagcccat aagtggctaa taaacaactt gatggtacct gtacactgcc 1140
agttccttct tccccggccg aggtttacac gtgatggcca tggcttcgcg tttcaggctg 1200
acttcccatt ccgactttcc agaggggtccg cggacgccgg gggttggctg cgtgaggccc 1260
acccttggtt ccccgctcc cgacaaacac aattgcttta cataaggggg aagccgcccc 1320
ccgttcagag tgcaaacatc tttcattata tttttcagtc gtcagcgaat tcaagtatgt 1380
cgctgacagg catgaaggcc 1400

<210> 103
<211> 3681
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

026172-005010PC - Sequence Listing_1.TXT

<400> 103

```

gccctttgtc atcgttggca tgctttttgc gtatgtacca tatgttgaat gtataatacgt      60
aacggttgac cgtctgagat gcgagctttg ggtcttgtca aatgcgtggc cgcacggctc      120
cctcgcaccc agccccgagg cgtcgcgcac ctggcgagga gcagaccac gccaaagaaag      180
tctagtccag catgtaacaa catcaggcaa tgtgacgttt tcggttcccg atttctctgc      240
cgctctttga cggcaggcac gggcgagcaa ccggcggcgc tcgcgtcagg cacgatggat      300
gcggcgctgc ccacctgtca atgtacccca ccagtctgtc gatcgctaca agcaaccttg      360
tgctccacat tcccacttgc agacagtcta gtcgattttg ccaagctgga tgtgaggatt      420
ggccatatct tggaggccaa gattcacccg gatgctgatg ggtacgtacg cgagccaggc      480
aggcagctgc gttgactttc tgattggcac aaagcttttg ctactctcaa taccaaccac      540
gtgccccttc tgcacacctg cttccttctg atgaccactc gccacgcatg tcgcagtctg      600
tacgtcgagc agatcgacct cggcgaggag gggggccctc gcaccatcgt gagtggcctg      660
gtccggcacg tgaccctgga ggaccttgtc ggccggcggg tgggtggtgct ggccaacctc      720
aagcctcgga gcatgcgcgg ggtcaaactc gctgggatgc tgctctgcgc cgccaacgcg      780
gatcacaccg cggtgaggcc gctgcgggtc ccggacgccg ccgtgacggg ggagcgggtc      840
tgggcggggg acgaggcact cctgtccacg gagcctgcca caccaatca ggtaaggaca      900
cgttatttgt gcgcatggtg cgaatgcgtg gtctgacctg ctgtgggtat gtgttggtgg      960
attggaaacc gaatgagggc cgttcaggat tgagcccttg gccccaccct gctcctctc      1020
tcacgcccgc aggtccagaa gaagaaaatc tgggaggcag tacagccgct gctgagagtg      1080
aacgcccagg ggatcgctac tgtggcagga gaggctatgg tgaccagtgc gggggcactg      1140
accgcgccc cgttggttga cgccgcgatt tcctgacgcg agcgactgat tcttgacctt      1200
tgagaagcca ccacagcacc attttcattg ttcatccttg atttcagtac gacttctcac      1260
catttcagta ctgtaggacc cccaaaatag tgtgatcacg ctcgcaaggc acctgtgtga      1320
tcacggggaa gggcgaattc ctttcttgcg ctatgacact tccagcaaaa ggtagggcgg      1380
gctgcgagac ggcttcccg cgtgcatgc aacaccgatg atgcttcgac cccccgaagc      1440
tccttcgggg ctgcatgggc gctccgatgc cgctccaggg cgagcgctgt ttaaatagcc      1500
aggccccga ttgcaaagac attatagcga gctaccaaag ccatattcaa acacctagat      1560
cactaccact tctacacagg cactcagagc ttgtgatcgc actccgctaa gggggcgcct      1620
cttcctcttc gtttcagtca caaccgcaa acggcgcgcc atgctgctgc aggccttcct      1680
gttcctgctg gccggcttcg ccgccaagat cagcgcctcc atgacgaacg agacgtccga      1740
ccgccccctg gtgcacttca cccccaacaa gggctggatg aacgaccca acggcctgtg      1800
gtacgacgag aaggacgcca agtggcacct gtacttcag tacaaccga acgacaccgt      1860
ctgggggacg cccttgttct ggggccacgc cacgtccgac gacctgacca actgggagga      1920
ccagcccatc gccatcgccc cgaagcgcaa cgactccggc gccttctccg gctccatggt      1980
ggtggactac aacaacacct ccggcttctt caacgacacc atcgaccgc gccagcgctg      2040

```

026172-005010PC - Sequence Listing_1.TXT

cgtaggccatc tggacctaca acacccccgga gtccgaggag cagtacatct cctacagcct	2100
ggacggcggc tacaccttca ccgagtacca gaagaacccc gtgctggccg ccaactccac	2160
ccagttccgc gacccgaagg tcttctgcta cgagccctcc cagaagtgga tcatgaccgc	2220
ggccaagtcc caggactaca agatcgagat ctactcctcc gacgacctga agtcctggaa	2280
gctggagtcc gcgttcgcca acgagggcctt cctcggctac cagtacgagt gccccggcct	2340
gatcgaggtc cccaccgagc aggaccccag caagtcctac tgggtgatgt tcatctccat	2400
caacccccgc gccccggccg gcggctcctt caaccagtac ttcgtcggca gcttcaacgg	2460
caccacttcc gaggccttcg acaaccagtc ccgcgtgggtg gacttcggca aggactacta	2520
cgccttcagc accttcttca acaccgaccc gacctacggg agcgccctgg gcatcgctg	2580
ggcctccaac tgggagtact ccgccttcgt gccaccaaac ccctggcgct cctccatgtc	2640
cctcgtgcgc aagttctccc tcaacaccga gtaccaggcc aacccggaga cggagctgat	2700
caacctgaag gccgagccga tcctgaacat cagcaacgcc ggcccctgga gccggttcgc	2760
caccaacacc acgttgacga aggccaacag ctacaacgtc gacctgtcca acagaccgg	2820
caccctggag ttcgagctgg tgtacgccgt caacaccacc cagacgatct ccaagtccgt	2880
gttcgcggac ctctccctct ggttcaaggg cctggaggac cccgaggagt acctccgcat	2940
gggcttcgag gtgtccgcgt cctccttctt cctggaccgc gggaacagca aggtgaagtt	3000
cgtgaaggag aacccctact tcaccaaccg catgagcgtg aacaaccagc ctttcaagag	3060
cgagaacgac ctgtcctact acaaggtgta cggcttgctg gaccagaaca tcctggagct	3120
gtacttcaac gacggcgacg tcgtgtccac caacacctac ttcatgacca ccgggaacgc	3180
cctgggctcc gtgaacatga cgacgggggt ggacaacctg ttctacatcg acaagttcca	3240
ggtgcgcgag gtcaagtgat taattaactc gaggcagcag cagctcggat agtatcgaca	3300
cactctggac gctggtcgtg tgatggactg ttgccgccac acttgctgcc ttgacctgtg	3360
aatatccctg ccgcttttat caaacagcct cagtgtgttt gatcttgtgt gtacgcgctt	3420
ttgcgagttg ctagctgctt gtgctatttg cgaataccac cccagcatc ccctccctc	3480
gtttcatatc gcttgcaccc caaccgcaac ttatctacgc tgcctgcta tccctcagcg	3540
ctgctcctgc tcctgctcac tgcccctcgc acagccttg tttgggctcc gcctgtattc	3600
tcctgggtact gcaacctgta aaccagcact gcaatgctga tgcacgggaa gtagtgggat	3660
gggaacacaa atggaaagct t	3681

<210> 104

<211> 3850

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 104

026172-005010PC - Sequence Listing_1.TXT

tttggcccccg ctttccagct ccg gatctgc tggcg tccgc cgcgagacgt gacatcgcac	60
gtcgccggga gcgccagctt gatcacttgg cagggggccg tgctctacaa ataccaggcc	120
ccgcggcggt cagttcgcac atccaatacc tgccgagcca tcttgccctac actttttatc	180
gactcctcta ctctgttcgc gagagcgctc ggtccaggct tggaattcgc cgaattcagc	240
tcgatcagtc gcttctgcaa ctgatctcgg ccgttcgcag actgcctttt ctcagcttgt	300
caggtagcga gttgttggtt tatatttatt cgatttcac tctgttgcat gtcttggtcg	360
tgctgtgcgt tctttctggg ccgcgctgtc gggtcgcatg ggctagctgt actcatgtta	420
gtcatgccgg tccgaccttg ttcgaggaag gccccacact gagcgtgccc tctttctaca	480
ccccttgctgc agaaattaga tagaaagcag aattcctttc ttgcgctatg acacttccag	540
caaaaggtag ggcgggctgc gagacggctt cccggcgctg catgcaacac cgatgatgct	600
tcgaccccc gaagctcctt cggggctgca tgggcgctcc gatgccgctc cagggcgagc	660
gctgtttaaa tagccaggcc cccgattgca aagacattat agcgagctac caaagccata	720
ttcaaacacc tagatcacta ccacttctac acaggccact cgagcttgtg atcgactcc	780
gctaaggggg cgctctttcc tcttcgtttc agtcacaacc cgcaaacggc gcgcatgct	840
gctgcaggcc ttcctgttcc tgctggccgg cttcgccgcc aagatcagcg cctccatgac	900
gaacgagacg tccgaccgcc ccctggtgca cttcaccccc aacaagggtt ggatgaacga	960
ccccaacggc ctgtggtacg acgagaagga cgccaagtgg cacctgtact tccagtacaa	1020
cccgaacgac accgtctggg ggacgccctt gttctggggc cacgccacgt ccgacgacct	1080
gaccaactgg gaggaccagc ccatcgccat cgccccgaag cgcaacgact ccggcgctt	1140
ctccggctcc atggtggtgg actacaacaa cacctccggc ttcttcaacg acaccatcga	1200
cccgcgccag cgctgcgtgg ccatctggac ctacaacacc ccggagtccg aggagcagta	1260
catctcctac agcctggacg gcggctacac cttcacccag taccagaaga accccgtgct	1320
ggccgccaac tccacccagt tccgcgaccc gaaggctctt tggtagcagc cctcccagaa	1380
gtggatcatg accgcggcca agtcccagga ctacaagatc gagatctact cctccgacga	1440
cctgaagtcc tggaagctgg agtccgcgtt cgccaacgag ggcttcctcg gctaccagta	1500
cgagtgcctc ggcctgatcg aggtccccac cgagcaggac ccagcaagt cctactgggt	1560
gatgttcac tccatcaacc ccggcgcccc ggccggcggc tccttcaacc agtacttcgt	1620
cggcagcttc aacggcaccc acttcgaggc cttcgacaac cagtcccgcg tgggtggactt	1680
cggaaggac tactacgccc tgcagacctt cttcaacacc gacccgacct acgggagcgc	1740
cctgggcatc gcgtgggcct ccaactggga gtactccgcc ttcgtgcca ccaaccctg	1800
gcgctcctcc atgtccctcg tgcgaagtt ctccctcaac accgagtacc aggccaaccc	1860
ggagacggag ctgatcaacc tgaaggccga gccgatcctg aacatcagca acgccggccc	1920
ctggagccgg ttcgccacca acaccaggtt gacgaaggcc aacagctaca acgtcgacct	1980
gtccaacagc accggcaccc tggagtcca gctggtgtac gccgtcaaca ccaccagac	2040

026172-005010PC - Sequence Listing_1.TXT

gatctccaag tccgtgttcg cggacctctc cctctggttc aagggcctgg aggaccccga	2100
ggagtacctc cgcattgggt tgcaggtgtc cgcgtcctcc ttcttcctgg accgcgggaa	2160
cagcaagggtg aagttcgtga aggagaaccc ctacttcacc aaccgcatga gcgtgaacaa	2220
ccagcccttc aagagcgaga acgacctgtc ctactacaag gtgtacggct tgctggacca	2280
gaacatcctg gagctgtact tcaacgacgg cgacgtcgtg tccaccaaca cctacttcac	2340
gaccaccggg aacgccctgg gctccgtgaa catgacgacg ggggtggaca acctgttcta	2400
catcgacaag ttccagggtg gcgagggtcaa gtgattaatt aactcgaggc agcagcagct	2460
cggatagtat cgacacactc tggacgctgg tcgtgtgatg gactgttgcc gccacacttg	2520
ctgccttgac ctgtgaatat ccctgccgct tttatcaaac agcctcagtg tgtttgatct	2580
tgtgtgtacg cgctttttgc agttgctagc tgcttgtgct atttgcgaa accacccccca	2640
gcatccccct ccctcgtttc atatcgcttg catcccaacc gcaacttacc tacgctgtcc	2700
tgctatccct cagcgtgct cctgctcctg ctactgccc ctgcacagc cttggtttgg	2760
gctccgcctg tatttcctg gtactgcaac ctgtaaacca gcaactgcaat gctgatgcac	2820
gggaagtagt gggatgggaa cacaatgga ccgacacgcc cccggcccag gtccagttct	2880
cctgggtcct ccagaggccc gtcgccatgt aaagtggcag agattggcgc ctgattcgat	2940
ttggatccaa ggatctccaa tcggtgatgg ggactgagtg cccaactacc acccttgac	3000
tatcgtcctc gcactattta ttcccacctt ctgctcgccc tgccgggcca ttgcgggcgt	3060
ttctgccctt gacgtatcaa tttcgcccct gctggcgcca ggattcttca ttctaataag	3120
aactcactcc cgccagctct gtacttttcc tgccggggccc ctgcatggct tgttcccaat	3180
gcttgctcga tcgacggcgc ccattgcccc cggcgctgcc gcattcatgt gaagaaacac	3240
ggaagagtgc gaagactgga agtgaattaa gactataaga agaggtagc agggattctc	3300
aggtgctcct aggaacggct tttccttcgc caagagaaac tgctactgct cgtgtcgcca	3360
cgggtggtaaa gccgccccat ctgcgatcca ccaggcccat ccgcggaact gcgatcagcc	3420
tgctggatcc ggactgccga cctgaccgct cgcattccacc attacaacc tccaattgga	3480
caccactccc acgtcctaaa gttcaccatg caagctgacg gatcgattc gccgatgcac	3540
tcgcctgcca cagagggtgt cgcttcggac tagcgtgcag gcgccccgag gccaccagca	3600
tgaccgatg gaagcgggca cggccgctgc tccaggctgc tggctcgctc agaccatag	3660
caacctccgc tgcgtcccta aatgtcacac agagcgtcct tgatgggtac ggatgggaga	3720
gaatctgatt gggcattgct ggtgcagtgc aggaagatgg caagtgcaca gtcagtcatt	3780
ctgtacaaac tggtgcctcg tagtattgac tcgtatagtg catagtatca tgcattgctg	3840
ttacttgcaa	3850

<210> 105

<211> 3108

<212> DNA

<213> Artificial Sequence

026172-005010PC - Sequence Listing_1.TXT

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 105

tttgcccccg ctttccagct ccgcatctgc tggcgtccgc cgcgagacgt gacatcgcac	60
gtcgccggga gcgccagctt gatcacttgg cagggggccg tgctctacaa ataccaggcc	120
ccgcggcggt cagttcgcac atccaatacc tgccgagcca tcttgccctac actttttatc	180
gactcctcta ctctgttcgc gagagcgctc ggtccaggct tgggaattcgc cgaattcagc	240
tcgatcagtc gcttctgcaa ctgatctcgg ccgttcgcag actgcctttt ctcagcttgt	300
caggtagcga gttgttgttt tatatttatt cgatttcatac tgtgttgcat gtcttggtcg	360
tgctgtgcgt tctttctggg ccgcgctgtc gggtcgcatg ggctagctgt actcatgtta	420
gtcatgccgg tccgaccttg ttcgaggaag gccccacact gagcgtgccc tctttctaca	480
ccccctgtgc agaaattaga tagaaagcaa tgctgctgca ggcccttcctg ttcctgctgg	540
ccggcttcgc cgccaagatc agcgccctca tgacgaacga gacgtccgac cgccccctgg	600
tgcacttcac cccaacaag ggctggatga acgaccccaa cggcctgtgg tacgacgaga	660
aggacgcaa gtggcacctg tacttccagt acaacccgaa cgacaccgtc tgggggacgc	720
ccttgttctg gggccacgcc acgtccgacg acctgaccaa ctgggaggac cagcccatcg	780
ccatcgcccc gaagcgcaac gactccggcg ctttctccgg ctccatgggtg gtggactaca	840
acaacacctc cggcttcttc aacgacacca tcgacccgcg ccagcgctgc gtggccatct	900
ggacctacaa cccccggag tccgaggagc agtacatctc ctacagcctg gacggcggct	960
acaccttcac cgagtaccag aagaaccccg tgctggccgc caactccacc cagttccgcg	1020
acccgaaggt cttctggtac gagccctccc agaagtggat catgaccgcg gccaagtccc	1080
aggactacaa gatcgagatc tactcctccg acgacctgaa gtcctggaag ctggagtccg	1140
cgttcgcaa cgagggcttc ctcggctacc agtacgagtg ccccggcctg atcgaggctc	1200
ccaccgagca ggaccccagc aagtcctact gggatgatgt catctccatc aaccccggcg	1260
ccccggcccg cggctccttc aaccagtact tcgtcggcag cttcaacggc acccacttcg	1320
aggccttcga caaccagtcc cgcgtggtgg acttcggcaa ggactactac gccctgcaga	1380
ccttcttcaa caccgacctg acctacggga gcgccctggg catcgctgg gcctccaact	1440
gggagtactc cgccttcgtg cccaccaacc cctggcgctc ctccatgtcc ctcgtgcgca	1500
agttctccct caacaccgag taccaggcca acccgagac ggagctgac aacctgaagg	1560
ccgagccgat cctgaacatc agcaacgccg gccctggag ccggttcgcc accaacacca	1620
cgttgacgaa ggccaacagc tacaacgtcg acctgtccaa cagcaccggc accctggagt	1680
tcgagctggt gtacgccgtc aacaccaccc agacgatctc caagtccgtg ttcgcggacc	1740
tctccctctg gttcaagggc ctggaggacc ccgaggagta cctccgcatg ggcttcgagg	1800
tgtccgcgtc ctcttcttc ctggaccgcg ggaacagcaa ggtgaagttc gtgaaggaga	1860
accctactt caccaaccgc atgagcgtga acaaccagcc cttcaagagc gagaacgacc	1920

026172-005010PC - Sequence Listing_1.TXT

tgtcctacta caaggtgtac ggcttgctgg accagaacat cctggagctg tactttcaacg	1980
acggcgacgt cgtgtccacc aacacctact tcatgaccac cggaacgcc ctgggctccg	2040
tgaacatgac gacgggggtg gacaacctgt tctacatcga caagttccag gtgcgcgagg	2100
tcaagtgacc gacacgcccc cggcccaggt ccagttctcc tgggtcttcc agaggcccg	2160
cgccatgtaa agtggcagag attggcgcct gattcgattt ggatccaagg atctccaatc	2220
ggtgatgggg actgagtgcc caactaccac ccttgacta tcgtcctcgc actattttatt	2280
cccaccttct gctcgccctg cggggcgatt gcgggcgttt ctgcccttga cgtatcaatt	2340
tcgcccctgc tggcgcgagg attcttcatt ctaataagaa ctactcccg ccagctctgt	2400
acttttctctg cggggccctt gcatggcttg ttcccaatgc ttgctcgatc gacggcgccc	2460
attgccacg gcgctgccgc atccatgtga agaaacacgg aagagtgcga agactggaag	2520
tgaattaaga gtataagaag aggtaccaag ggattctcag gtgctcttag gaacggcttt	2580
tccttcgcca agagaaactg ctactgctcg tgctgccacg gtggtcaagc cgccccatct	2640
gcatccacc agggccatcc gcggactcgc gatcagcctg ctggatccgg actgccgacc	2700
tgaccgctcg catccaccat tacaaccctc caattggaca ccactcccac gtcctaaagt	2760
tcaccatgca agctgatcga tcgcattcgc cgatgcactc gcctgccaca gaggtgtgcg	2820
cttcggacta gcgtgcaggc gccccgaggc caccagcatg caccgatgga agcgggcacg	2880
gccgctgctc caggctcgtg gctcgtcag acccatagca acctccgctg cgtccctaaa	2940
tgtcacacag agcgtctttg atgggtacgg atgggagaga atctgattgg gcattgctgg	3000
tgcagtgcag gaagatggca agtgcacagt cagtcagtgt gtacaaactg gtgcctcgta	3060
gtattgactc gtatagtgc tagtatcatg catggtcgtt acttgcaa	3108

<210> 106

<211> 559

<212> DNA

<213> *Chlorella luteoviridis*

<400> 106

tggtgaagaa tgagccggcg acttatagga agtggcgtgg ttaaggaatt ttccgaagcc	60
caagcgaaag caagttttta aaatagcgat atttgtcact ttttatggac ccgaaccgg	120
gtgatctaac cgtgaccagg atgaagcttg ggtaacacca agtgaaggct cgaactcttc	180
gatcttttaa aatcgtgaga tgagttgcgg ttagtaggtg aaatgccaat cgaactcgga	240
gctagctggg tctccccgaa atgtgttgag gcgcagcgat gaatgacaaa acaaatagta	300
cgggtgtaggg gtaaagcact gtttcggtgc gggctgcgaa agcggtagca aatcgtggca	360
aactcagaat actacgcttg tataaccattc atcagtgaga ctgtggggga taagctccat	420
agtcaagagg gaaacagccc agatcaccag ttaaggcccc aaaatgacag ctaagtggca	480
aaggagggtga aagtgcagaa acaaccagga ggtttgccca gaagcagcca tcctttaaag	540
agtgcgtaat agctcactg	559

026172-005010PC - Sequence Listing_1.TXT

<210> 107
 <211> 1841
 <212> DNA
 <213> *Cuphea palustris*

<400> 107
 gaatttccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct 60
 tccccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcgggggctgc 120
 atggg'gcctc cgatgccgct ccagggcgag cgctgtttta atagccaggc ccccgattgc 180
 aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta 240
 cacaggccac tcgagcttgt gatcgactc cgctaagggg ggcctcttc ctcttcgttt 300
 cagtcacaac ccgcaaacac tagtatggcc accgcatcca ctttctcggc gttcaatgcc 360
 cgctgcggcg acctgcgtcg ctccggcgggc tccgggcccc ggcgcccagc gagggcccctc 420
 cccgtgcgcg ggcgcgccag catgctgctg tcggcggtga ccacggtctt cggcgtggcc 480
 gagaagcagt ggcccatgct ggaccgcaag tccaagcgcc ccgacatgct ggtcgagccc 540
 ctggg'cgctg accgcatcgt ctacgacggc gtgagcttcc gccagtcgtt ctccatccgc 600
 agctacgaga tcggcgccga ccgcaccgcc tcgatcgaga cgctgatgaa catgttccag 660
 gagacctccc tgaaccactg caagatcatc ggcctgctga acgacggctt cggccgcacg 720
 cccgagatgt gcaagcgca cctgatctgg gtcgtgacca agatgcagat cgaggtgaac 780
 cgctacccca cgtggggcgga caccatcgag gtcaacacgt gggtgagcgc ctccgggcaag 840
 cacggcatgg gccgcgactg gctgatctcc gactgccaca ccggcgagat cctgatccgc 900
 gcgacgagcg tctggg'cgat gatgaaccag aagacccgcc gcctgtcgaa gatcccctac 960
 gaggtgcgcc aggagatcga gccccagttc gtcgactccg ccccgatgat cgtggacgac 1020
 cgcaagttcc acaagctgga cctgaagacg ggcgacagca tctgcaacgg cctgaccccc 1080
 cgctggacgg acctggacgt gaaccagcac gtcaacaacg tgaagtacat cggctggatc 1140
 ctgcagtcgg tccccaccga ggtgttcgag acgcaggagc tgtcgggcct gaccctggag 1200
 taccgccgcg agtgcggccg cgactccgtg ctggagagcg tcacggccat ggacccctcg 1260
 aaggaggggcg accgctccct gtaccagcac ctgctgcgcc tggaggacgg cgcggacatc 1320
 gtgaagggcc gcaccgagtg gcgccccaa aacgccggcg ccaagggcgc catcctgacg 1380
 ggcaagacca gcaacggcaa ctcgatctcc tgactcgagt taattaactc gaggcagcag 1440
 cagctcggat agtatcgaca cactctggac gctggctgtg tgatggactg ttgccgccac 1500
 acttgctgcc ttgacctgtg aatatccctg ccgcttttat caaacagcct cagtgtgttt 1560
 gatctt'gtgt gtacgcgctt ttgcgagttg ctagctgctt gtgctatttg cgaataccac 1620
 cccagcatc cccttccctc gtttcatac gcttgcaccc caaccgcaac ttatctacgc 1680
 tgcctgcta tccctcagcg ctgctcctgc tcctgctcac tgcccctcgc acagccttgg 1740
 tttgggctcc gcctgtattc tcctgggtact gcaacctgta aaccagcact gcaatgctga 1800
 tgcacgggaa gtagtgggat gggaacacaa atggaaagct t 1841

026172-005010PC - Sequence Listing_1.TXT

<210> 108
<211> 1010
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 108
ggcgcgcccc gctgccccgac tggagcatgc tgctggccgc gatcaccacc ctgttcctgg 60
cggccgagaa gcagtggatg atgctggact ggaagcccaa gcgccccgac atgctggtgg 120
accccttcgg cctggggccgc ttcgtgcagg acggcctggt gttccgcaac aacttcagca 180
tccgcagcta cgagatcggc gcggaccgca ccgccagcat cgagaccctg atgaaccacc 240
tgcaggagac cgccctgaac cacgtgaaga gcgtgggcct gctggaggac ggcctgggca 300
gcacccgcga gatgagcctg cgcaacctga tctgggtggt gaccaagatg caggtggcgg 360
tggaccgcta ccccacctgg ggcgacgagg tgcaggtgag cagctgggcg accgccatcg 420
gcaagaacgg catgcgccgc gagtggatcg tgaccgactt ccgcaccggc gagaccctgc 480
tgcgcgccac cagcgtgtgg gtgatgatga acaagctgac ccgccgcatc agcaagatcc 540
ccgaggaggt gtggcacgag atcgccccca gcttcacatga cgcgcccccc ctgcccaccg 600
tggaggacga cggccgcaag ctgacccgct tcgacgagag cagcgccgac ttcattccgca 660
agggcctgac cccccgctgg agcgacctgg acatcaacca gcacgtgaac aacgtgaagt 720
acatcggtcg gctgctggag agcgcgcccc ccgagatcca cgagagccac gagatcgcca 780
gcctgaccct ggagtaccgc cgcgagtgcg gccgcgacag cgtgctgaac agcgccacca 840
aggtgagcga cagcagccag ctgggcaaga gcgccgtgga gtgcaaccac ctggtgcgcc 900
tgcagaacgg cggcgagatc gtgaagggcc gcaccgtgtg gcgccccaaag cgccccctgt 960
acaacgacgg cgccgtggtg gacgtgcccc ccaagaccag ctgactcgag 1010

<210> 109
<211> 5472
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 109
ggtacccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct 60
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc 120
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc 180
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accatttcta 240
cacaggccac tcgagcttgt gatcgcatc cgctaagggg gcgcctcttc ctcttcgttt 300
cagtcacaac ccgcaaactc tagaatatca atgctgctgc aggccttcct gttcctgctg 360

026172-005010PC - Sequence Listing_1.TXT

gccggcttcg ccgccaagat cagcgctcc atgacgaacg agacgtccga ccgccccctg	420
gtgcacttca cccccaacaa gggctggatg aacgacccca acggcctgtg gtacgacgag	480
aaggacgcca agtggcacct gtacttccag tacaacccga acgacaccgt ctgggggacg	540
cccttgttct ggggccacgc cacgtccgac gacctgacca actgggagga ccagcccatc	600
gccatcgccc cgaagcgcaa cgactccggc gccttctccg gctccatggg ggtggactac	660
aacaacacct ccggcttctt caacgacacc atcgacccgc gccagcgctg cgtggccatc	720
tggacctaca acaccccgga gtccgaggag cagtacatct cctacagcct ggacggcggc	780
tacaccttca ccgagtacca gaagaacccc gtgctggccg ccaactccac ccagttccgc	840
gacccgaagg tcttctggta cgagccctcc cagaagtgga tcatgaccgc ggccaagtcc	900
caggactaca agatcgagat ctactcctcc gacgacctga agtcctggaa gctggagtcc	960
gcgttcgcca acgagggctt cctcggctac cagtacgagt gccccggcct gatcgaggtc	1020
cccaccgagc aggaccccag caagtcctac tgggtgatgt tcatctccat caaccccggc	1080
gccccggccg gcggctcctt caaccagtac ttcgtcggca gcttcaacgg caccacttc	1140
gaggccttcg acaaccagtc ccgcgtggtg gacttcggca aggactacta cgccctgcag	1200
accttcttca acaccgaccc gacctacggg agcgccctgg gcatcgctg ggcctccaac	1260
tgggagtact ccgccttcgt gccaccaac ccctggcgct cctccatgtc cctcgtgcgc	1320
aagttctccc tcaacaccga gtaccaggcc aacccggaga cggagctgat caacctgaag	1380
gccgagccga tcctgaacat cagcaacgcc ggcccctgga gccggttcgc caccaacacc	1440
acgttgacga aggccaacag ctacaacgtc gacctgtcca acagcaccgg caccctggag	1500
ttcgagctgg tgtacgccgt caacaccacc cagacgatct ccaagtccgt gttcgcggac	1560
ctctccctct gggtcaaggg cctggaggac cccgaggagt acctccgcat gggcttcgag	1620
gtgtccgcgt cctccttctt cctggaccgc gggaaacagca aggtgaagtt cgtgaaggag	1680
aacccctact tcaccaaccg catgagcgtg aacaaccagc ctttcaagag cgagaacgac	1740
ctgtcctact acaaggtgta cggcttgctg gaccagaaca tcctggagct gtacttcaac	1800
gacggcgacg tcgtgtccac caacacctac ttcatgacca ccgggaacgc cctgggctcc	1860
gtgaacatga cgacgggggt ggacaacctg ttctacatcg acaagttcca ggtgcgcgag	1920
gtcaagtgac aattggcagc agcagctcgg atagtatcga cacactctgg acgctggctg	1980
tgtgatggac tggtgccgcc acacttgctg ccttgacctg tgaatatccc tgccgctttt	2040
atcaaacagc ctcagtgtgt ttgatcttgt gtgtacgcgc ttttgcgagt tgctagctgc	2100
ttgtgctatt tgcgaatacc acccccagca tccccctccc tcgtttcata tcgcttgcac	2160
cccaaccgca acttatctac gctgtcctgc tatccctcag cgctgctcct gctcctgctc	2220
actgcccctc gcacagcctt ggtttgggct ccgcctgtat tctcctggta ctgcaacctg	2280
taaaccagca ctgcaatgct gatgcacggg aagtagtggg atgggaacac aaatggagga	2340
tcccgcgtct cgaacagagc gcgcagagga acgctgaagg tctcgctct gtcgcacctc	2400

026172-005010PC - Sequence Listing_1.TXT

agcgcgccat acaccacaat aaccaccta cgaatgcgct tggttcttcg tccattagcg	2460
aagcggtccg ttcacacacg tgccacgttg gcgaggtggc aggtgacaat gatcgggtga	2520
gctgatggtc gaaacgttca cagcctaggg atatcgaatt ccgcctgcaa cgcaagggca	2580
gccacagccg ctcccacccg ccgctgaacc gacacgtgct tgggcgcctg ccgcctgcct	2640
gccgcatgct tgtgctgggt aggctgggca gtgctgccat gctgattgag gcttggttca	2700
tcgggtggaa gcttatgtgt gtgctgggct tgcattgccg gcaatgcgca tgggtggcaag	2760
agggcgccag cacttgctgg agctgccggt gtgcctccag gtggttcaat cgcgccagcc	2820
agagggattt cagatgatcg cgcgtacagg ttgagcagca gtgtcagcaa aggtagcagt	2880
ttgccagaat gatcgggttca gctgttaatc aatgccagca agagaagggg tcaagtgcaa	2940
acacgggcat gccacagcac gggcaccggg gagggtgaat gcaccaccaa gtgtgtgcga	3000
gccagcatcg ccgcctggct gtttcagcta caacggcagg agtcatccaa cgtaaccatg	3060
agctgatcaa cactgcaatc atcgggctgg cgtgatgcaa gcatgcctgg cgaagacaca	3120
tgggtgtcgg atgctgccgg ctgctgcctg ctgcgcacgc cgttgagttg gcagcaggct	3180
cagccatgca ctggatggca gctgggctgc cactgcaatg tgggtgatag gatgcaagtg	3240
gagcgaatac caaacctctt ggctgcttgc tgggttgcat ggcattgcac catcagcagg	3300
agcgcatgcg aagggaactg ccccatgcac gccatgccaa accggagcgc accgagtgtc	3360
cacactgtca ccaggcccg cagctttgca gaaccatgct catggacgca tgtagcgtg	3420
acgtcccttg acggcgctcc tctcgggtgt gggaaacgca atgcagcaca ggcagcagag	3480
gcggcgccag cagagcgccg gcagcagcgg cggggggccac ctttcttgcg gggctcgcgc	3540
ccagccagcg gtgatgcgct gatcccaaac gaggttacat tcatttgcat gcctggagaa	3600
gcgaggctgg ggcctttggg ctggtgcagc ccgcaatgga atgcgggacc gccaggctag	3660
cagcaaaggc gcctccccta ctccgcatcg atgttccata gtgcattgga ctgcatttgg	3720
gtggggcgcc cggctgtttc tttcgtgttg caaaacgcgc cagctcagca acctgtccc	3780
tgggtccccc gtgccgatga aatcgtgtgc acgccgatca gctgattgcc cggctcgcga	3840
agtaggcgcc ctcttttctg ctccgctct ctccgtccc cactagtagt ggccaccgca	3900
tccactttct cggcgttcaa tgcccgctgc ggcgacctgc gtcgctcggc gggctccggg	3960
ccccggcgcc cagcgaggcc cctccccgtg cgcgggctgc ccagctgcc cgactggagc	4020
cgcttgctga ccgccatcac caccgtgttc gtgaagtcca agcgcgccga catgcacgac	4080
cgcaagtcca agcgcgccga catgctgggt gacagcttcg gcctggagtc caccgtgcag	4140
gacggcctgg tgttccgcca gtccttctcc atccgctcct acgagatcgg caccgaccgc	4200
accgccagca tcgagaccct gatgaaccac ctgcaggaga cctccctgaa cactgcaag	4260
agcaccggca tcctgctgga cggcttcggc cgcaccctgg agatgtgcaa gcgcgacctg	4320
atctgggtgg tgatcaagat gcagatcaag gtgaaccgct acccgcctg gggcgacacc	4380
gtggagatca acaccgctt cagccgcctg ggcaagatcg gcatgggccc cgactggctg	4440

026172-005010PC - Sequence Listing_1.TXT

atctccgact gcaacaccgg cgagatcctg gtgcgcgcca ccagcgcccta cgccatgatg	4500
aaccagaaga cccgccgcct gtccaagctg ccctacgagg tgcaccagga gatcgtgccc	4560
ctgttcgttg acagccccgt gatcgaggac tccgacctga aggtgcacaa gttcaagggtg	4620
aagaccggcg acagcatcca gaagggcctg acccccggct ggaacgacct ggacgtgaac	4680
cagcacgtgt ccaacgtgaa gtacatcggc tggatcctgg agagcatgcc caccgagggtg	4740
ctggagaccc aggagctgtg ctccctggcc ctggagtacc gccgcgagtg cggccgcgac	4800
tccgtgctgg agagcgtgac cgccatggac ccagcaagg tgggcgtgcg ctcccagtac	4860
cagcacctgc tgcgcctgga ggacggcacc gccatcgtga acggcgccac cgagtggcgc	4920
cccaagaacg ccggcgccaa cggcgccatc tccaccggca agaccagcaa cggcaactcc	4980
gtgtccatgg actacaagga ccacgacggc gactacaagg accacgacat cgactacaag	5040
gacgacgacg acaagtgact cgaggcagca gcagctcgga tagtatcgac acactctgga	5100
cgctggtcgt gtgatggact gttgccgcca cacttgctgc cttgacctgt gaatatccct	5160
gccgctttta tcaaacagcc tcagtgtgtt tgatcttggtg tgtacgcgct tttgcgagtt	5220
gctagctgct tgtgctatctt gcgaatacca cccccagcat ccccttccct cgtttcatat	5280
cgcttgcatc ccaaccgcaa cttatctacg ctgtcctgct atccctcagc gctgctcctg	5340
ctcctgctca ctgccccctg cacagccttg gtttgggctc cgcctgtatt ctcttggtac	5400
tgcaacctgt aaaccagcac tgcaatgctg atgcacggga agtagtggga tgggaacaca	5460
aatggaaagc tt	5472

<210> 110

<211> 5451

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 110

ggtacccttt cttgcgtat gacacttcca gcaaaaggta gggcgggctg cgagacggct	60
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	120
atgggcgctc cgatgccgct ccagggcgag cgctgtttta atagccaggc ccccgattgc	180
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	240
cacaggccac tcgagcttgt gatcgcactc cgctaagggg gcgcctcttc ctcttcgttt	300
cagtcacaac ccgcaaaactc tagaatatca atgctgctgc aggccttcct gttcctgctg	360
gccggcttcg ccgccaagat cagcgcctcc atgacgaacg agacgtccga ccgccccctg	420
gtgcacttca cccccaacaa gggctggatg aacgacccca acggcctgtg gtacgacgag	480
aaggacgcca agtggcacct gtacttccag tacaaccgga acgacaccgt ctgggggacg	540
cccttgcttct ggggccacgc cacgtccgac gacctgacca actgggagga ccagcccatc	600

026172-005010PC - Sequence Listing_1.TXT

gccatcgccc cgaagcgcaa cgactccggc gccttctccg gctccatggg ggtggactac	660
aacaacacct ccggcttctt caacgacacc atcgacccgc gccagcgctg cgtggccatc	720
tggacctaca acaccccgga gtccgaggag cagtacatct cctacagcct ggacggcggc	780
tacaccttca ccgagtacca gaagaacccc gtgctggccg ccaactccac ccagttccgc	840
gacccgaagg tcttctggta cgagccctcc cagaagtgga tcatgaccgc ggccaagtcc	900
caggactaca agatcgagat ctactcctcc gacgacctga agtcctggaa gctggagtcc	960
gcgttcgcca acgagggctt cctcggctac cagtacgagt gccccggcct gatcgaggtc	1020
cccaccgagc aggaccccag caagtcctac tgggtgatgt tcatctccat caaccccggc	1080
gccccggccg gcggctcctt caaccagtac ttcgtcggca gcttcaacgg caccacttc	1140
gaggccttcg acaaccagtc ccgcgtggtg gacttcggca aggactacta cgccctgcag	1200
accttcttca acaccgaccc gacctacggg agcgccctgg gcatcgcgct ggccctcaac	1260
tgggagtact ccgccttcgt gccaccaac ccctggcgct cctccatgtc cctcgtgcgc	1320
aagttctccc tcaacaccga gtaccaggcc aacccggaga cggagctgat caacctgaag	1380
gccgagccga tctgaacat cagcaacgcc ggccccctgga gccggttcgc caccaacacc	1440
acgttgacga aggccaacag ctacaacgtc gacctgtcca acagcaccgg caccctggag	1500
ttcgagctgg tgtacgccgt caacaccacc cagacgatct ccaagtccgt gttcgcggac	1560
ctctccctct ggttcaaggg cctggaggac cccgaggagt acctccgcat gggcttcgag	1620
gtgtccgcgt cctccttctt cctggaccgc gggaacagca aggtgaagtt cgtgaaggag	1680
aacccctact tcaccaaccg catgagcgctg aacaaccagc ctttcaagag cgagaacgac	1740
ctgtcctact acaaggtgta cggcttgctg gaccagaaca tcttgagct gtacttcaac	1800
gacggcgacg tcgtgtccac caacacctac ttcatgacca ccgggaacgc cctgggctcc	1860
gtgaacatga cgacgggggt ggacaacctg ttctacatcg acaagttcca ggtgcgcgag	1920
gtcaagtgac aattggcagc agcagctcgg atagtatcga cacactctgg acgctggctg	1980
tgtgatggac tgttgccgcc aacttgctg ccttgacctg tgaatatccc tgccgctttt	2040
atcaaacagc ctcagtgtgt ttgatcttgt gtgtacgcgc ttttgcgagt tgctagctgc	2100
ttgtgctatt tgcaataacc acccccagca tccccttccc tcgtttcata tcgcttgcac	2160
cccaaccgca acttatctac gctgtcctgc tatccctcag cgctgctcct gctcctgctc	2220
actgcccctc gcacagcctt ggtttgggct ccgcctgtat tctcctggta ctgcaacctg	2280
taaaccagca ctgcaatgct gatgcacggg aagtagtggg atgggaacac aaatggagga	2340
tcccgcgtct cgaacagagc gcgcagagga acgctgaagg tctcgcctct gtcgcacctc	2400
agcgcggcat acaccacaat aaccacctga cgaatgcgct tggttcttcg tccattagcg	2460
aagcgtccgg ttcacacacg tgccacgttg gcgaggtggc aggtgacaat gatcggtgga	2520
gctgatggtc gaaacgttca cagcctaggg atatcgaatt ccgcctgcaa cgcaagggca	2580
gccacagccg ctcccacccg ccgctgaacc gacacgtgct tgggcgcctg ccgcctgcct	2640

026172-005010PC - Sequence Listing_1.TXT

gccgcatgct tgtgctggtg aggctgggca gtgctgccat gctgattgag gcttgggttca	2700
tcgggtggaa gcttatgtgt gtgctgggct tgcattgccg gcaatgcgca tgggtggcaag	2760
agggcgagcag cacttgctgg agctgccgag gtgcctccag gtgggttcaat cgcggcagcc	2820
agagggattt cagatgatcg cgcgtacagg ttgagcagca gtgtcagcaa aggtagcagt	2880
ttgccagaat gatcgggttca gctgttaatc aatgccagca agagaagggg tcaagtgcaa	2940
acacgggcat gccacagcac gggcaccggg gagtggaatg gcaccaccaa gtgtgtgcga	3000
gccagcatcg ccgcctggct gtttcagcta caacggcagg agtcatccaa cgtaaccatg	3060
agctgatcaa cactgcaatc atcggggcgg cgatgatgcaa gcatgcctgg cgaagacaca	3120
tgggtgtgcg atgctgccg ctgctgcctg ctgcgcacgc cgttgagttg gcagcaggct	3180
cagccatgca ctggatggca gctgggctgc cactgcaatg tgggtggatag gatgcaagtg	3240
gagcgaatac caaacctctt ggctgcttgc tgggttgcat ggcattgcac catcagcagg	3300
agcgcatgag aagggaactg ccccatgcac gccatgcaa accggagcgc accgagtgtc	3360
cacactgtca ccaggccgc aagctttgca gaaccatgct catggacgca tgtagcgtg	3420
acgtcccttg acggcgctcc tctcgggtgt gggaaacgca atgcagcaca ggcagcagag	3480
gcggcgagcag cagagcgagc gcagcagcgc cgggggccac cttcttgcg gggtcgcgcc	3540
ccagccagcg gtgatgcgt gatcccaaac gagttcacat tcatttgcat gcctggagaa	3600
gcgaggctgg ggcctttggg ctggtgcagc ccgcaatgga atgcgggacc gccaggctag	3660
cagcaaaggc gcctccccta ctccgcatcg atgttcata gtgcattgga ctgcatttgg	3720
gtggggcggc cggctgtttc tttcgtgttg caaaacgcgc cagctcagca acctgtccc	3780
tgggtccccc gtgccgatga aatcgtgtgc acgccgatca gctgattgcc cggctcgcga	3840
agtaggcgcc ctcttttctg ctgcacctct ctccgtccc cactagtag gacgttcggg	3900
gtcgcctcc cggccatggg ccgcggtgtc tcccttcccc ggcccagggt cgcggtgcgc	3960
gcccagtcgg cgagtcagg tttggagagc gggcgcgccc ccgactggtc catgctgttc	4020
gccgtgatca ccaccatctt cagcgccgcc gagaagcagt ggaccaacct ggagtggag	4080
ccaagccca agctgcccc gctgctggac gaccattcg gcctgcacgg cctggtgttc	4140
cgccgcacct tcgccatccg ctccctacgag gtgggcccc accgcagcac ctccatcctg	4200
gccgtgatga accacatgca ggaggccacc ctgaaccacg ccaagagcgt gggcatcctg	4260
ggcgacggct tcggcaccac cctggagatg tccaagcgcg acctgatgtg ggtggtgcgc	4320
cgcacccacg tggccgtgga gcgctacccc acctggggcg acaccgtgga ggtggagtgc	4380
tggatcggcg ccagcggcaa caacggcatg cgccgcgact tcctggtgcg cgactgcaag	4440
accggcgaga tcctgacctg ctgcacctcc ctgagcgtgc tgatgaacac ccgcacccgc	4500
cgcctgagca ccatccccga cgaggtgcgc ggcgagatcg gccccgcctt catcgacaac	4560
gtggccgtga aggacgacga gatcaagaag ctgcagaagc tgaacgactc caccgccgac	4620
tacatccagg gcggcctgac cccccgtgg aacgacctg acgtgaacca gcacgtgaac	4680

026172-005010PC - Sequence Listing_1.TXT

aacctgaagt acgtggcctg ggtgttcgag accgtgcccg acagcatctt cgagtcccac	4740
cacatcagct ccttcaccct ggagtaccgc cgcgagtgc cccgcgactc cgtgctgcgc	4800
agcctgacca ccgtgagcgg cggcagctcc gaggccggcc tgggtgtgcga ccacctgctg	4860
cagctggagg gcggcagcga ggtgctgcgc gcccgcaccg agtggcgccc caagctgacc	4920
gactccttcc gcggcatcag cgtgatcccc gccgagcccc gcgtgatgga ctacaaggac	4980
cacgacggcg actacaagga ccacgacatc gactacaagg acgacgacga caagtgactc	5040
gaggcagcag cagctcggat agtatcgaca cactctggac gctggtcgtg tgatggactg	5100
ttgccgccac acttgctgcc ttgacctgtg aatatccctg ccgcttttat caaacagcct	5160
cagtgtgttt gatcttgtgt gtacgcgctt ttgcgagttg ctagctgctt gtgctatttg	5220
cgaataccac ccccagcatc cccttccctc gtttcatatc gcttgcattc caaccgcaac	5280
ttatctacgc tgtcctgcta tccctcagcg ctgctcctgc tcctgctcac tgcccctcgc	5340
acagccttgg tttgggctcc gcctgtattc tcctggctact gcaacctgta aaccagcact	5400
gcaatgctga tgcacgggaa gtagtgggat gggaacacaa atggaaagct t	5451

<210> 111

<211> 5454

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 111

ggtacccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	60
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	120
atgggcgctc cgatgccgct ccagggcgag cgctgtttta atagccaggc ccccgattgc	180
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	240
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	300
cagtcacaac ccgcaaactc tagaatatca atgctgctgc aggccttcct gttcctgctg	360
gccggcttcg ccgccaagat cagcgcctcc atgacgaacg agacgtccga ccgccccctg	420
gtgcacttca cccccaacaa gggctggatg aacgacccca acggcctgtg gtacgacgag	480
aaggacgcca agtggcacct gtacttccag tacaacccga acgacaccgt ctgggggacg	540
cccttgttct ggggccacgc cacgtccgac gacctgacca actgggagga ccagcccatc	600
gccatcgccc cgaagcgcaa cgactccggc gccttctccg gctccatggg ggtggactac	660
aacaacacct ccggcttctt caacgacacc atcgaccgc gccagcgctg cgtggccatc	720
tggacctaca acaccccgga gtccgaggag cagtacatct cctacagcct ggacggcggc	780
tacaccttca ccgagtacca gaagaacccc gtgctggccg ccaactccac ccagttccgc	840
gacccgaagg tcttctggta cgagccctcc cagaagtgga tcatgaccgc ggccaagtcc	900
caggactaca agatcgagat ctactcctcc gacgacctga agtcctggaa gctggagtcc	960

026172-005010PC - Sequence Listing_1.TXT

gcgttcgcca acgaggggctt cctcggctac cagtacgagt gccccggcct gatcgaggtc	1020
cccaccgagc aggaccccag caagtcctac tgggtgatgt tcatctccat caaccccggc	1080
gccccggccg gcggctcctt caaccagtac ttcgctcggca gcttcaacgg caccacttc	1140
gaggccttcg acaaccagtc ccgcgtggtg gacttcggca aggactacta cgccctgcag	1200
accttcttca acaccgaccc gacctacggg agcgccctgg gcatcgcggtg ggcctccaac	1260
tgggagtact ccgccttcgt gccaccaac ccctggcgct cctccatgtc cctcgtgcgc	1320
aagttctccc tcaacaccga gtaccaggcc aacccggaga cggagctgat caacctgaag	1380
gccgagccga tcctgaacat cagcaacgcc ggcccctgga gccggttcgc caccaacacc	1440
acgttgacga aggccaacag ctacaacgtc gacctgtcca acagcaccgg caccctggag	1500
ttcgagctgg tgtacccgt caacaccacc cagacgatct ccaagtccgt gttcgcggac	1560
ctctccctct ggttcaaggg cctggaggac cccgaggagt acctccgcat gggcttcgag	1620
gtgtccgct cctccttctt cctggaccgc gggaacagca aggtgaagtt cgtgaaggag	1680
aacccctact tcaccaaccg catgagcgtg aacaaccagc cttcaagag cgagaacgac	1740
ctgtcctact acaagggtga cggcttgctg gaccagaaca tcctggagct gtacttcaac	1800
gacggcgacg tcgtgtccac caacacctac ttcatgacca ccgggaacgc cctgggctcc	1860
gtgaacatga cgacgggggt ggacaacctg ttctacatcg acaagttcca ggtgcgcgag	1920
gtcaagtgac aattggcagc agcagctcgg atagtatcga cacactctgg acgctggctg	1980
tgtgatggac tgttgccgcc acacttgctg ccttgacctg tgaatatccc tgccgctttt	2040
atcaaacagc ctcaagtgtgt ttgatcttgt gtgtacgcgc ttttgcgagt tgctagctgc	2100
ttgtgctatt tgcgaatacc acccccagca tccccttccc tcgtttcata tcgcttgcat	2160
cccaaccgca acttatctac gctgtcctgc tatccctcag cgctgctcct gctcctgctc	2220
actgcccctc gcacagcctt ggtttgggct ccgcctgtat tctcctggta ctgcaacctg	2280
taaaccagca ctgcaatgct gatgcacggg aagtagtggg atgggaacac aaatggagga	2340
tcccgcgtct cgaacagagc gcgcagagga acgctgaagg tctgcctct gtcgcacctc	2400
agcgcgcat acaccacaat aaccacctga cgaatgcgct tggttcttcg tccattagcg	2460
aagcgtccgg ttcacacacg tgccacgttg gcgagggtggc aggtgacaat gatcggtgga	2520
gctgatggtc gaaacgttca cagcctaggg atatcgaatt ccgcctgcaa cgcaagggca	2580
gccacagccg ctccccacccg ccgctgaacc gacacgtgct tgggcgcctg ccgcctgcct	2640
gccgcatgct tgtgtggtg aggctgggca gtgctgccat gctgattgag gcttggttca	2700
tcgggtggaa gcttatgtgt gtgctgggct tgcattgccg gcaatgcgca tgggtggcaag	2760
agggcggcag cacttgctgg agctgccgcg gtgcctccag gtggttcaat cgcggcagcc	2820
agagggattt cagatgatcg cgcgtacagg ttgagcagca gtgtcagcaa aggtagcagt	2880
ttgccagaat gatcgggttca gctgttaatc aatgccagca agagaagggg tcaagtgcaa	2940
acacgggcat gccacagcac gggcaccggg gagtgggaatg gcaccaccaa gtgtgtgcga	3000

026172-005010PC - Sequence Listing_1.TXT

gccagcatcg ccgcctggct gtttcagcta caacggcagg agtcatccaa cgtaaccatg	3060
agctgatcaa cactgcaatc atcgggcggg cgtgatgcaa gcatgcctgg cgaagacaca	3120
tgggtgtgcgg atgctgccgg ctgctgcctg ctgcgcacgc cgttgagttg gcagcaggct	3180
cagccatgca ctggatggca gctgggctgc cactgcaatg tggtaggatag gatgcaagtg	3240
gagcgaatac caaacctctt ggctgcttgc tgggttgcat ggcacgcac catcagcagg	3300
agcgcctgca aagggaactg ccccatgcac gccatgcca accggagcgc accgagtgtc	3360
cacactgtca ccaggcccg cagctttgca gaaccatgct catggacgca ttagcgctg	3420
acgtcccttg acggcgctcc tctcgggtgt gggaaacgca atgcagcaca ggcagcagag	3480
gcggcggcag cagagcggcg gcagcagcgg cgggggccac ctttcttgcg gggtcgcgcc	3540
ccagccagcg gtgatgcgt gatcccaaac gagttcacat tcatttgcat gcctggagaa	3600
gcgaggctgg ggccttttgg ctggtgcagc ccgcaatgga atgcgggacc gccaggctag	3660
cagcaaaggc gcctccccta ctccgcatcg atgttcata gtgcattgga ctgcatttgg	3720
gtggggcggc cggctgtttc tttcgtgttg caaaacgcgc cagctcagca acctgtccc	3780
tgggtccccc gtgccgatga aatcgtgtgc acgccgatca gctgattgcc cggctcgcga	3840
agtaggcgcc ctcttttctg ctccgctct ctccgtcccg ccactagtat ggccaccgca	3900
tccactttct cggcgttcaa tgcccgctgc ggcgacctgc gtcgctcggc gggctccggg	3960
ccccggcgcc cagcgaggcc cctccccgtg cgcgggcgcg ccccgactg gtccatgctg	4020
ttcgccgtga tcaccaccat cttctccgcc gccgagaagc agtggaccaa cctggagtgg	4080
aagcccaagc ccaaccccc ccagctgctg gacgaccact tcggcccca cggcctggtg	4140
ttccgccgca ctttcgcat ccgcagctac gaggtgggcc ccgaccgctc caccagcatc	4200
gtggccgtga tgaaccacct gcaggaggcc gccctgaacc acgccaagtc cgtgggcatc	4260
ctgggcgacg gcttcggcac caccctggag atgtccaagc gcgacctgat ctgggtggtg	4320
aagcgcaccc acgtggccgt ggagcgctac cccgcctggg gcgacaccgt ggaggtggag	4380
tgctgggtgg gcgcctccgg caacaacggc cgccgccacg acttcctggt gcgcgactgc	4440
aagaccggcg agatcctgac ccgctgcacc tccctgagcg tgatgatgaa caccgcacc	4500
cggcgctga gcaagatccc cgaggagggt gcggcgaga tcggccccgc cttcatcgac	4560
aacgtggccg tgaaggacga ggagatcaag aagccccaga agctgaacga ctccaccgcc	4620
gactacatcc agggcggcct gacccccgc tggaaacgacc tggacatcaa ccagcacgtg	4680
aacaacatca agtacgtgga ctggatcctg gagaccgtgc ccgacagcat cttcgagagc	4740
caccacatct cctccttcac catcgagtac cgccgcgagt gcacatgga cagcgtgctg	4800
cagtccctga ccaccgtgag cggcggctcc tccgaggccg gcctggtgtg cgagcacctg	4860
ctgcagctgg agggcggcag cgagggtgct gcgcgaaga ccgagtggcg cccaagctg	4920
accgactcct tccgcggcat cagcgtgatc cccgccgagt ccagcgtgat ggactacaag	4980
gaccacgacg gcgactacaa ggaccacgac atcgactaca aggacgacga cgacaagtga	5040

026172-005010PC - Sequence Listing_1.TXT

ctcgaggcag cagcagctcg gatagtatcg acacactctg gacgctggtc gtgtgatgga	5100
ctgttgccgc cacacttgct gccttgacct gtgaatatcc ctgccgcttt tatcaaacag	5160
cctcagtgtg tttgatcttg tgtgtacgcg cttttgagag ttgctagctg cttgtgctat	5220
ttgcaatac cccccccagc atcccccttc ctcgtttcat atcgcttgca tcccaaccgc	5280
aacttatcta cgctgtcctg ctatccctca gcgctgctcc tgctcctgct cactgcccct	5340
cgcacagcct tggtttgggc tccgcctgta ttctcctggg actgcaacct gtaaaccagc	5400
actgcaatgc tgatgcacgg gaagtagtgg gatgggaaca caaatggaaa gctt	5454

<210> 112

<211> 2933

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 112

agagagcgga ggtgggggttg tgagggtgggg ttgctgacca ggagctcgcg tcgccgagcg	60
cgactcgcac acggtccagt tcccccccc tccgccc aaa cgcaagcctc ccatcttgat	120
gcctttccgg ccacctatac tttttcttag ttgctgttaa catccagacc gtcctgaata	180
ataacaatgc cctgtgtcaa gtgcattcct aaaaaaatc tgtcccaacc aacaatccca	240
cctgaaatac caccagccct gcccagtaca ctcttccaat accatctccc tacctccacg	300
cgcaagcgac ccccatgcgc gaccaggctc gaaagtgatt tatgacttga gacgagcgag	360
tggcgggcgcg gtcgactgcc ttttcatcac gtgccgtacg tcggcgaccg ctagggtttt	420
gcacggcaac gcacggcttc gccaaaccga ccagccagga cctcgactac tctaccgca	480
attcgctca agaagtcgcc aaatgtgcc tacaccattc ctacagcac tgttcaaact	540
tgatgccaat ttgacattc gggttgctcg ttggctgcgc ccacatcggc cgtgagtga	600
gcaggcgga tcggacacgg aggacgcggc gtcacgcccc gaacgcagcc cgtaactcta	660
catcaacacg acgtgttgcg taatcccgcc cggtgcgca tcgtgccaac ccattcgca	720
tggatggctg gaaaatgggt tgccaactgc cctgagggag gctctcgca aacgggcacg	780
tccctgaaac cgaaactgtg gccttgctgt cggccacgca agcacgtgga ccctaaacac	840
caagaaaatc agtaaacaag gttgacatcc tctacgggag aattgtttgc ccaacccttc	900
atcgcacact gccattataa tgcatttagc tcggcgacaa gtttagaaaa ggcaggctgc	960
attgtttcat ttgcggtgg cggcgtgggt gccatttta cgagggtttg gctcccgggc	1020
agcgaccgag ccaggctcag tccctctcgc ccgtcgacaa tgttgcgaa cccacaagcg	1080
gctaacaaca acttgatgg acctgtacac tgccaattcc ttcttccccg gccgaggttt	1140
acacgtgatg gccatggctt cgcattcagg ccgacttccc attccgactt tccagagggt	1200
ccgcggacgc tgggggttg ctgcctgagg cccacccttt gttccccgcg tcccgaacaa	1260

026172-005010PC - Sequence Listing_1.TXT

cacaattgcg ttacataagg gggagccgcc cccgttcaga gtgcagaaat ctttcactat	1320
attttccagt cgtcagcgaa atcaagtact agtatggcca ccgcatccac tttctcggcg	1380
ttcaatgccc gctgcggcga cctgcgtcgc tcggcgggct ccgggccccg gcgcccagcg	1440
aggccccctcc ccgtgcgcgg gcgcgcccc gactgggtcca tgctgttcgc cgtgatcacc	1500
accatcttct ccgccgccga gaagcagtgg accaacctgg agtgggaagcc caagcccaac	1560
cccccccagc tgctggacga ccacttcggc cccacggcc tgggtgttcg ccgcaccttc	1620
gccatccgca gctacgaggt gggccccgac cgctccacca gcatcgtggc cgtgatgaac	1680
cacctgcagg aggccgccct gaaccacgcc aagtccgtgg gcatcctggg cgacggcttc	1740
ggcaccaccc tggagatgtc caagcgcgac ctgatctggg tggatgaagcg caccacgtg	1800
gccgtggagc gctacccgc ctggggcgac accgtggagg tggagtgtg ggtgggcgcc	1860
tccggcaaca acggccgccg ccacgacttc ctggtgcgcg actgcaagac cggcgagatc	1920
ctgacccgct gcacctccct gagcgtgatg atgaacaccc gcacccgccg cctgagcaag	1980
atccccgagg aggtgcgcgg cgagatcggc cccgccttca tcgacaacgt ggccgtgaag	2040
gacgaggaga tcaagaagcc ccagaagctg aacgactcca ccgccgacta catccagggc	2100
ggcctgaccc cccgctggaa cgacctggac atcaaccagc acgtgaacaa catcaagtac	2160
gtggactgga tcttgagac cgtgcccgc agcatcttcg agagccacca catctcctcc	2220
ttcaccatcg agtaccgccg cgagtgcacc atggacagcg tgctgcagtc cctgaccacc	2280
gtgagcggcg gctcctccga ggccggcctg gtgtgcgagc acctgctgca gctggagggc	2340
ggcagcgagg tgctgcgcgc caagaccgag tggcgcccc aagtgaccga ctcttccgc	2400
ggcatcagcg tgatccccgc cgagtccagc gtgatggact acaaggacca cgacggcgac	2460
tacaaggacc acgacatcga ctacaaggac gacgacgaca agtgactcga gttaattaac	2520
tcgaggcagc agcagctcgg atagtatcga cacactctgg acgctggtcg tgtgatggac	2580
tgttgccgcc acatttgctg ccttgacctg tgaatatccc tgccgctttt atcaaacagc	2640
ctcagtgtgt ttgatcttgt gtgtacgcgc ttttgcgagt tgctagctgc ttgtgctatt	2700
tgcgaatacc acccccagca tccccctccc tcgtttcata tcgcttgcat cccaaccgca	2760
acttatctac gctgtcctgc tatccctcag cgctgctcct gtcctgctc actgcccctc	2820
gcacagcctt ggtttgggct ccgcctgtat tctcctggta ctgcaacctg taaaccagca	2880
ctgcaatgct gatgcacggg aagtagtggg atgggaacac aaatggaaag ctt	2933

<210> 113

<211> 4817

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 113

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac

60

026172-005010PC - Sequence Listing_1.TXT

gtgcttgggc gcctgccgcc tgccctgccgc atgcttgtgc tggtagaggct gggcagtgtc	120
gccatgtctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgc	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccagggtggt tcaatcgcg cagccagagg gatttcagat gatcgcgcg acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcgggctga	540
tgcaagcatg cctggcgaag acacatggtg tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggtcagcc atgcaactga tggcagctgg gctgccactg	660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcatggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg ccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc cttgacggc gtcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960
gccacccttc ttgcggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgctg gagaagcag gctggggcct ttgggctggt gcagcccgca	1080
atggaatgcg ggaccgccag gctagcagca aaggcgcctc ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt ccccgctgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcgaagtag gcgcccctc ttctgctcgc cctctctccg	1320
tccgcctctc agaatatcaa tgatcgagca ggacggcctc cagccggct ccccgccgc	1380
ctgggtggag cgctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgctgtccg cccagggccg ccccgctgctg ttcgtgaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgcccgctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtggt gaccgaggcc ggccgcgact ggctgtgtct	1620
gggcgagggtg cccggccagg acctgtgtc ctccacctg gccccgccg agaagggtgtc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gcccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcgc ccgcaccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggcccc gccgagctgt tcgcccgcct	1860
gaaggccccg atgcccagc gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggcgt	1980
ggccgaccgc taccaggaca tcgccctggc ccccgcgac atcgccgagg agctgggcgg	2040
cgagtgggcc gaccgcttcc tgggtgtgta cggcatcgcc gccccgact cccagcgc	2100

026172-005010PC - Sequence Listing_1.TXT

cgctttctac cgcttgctgg acgagttctt ctgacaattg gcagcagcag ctcggatagt	2160
atcgacacac tctggacgct ggctggtgta tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctattttgca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgctg ctctgctcc tgctcactgc ccctcgaca gccttggtt gggctccgcc	2460
tgtattctcc tggactgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccg cgtctcgaac agagcgcgca gaggaacgct	2580
gaaggctctg cctctgtgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt ctctgctcat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcaggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	2820
tcccgcgct gcatgcaaca ccgatgatgc ttcgacccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacgg cgcgccatgg tggccgccc gcctccagc gccttcttc	3120
ccgtgcccgc ccccgcgcc tcccccaagc ccggcaagtt cggcaactgg ccctccagcc	3180
tgagcccctc cttcaagccc aagtccatcc ccaacggcgg ctccagggtg aaggccaacg	3240
acagcgcaca cccaaggcc aacggctccg ccgtgagcct gaagagcggc agcctgaaca	3300
cccaggagga cacctcctcc agcccccccc ccgcacctt cctgcaccag ctgcccgact	3360
ggagccgcct gctgaccgcc atcaccaccg tgttcgtgaa gtccaagcgc cccgacatgc	3420
acgaccgcaa gtccaagcgc cccgacatgc tgggtggacag cttcggcctg gagtccaccg	3480
tgcaggacgg cctggtgttc cgccagtcct tctccatccg ctctacgag atcggcaccg	3540
accgcaccgc cagcatcgag accctgatga accacctgca ggagacctc ctgaaccact	3600
gcaagagcac cggcatcctg ctggacggct tcggccgcac cctggagatg tgcaagcgcg	3660
acctgatctg ggtggtgatc aagatgcaga tcaagggtgaa ccgctacccc gcctggggcg	3720
acaccgtgga gatcaacacc cgcttcagcc gcctgggcaa gatcggcctg ggccgcgact	3780
ggctgatctc cgactgcaac accggcgaga tcctggtgcg cgccaccagc gcctacgcca	3840
tgatgaacca gaagaccgc cgctgtcca agctgcccta cgaggtgcac caggagatcg	3900
tgcccctgtt cgtggacagc cccgtgatcg aggactccga cctgaagggtg cacaagttca	3960
agggtgaagac cggcgacagc atccagaagg gcctgacccc cggttggaac gacctggacg	4020
tgaaccagca cgtgtccaac gtgaagtaca tcggctggat cctggagagc atgcccaccg	4080
agggtgctgga gacccaggag ctgtgctccc tggccctgga gtaccgccc gagtgccggc	4140

026172-005010PC - Sequence Listing_1.TXT

gcgactccgt gctggagagc gtgaccgcca tggaccccag caaggtgggc gtgcgctccc	4200
agtaccagca cctgctgcmc ctggaggacg gcaccgccat cgtgaacggc gccaccgagt	4260
ggcgccccaa gaacgccggc gccaacggcg ccatctccac cggcaagacc agcaacggca	4320
actccgtgtc catggactac aaggaccacg acggcgacta caaggaccac gacatcgact	4380
acaaggacga cgacgacaag tgactcgagg cagcagcagc tcggatagta tcgacacact	4440
ctggacgctg gtcgtgtgat ggactgttgc cgccacactt gctgccttga cctgtgaata	4500
tccctgccgc ttttatcaaa cagcctcagt gtgtttgatc ttgtgtgtac gcgcttttgc	4560
gagttgctag ctgcttgtgc tatttgcgaa taccaccccc agcatcccct tccctcgttt	4620
catatcgctt gcataccaaac cgcaacttat ctacgctgtc ctgctatccc tcagcgtgc	4680
tcctgctcct gctcactgcc cctcgcacag ccttggtttg ggctccgcct gtattctcct	4740
ggtagtcaa cctgtaaacc agcactgcaa tgctgatgca cgggaagtag tgggatggga	4800
acacaaatgg aaagctt	4817

<210> 114

<211> 4665

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 114

ggtagccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgctgccgc atgcttgtgc tggtaggct gggcagtgc	120
gccatgctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgc	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccagggtgt tcaatcgcg cagccagagg gatttcagat gatcgcgct acaggtttag	300
cagcagtgtc agcaaaggta gcagtttgcc agaatactg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcagccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcgggctga	540
tgcaagcatg cctggcgaag acacatggtg tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggctcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcattggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgcat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gctcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960

026172-005010PC - Sequence Listing_1.TXT

gccacccttc ttgcgggggc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgcctg gagaagcgag gctggggcct ttgggctggt gcagcccgc	1080
atggaatgcg ggaccgccag gctagcagca aaggcgccct ccctactccg catcgatgtt	1140
ccatagtgc tttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcaagtag gcgccctcct ttctgctcg cctctctccg	1320
tccgcctct agaatatcaa tgatcgagca ggacggcctc cacgccggct cccccgccgc	1380
ctgggtggag cgcctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgcctgtccg ccagggccg ccccgctgctg ttcgtgaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgcccgctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtggt gaccgaggcc ggccgcgact ggctgctgct	1620
gggcgaggtg cccggccagg acctgctgtc ctccacctg gccccgccg agaagggtgc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gccccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcgc ccgcacccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggcccc gccgagctgt tcgcccgcct	1860
gaaggccgc atgcccgcg gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggcgt	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggcgg	2040
cgagtgggcc gaccgcttcc tgggtgctga cggcatcgcc gccccgact ccagcgc	2100
cgcttctac cgcctgctgg acgagttctt ctgacaattg gcagcagcag ctcgatagt	2160
atcgacacac tctggacgct ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgtg ctctgctcc tgctactgc ccctcgaca gccttggttt gggctccgcc	2460
tgtattctcc tggactgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatccc cgtctcgaac agagcgcgca gaggaacgct	2580
gaaggctctg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcaggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcgctat gacacttcca gaaaaggta gggcgggctg cgagacggct	2820
tcccgcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000

026172-005010PC - Sequence Listing_1.TXT

cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacac tagtatgacg ttccggggtcg ccctcccggc catggggccg	3120
ggtgtctccc ttccccggcc caggggtcgcg gtgcgcgccc agtcggcgag tcaggttttg	3180
gagagcgggc gcgcccagct gcccgactgg agccgcctgc tgaccgccat caccaccgtg	3240
ttcgtgaagt ccaagcgccc cgacatgcac gaccgcaagt ccaagcgccc cgacatgctg	3300
gtggacagct tcggcctgga gtccaccgtg caggacggcc tgggtgttccg ccagtccttc	3360
tccatccgct cctacgagat cggcaccgac cgcaccgcca gcatcgagac cctgatgaac	3420
cacctgcagg agacctccct gaaccactgc aagagcaccg gcatcctgct ggacggcttc	3480
ggccgcaccc tggagatgtg caagcgcgac ctgatctggg tggatgatcaa gatgcagatc	3540
aagggtgaacc gctaccccg cctggggcgac accgtggaga tcaacacccg cttcagccgc	3600
ctgggcaaga tcggcatggg ccgcgactgg ctgatctccg actgcaacac cggcgagatc	3660
ctggtgcgcg ccaccagcgc ctacgccatg atgaaccaga agacccgccg cctgtccaag	3720
ctgccctacg aggtgcacca ggagatcgtg cccctgttcg tggacagccc cgtgatcgag	3780
gactccgacc tgaaggtgca caagttcaag gtgaagaccg gcgacagcat ccagaagggc	3840
ctgacccccg gctggaacga cctggacgtg aaccagcacg tgtccaacgt gaagtacatc	3900
ggctggatcc tggagagcat gcccaccgag gtgctggaga cccaggagct gtgctccctg	3960
gccctggagt accgccgcga gtgcggccgc gactccgtgc tggagagcgt gaccgccatg	4020
gaccccagca aggtgggcgt gcgctcccag taccagcacc tgctgcgcct ggaggacggc	4080
accgccatcg tgaacggcgc caccgagtgg cgccccaaaga acgcccggcg caacggcgcc	4140
atctccaccg gcaagaccag caacggcaac tccgtgtcca tggactacaa ggaccacgac	4200
ggcgactaca aggaccacga catcgactac aaggacgacg acgacaagtg actcgaggca	4260
gcagcagctc ggatagtatc gacacactct ggacgctggg cgtgtgatgg actgttgccg	4320
ccacacttgc tgccttgacc tgtgaatatc cctgccgctt ttatcaaaca gcctcagtgt	4380
gtttgatctt gtgtgtacgc gcttttgca gttgctagct gcttgtgcta tttgcgaata	4440
ccacccccag catccccctt cctcgtttca tatcgcttgc atcccaaccg caacttatct	4500
acgctgtcct gctatccctc agcgctgctc ctgctcctgc tcaactgcccc tcgcacagcc	4560
ttggtttggg ctccgcctgt attctcctgg tactgcaacc tgtaaaccag cactgcaatg	4620
ctgatgcacg ggaagtagtg ggatgggaac acaaatggaa agctt	4665

<210> 115

<211> 4668

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 115

ggtagccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac

60

026172-005010PC - Sequence Listing_1.TXT

gtgcttgggc gcctgccgcc tgccctgccgc atgcttgtgc tggtagaggct gggcagtgtc	120
gccatgtctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgc	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccagggtggt tcaatcgcgg cagccagagg gatttcagat gatcgcgcggt acagggttag	300
cagcagtgtc agcaaaggta gcagtttgcc agaattgatcg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaaacctg caatcatcgg gcgggctga	540
tgcaagcatg cctggcgaag acacatggtg tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggttcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcattggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg ccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc cttgacggc gctcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960
gccacccttc ttgcggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgctg gagaagcgag gctggggcct ttgggctggt gcagcccgca	1080
atggaatgcg ggaccgccag gctagcagca aaggcgccct ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcgaaagtag gcgccctcct ttctgctcgc cctctctccg	1320
tcccgcctct agaatatcaa tgatcgagca ggacggcctc cacgccggct cccccgccgc	1380
ctgggtggag cgctgttctg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgctgtccg cccagggccg ccccgctgctg ttcgtgaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgccgcctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtggt gaccgaggcc ggccgcgact ggctgctgct	1620
gggcgaggtg cccggccagg acctgtgtc ctccacctg gccccgccg agaagggtgtc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac ccgccacct gcccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcg cgcacccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggcccc gccgagctgt tcgccccct	1860
gaaggccccg atgccccagc gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggcgt	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggcgg	2040
cgagtgggcc gaccgcttcc tgggtgctga cggcatcgcc gccccgact ccagcgc	2100

026172-005010PC - Sequence Listing_1.TXT

cgcccttctac cgctgctgg acgagttctt ctgacaattg gcagcagcag ctcggatagt	2160
atcgacacac tctggacgct ggctgctgta tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgcga ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcatcccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgctg ctctgctcc tgctcactgc ccctgcaca gccttggttt gggctccgcc	2460
tgtattctcc tggactgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccg cgtctcgaa agagcgcgca gaggaacgct	2580
gaaggctctg cctctgtgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcaggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcgtat gacacttcca gcaaaaggta gggcgggctg cgagacggct	2820
tcccggcgct gcatgcaaca ccgatgatgc ttcgacccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacac tagtatggct atcaagacga acaggcagcc tgtggagaag	3120
cctccgttca cgatcgggac gctgcgcaag gccatccccg cgactgttt cgagcgctcg	3180
gcgcttcgtg ggcgcgcca gctgcccga tggagccgcc tgctgaccgc catcaccacc	3240
gtgttcgtga agtccaagcg ccccgacatg cacgaccgca agtccaagcg ccccgacatg	3300
ctggtggaca gcttcggcct ggagtcacc gtgcaggacg gcctggtgtt ccgccagtcc	3360
ttctccatcc gctcctacga gatcggcacc gaccgcaccg ccagcatcga gaccctgatg	3420
aaccacctgc aggagacct cctgaaccac tgcaagagca ccggcatcct gctggacggc	3480
ttcggccgca ccctggagat gtgcaagcgc gacctgatct ggggtggtgat caagatgcag	3540
atcaaggtga accgctaccc cgcctggggc gacaccgtgg agatcaaac ccgcttcagc	3600
cgcctgggca agatcggcat gggccgcgac tggctgatct ccgactgcaa caccggcgag	3660
atcctggtgc gcgccaccag cgcctacgcc atgatgaacc agaagacccg ccgcctgtcc	3720
aagctgccct acgaggtgca ccaggagatc gtgcccctgt tcgtggacag ccccgatgc	3780
gaggactccg acctgaaggt gcacaagttc aaggtgaaga ccggcgacag catccagaag	3840
ggcctgaccc ccggctggaa cgacctggac gtgaaccagc acgtgtccaa cgtgaagtac	3900
atcggctgga tcctggagag catgcccacc gaggtgctgg agaccagga gctgtgctcc	3960
ctggccctgg agtaccgccg cgagtgcggc cgcgactccg tgctggagag cgtgaccgcc	4020
atggacccca gcaaggtggg cgtgcgctcc cagtaccagc acctgctgcg cctggaggac	4080
ggcaccgcca tcgtgaacgg cgccaccgag tggcgcccca agaagccgg cgccaacggc	4140

026172-005010PC - Sequence Listing_1.TXT

gccatctcca ccggaagac cagcaacggc aactccgtgt ccatggacta caaggaccac	4200
gacggcgact acaaggacca cgacatcgac tacaaggacg acgacgacaa gtgactcgag	4260
gcagcagcag ctcgatagt atcgacacac tctggacgct ggtcgtgtga tggactgttg	4320
ccgccacact tgctgccttg acctgtgaat atccctgccg cttttatcaa acagcctcag	4380
tgtgtttgat cttgtgtgta cgcgcttttg cgagttgcta gctgcttggt ctatttgca	4440
ataccacccc cagcatcccc ttccctcggt tcatatcgct tgcaccccaa ccgcaactta	4500
tctacgctgt cctgctatcc ctacgctg ctccctgctc tgctcactgc ccctcgca	4560
gccttggttt gggctccgcc tgtattctcc tggactgca acctgtaaac cagcactgca	4620
atgctgatgc acgggaagta gtgggatggg aacacaaatg gaaagctt	4668

<210> 116

<211> 4668

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 116

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgcctgccgc atgcttggtc tggtagggct gggcagtgtc	120
gccatgctga ttgaggcttg gttcatcggg tggaaagctta tgtgtgtgct gggcttgcat	180
gccgggcaat gcgcatgggt gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccagggtggt tcaatcgcgg cagccagagg gatttcagat gatcgcgctg acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaattgatc gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaaacctg caatcatcgg gcgggctgta	540
tgcaagcatg cctggcgaag acacatgggt tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggtcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtgggt gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcattggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gtcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960
gccacccttc ttgcggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgcctg gagaagcgag gctggggcct ttgggctggg gcagcccgca	1080
atggaatgca ggaccgccag gctagcagca aaggcgcctc ccctactccg catcgatgtt	1140

026172-005010PC - Sequence Listing_1.TXT

ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cggaagtag gcgccctcct ttctgctcgc cctctctccg	1320
tcccgcctct agaatatcaa tgatcgagca ggacggcctc cacgccggct cccccgccgc	1380
ctgggtggag cgctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgctgtccg ccagggccg ccccgctgtg ttcgtgaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgcccgcctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtggg gaccgaggcc ggccgcgact ggctgctgct	1620
gggcgaggtg cccggccagg acctgctgtc ctccacctg gccccgccg agaaggtgtc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gcccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcg cgcacccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggcccc gccgagctgt tcgcccgcct	1860
gaaggccccg atgcccgacg gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggctg	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggagg	2040
cgagtgggccc gaccgcttcc tgggtgctga cggcatcgcc gccccgact cccagcgcat	2100
cgcttctac cgctgtctgg acgagttctt ctgacaattg gcagcagcag ctcggatagt	2160
atcgacacac tctggacgct ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttgct ctatttgca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcatcccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgctg ctctgtctcc tgctcactgc ccctcgaca gccttggttt gggctccgcc	2460
tgtattctcc tggactgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccg cgtctcgaac agagcgcgca gaggaacgct	2580
gaaggctctg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcaggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	2820
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggagctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacac tagtatggcc accgcatcca ctttctcggc gttcaatgcc	3120
cgctgcggcg acctgcgtcg ctggcgggg tccgggcccc ggcgcccagc gagggccctc	3180

026172-005010PC - Sequence Listing_1.TXT

cccgtgcgcg ggcgcgcccc gctgcccgcac tggagccgcc tgctgaccgc catcaccacc	3240
gtgttcgtga agtccaagcg ccccgacatg cacgaccgca agtccaagcg ccccgacatg	3300
ctgggtggaca gcttcggcct ggagtccacc gtgcaggacg gcctgggtgtt ccgccagtcc	3360
ttctccatcc gctcctacga gatcggcacc gaccgcaccg ccagcatcga gaccctgatg	3420
aaccacctgc aggagacctc cctgaaccac tgcaagagca ccggcatcct gctggacggc	3480
ttcggccgca ccctggagat gtgcaagcgc gacctgatct ggggtgggtgat caagatgcag	3540
atcaagggtga accgctaccc cgcctggggc gacaccgtgg agatcaacac ccgcttcagc	3600
cgcctgggca agatcggcat gggccgcgac tggctgatct ccgactgcaa caccggcgag	3660
atcctgggtgc gcgccaccag cgcctacgcc atgatgaacc agaagacctg ccgcctgtcc	3720
aagctgccct acgaggtgca ccaggagatc gtgcccctgt tcgtggacag ccccgatgatc	3780
gaggactccg acctgaaggt gcacaagttc aagggtgaaga ccggcgacag catccagaag	3840
ggcctgaccc ccggctggaa cgacctggac gtgaaccagc acgtgtccaa cgtgaagtac	3900
atcggctgga tcctggagag catgcccacc gaggtgctgg agaccagga gctgtgctcc	3960
ctggccctgg agtaccgccg cgagtgcggc cgcgactccg tgctggagag cgtgaccgcc	4020
atggacccca gcaagggtggg cgtgcgctcc cagtaccagc acctgctgcg cctggaggac	4080
ggcaccgcca tcgtgaacgg cgccaccgag tggcgccccca agaacgccgg cgccaacggc	4140
gccatctcca ccggcaagac cagcaacggc aactccgtgt ccatggacta caaggaccac	4200
gacggcgact acaaggacca cgacatcgac tacaaggacg acgacgaaa gtgactcgag	4260
gcagcagcag ctcggatagt atcgacacac tctggacgct ggtcgtgtga tggactgttg	4320
ccgccacact tgctgccttg acctgtgaat atcccctgcc cttttatcaa acagcctcag	4380
tgtgtttgat cttgtgtgta cgcgcttttg cgagttgcta gctgcttgct ctatttgca	4440
ataccacccc cagcatcccc ttccctcggt tcatatcgct tgcattccaa ccgcaactta	4500
tctacgctgt cctgctatcc ctacgcgctg ctccctgctcc tgctcactgc ccctcgaca	4560
gccttggttt gggctccgcc tgtattctcc tggactgca acctgtaaac cagcactgca	4620
atgctgatgc acgggaagta gtgggatggg aacacaaatg gaaagctt	4668

<210> 117

<211> 4656

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 117

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgcctgccgc atgcttgctg tggtaggct gggcagtgc	120
gccatgctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgcat	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240

026172-005010PC - Sequence Listing_1.TXT

tccaggtggt tcaatcgcgg cagccagagg gatttcagat gatcgcgcggt acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcgggctga	540
tgcaagcatg cctggcgaag acacatggtg tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggtcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcatggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc cttgacggc gctcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960
gccacccttc ttgcggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcatgcctg gagaagcgag gctggggcct ttgggctggt gcagcccga	1080
atggaatgcg ggaccgccag gctagcagca aaggcgccct ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcaagtag gcgccctcct ttctgctcgc cctctctccg	1320
tcccgcctct agaatatcaa tgatcgagca ggacggcctc cacgccggct cccccgccgc	1380
ctgggtggag cgctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgctgtccg cccagggccg ccccgctgctg ttcgtgaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgcccgccctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtggt gaccgaggcc ggccgcgact ggctgctgct	1620
gggcgaggtg cccggccagg acctgctgtc ctcccacctg gccccgccg agaagggtgc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gcccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcg cgcacccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggccccc gccgagctgt tcgcccgcct	1860
gaaggccccg atgcccagc gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggctg	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggctg	2040
cgagtgggcc gaccgcttcc tgggtgctgta cggcatcgcc gccccgact cccagcgc	2100
cgcttctac cgctgctgg acgagttctt ctgacaattg gcagcagcag ctcggatagt	2160
atcgacacac tctggacgct ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280

026172-005010PC - Sequence Listing_1.TXT

cgcgcttttg	cgagttgcta	gctgcttg	ctatttgcga	ataccacccc	cagcatcccc	2340
ttccctcggt	tcatatcgct	tgcatcccaa	ccgcaactta	tctacgctgt	cctgctatcc	2400
ctcagcgctg	ctcctgctcc	tgctcactgc	ccctcgcaca	gccttggttt	gggctccgcc	2460
tgtattctcc	tggtactgca	acctgtaaac	cagcactgca	atgctgatgc	acgggaagta	2520
gtgggatggg	aacacaaatg	gaggatcccc	cgtctcgaac	agagcgcgca	gaggaacgct	2580
gaaggctctg	cctctgtcgc	acctcagcgc	ggcatacacc	acaataacca	cctgacgaat	2640
gcgcttggtt	cttcgtccat	tagcgaagcg	tccggttcac	acacgtgcca	cgttggcgag	2700
gtggcaggtg	acaatgatcg	gtggagctga	tggtcgaaac	gttcacagcc	tagggatata	2760
gaattccttt	cttgcgctat	gacacttcca	gcaaaaggta	gggcgggctg	cgagacggct	2820
tcccggcgct	gcatgcaaca	ccgatgatgc	ttcgaccccc	cgaagctcct	tcggggctgc	2880
atgggcgctc	cgatgccgct	ccagggcgag	cgctgtttaa	atagccaggc	ccccgattgc	2940
aaagacatta	tagcgagcta	ccaaagccat	attcaaacac	ctagatcact	accacttcta	3000
cacaggccac	tcgagcttgt	gatcgcactc	cgctaagggg	gcgcctcttc	ctcttcgttt	3060
cagtcacaac	ccgcaaacac	tagtatggct	tccgcggcat	tcacatgtc	ggcgtgcccc	3120
gcgatgactg	gcagggcccc	tggggcacgt	cgctccggac	ggccagtcgc	caccgcctg	3180
agggggcgcg	ccccgactg	gagccgcctg	ctgaccgcca	tcaccaccgt	gttcgtgaag	3240
tccaagcgcc	ccgacatgca	cgaccgcaag	tccaagcgcc	ccgacatgct	ggtggacagc	3300
ttcggcctgg	agtccaccgt	gcaggacggc	ctgggtgttc	gccagtcctt	ctccatccgc	3360
tcctacgaga	tcggcaccga	ccgcaccgcc	agcatcgaga	ccctgatgaa	ccacctgcag	3420
gagacctccc	tgaaccactg	caagagcacc	ggcatcctgc	tggacggctt	cggccgcacc	3480
ctggagatgt	gcaagcgcga	cctgatctgg	gtggtgatca	agatgcagat	caaggtgaac	3540
cgctaccccc	cctggggcga	caccgtggag	atcaaacacc	gcttcagccg	cctgggcaag	3600
atcggcatgg	gccgcgactg	gctgatctcc	gactgcaaca	ccggcgagat	cctggtgcgc	3660
gccaccagcg	cctacgccat	gatgaaccag	aagacccgcc	gcctgtccaa	gctgccctac	3720
gaggtgcacc	aggagatcgt	gcccctgttc	gtggacagcc	ccgtgatcga	ggactccgac	3780
ctgaagggtg	acaagttcaa	ggtgaagacc	ggcgacagca	tccagaaggg	cctgaccccc	3840
ggctggaacg	acctggacgt	gaaccagcac	gtgtccaacg	tgaagtacat	cggctggatc	3900
ctggagagca	tgcccaccga	ggtgctggag	accaggagc	tgtgctccct	ggccctggag	3960
taccgccgcg	agtgcggccg	cgactccgtg	ctggagagcg	tgaccgccat	ggacccagc	4020
aagggtggcg	tgcgtccca	gtaccagcac	ctgctgcgcc	tggaggacgg	caccgccatc	4080
gtgaacggcg	ccaccgagtg	gcgccccaa	aacgccggcg	ccaacggcgc	catctccacc	4140
ggcaagacca	gcaacggcaa	ctccgtgtcc	atggactaca	aggaccacga	cggcgactac	4200
aaggaccacg	acatcgacta	caaggacgac	gacgacaagt	gactcgaggc	agcagcagct	4260
cggatagtat	cgacacactc	tggacgctgg	tcgtgtgatg	gactgttgcc	gccacacttg	4320

026172-005010PC - Sequence Listing_1.TXT

ctgccttgac ctgtgaatat ccctgccgct tttatcaaac agcctcagtg tgtttgatct	4380
tgtgtgtacg cgctttttgcg agttgctagc tgcttgtgct atttgcgaat accaccccca	4440
gcatccccctt ccctcgtttc atatcgcttg catcccaacc gcaacttatc tacgctgtcc	4500
tgctatccct cagcgctgct cctgctcctg ctactgccc ctgcacagc cttggtttgg	4560
gctccgctg tattctcctg gtactgcaac ctgtaaacca gactgcaat gctgatgcac	4620
gggaagtagt gggatgggaa cacaatgga aagctt	4656

<210> 118

<211> 4721

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 118

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgcctgccgc atgcttgtgc tggtagaggct gggcagtgc	120
gccatgctga ttgaggcttg gttcatcggg tggaaagctta tgtgtgtgct gggcttgc	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccaggtggt tcaatcgcgg cagccagagg gatttcagat gatcgcgcgat acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaagatgacg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcagtcacac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcgggctg	540
tgcaagcatg cctggcgaag acacatggtg tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggtcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcatggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gtcctctcgc ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcggg	960
gccacccttc ttgcggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcatgcctg gagaagcgag gctggggcct ttgggctggg gcagcccgca	1080
atggaatgcg ggaccgccag gctagcagca aaggcgctc ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcgaagtag gcgcctcct ttctgctcgc cctctctccg	1320

026172-005010PC - Sequence Listing_1.TXT

tccccgcctct agaatatcaa tgatcgagca ggacggcctc cacgccggct cccccgccgc	1380
ctgggtggag cgcctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgcctgtccg cccagggccg ccccgctgtg ttcgtgaaga cgcacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgcccgctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgcctgc tggacgtggt gaccgaggcc ggccgcgact ggctgctgct	1620
gggagagggtg cccggccagg acctgctgtc ctccacctg gccccgccg agaagggtgc	1680
catcatggcc gacgcatgc gccgcctgca caccctggac cccgccacct gccccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcg cgcacccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggcccc gccgagctgt tcgccccct	1860
gaaggcccg atgcccagc gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggct	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggctg	2040
cgagtgggccc gaccgcttcc tgggtgctgta cggcatcgcc gccccgact cccagcgcat	2100
cgccttctac cgcctgctgg acgagttctt ctgacaattg gcagcagcag ctcggatagt	2160
atcgacacac tctggacgct ggtcgtgtga tggactgtt ccgccacact tgcctgtg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaacta tctacgctgt cctgctatcc	2400
ctcagcgctg ctctgtctcc tgcctactgc ccctcgaca gccttggttt gggctccgcc	2460
tgtattctcc tggactgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatccc cgtctcgaa agagcgcga gaggaacgct	2580
gaaggctctg cctctgtgc acctcagcg ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttgccgag	2700
gtggcagggtg acaatgatcg gtggagctga tggctgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcgtat gacacttcca gaaaaggta gggcgggctg cgagacggct	2820
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacgg cgcgccatgg ccaccaccag cctggcctcc gccttctgct	3120
ccatgaaggc cgtgatgctg gccgcgacg gccgcggcat gaagccccgc agctccgacc	3180
tgcagctgcg cgccggcaac gccccacct ccctgaagat gatcaacggc accaagttca	3240
gctacaccga gagcctgaag cgctgcccc actggtccat gctgttcgcc gtgatcacca	3300
ccatcttcag cgccgccgag aagcagtgga ccaacctgga gtggaagccc aagcccaagc	3360

026172-005010PC - Sequence Listing_1.TXT

tgccccagct gctggacgac cacttcggcc tgcacggcct ggtgttccgc cgcaccttcg	3420
ccatccgctc ctacgaggtg ggccccgacc gcagcacctc catcctggcc gtgatgaacc	3480
acatgcagga ggccaccctg aaccacgcca agagcgtggg catcctgggc gacggcttcg	3540
gcaccaccct ggagatgtcc aagcgcgacc tgatgtgggt ggtgcgccgc acccacgtgg	3600
ccgtggagcg ctaccccacc tggggcgaca ccgtggaggt ggagtgtctg atcggcgcca	3660
gcggaacaa cggcatgcgc cgcgacttcc tggcgcgca ctgcaagacc ggcgagatcc	3720
tgaccgcgtg cacctccctg agcgtgtga tgaacaccgc caccgcccgc ctgagcacca	3780
tccccgacga ggtgcgcggc gagatcggcc ccgccttcac cgacaacgtg gccgtgaagg	3840
acgacgagat caagaagctg cagaagctga acgactccac cggcgactac atccagggcg	3900
gcctgacccc ccgctggaac gacctggacg tgaaccagca cgtgaacaac ctgaagtacg	3960
tggcctgggt gttcgagacc gtgcccga caatcttcga gtcccaccac atcagctcct	4020
tcaccctgga gtaccgccgc gagtgcaccc gcgactccgt gctgcgcagc ctgaccaccg	4080
tgagcggcgg cagctccgag gccggcctgg tgtgcgacca cctgctgcag ctggagggcg	4140
gcagcgaggt gctgcgcgcc cgcaccgagt ggcgccccaa gctgaccgac tccttccgcg	4200
gcatcagcgt gatccccgcc gagccccgcg tgatggacta caaggaccac gacggcgact	4260
acaaggacca cgacatcgac tacaaggacg acgacgacaa gtgatgactc gaggcagcag	4320
cagctcggat agtatcgaca cactctggac gctggtcgtg tgatggactg ttgccgccac	4380
acttgctgcc ttgacctgtg aatatccctg ccgcttttat caaacagcct cagtgtgttt	4440
gatcttgtgt gtacgcgctt ttgcgagttg ctagtgtgtt gtgctatttg cgaataccac	4500
ccccagcatc cccttccctc gtttcatatc gcttgcaccc caaccgcaac ttatctacgc	4560
tgtcctgcta tccctcagcg ctgctcctgc tcctgctcac tgcccctcgc acagccttgg	4620
tttgggctcc gcctgtattc tcctggtact gcaacctgta aaccagcact gcaatgctga	4680
tgcacgggaa gtagtgggat gggaacacaa atggaaagct t	4721

<210> 119

<211> 4650

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 119

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgctgcccgc atgcttgtgc tggtagggct gggcagtgct	120
gccatgctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgcac	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccagggtgg tcaatcgcgg cagccagagg gatttcagat gatcgcgctg acaggttgag	300
cagcagtgct agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc	360

026172-005010PC - Sequence Listing_1.TXT

cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccgggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaaacactg caatcatcgg gcgggagtgga	540
tgcaagcatg cctggcgaag acacatgggtg tgcggatgct gccggctgct gcctgctgctg	600
cacgccgttg agttggcagc aggtcagcc atgactgga tggcagctgg gctgccactg	660
caatgtgggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcattggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgtcatgga acgcatgtag cgctgacgtc ccttgacggc gctcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960
gccacccttc ttgcggggtc gcgccccagc cagcggatgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgctg gagaagcag gctggggcct ttgggctggt gcagcccgca	1080
atggaatgca ggaccgccag gctagcagca aaggcgcctc ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt ccccgctgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcaagtag gcgcctcctc ttctgctcgc cctctctccg	1320
tccgcctctc agaatatcaa tgatcgagca ggacggcctc cacgccggct ccccgccgc	1380
ctgggtggag cgcctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgcctgtccg cccagggccg cccgctgctg ttctgtaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgcccgctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtgggt gaccgaggcc ggccgcgact ggctgctgct	1620
gggcgagggtg cccggccagg acctgctgtc ctcccacctg gccccgccc agaaggtgtc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gccccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcgc ccgcacccgc atggaggccg gcctgggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggccccc gccgagctgt tcgcccgcct	1860
gaaggcccg c atgcccagc gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcacg gactgcggcc gcctgggctg	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggagg	2040
cgagtgggcc gaccgcttcc tgggtgctga cggcatcgcc gccccgact cccagcgc	2100
cgccttctac cgcctgctgg acgagttctt ctgacaattg gcagcagcag ctcggatagt	2160
atcgacacac tctggacgct ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgcca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaactta tctacgctgt cctgctatcc	2400

026172-005010PC - Sequence Listing_1.TXT

ctcagcgctg ctctgtctcc tgctcactgc ccctcgcaca gccttggttt gggctccgcc	2460
tgtattctcc tggtactgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccc cgtctcgaac agagcgcgca gaggaacgct	2580
gaaggtctcg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcaggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	2820
tccccggcgt gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacac tagtatgacg ttcggggtcg ccctccccgc catggggccgc	3120
ggtgtctccc ttccccggcc cagggtcgcg gtgcgcgccc agtcggcgag tcaggttttg	3180
gagagcgggc gcgccccga ctggtccatg ctgttcgccg tgatcaccac catcttcagc	3240
gccgccgaga agcagtggaac caacctggag tggaagccca agcccaagct gccccagctg	3300
ctggacgacc acttcggcct gcacggcctg gtgttccgcc gcaccttcgc catccgctcc	3360
tacgaggtgg gccccgaccg cagcacctcc atcctggccg tgatgaacca catgcaggag	3420
gccacctga accacgcca gagcgtgggc atcctggggc acggcttcgg caccacctg	3480
gagatgtcca agcgcgacct gatgtgggtg gtgcgcgcca cccacgtggc cgtggagcgc	3540
tacccacact ggggcgacac cgtggaggtg gagtgctgga tcggcgccag cggcaacaac	3600
ggcatgcgcc gcgacttcct ggtgcgcgac tgcaagaccg gcgagatcct gacctgctgc	3660
acctccctga gcgtgctgat gaacacccgc acccgccgcc tgagcaccat ccccgacgag	3720
gtgcgcggcg agatcggccc cgccttcac gacaacgtgg ccgtgaagga cgacgagatc	3780
aagaagctgc agaagctgaa cgactccacc gccgactaca tccagggcgg cctgaccccc	3840
cgctggaacg acctggacgt gaaccagcac gtgaacaacc tgaagtacgt ggcctgggtg	3900
ttcgagaccg tgccccgacag catcttcgag tcccaccaca tcagctcctt caccctggag	3960
taccgccgcg agtgcacccg cgactccgtg ctgcgcagcc tgaccaccgt gagcggcggc	4020
agctccgagg ccggcctggt gtgcgaccac ctgctgcagc tggagggcgg cagcgaggtg	4080
ctgcgcgccc gcaccgagtg gcgccccaa ctgaccgact ccttcgcgg catcagcgtg	4140
atccccgccg agccccgcgt gatggactac aaggaccacg acggcgacta caaggaccac	4200
gacatcgact acaaggacga cgacgacaag tgatgactcg aggcagcagc agctcggata	4260
gtatcgacac actctggacg ctggtcgtgt gatggactgt tgccgccaca cttgctgcct	4320
tgacctgtga atatccctgc cgcttttatc aaacagcctc agtgtgtttg atcttgctg	4380
tacgcgcttt tgcgagttgc tagctgcttg tgctatttgc gaataccacc cccagcatcc	4440

026172-005010PC - Sequence Listing_1.TXT

ccttcctcgc tttcatatcg cttgcatccc aaccgcaact tatctacgct gtcctgctat	4500
ccctcagcgc tgctcctgct cctgctcact gcccctcgca cagccttggt ttgggctccg	4560
cctgtattct cctggtactg caacctgtaa accagcactg caatgctgat gcacgggaag	4620
tagtgggatg ggaacacaaa tggaaagctt	4650

<210> 120

<211> 4653

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 120

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgcctgccgc atgcttggtc tggtagaggct gggcagtgtc	120
gccatgctga ttgaggcttg gttcatcggg tggaaagctta tgtgtgtgct gggcttgcat	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccaggtggt tcaatcgcg cagccagagg gatttcagat gatcgcgct acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcgggctgta	540
tgcaagcatg cctggcgaa acacatggtg tgcggatgct gccggctgct gcctgctgctg	600
cacgccgttg agttggcagc aggtcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcatggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gctcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960
gccacccttc ttgcgggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgctg gagaagcgag gctggggcct ttgggctggt gcagcccgca	1080
atggaatgct ggaccgccag gctagcagca aaggcgcctc ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcgaaagtag gcgcccctct ttctgctcgc cctctctccg	1320
tccgcctct agaatatcaa tgatcgagca ggacggcctc cagccggct ccccgccgc	1380
ctgggtggag cgctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc	1440

026172-005010PC - Sequence Listing_1.TXT

cgccgtgttc cgcctgtccg cccagggccg ccccgtgctg ttcgtgaaga ccgacctgtc	1500
cggcgccttg aacgagctgc aggacgaggg cgccgcctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtggt gaccgaggcc ggccgcgact ggctgctgct	1620
gggcgaggtg cccggccagg acctgctgtc ctcccacctg gccccgcgg agaaggtgtc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac ccgcccacct gccccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcgc ccgcacccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggccccc gccgagctgt tcgcccgcct	1860
gaaggcccg atgcccgcg gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggcgt	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgcac atcgccgagg agctgggcgg	2040
cgagtgggccc gaccgcttcc tgggtgctgta cggcatcgcc gcccccgact cccagcgcat	2100
cgccttctac cgctgctgg acgagttctt ctgacaattg gcagcagcag ctcgatagt	2160
atcgacacac tctggacgtt ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgtg ctctgtctcc tgctcactgc ccctcgca ca gccttggttt gggctccgcc	2460
tgtattctcc tggtagtgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccg cgtctcgaac agagcgcgca gaggaacgct	2580
gaagggtctg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcaggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcgtat gacacttcca gcaaaaggta gggcgggctg cgagacggct	2820
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgcactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcaaac ccgcaaacac tagtatggct atcaagacga acaggcagcc tgtggagaag	3120
cctccgttca cgatcgggac gctgcgcaag gccatccccg cgcactgttt cgagcgctcg	3180
gcgcttcgtg ggccgcgccc cgactggtcc atgctgttcg ccgtgatcac caccatcttc	3240
agcgcgccc agaagcagtg gaccaacctg gagtggaagc ccaagcccaa gctgccccag	3300
ctgctggacg accacttcgg cctgcacggc ctggtgttcc gccgcacctt cgccatccgc	3360
tcctacgagg tgggccccga ccgcagcacc tccatcctgg ccgtgatgaa ccacatgcag	3420
gaggccaccc tgaaccacgc caagagcgtg ggcatacctg gcgacggctt cggcaccacc	3480

026172-005010PC - Sequence Listing_1.TXT

ctggagatgt ccaagcgcgga cctgatgtgg gtggtgcgcc gcacccacgt ggccgtggag	3540
cgctacccca cctggggcgga caccgtggag gtggagtgtc ggatcgggcg cagcggcaac	3600
aacggcatgc gccgcgactt cctggtgctg gactgcaaga ccggcgagat cctgacccgc	3660
tgcacctccc tgagcgtgtc gatgaacacc cgcacccgcc gcctgagcac catccccgac	3720
gaggtgctgc gcgagatcgg ccccgccctt atcgacaacg tggccgtgaa ggacgacgag	3780
atcaagaagc tgcagaagct gaacgactcc accgccgact acatccaggg cggcctgacc	3840
ccccgctgga acgacctgga cgtgaaccag cacgtgaaca acctgaagta cgtggcctgg	3900
gtgttcgaga ccgtgcccga cagcatcttc gagtcccacc acatcagctc cttcacctg	3960
gagtaccgcc gcgagtgcac ccgcgactcc gtgctgctga gcctgaccac cgtgagcggc	4020
ggcagctccg agggccggct ggtgtgctgc cacctgctgc agctggaggg cggcagcgag	4080
gtgctgctgc cccgcaccga gtggcgcccc aagctgaccg actccttccg cggcatcagc	4140
gtgatccccg ccgagccccg cgtgatggac tacaaggacc acgacggcga ctacaaggac	4200
cacgacatcg actacaagga cgacgacgac aagtgatgac tcgaggcagc agcagctcgg	4260
atagtatcga cacactctgg acgctggctg tgtgatggac tgttgccgcc acacttgctg	4320
ccttgacctg tgaatatccc tgccgctttt atcaaacagc ctcatgtgtt ttgatcttgt	4380
gtgtacgcgc ttttgcgagt tgctagctgc ttgtgctatt tgcaataacc acccccagca	4440
tccccctccc tcgtttcata tcgcttgcac cccaaccgca acttatctac gctgtcctgc	4500
tatccctcag cgctgctcct gctcctgctc actgcccctc gcacagcctt ggtttgggct	4560
ccgcctgtat tctcctggta ctgcaacctg taaaccagca ctgcaatgct gatgcacggg	4620
aagtagtggg atgggaacac aaatggaaag ctt	4653

<210> 121

<211> 4653

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 121

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgctgccgc atgcttgtgc tggtagaggct gggcagtgtc	120
gccatgctga ttgaggcttg gttcatcggg tggaaagtta tgtgtgtgct gggcttgcac	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccagggtgg tcaatcgcgg cagccagagg gatttcagat gatcgcgctg acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcatgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcgggctgta	540

026172-005010PC - Sequence Listing_1.TXT

tgcaagcatg cctggcgaag acacatgggtg tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggtcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcattggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gtcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960
gccacccttc ttgcggggtc gcgccccagc cagcggatgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgcctg gagaagcag gctggggcct ttgggctggt gcagcccga	1080
atggaatgca ggaccgccag gctagcagca aaggcgcctc ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcgaagtag gcgcctcct ttctgctcgc cctctctccg	1320
tcccgcctct agaatatcaa tgatcgagca ggacggcctc cacgccggct cccccgccgc	1380
ctgggtggag cgctgttctg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgctgtccg cccagggccg ccccgctgctg ttctgtaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgcccgctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtggt gaccgaggcc ggccgcgact ggctgctgct	1620
gggcgagggtg cccggccagg acctgctgtc ctcccacctg gccccgccg agaaggtgtc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gccccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcgc ccgcacccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggcccc gccgagctgt tcgcccgcct	1860
gaaggccccg atgcccagc gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggcgt	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggcgg	2040
cgagtgggcc gaccgcttcc tgggtgctgta cggcatcgcc gccccgact cccagcgc	2100
cgccttctac cgctgctgg acgagttctt ctgacaattg gcagcagcag ctcggatagt	2160
atcgacacac tctggacgct ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgtg ctctgctcc tgctcactgc ccctcgaca gccttggttt gggctccgcc	2460
tgtattctcc tggtagtga acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccc cgtctcgaac agagcgcgca gaggaacgct	2580

026172-005010PC - Sequence Listing_1.TXT

gaagggtctcg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgccca cggtggcgag	2700
gtggcaggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatac	2760
gaatttccttt cttgcgtat gacacttcca gcaaaaggta gggcgggctg cgagacggct	2820
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacac tagtatggcc accgcatcca ctttctcggc gttcaatgcc	3120
cgctgcggcg acctgcgtcg ctccggcgggc tccgggcccc ggcgccagc gaggccccctc	3180
cccgtgcgcg ggcgcgcccc cgactggctc atgctgttcg ccgtgatcac caccatcttc	3240
agcgccgccc agaagcagtg gaccaacctg gagtggaagc ccaagcccaa gctgccccag	3300
ctgctggacg accacttcgg cctgcacggc ctgggtgttc gccgcacctt cgccatccgc	3360
tcctacgagg tgggccccga ccgcagcacc tccatcctgg ccgtgatgaa ccacatgcag	3420
gaggccaccc tgaaccacgc caagagcgtg ggcattcctg gcgacggctt cggcaccacc	3480
ctggagatgt ccaagcgga cctgatgtgg gtgggtgcgc gcacccacgt ggccgtggag	3540
cgctacccca cctggggcga caccgtggag gtggagtgtt ggatcggcgc cagcggcaac	3600
aacggcatgc gccgcgactt cctgggtgcgc gactgcaaga ccggcgagat cctgacccgc	3660
tgcacctccc tgagcgtgct gatgaacacc cgcacccgcc gcctgagcac catccccgac	3720
gaggtgcgcg gcgagatcgg ccccgccctt atcgacaacg tggccgtgaa ggacgacgag	3780
atcaagaagc tgcagaagct gaacgactcc accgccgact acatccaggg cggcctgacc	3840
ccccgctgga acgacctgga cgtgaaccag cacgtgaaca acctgaagta cgtggcctgg	3900
gtgttcgaga ccgtgcccga cagcatcttc gagtcccacc acatcagctc cttcacctg	3960
gagtaccgcc gcgagtgac ccgcgactcc gtgctgcgca gcctgaccac cgtgagcggc	4020
ggcagctccg aggccggcct ggtgtgcgac cacctgctgc agctggaggg cggcagcgag	4080
gtgctgcgcg cccgcaccga gtggcgcccc aagctgaccg actccttcg cggcatcagc	4140
gtgatccccg ccgagccccg cgtgatggac tacaaggacc acgacggcga ctacaaggac	4200
cacgacatcg actacaagga cgacgacgac aagtgatgac tcgaggcagc agcagctcgg	4260
atagtatcga cacactctgg acgctggctg tgtgatggac tgttgccgcc acacttgctg	4320
ccttgacctg tgaatatccc tgccgctttt atcaaacagc ctcagtgtgt ttgatcttgt	4380
gtgtacgcgc ttttgcgagt tgctagctgc ttgtgctatt tgcgaatacc acccccagca	4440
tccccttccc tcgtttcata tcgcttgcat cccaaccgca acttatctac gctgtcctgc	4500
tatccctcag cgctgctcct gctcctgctc actgcccctc gcacagcctt ggtttgggct	4560
ccgcctgtat tctcctggta ctgcaacctg taaaccagca ctgcaatgct gatgcacggg	4620

026172-005010PC - Sequence Listing_1.TXT

aagtagtggg atgggaacac aaatggaaag ctt

4653

<210> 122

<211> 4647

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 122

```

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac      60
gtgcttgggc gcctgccgcc tgcctgccgc atgcttgtgc tggtagaggct gggcagtgtc      120
gccatgtctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgcac      180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc      240
tccagggtggt tcaatcgcgg cagccagagg gatttcagat gatcgcgctg acaggttgag      300
cagcagtgtc agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc      360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg      420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg      480
gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcggggcgtga      540
tgcaagcatg cctggcgaaag acacatggtg tgcggatgct gccggctgct gcctgctgcg      600
cacgccgttg agttggcagc aggtcagcc atgcaactgga tggcagctgg gctgccactg      660
caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt      720
tgcatggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat      780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc      840
atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gtcctctcgc ggtgtgggaa      900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg      960
gccacccttc ttgcgggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt     1020
cacattcatt tgcattgctg gagaagcgag gctggggcct ttgggctggt gcagcccgca     1080
atggaatgcg ggaccgccag gctagcagca aaggcgcctc ccctactccg catcgatggt     1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa     1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc     1260
gatcagctga ttgcccggct cgcgaagtag gcgccctcct ttctgctcgc cctctctccg     1320
tcccgcctct agaatatcaa tgatcgagca ggacggcctc cacgccggct cccccgccgc     1380
ctgggtggag cgcctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc     1440
cgccgtgttc cgcctgtccg cccagggccg ccccgtgctg ttcgtgaaga ccgacctgtc     1500
cggcgccctg aacgagctgc aggacgaggc cgcccgcctg tcctggctgg ccaccaccgg     1560
cgtgccctgc gccgccgtgc tggacgtggt gaccgaggcc ggccgcgact ggctgctgct     1620

```

026172-005010PC - Sequence Listing_1.TXT

gggcgaggtg cccggccagg acctgctgtc ctccacctg gcccccgccg agaaggtgtc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gccccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcgc ccgcacccgc atggaggccg gcctgggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggccccc gccgagctgt tcgcccgcct	1860
gaaggcccg c atgcccagc gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggcgt	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgcac atcgccgagg agctgggcgg	2040
cgagtgggccc gaccgcttcc tgggtgctgta cggcatcgcc gccccgact cccagcgcat	2100
cgccttctac cgcctgctgg acgagttctt ctgacaattg gcagcagcag ctcggaatag	2160
atcgacacac tctggacgct ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgctg ctctgtctcc tgctcactgc ccctcgca ca gccttggttt gggctccgcc	2460
tgtattctcc tgggtactgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccg cgtctcgaac agagcgcgca gaggaacgct	2580
gaagggtctcg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt ctctgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcagggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	2820
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttta atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcaaac ccgcaaacac tagtatggct tccgcggcat tcaccatgtc ggcgtgcccc	3120
gcgatgactg gcagggcccc tggggcacgt cgctccggac ggccagtcgc caccgcctg	3180
agggggcgcg ccccgactg gtccatgctg ttcgccgtga tcaccacat cttcagcgcc	3240
gccgagaagc agtggacca cctggagtgg aagcccaagc ccaagctgcc ccagctgctg	3300
gacgaccact tcggcctgca cggcctgggt ttccgccgca ctttcgcat ccgctcctac	3360
gaggtgggccc ccgaccgag cacctccatc ctggccgtga tgaaccacat gcaggaggcc	3420
acctgaacc acgccaagag cgtgggcatc ctgggcgac gcttcggcac caccctggag	3480
atgtccaagc gcgacctgat gtgggtgggt cgccgcaccc acgtggccgt ggagcgctac	3540
cccacctggg gcgacaccgt ggaggtggag tgctggatcg gcgccagcgg caacaacggc	3600
atgcgccgcg acttcttggt gcgcgactgc aagaccggcg agatcctgac ccgctgcacc	3660

026172-005010PC - Sequence Listing_1.TXT

tccctgagcg tgctgatgaa caccgcacc cgccgcctga gcaccatccc cgacgaggtg	3720
cgcggcgaga tcggccccgc cttcatcgac aacgtggccg tgaaggacga cgagatcaag	3780
aagctgcaga agctgaacga ctccaccgcc gactacatcc agggcggcct gacccccgc	3840
tggaaacgacc tggacgtgaa ccagcacgtg aacaacctga agtacgtggc ctgggtgttc	3900
gagaccgtgc ccgacagcat cttcgagtcc caccacatca gctccttcac cctggagtac	3960
cgccgcgagt gacccgcga ctccgtgctg cgcagcctga ccaccgtgag cggcggcagc	4020
tccgaggccg gcctgggtgtg cgaccacctg ctgcagctgg agggcggcag cgaggtgctg	4080
cgcgcccgca ccgagtggcg cccaagctg accgactcct tccgcggcat cagcgtgatc	4140
cccgcggagc cccgcgtgat ggactacaag gaccacgacg gcgactacaa ggaccacgac	4200
atcgactaca aggacgacga cgacaagtga tgactcgagg cagcagcagc tcggatagta	4260
tcgacacact ctggacgctg gtcgtgtgat ggactgttg cgcacactt gctgccttga	4320
cctgtgaata tccctgccgc ttttatcaaa cagcctcagt gtgtttgatc ttgtgtgtac	4380
gcgcttttgc gagttgctag ctgcttgtgc tatttgcgaa taccaccccc agcatcccct	4440
tccctcgttt catatcgctt gcatcccaac cgcaacttat ctacgctgtc ctgctatccc	4500
tcagcgctgc tcctgctcct gctcactgcc cctcgcacag ccttggtttg ggctccgcct	4560
gtattctcct ggtactgcaa cctgtaaac agcactgcaa tgctgatgca cgggaagtag	4620
tgggatggga acacaaatgg aaagctt	4647

<210> 123

<211> 4721

<212> DNA

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 123

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgctgccgc atgcttgtgc tggtagggct gggcagtgtc	120
gccatgctga ttgaggcttg gttcatcggg tggaaagtta tgtgtgtgct gggcttgcac	180
gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccaggtggt tcaatcgcgg cagccagagg gatttcagat gatcgcgctg acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaattgatc gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaaacctg caatcatcgg gcgggcgtga	540
tgcaagcatg cctggcgaag acacatgggt tgcggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggtcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtgggt gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720

026172-005010PC - Sequence Listing_1.TXT

tgcattggcat cgcacccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840
atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gctcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg	960
gccacccttc ttgcggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgctg gagaagcag gctggggcct ttgggctggg gcagcccgca	1080
atggaatgcg ggaccgccag gctagcagca aaggcgcctc ccctactccg catcgatgtt	1140
ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcaagtag gcgcctctct ttctgctcgc cctctctccg	1320
tcccgcctct agaatatcaa tgatcgagca ggacggcctc cagccggct cccccgccgc	1380
ctgggtggag cgctgttctg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgctgtccg cccaggggcg ccccgctgtg ttctggaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgccgcctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgccgtgc tggacgtggg gaccgaggcc ggccgcgact ggctgctgct	1620
gggcgagggtg cccggccagg acctgctgtc ctccacctg gccccgccg agaagggtgc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gcccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcgc ccgcacccgc atggaggccg gcctgggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggcccc gccgagctgt tcgcccgcct	1860
gaaggccccg atgcccagc gcgaggacct ggtggtgacc cagggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggctg	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggagg	2040
cgagtgggccc gaccgcttcc tgggtgctgta cggcatcgcc gccccgact cccagcgc	2100
cgcttctac cgctgtgtg acgagttctt ctgacaattg gcagcagcag ctcgatagt	2160
atcgacacac tctggacgct ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgcc cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgcga ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgtg ctctgctcc tgctcactgc ccctgcaca gccttggtt gggctccgcc	2460
tgtattctcc tggtagtga acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccc cgtctcgaac agagcgcgca gaggaacgct	2580
gaaggctctg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcagggtg acaatgatcg gtggagctga tggctcgaac gttcacagcc tagggatatc	2760

026172-005010PC - Sequence Listing_1.TXT

gaatttccttt cttgcgctat gacactttcca gcaaaaggta gggcgggctg cgagacggct	2820
tcccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttaa atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacgg cgcgccatgg ccaccacctc cctggcctcc gccttctgca	3120
gcatgaaggc cgtgatgctg gcccgcgacg gccgcggcat gaagccccgc tccagcgacc	3180
tgcagctgcg cgccggcaac gcccagacct ccctgaagat gatcaacggc accaagttct	3240
cctacaccga gagcctgaag aagctgcccc actggtccat gctgttcgcc gtgatcacca	3300
ccatcttctc cgccgccgag aagcagtgga ccaacctgga gtggaagccc aagcccaacc	3360
ccccccagct gctggacgac cacttcggcc cccacggcct ggtgttccgc cgcaccttcg	3420
ccatccgcag ctacgaggtg ggccccgacc gctccaccag catcgtggcc gtgatgaacc	3480
acctgcagga ggccgccctg aaccacgcca agtccgtggg catcctgggc gacggcttcg	3540
gcaccaccct ggagatgtcc aagcgcgacc tgatctgggt ggtgaagcgc acccacgtgg	3600
ccgtggagcg ctaccccgcc tggggcgaca ccgtggaggt ggagtgcctg gtgggcgctt	3660
ccggcaacaa cggccgccg cacttctcc tggcgcgca ctgcaagacc ggcgagatcc	3720
tgacccgctg cacctccctg agcgtgatga tgaacacccg caccgcccgc ctgagcaaga	3780
tccccgagga ggtgcgcggc gagatcggcc ccgccttcac cgacaacgtg gccgtgaagg	3840
acgaggagat caagaagccc cagaagctga acgactccac cgccgactac atccagggcg	3900
gcctgacccc ccgctggaac gacctggaca tcaaccagca cgtgaacaac atcaagtacg	3960
tggactggat cctggagacc gtgcccgaca gcatcttcga gagccaccac atctcctcct	4020
tcaccatcga gtaccgccgc gagtgcacca tggacagcgt gctgcagtcc ctgaccaccg	4080
tgagcggcgg ctctcccgag gccggcctgg tgtgcgagca cctgctgcag ctggagggcg	4140
gcagcgaggt gctgcgcgcc aagaccgagt ggcgccccaa gctgaccgac tccttcgcg	4200
gcatcagcgt gatccccgcc gagtccagcg tgatggacta caaggaccac gacggcgact	4260
acaaggacca cgacatcgac tacaaggacg acgacgacaa gtgatgactc gaggcagcag	4320
cagctcggat agtatcgaca cactctggac gctggctcgtg tgatggactg ttgccgccac	4380
acttgctgcc ttgacctgtg aatatccctg ccgcttttat caaacagcct cagtgtgttt	4440
gatcttgtgt gtacgcgctt ttgcgagttg ctagctgctt gtgctatttg cgaataccac	4500
ccccagcatc ccttccctc gtttcatatc gcttgcaccc caaccgcaac ttatctacgc	4560
tgtcctgcta tccctcagcg ctgctcctgc tcctgctcac tgcccctcgc acagccttgg	4620
tttgggctcc gcctgtattc tcctgggtact gcaacctgta aaccagcact gcaatgctga	4680
tgcacgggaa gtagtgggat gggaacacaa atggaaagct t	4721

026172-005010PC - Sequence Listing_1.TXT

<210> 124
 <211> 4650
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 124
 ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac 60
 gtgcttgggc gcctgccgcc tgcctgccgc atgcttggtc tggtagaggct gggcagtgtc 120
 gccatgctga ttgaggcttg gttcatcggg tggaagctta tgtgtgtgct gggcttgcat 180
 gccgggcaat gcgcatggtg gcaagagggc ggcagcactt gctggagctg ccgcggtgcc 240
 tccagggtggt tcaatcgcgg cagccagagg gatttcagat gatcgcgctg acagggttag 300
 cagcagtgtc agcaaaggta gcagtttgcc agaatgatcg gttcagctgt taatcaatgc 360
 cagcaagaga aggggtcaag tgcaaacacg ggcagtgccac agcacgggca ccggggagtg 420
 gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg 480
 gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcgggctgta 540
 tgcaagcatg cctggcgaag acacatggtg tgcggatgct gccggctgct gcctgctgcg 600
 cagcgcgttg agttggcagc aggtcagcc atgcactgga tggcagctgg gctgccactg 660
 caatgtggtg gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt 720
 tgcattggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat 780
 gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc 840
 atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gtcctctctg ggtgtgggaa 900
 acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcgggg 960
 gccacccttc ttgcgggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt 1020
 cacattcatt tgcattgctg gagaagcgag gctggggcct ttgggctggt gcagcccgca 1080
 atggaatgcg ggaccgccag gctagcagca aaggcgcctc ccctactccg catcgatgtt 1140
 ccatagtgca ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa 1200
 cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc 1260
 gatcagctga ttgcccggct cgcgaagtag gcgcccctct ttctgctcgc cctctctccg 1320
 tcccgcctct agaatatcaa tgatcgagca ggacggcctc cagccgggt ccccgccgc 1380
 ctgggtggag cgcctgttcg gctacgactg ggcccagcag accatcggct gctccgacgc 1440
 cgccgtgttc cgcctgtccg cccagggccg ccccgtgctg ttcgtgaaga ccgacctgtc 1500
 cggcgccctg aacgagctgc aggacaggc cggccgcctg tcctggctgg ccaccaccgg 1560
 cgtgccctgc gccgcccgtg tggacgtggt gaccgaggcc ggccgcgact ggctgctgct 1620
 gggcgagggtg cccggccagg acctgctgtc ctccacactg gccccgccg agaagggtgtc 1680
 catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gccccttcga 1740

026172-005010PC - Sequence Listing_1.TXT

ccaccaggcc aagcaccgca tcgagcgcgc ccgcacccgc atggaggccg gcctggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggccccc gccgagctgt tcgcccgcct	1860
gaaggccccg atgcccgcg gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggtttcatc gactgcggcc gcctgggcgt	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgcac atcgccgagg agctgggcgg	2040
cgagtgggcc gaccgcttcc tgggtctgta cggcatcgcc gccccgact cccagcgcac	2100
cgctttctac cgctgtctgg acgagttctt ctgacaattg gcagcagcag ctcggatagt	2160
atcgacacac tctggacgct ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgcca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcattccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgctg ctctgtctcc tgctcactgc ccctcgaca gccttggttt gggctccgcc	2460
tgtattctcc tgggtactgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccc cgtctcgaa agagcgcgca gaggaacgct	2580
gaaggctctg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcagggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatata	2760
gaattccttt ctgctgctat gacacttcca gcaaaaggta gggcgggctg cgagacggct	2820
tcccgcgct gcattgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880
atgggcgctc cgatgccgct ccagggcgag cgctgtttta atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacac tagtatgacg ttcggggctg ccctcccggc catgggcccgc	3120
ggtgtctccc ttccccggcc cagggtcgcg gtgcgcgccc agtcggcgag tcaggttttg	3180
gagagcgggc gcgccccga ctggtccatg ctgttcgcg tgatcaccac catcttctcc	3240
gccgcccaga agcagtggac caacctggag tggaagccca agcccaaccc ccccagctg	3300
ctggacgacc acttcggccc ccacggcctg gtgttcgcg gcaccttcgc catccgcagc	3360
tacgagggtg gccccgaccg ctccaccagc atcgtggccg tgatgaacca cctgcaggag	3420
gccgccctga accacgcca gtccgtgggc atcctgggcg acggcttcgg caccaccctg	3480
gagatgtcca agcgcgacct gatctgggtg gtgaagcgca cccacgtggc cgtggagcgc	3540
tacccgcctt ggggcgacac cgtggagggt gagtgcctgg tgggcgcctc cggcaacaac	3600
ggccgcccgc acgacttcct ggtgcgcgac tgcaagaccg gcgagatcct gacccgctgc	3660
acctccctga gcgtgatgat gaacacccgc acccgccgcc tgagcaagat ccccaggag	3720
gtgcgcggcg agatcggccc cgccttcac gacaacgtgg ccgtgaagga cgaggagatc	3780

026172-005010PC - Sequence Listing_1.TXT

aagaagcccc agaagctgaa cgactccacc gccgactaca tccagggcgg cctgaccccc	3840
cgctggaacg acctggacat caaccagcac gtgaacaaca tcaagtacgt ggactggatc	3900
ctggagaccg tgcccgcagc catcttcgag agccaccaca tctcctcctt caccatcgag	3960
taccgccgcg agtgcacat ggacagcgtg ctgcagtccc tgaccaccgt gagcggcggc	4020
tcctccgagg ccggcctggt gtgcgagcac ctgctgcagc tggagggcgg cagcgagggtg	4080
ctgcgcgcca agaccgagtg gcgccccaaag ctgaccgact ccttccgcgg catcagcgtg	4140
atccccgccc agtccagcgt gatggactac aaggaccacg acggcgacta caaggaccac	4200
gacatcgact acaaggacga cgacgacaag tgatgactcg aggcagcagc agctcggata	4260
gtatcgacac actctggacg ctggtcgtgt gatggactgt tgccgccaca cttgctgcct	4320
tgacctgtga atatccctgc cgcttttatc aaacagcctc agtgtgtttg atcttgtgtg	4380
tacgcgcttt tgcgagttgc tagctgcttg tgctatttgc gaataccacc cccagcatcc	4440
ccttccctcg tttcatatcg cttgcatccc aaccgcaact tatctacgct gtcctgctat	4500
ccctcagcgc tgctcctgct cctgctcact gccctcgca cagccttggt ttgggctccg	4560
cctgtattct cctggtactg caacctgtaa accagcactg caatgctgat gcacgggaag	4620
tagtgggatg ggaacacaaa tggaaagctt	4650

<210> 125

<211> 4653

<212> DNA

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 125

ggtacccgcc tgcaacgcaa gggcagccac agccgctccc acccgccgct gaaccgacac	60
gtgcttgggc gcctgccgcc tgctgccgc atgcttgctg tggtagggct gggcagtgc	120
gccatgctga ttgaggcttg gttcatcggg tggaaagctta tgtgtgtgct gggcttgcat	180
gccgggcaat gcgcatgggt gcaagagggc ggcagcactt gctggagctg ccgcggtgcc	240
tccagggtggt tcaatcgcgg cagccagagg gatttcagat gatcgcgctg acaggttgag	300
cagcagtgtc agcaaaggta gcagtttgcc agaagatgct gttcagctgt taatcaatgc	360
cagcaagaga aggggtcaag tgcaaacacg ggcattgccac agcacgggca ccggggagtg	420
gaatggcacc accaagtgtg tgcgagccag catcgccgcc tggctgtttc agctacaacg	480
gcaggagtca tccaacgtaa ccatgagctg atcaacactg caatcatcgg gcgggctga	540
tgcaagcatg cctggcgaag acacatgggt tgccggatgct gccggctgct gcctgctgcg	600
cacgccgttg agttggcagc aggctcagcc atgcactgga tggcagctgg gctgccactg	660
caatgtgggt gataggatgc aagtggagcg aataccaaac cctctggctg cttgctgggt	720
tgcatggcat cgcaccatca gcaggagcgc atgcgaaggg actggcccca tgcacgccat	780
gccaaaccgg agcgcaccga gtgtccacac tgtcaccagg cccgcaagct ttgcagaacc	840

026172-005010PC - Sequence Listing_1.TXT

atgctcatgg acgcatgtag cgctgacgtc ccttgacggc gctcctctcg ggtgtgggaa	900
acgcaatgca gcacaggcag cagaggcggc ggcagcagag cggcggcagc agcggcggg	960
gccacccttc ttgcggggtc gcgccccagc cagcgggtgat gcgctgatcc caaacgagtt	1020
cacattcatt tgcattgcctg gagaagcgag gctggggcct ttgggctggg gcagcccgc	1080
atggaatgcg ggaccgccag gctagcagca aaggcgccct ccctactccg catcgatgtt	1140
ccatagtga ttggactgca tttgggtggg gcggccggct gtttctttcg tgttgcaaaa	1200
cgcgccagct cagcaacctg tcccgtgggt cccccgtgcc gatgaaatcg tgtgcacgcc	1260
gatcagctga ttgcccggct cgcgaaagtag gcgcccctct ttctgctcgc cctctctccg	1320
tccgcctct agaatatcaa tgatcgagca ggacggcctc cacgccggct cccccgcgc	1380
ctgggtggag cgctgtttcg gctacgactg ggcccagcag accatcggct gctccgacgc	1440
cgccgtgttc cgctgttccg cccaggggcg ccccgctgtg ttctgtaaga ccgacctgtc	1500
cggcgccctg aacgagctgc aggacgaggc cgccgcctg tcctggctgg ccaccaccgg	1560
cgtgccctgc gccgcctgc tggacgtggg gaccgaggcc ggccgcgact ggctgctgct	1620
gggagagggtg cccggccagg acctgctgtc ctccacctg gccccgcgc agaagggtgc	1680
catcatggcc gacgccatgc gccgcctgca caccctggac cccgccacct gcccttcga	1740
ccaccaggcc aagcaccgca tcgagcgcg ccgcacccgc atggaggccg gcctgggtgga	1800
ccaggacgac ctggacgagg agcaccaggg cctggccccc gccgagctgt tcgcccgcct	1860
gaaggccgc atgcccagc gcgaggacct ggtggtgacc cacggcgacg cctgcctgcc	1920
caacatcatg gtggagaacg gccgcttctc cggcttcac gactgcggcc gcctgggctg	1980
ggccgaccgc taccaggaca tcgccctggc caccgcgac atcgccgagg agctgggctg	2040
cgagtgggcc gaccgcttcc tgggtgctgta cggcatcgcc gccccgact cccagcgcat	2100
cgccttctac cgctgctgg acgagttctt ctgacaattg gcagcagcag ctcggaatg	2160
atcgacacac tctggacgt ggtcgtgtga tggactgttg ccgccacact tgctgccttg	2220
acctgtgaat atccctgccg cttttatcaa acagcctcag tgtgtttgat cttgtgtgta	2280
cgcgcttttg cgagttgcta gctgcttggt ctatttgca ataccacccc cagcatcccc	2340
ttccctcggt tcatatcgct tgcatcccaa ccgcaactta tctacgctgt cctgctatcc	2400
ctcagcgctg ctctgctcc tgctcactgc cctcgcaca gccttggttt gggctccgcc	2460
tgtattctcc tggtagtgca acctgtaaac cagcactgca atgctgatgc acgggaagta	2520
gtgggatggg aacacaaatg gaggatcccg cgtctcgaa agagcgcgca gaggaacgct	2580
gaaggctctg cctctgtcgc acctcagcgc ggcatacacc acaataacca cctgacgaat	2640
gcgcttggtt cttcgtccat tagcgaagcg tccggttcac acacgtgcca cgttggcgag	2700
gtggcagggtg acaatgatcg gtggagctga tggtcgaaac gttcacagcc tagggatatc	2760
gaattccttt cttgcctat gacacttcca gaaaaggta gggcgggctg cgagacggct	2820
tccggcgct gcatgcaaca ccgatgatgc ttcgaccccc cgaagctcct tcggggctgc	2880

026172-005010PC - Sequence Listing_1.TXT

atgggcgctc cgatgccgct ccagggcgag cgctgtttta atagccaggc ccccgattgc	2940
aaagacatta tagcgagcta ccaaagccat attcaaacac ctagatcact accacttcta	3000
cacaggccac tcgagcttgt gatcgactc cgctaagggg gcgcctcttc ctcttcgttt	3060
cagtcacaac ccgcaaacac tagtatggct atcaagacga acaggcagcc tgtggagaag	3120
cctccgttca cgatcgggac gctgcgcaag gccatccccg cgactgttt cgagcgctcg	3180
gcgcttcgtg ggcgcgcccc cgactggtcc atgctgttcg ccgtgatcac caccatcttc	3240
tccgccgccc agaagcagtg gaccaacctg gagtggaagc ccaagcccaa cccccccag	3300
ctgctggacg accacttcgg cccccacggc ctggtgttcc gccgcacctt cgccatccgc	3360
agctacgagg tgggccccga ccgctccacc agcatcgtgg ccgtgatgaa ccacctgcag	3420
gaggccgccc tgaaccacgc caagtccgtg ggcacctctg gcgacggcct cggcaccacc	3480
ctggagatgt ccaagcgcg cctgatctgg gtggtgaagc gcacccacgt ggccgtggag	3540
cgctaccccc cctggggcga caccgtggag gtggagtgtt ggggtggcgc ctccggcaac	3600
aacggccgccc gccacgactt cctggtgcgc gactgcaaga ccggcgagat cctgaccgc	3660
tgcacctccc tgagcgtgat gatgaacacc cgcacccgcc gcctgagcaa gatccccgag	3720
gagggtgcgc gcgagatcgg cccgccttc atcgacaacg tggccgtgaa ggacgaggag	3780
atcaagaagc cccagaagct gaacgactcc accgccgact acatccaggg cggcctgacc	3840
ccccgctgga acgacctgga catcaaccag cacgtgaaca acatcaagta cgtggactgg	3900
atcctggaga ccgtgcccga cagcatcttc gagagccacc acatctctc cttaccatc	3960
gagtaccgcc gcgagtgcac catggacagc gtgctgcagt ccctgaccac cgtgagcggc	4020
ggctcctccg aggccggcct ggtgtgcgag cacctgctgc agctggaggg cggcagcgag	4080
gtgctgcgcg ccaagaccga gtggcgcccc aagctgaccg actccttccg cggcatcagc	4140
gtgatccccg ccgagtccag cgtgatggac tacaaggacc acgacggcga ctacaaggac	4200
cacgacatcg actacaagga cgacgacgac aagtgatgac tcgaggcagc agcagctcgg	4260
atagtatcga cacactctgg acgctggctg tgtgatggac tgttgccgcc acacttgctg	4320
ccttgacctg tgaatatccc tgccgctttt atcaaacagc ctcagtgtgt ttgatcttgt	4380
gtgtacgcgc ttttgcgagt tgctagctgc ttgtgctatt tgcaataacc acccccagca	4440
tccccctccc tcgtttcata tcgcttgcat cccaaccgca acttatctac gctgtcctgc	4500
tatccctcag cgctgctcct gctcctgctc actgcccctc gcacagcctt ggtttgggct	4560
ccgcctgtat tctcctggta ctgcaacctg taaaccagca ctgcaatgct gatgcacggg	4620
aagtagtggg atgggaacac aaatggaaag ctt	4653

<210> 126

<211> 3669

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

```

<400> 126
cccgtgatca cacaggtgcc ttgcgagcgt gatcacacta ttttgggggt cctacagtac      60
tgaaatggtg agaagtcgta ctgaaatcaa ggatgaacaa tgaaaatggt gctgtggtgg      120
cttctcaaag gtcaagaatc agtcgctcgc gtcaggaaat cgcggcgtca accagcgtgg      180
gcgcggtcag tggccccgca ctggtcacca tagcctctcc tgccacagta gcgatcccct      240
gggcgttcac tctcagcagc ggctgtactg cctcccagat tttcttcttc tggacctgcg      300
ggcgtgagag gatgagcagg gtggggccaa gggctcaatc ctgaacggcc ctcatcgggt      360
ttccaatccc acaacacata cccacagcag gtcagaccac gcattcgcac catgcgacc      420
aaataacgtg tccttacctg attgggtgtg gcaggctccg tggacaggag tgcctcgccc      480
cccgcccaga cccgctcccc cgtcacggcg gcgtccggga cccgcagcgg ctccaccgcg      540
gtgtgatccg cgttggcggc gcagagcagc atcccagccg atttgacccc gcgcatgctc      600
cgaggcttga ggttggccag caccaccacc cgccggccga caaggctctc cagggtcacg      660
tgccggacca ggccactcac gatggtgcga gggccccctt cctcgccgag gtcgatctgc      720
tcgacgtaca gactgcgaca tgcgtggcga gtggtcatca gaaggaagca ggtgtgcaga      780
aggggcacgt ggttgggtatt gagagtagcc aaagctttgt gccaatcaga aagtcaacgc      840
agctgcctgc ctggctcgcg tacaattcct ttcttgcgct atgacacttc cagcaaaagg      900
tagggcgggc tgcgagacgg cttcccggcg ctgcatgcaa caccgatgat gcttcgacct      960
cccgaagctc cttcgggggt gcatgggcgc tccgatgccg ctccagggcg agcgtgttt      1020
aaatagccag gcccccgatt gcaaagacat tatagcgagc taccaaagcc atattcaaac      1080
acctagatca ctaccacttc tacacaggcc actcgagctt gtgatcgac tccgctaagg      1140
gggcgcctct tctcttcgt ttcagtcaca acccgcaaac ggcgcgccat gctgctgcag      1200
gccttcctgt tctgctggc cggttcgcc gccaatgca gcgcctccat gacgaacgag      1260
acgtccgacc gccccctggt gcacttcacc cccaacaagg gctggatgaa cgacccaac      1320
ggcctgtggt acgacgagaa ggacgccaag tggcacctgt acttcagta caacccgaac      1380
gacaccgtct gggggacgcc cttgttctgg ggccacgcca cgtccgacga cctgaccaac      1440
tgaggaggacc agcccatcgc catcgccccg aagcgcaacg actccggcgc cttctccggc      1500
tccatggtgg tggactacaa caacacctcc ggcttcttca acgacacat cgacccgcgc      1560
cagcgtcgcg tggccatctg gacctacaac acccggagt ccgaggagca gtacatctcc      1620
tacagcctgg acggcggcta cacttcacc gagtaccaga agaaccccggt gctggccgcc      1680
aactccaccc agttccgcga cccgaaggct ttctggtacg agccctccca gaagtggatc      1740
atgaccgcgg ccaagtccca ggactacaag atcgagatct actcctccga cgacctgaag      1800
tcctggaagc tggagtcgcg gttcgccaac gagggcttcc tcggctacca gtacgagtgc      1860
cccggcctga tcgagggtccc caccgagcag gacccagca agtcctactg ggtgatgttc      1920

```

026172-005010PC - Sequence Listing_1.TXT

atctccatca accccggcgc cccggccggc ggctccttca accagtactt cgtcggcagc	1980
ttcaacggca ccacttcga ggccttcgac aaccagtccc gcgtgggtgga cttcggcaag	2040
gactactacg ccctgcagac cttcttcaac accgacctga cctacgggag cgccctgggc	2100
atcgcggtgg cctccaactg ggagtactcc gccttcgtgc ccaccaaccc ctggcgctcc	2160
tccatgtccc tcgtgcgcaa gttctccctc aacaccgagt accaggccaa cccggagacg	2220
gagctgatca acctgaaggc cgagccgatc ctgaacatca gcaacgccgg cccctggagc	2280
cggttcgcca ccaacaccac gttgacgaag gccaacagct acaacgtcga cctgtccaac	2340
agcaccggca ccctggagtt cgagctggtg tacgccgtca acaccacca gacgatctcc	2400
aagtccgtgt tcgcggacct ctccctctgg ttcaagggcc tggaggacct cgaggagtac	2460
ctccgcatgg gcttcgaggt gtccgcgtcc tccttcttcc tggaccgcgg gaacagcaag	2520
gtgaagttcg tgaaggagaa cccctacttc accaaccgca tgagcgtgaa caaccagccc	2580
ttcaagagcg agaacgacct gtcctactac aagggtgtac gcttgctgga ccagaacatc	2640
ctggagctgt acttcaacga cggcgacgtc gtgtccacca acacctactt catgaccacc	2700
gggaacgccc tgggctccgt gaacatgacg acgggggtgg acaacctgtt ctacatcgac	2760
aagttccagg tgcgcgaggt caagtgatta attaaactga ggcagcagca gctcggatag	2820
tatcgacaca ctctggacgc tggctgtgtg atggactgtt gccgccacac ttgctgcctt	2880
gacctgtgaa tatccctgcc gcttttatca aacagcctca gtgtgtttga tcttgtgtgt	2940
acgcgctttt gcgagttgct agctgcttgt gctatttgcg aataccaccc ccagcatccc	3000
cttccctcgt ttcatatcgc ttgcatccca accgcaactt atctacgctg tcctgctatc	3060
cctcagcgct gtcctgctc ctgctcactg cccctcgcac agccttggtt tgggctccgc	3120
ctgtattctc ctggtactgc aacctgtaaa ccagcactgc aatgctgatg cacgggaagt	3180
agtgggatgg gaacacaaat ggaaagcttg agctcggtac ccgtacccat cagcatccgg	3240
gtgaatcttg gcctccaaga tatggccaat cctcacatcc agcttggtgaa aatcgactag	3300
actgtctgca agtgggaatg tggagcacia gggtgcttgt agcgatcgac agactggtgg	3360
ggtacattga cagggtgggca gcgccgcatc catcgtgcct gacgcgagcg ccgccggtt	3420
ctcgcccgtg cctgccgtca aagagcggca gagaaatcgg gaaccgaaaa cgtcacattg	3480
cctgatgttg ttacatgctg gactagactt tcttggcgtg ggtctgctcc tcgccaggtg	3540
cgcgacgcct cggggctggg tgcgaggag ccgtgcggcc acgcatttga caagacccaa	3600
agctcgcac tcagacggtc aaccgttcgt attatacatt caacatatgg tacatacgca	3660
aaaagcatg	3669

<210> 127

<211> 39

<212> PRT

<213> Prototheca moriformis

<400> 127

Met Thr Phe Gly Val Ala Leu Pro Ala Met Gly Arg Gly Val Ser Leu

1 5 10 15
 Pro Arg Pro Arg Val Ala Val Arg Ala Gln Ser Ala Ser Gln Val Leu
 20 25 30

Glu Ser Gly Arg Ala Gln Leu
 35

<210> 128
 <211> 40
 <212> PRT
 <213> Prototheca moriformis

<400> 128
 Met Ala Ile Lys Thr Asn Arg Gln Pro Val Glu Lys Pro Pro Phe Thr
 1 5 10 15

Ile Gly Thr Leu Arg Lys Ala Ile Pro Ala His Cys Phe Glu Arg Ser
 20 25 30

Ala Leu Arg Gly Arg Ala Gln Leu
 35 40

<210> 129
 <211> 36
 <212> PRT
 <213> Prototheca moriformis

<400> 129
 Met Ala Ser Ala Ala Phe Thr Met Ser Ala Cys Pro Ala Met Thr Gly
 1 5 10 15

Arg Ala Pro Gly Ala Arg Arg Ser Gly Arg Pro Val Ala Thr Arg Leu
 20 25 30

Arg Gly Arg Ala
 35

<210> 130
 <211> 40
 <212> PRT
 <213> Chlorella protothecoides

<400> 130
 Met Ala Thr Ala Ser Thr Phe Ser Ala Phe Asn Ala Arg Cys Gly Asp
 1 5 10 15

Leu Arg Arg Ser Ala Gly Ser Gly Pro Arg Arg Pro Ala Arg Pro Leu
 20 25 30

Pro Val Arg Gly Arg Ala Gln Leu
 35 40

<210> 131
 <211> 87
 <212> PRT

<213> *Cuphea hookeriana*

<400> 131

Met Val Ala Ala Ala Ser Ser Ala Phe Phe Pro Val Pro Ala Pro
1 5 10 15Gly Ala Ser Pro Lys Pro Gly Lys Phe Gly Asn Trp Pro Ser Ser Leu
20 25 30Ser Pro Ser Phe Lys Pro Lys Ser Ile Pro Asn Gly Gly Phe Gln Val
35 40 45Lys Ala Asn Asp Ser Ala His Pro Lys Ala Asn Gly Ser Ala Val Ser
50 55 60Leu Lys Ser Gly Ser Leu Asn Thr Gln Glu Asp Thr Ser Ser Ser Pro
65 70 75 80Pro Pro Arg Thr Phe Leu His
85

<210> 132

<211> 60

<212> PRT

<213> *Umbellularia californica*

<400> 132

Met Ala Thr Thr Ser Leu Ala Ser Ala Phe Cys Ser Met Lys Ala Val
1 5 10 15Met Leu Ala Arg Asp Gly Arg Gly Met Lys Pro Arg Ser Ser Asp Leu
20 25 30Gln Leu Arg Ala Gly Asn Ala Pro Thr Ser Leu Lys Met Ile Asn Gly
35 40 45Thr Lys Phe Ser Tyr Thr Glu Ser Leu Lys Arg Leu
50 55 60

<210> 133

<211> 60

<212> PRT

<213> *Cinnamomum camphora*

<400> 133

Met Ala Thr Thr Ser Leu Ala Ser Ala Phe Cys Ser Met Lys Ala Val
1 5 10 15Met Leu Ala Arg Asp Gly Arg Gly Met Lys Pro Arg Ser Ser Asp Leu
20 25 30Gln Leu Arg Ala Gly Asn Ala Gln Thr Ser Leu Lys Met Ile Asn Gly
35 40 45Thr Lys Phe Ser Tyr Thr Glu Ser Leu Lys Lys Leu
Page 142

50

55

60

<210> 134

<211> 1104

<212> DNA

<213> Prototheca moriformis

<400> 134

```

atggcaccga ccagcctgct tgccagtact ggcgtctctt ccgcttctct gtggtcctct      60
gcgcgctcca gcgcgctgcgc ttttccggtg gatcatgcgg tccgtggcgc accgcagcgg      120
ccgctgcccc tgcagcgccg ctgcttccga acagtggcgg tcagggccgc acccgcggtg      180
gccgtccgtc cggaaccgcg ccaagagttt tgggagcagc ttgagccctg caagatggcg      240
gaggacaagc gcatcttcct ggaggagcac cgcattcggg gcaacgaggt gggcccctcg      300
cagcggctga cgatcacggc ggtggccaac atcctgcagg aggcggcggg caaccacgcg      360
gtggccatgt ggggcccggag ctcgaggagg ttccgcgacgg acccgagagct gcaggaggcg      420
ggtctcatct ttgtgatgac gcgcatgcag atccaaatgt accgctaccc gcgctggggc      480
gacctgatgc aggtggagac ctggttccag acggcgggca agctaggcgc gcagcgcgag      540
tgggtgctgc gcgacaagct gaccggcgag gcgctggggc cggccacctc cagctgggtc      600
atgatcaaca tccgcacgcg ccggccgtgc cgcatgcccg agctcgtccg cgtcaagtgc      660
gccttcttcg cgcgcgagcc gccgcgcctg gcgctgccgc ccacggtcac gcgcgccaag      720
ctgccccaca tcgcgacgcc ggcgccgtg cgcgggcacc gccaggtcgc gcgccgcacc      780
gacatggaca tgaacgggca cgtgaacaac gtggcctacc tggcctgggt cctggaggcc      840
gtgcccagac acgtcttcag cgactaccac ctctaccaga tggagatcga cttcaaggcc      900
gagtgccacg cgggcgacgt catctcctcc caggccgagc agatccccgc ccaggaggcg      960
ctcacgcaca acggcgccgg ccgaaccccc tcctgcttcg tccatagcat tctgcgcgcc     1020
gagaccgagc tcgtccgcgc gcgaaccaca tggtcggccc ccacgcacgc gcccgccgcc     1080
aagccgcccc aggcgagcca ctga                                           1104

```

<210> 135

<211> 1104

<212> DNA

<213> Prototheca moriformis

<400> 135

```

atggcaccga ccagcctgct tgcccgtact ggcgtctctt ccgcttctct gtgctcctct      60
acgcgctccg gcgcgctgcgc ttttccggtg gatcatgcgg tccgtggcgc accgcagcgg      120
ccgctgcccc tgcagcgccg ctgcttccga acagtggctg tcagggccgc acccgcagta      180
gccgtccgtc cggaaccgcg ccaagagttt tgggagcagc ttgagccctg caagatggcg      240
gaggacaagc gcatcttcct ggaggagcac cgcattcgtg gcaacgaggt gggcccctcg      300
cagcggctga cgatcacggc ggtggccaac atcctgcagg aggcggcggg caaccacgcg      360
gtggccatgt ggggtcggag ctcgaggagg ttccgcgacgg acccgagagct gcaggaggcg      420

```

026172-005010PC - Sequence Listing_1.TXT

```

ggcctcatct ttgtgatgac gcgcatgcag atccaaatgt accgctaccc gcgctggggc 480
gacctgatgc aggtggagac ctggttccag acggcgggca agctaggcgc gcagcgcgag 540
tgggtgctgc gcgacaagct gaccggcgag gcgctggggc cggccacctc cagctgggtc 600
atgatcaaca tccgcacgcg ccggccgtgc cgcattgccg agctcgtccg cgtcaagtcg 660
gccttcttcg cgcgcgagcc gccgcgcctg gcgctgccgc ccgcggtcac gcgtgccaaag 720
ctgcccaca tgcgcagccc ggccgcctg cgcgggcacc gccaggtcgc gcgccgcacc 780
gacatggaca tgaacggcca cgtgaacaac gttgcctacc tggcctggtg cctggaggcc 840
gtgcccagac acgtcttcag cgactaccac ctctaccaga tggagatcga cttcaaggcc 900
gagtgccacg cgggcgacgt catctctctc caggccgagc agatcccgcc ccaggaggcg 960
ctcacgcaca acggcgccgg ccgaacccc tctgtcttcg tccatagcat tctgcgcgcc 1020
gagaccgagc tcgtccgcgc gcgaaccaca tggtcggccc ccatcgacgc gcccgccgcc 1080
aagccgcca aggcgagcca ctga 1104

```

<210> 136

<211> 367

<212> PRT

<213> Prototheca moriformis

<400> 136

```

Met Ala Pro Thr Ser Leu Leu Ala Ser Thr Gly Val Ser Ser Ala Ser
1           5           10           15

```

```

Leu Trp Ser Ser Ala Arg Ser Ser Ala Cys Ala Phe Pro Val Asp His
           20           25           30

```

```

Ala Val Arg Gly Ala Pro Gln Arg Pro Leu Pro Met Gln Arg Arg Cys
           35           40           45

```

```

Phe Arg Thr Val Ala Val Arg Ala Ala Pro Ala Val Ala Val Arg Pro
           50           55           60

```

```

Glu Pro Ala Gln Glu Phe Trp Glu Gln Leu Glu Pro Cys Lys Met Ala
65           70           75           80

```

```

Glu Asp Lys Arg Ile Phe Leu Glu Glu His Arg Ile Arg Gly Asn Glu
           85           90           95

```

```

Val Gly Pro Ser Gln Arg Leu Thr Ile Thr Ala Val Ala Asn Ile Leu
           100          105          110

```

```

Gln Glu Ala Ala Gly Asn His Ala Val Ala Met Trp Gly Arg Ser Ser
           115          120          125

```

```

Glu Gly Phe Ala Thr Asp Pro Glu Leu Gln Glu Ala Gly Leu Ile Phe
           130          135          140

```

```

Val Met Thr Arg Met Gln Ile Gln Met Tyr Arg Tyr Pro Arg Trp Gly
Page 144

```

026172-005010PC - Sequence Listing_1.TXT

```

145          150          155          160
Asp Leu Met Gln Val Glu Thr Trp Phe Gln Thr Ala Gly Lys Leu Gly
          165          170          175

Ala Gln Arg Glu Trp Val Leu Arg Asp Lys Leu Thr Gly Glu Ala Leu
          180          185          190

Gly Ala Ala Thr Ser Ser Trp Val Met Ile Asn Ile Arg Thr Arg Arg
          195          200          205

Pro Cys Arg Met Pro Glu Leu Val Arg Val Lys Ser Ala Phe Phe Ala
          210          215          220

Arg Glu Pro Pro Arg Leu Ala Leu Pro Pro Thr Val Thr Arg Ala Lys
          225          230          235

Leu Pro Asn Ile Ala Thr Pro Ala Pro Leu Arg Gly His Arg Gln Val
          245          250          255

Ala Arg Arg Thr Asp Met Asp Met Asn Gly His Val Asn Asn Val Ala
          260          265          270

Tyr Leu Ala Trp Cys Leu Glu Ala Val Pro Glu His Val Phe Ser Asp
          275          280          285

Tyr His Leu Tyr Gln Met Glu Ile Asp Phe Lys Ala Glu Cys His Ala
          290          295          300

Gly Asp Val Ile Ser Ser Gln Ala Glu Gln Ile Pro Pro Gln Glu Ala
          305          310          315          320

Leu Thr His Asn Gly Ala Gly Arg Asn Pro Ser Cys Phe Val His Ser
          325          330          335

Ile Leu Arg Ala Glu Thr Glu Leu Val Arg Ala Arg Thr Thr Trp Ser
          340          345          350

Ala Pro Ile Asp Ala Pro Ala Ala Lys Pro Pro Lys Ala Ser His
          355          360          365

<210> 137
<211> 367
<212> PRT
<213> Prototheca moriformis

<400> 137
Met Ala Pro Thr Ser Leu Leu Ala Arg Thr Gly Val Ser Ser Ala Ser
1          5          10          15

Leu Cys Ser Ser Thr Arg Ser Gly Ala Cys Ala Phe Pro Val Asp His
          20          25          30

```

026172-005010PC - Sequence Listing_1.TXT

Ala Val Arg Gly Ala Pro Gln Arg Pro Leu Pro Met Gln Arg Arg Cys
 35 40 45
 Phe Arg Thr Val Ala Val Arg Ala Ala Pro Ala Val Ala Val Arg Pro
 50 55 60
 Glu Pro Ala Gln Glu Phe Trp Glu Gln Leu Glu Pro Cys Lys Met Ala
 65 70 75 80
 Glu Asp Lys Arg Ile Phe Leu Glu Glu His Arg Ile Arg Gly Asn Glu
 85 90 95
 Val Gly Pro Ser Gln Arg Leu Thr Ile Thr Ala Val Ala Asn Ile Leu
 100 105 110
 Gln Glu Ala Ala Gly Asn His Ala Val Ala Met Trp Gly Arg Ser Ser
 115 120 125
 Glu Gly Phe Ala Thr Asp Pro Glu Leu Gln Glu Ala Gly Leu Ile Phe
 130 135 140
 Val Met Thr Arg Met Gln Ile Gln Met Tyr Arg Tyr Pro Arg Trp Gly
 145 150 155 160
 Asp Leu Met Gln Val Glu Thr Trp Phe Gln Thr Ala Gly Lys Leu Gly
 165 170 175
 Ala Gln Arg Glu Trp Val Leu Arg Asp Lys Leu Thr Gly Glu Ala Leu
 180 185 190
 Gly Ala Ala Thr Ser Ser Trp Val Met Ile Asn Ile Arg Thr Arg Arg
 195 200 205
 Pro Cys Arg Met Pro Glu Leu Val Arg Val Lys Ser Ala Phe Phe Ala
 210 215 220
 Arg Glu Pro Pro Arg Leu Ala Leu Pro Pro Ala Val Thr Arg Ala Lys
 225 230 235 240
 Leu Pro Asn Ile Ala Thr Pro Ala Pro Leu Arg Gly His Arg Gln Val
 245 250 255
 Ala Arg Arg Thr Asp Met Asp Met Asn Gly His Val Asn Asn Val Ala
 260 265 270
 Tyr Leu Ala Trp Cys Leu Glu Ala Val Pro Glu His Val Phe Ser Asp
 275 280 285
 Tyr His Leu Tyr Gln Met Glu Ile Asp Phe Lys Ala Glu Cys His Ala
 290 295 300

026172-005010PC - Sequence Listing_1.TXT

Gly Asp Val Ile Ser Ser Gln Ala Glu Gln Ile Pro Pro Gln Glu Ala
305 310 315 320

Leu Thr His Asn Gly Ala Gly Arg Asn Pro Ser Cys Phe Val His Ser
325 330 335

Ile Leu Arg Ala Glu Thr Glu Leu Val Arg Ala Arg Thr Thr Trp Ser
340 345 350

Ala Pro Ile Asp Ala Pro Ala Ala Lys Pro Pro Lys Ala Ser His
355 360 365

<210> 138

<211> 328

<212> PRT

<213> Cuphea hookeriana

<400> 138

Gln Leu Pro Asp Trp Ser Arg Leu Leu Thr Ala Ile Thr Thr Val Phe
1 5 10 15

Val Lys Ser Lys Arg Pro Asp Met His Asp Arg Lys Ser Lys Arg Pro
20 25 30

Asp Met Leu Val Asp Ser Phe Gly Leu Glu Ser Thr Val Gln Asp Gly
35 40 45

Leu Val Phe Arg Gln Ser Phe Ser Ile Arg Ser Tyr Glu Ile Gly Thr
50 55 60

Asp Arg Thr Ala Ser Ile Glu Thr Leu Met Asn His Leu Gln Glu Thr
65 70 75 80

Ser Leu Asn His Cys Lys Ser Thr Gly Ile Leu Leu Asp Gly Phe Gly
85 90 95

Arg Thr Leu Glu Met Cys Lys Arg Asp Leu Ile Trp Val Val Ile Lys
100 105 110

Met Gln Ile Lys Val Asn Arg Tyr Pro Ala Trp Gly Asp Thr Val Glu
115 120 125

Ile Asn Thr Arg Phe Ser Arg Leu Gly Lys Ile Gly Met Gly Arg Asp
130 135 140

Trp Leu Ile Ser Asp Cys Asn Thr Gly Glu Ile Leu Val Arg Ala Thr
145 150 155 160

Ser Ala Tyr Ala Met Met Asn Gln Lys Thr Arg Arg Leu Ser Lys Leu
165 170 175

Pro Tyr Glu Val His Gln Glu Ile Val Pro Leu Phe Val Asp Ser Pro
Page 147

180

185

190

Val Ile Glu Asp Ser Asp Leu Lys Val His Lys Phe Lys Val Lys Thr
 195 200 205

Gly Asp Ser Ile Gln Lys Gly Leu Thr Pro Gly Trp Asn Asp Leu Asp
 210 215 220

Val Asn Gln His Val Ser Asn Val Lys Tyr Ile Gly Trp Ile Leu Glu
 225 230 235 240

Ser Met Pro Thr Glu Val Leu Glu Thr Gln Glu Leu Cys Ser Leu Ala
 245 250 255

Leu Glu Tyr Arg Arg Glu Cys Gly Arg Asp Ser Val Leu Glu Ser Val
 260 265 270

Thr Ala Met Asp Pro Ser Lys Val Gly Val Arg Ser Gln Tyr Gln His
 275 280 285

Leu Leu Arg Leu Glu Asp Gly Thr Ala Ile Val Asn Gly Ala Thr Glu
 290 295 300

Trp Arg Pro Lys Asn Ala Gly Ala Asn Gly Ala Ile Ser Thr Gly Lys
 305 310 315 320

Thr Ser Asn Gly Asn Ser Val Ser
 325

<210> 139

<211> 322

<212> PRT

<213> Umbellularia californica

<400> 139

Pro Asp Trp Ser Met Leu Phe Ala Val Ile Thr Thr Ile Phe Ser Ala
 1 5 10 15

Ala Glu Lys Gln Trp Thr Asn Leu Glu Trp Lys Pro Lys Pro Lys Leu
 20 25 30

Pro Gln Leu Leu Asp Asp His Phe Gly Leu His Gly Leu Val Phe Arg
 35 40 45

Arg Thr Phe Ala Ile Arg Ser Tyr Glu Val Gly Pro Asp Arg Ser Thr
 50 55 60

Ser Ile Leu Ala Val Met Asn His Met Gln Glu Ala Thr Leu Asn His
 65 70 75 80

Ala Lys Ser Val Gly Ile Leu Gly Asp Gly Phe Gly Thr Thr Leu Glu
 85 90 95

026172-005010PC - Sequence Listing_1.TXT

Met Ser Lys Arg Asp Leu Met Trp Val Val Arg Arg Thr His Val Ala
100 105 110

Val Glu Arg Tyr Pro Thr Trp Gly Asp Thr Val Glu Val Glu Cys Trp
115 120 125

Ile Gly Ala Ser Gly Asn Asn Gly Met Arg Arg Asp Phe Leu Val Arg
130 135 140

Asp Cys Lys Thr Gly Glu Ile Leu Thr Arg Cys Thr Ser Leu Ser Val
145 150 155 160

Leu Met Asn Thr Arg Thr Arg Arg Leu Ser Thr Ile Pro Asp Glu Val
165 170 175

Arg Gly Glu Ile Gly Pro Ala Phe Ile Asp Asn Val Ala Val Lys Asp
180 185 190

Asp Glu Ile Lys Lys Leu Gln Lys Leu Asn Asp Ser Thr Ala Asp Tyr
195 200 205

Ile Gln Gly Gly Leu Thr Pro Arg Trp Asn Asp Leu Asp Val Asn Gln
210 215 220

His Val Asn Asn Leu Lys Tyr Val Ala Trp Val Phe Glu Thr Val Pro
225 230 235 240

Asp Ser Ile Phe Glu Ser His His Ile Ser Ser Phe Thr Leu Glu Tyr
245 250 255

Arg Arg Glu Cys Thr Arg Asp Ser Val Leu Arg Ser Leu Thr Thr Val
260 265 270

Ser Gly Gly Ser Ser Glu Ala Gly Leu Val Cys Asp His Leu Leu Gln
275 280 285

Leu Glu Gly Gly Ser Glu Val Leu Arg Ala Arg Thr Glu Trp Arg Pro
290 295 300

Lys Leu Thr Asp Ser Phe Arg Gly Ile Ser Val Ile Pro Ala Glu Pro
305 310 315 320

Arg Val

<210> 140

<211> 345

<212> PRT

<213> Cinnamomum camphora

<400> 140

Pro Asp Trp Ser Met Leu Phe Ala Val Ile Thr Thr Ile Phe Ser Ala
Page 149

```

1           5           10           15
Ala Glu Lys Gln Trp Thr Asn Leu Glu Trp Lys Pro Lys Pro Asn Pro
20           25           30
Pro Gln Leu Leu Asp Asp His Phe Gly Pro His Gly Leu Val Phe Arg
35           40           45
Arg Thr Phe Ala Ile Arg Ser Tyr Glu Val Gly Pro Asp Arg Ser Thr
50           55           60
Ser Ile Val Ala Val Met Asn His Leu Gln Glu Ala Ala Leu Asn His
65           70           75           80
Ala Lys Ser Val Gly Ile Leu Gly Asp Gly Phe Gly Thr Thr Leu Glu
85           90           95
Met Ser Lys Arg Asp Leu Ile Trp Val Val Lys Arg Thr His Val Ala
100          105          110
Val Glu Arg Tyr Pro Ala Trp Gly Asp Thr Val Glu Val Glu Cys Trp
115          120          125
Val Gly Ala Ser Gly Asn Asn Gly Arg Arg His Asp Phe Leu Val Arg
130          135          140
Asp Cys Lys Thr Gly Glu Ile Leu Thr Arg Cys Thr Ser Leu Ser Val
145          150          155          160
Met Met Asn Thr Arg Thr Arg Arg Leu Ser Lys Ile Pro Glu Glu Val
165          170          175
Arg Gly Glu Ile Gly Pro Ala Phe Ile Asp Asn Val Ala Val Lys Asp
180          185          190
Glu Glu Ile Lys Lys Pro Gln Lys Leu Asn Asp Ser Thr Ala Asp Tyr
195          200          205
Ile Gln Gly Gly Leu Thr Pro Arg Trp Asn Asp Leu Asp Ile Asn Gln
210          215          220
His Val Asn Asn Ile Lys Tyr Val Asp Trp Ile Leu Glu Thr Val Pro
225          230          235          240
Asp Ser Ile Phe Glu Ser His His Ile Ser Ser Phe Thr Ile Glu Tyr
245          250          255
Arg Arg Glu Cys Thr Met Asp Ser Val Leu Gln Ser Leu Thr Thr Val
260          265          270
Ser Gly Gly Ser Ser Glu Ala Gly Leu Val Cys Glu His Leu Leu Gln

```

275

280

285

Leu Glu Gly Gly Ser Glu Val Leu Arg Ala Lys Thr Glu Trp Arg Pro
 290 295 300

Lys Leu Thr Asp Ser Phe Arg Gly Ile Ser Val Ile Pro Ala Glu Ser
 305 310 315 320

Ser Val Met Asp Tyr Lys Asp His Asp Gly Asp Tyr Lys Asp His Asp
 325 330 335

Ile Asp Tyr Lys Asp Asp Asp Asp Lys
 340 345

<210> 141

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 141

Lys Asp Glu Leu

1

<210> 142

<211> 6

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown: Higher plant fatty acyl-ACP thioesterase sequence

<400> 142

Leu Asp Met Asn Gln His

1

5

<210> 143

<211> 6

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown: Algal fatty acyl-ACP thioesterase sequence

<400> 143

Met Asp Met Asn Gly His

1

5